Molecular and biochemical characterisation of key enzymes involved in mycolic acid biosynthesis from Mycobacterium tuberculosis by Brown, Alistair Karl
Molecular and biochemical 
characterisation of key enzymes 
involved in mycolic acid biosynthesis 
from Mycobacterium tuberculosis 
A thesis submitted to the 
University of Newcastle upon Tyne 
for the degree of Doctor of Philosophy 
August 2004 
Alistair K. Brown, B. Sc. (Hons) 
NEWCASTLE UNIVERSITY LIBRARY 
---------------------------- 
204 06155 8 
---------------------------- 
Abstract 
Mycolic acids are the dominant feature of the Mycobacterium tuberculosis cell wall, 
providing the basis for its lipid-rich permeability barrier. These oc-alkyl, P-hydroxy fatty acids 
are thought to be formed by the Claisen-type condensation of a long C56 meromycolic acid and 
a shorter C24-C26 fatty acid. These component fatty acids are produced via a combination of 
type I and 11 fatty acid synthase (FAS) systems. The C16-C26 fatty acyl products of FAS-I are 
elongated by FAS-II with simultaneous modification to form meromycolic acids, which are 
then condensed with the C24-C26 fatty acyl chain. These studies aimed to characterise key 
enzymes of FAS-11 (mtFabH, KasA) and enzymes possibly involved in the Claisen-type 
condensation reaction to form mycolatic acids (Accl) enzymes, Pksl3, FadD32). 
The P-ketoacyl ACP synthase (KAS) III (mtFabH) is proposed to link FAS-I and FAS-11, 
catalyzing the condensation of FAS-1-derived acyl-CoA with malonyl-Acyl Carrier Protein 
(ACP). The acyl-CoA chain length specificity of mtFabH was assessed in vitro . When using 
E. coll, the preferred substrates were C12- and C14-CoA. However, with the mycobacterial ACP 
(AcpM), the enzyme was able to utilise longer (up tp C2o) acyl-CoA chains. The substitution 
of residues implicated in acyl-CoA chain length specificity totally abrogated overall KAS 
activity and reduced the transacylation activity of the enzyme. Mutation of the proposed 
catalytic triad residues confirmed that Cys122 is essential for transacylation and His258 is 
essential for malonyl-AcpM decarboxylation. 
KasA, which belongs to the FAS-11 system, utilises palmitoyl-ACP rather than short-chain 
acyl-ACP primers. Purified recombinant KasA had in vitro KAS activity that was highly 
sensitive to cerulenin, a well-known KAS inhibitor. Mutation of proposed catalytic residues 
Cys 17 1, His31 1, Lys340 and His345 inactivated the enzyme completely. 
Four putative accD genes were found in Corynebacterium glutamicum. Overexpression of 
each gene resulted in increased acyl-CoA dependent 14CO2 fixation in vitro, providing 
evidence that the accD genes encode a family of carboxyltransferases. Disruption of either 
accD2 or accD3 led to complete and specific loss of mycolic acids. These two 
carboxyltransferases are also retained in all Corynebacterianeae, including M. leprae, and 
probably provide a carboxylated. intennediate for condensation of the mero-chain and CC- 
branch directed by thepks]3-encoded polyketide synthase. 
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1.1 General introduction 
In terms of infectious disease Mycobacterium tuberculosis, as the cause of tuberculosis (TB), 
is the leading cause of morbidity and mortality worldwide accounting for 26 % of all 
preventable adult deaths globally (Ramaswamy & Musser, 1998). Approximately 8 million 
infections and 2 million deaths are recorded each year (WHO, 2003). Chemotherapy, mainly 
through the use of isoniazid (INH) and rifampin (RIF), coupled with the use of the BCG 
vaccine has been the method of choice to combat the increasing TB problem. Clinically 
isolated strains of M. tuberculosis resistant to specific antimycobacterial agents are recovered 
readily from both immuno-competent and immuno-compromised patients. More recently, 
multi-drug resistant strains of M. tuberculosis (MDR-TB) have emerged, severely hindering 
efforts towards prevention and control. Increases in the median rates of primary resistance to 
front-line drugs have been observed, with rates for INH , streptomycin, RIF and ethambutol 
(EMB) being recorded as 4.1 %, 3.5 %, 0.2 % and 0.1 % respectively (Cohn et al., 1997). The 
median rates of acquired secondary resistance were observed to be much higher than primary 
resistance. 
The current treatment procedure for M tuberculosis uses an initial 2-month period of daily 
therapy with INH, RIF, and pyrazinamide (PZA), plus either streptomycin or EMB. During 
this period sputa tend to be culture-negative. This regimen is then followed by daily therapy 
with INH and one other primary drug for the next 4 months, resulting with successful therapy 
in clearing of shadows on chest X-rays. Ethionamide (ETH), cycloserine, p-amino-salicylic 
acid, thioacetazone, kanamycin, capreomycin, viomycin, amikacin and fluoroquinolones are 
used as secondary or alternative agents to treat TB infections (Stratton & Reed, 1986). 
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New strategies and approaches are needed to fight against TB. The elucidation of the M. 
tuberculosis H37Rv and CDC1551 (Cole et al., 1998; Fleischmann et al., 2002) genome 
sequences and the development of new molecular techniques has accelerated research in 
different fields of investigation, such as: 
o New vaccines. 
* New drug targets and drug development. 
Identification of correlates ofprotective immunity. 
Mechanisms of intracellular survival andpathogenesis. 
* Genome-driven research. 
Bacilli that are considered to be members of the genus Mycobacterium have the following 
characteristics; aerobic, non-motile, non-sporeforming. rod-shaped and are 0.2-0.7 x 1.0-10.0 
gm in size. Mycobacteria belong to the Actinomycetale family and, therefore, are closely Z: ' 
related to nocardia, rhodococci and corynebacteria. One of the main characteristics of the 
genus Mycobacterium is a complex cell envelope, which is responsible for its acid-fast 
staining properties with the Zeihl-Neelsen stain (Figure 1.1). 
F- 
. 
At 
' .4 
Figure 1.1 Acid-fast M. tuberculosis (red-stained) visualised using the Zeihl-Neelsen 
stain 
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Members of the Mycobacterium genus can be sub-grouped according to their growth 
characteristics i. e. fast-growing and slow-growing (Table 1.1). The slow-growers include most 
of the major human and animal pathogens, whereas the fast growers, other than M. chelonae 
which has been shown to be a turtle pathogen (Parish & Stoker, 1999) include mainly non- 
pathogenic species. 
Table 1.1 Mycohacterium spp. 
Siow-growers Fast-growers 
Mycobaclerium africanum Mycobacterium aurum 
Mycobaclerium asiaticum Mycobacterium chelonae 
Mycobaeterium avium Mycobacterium duvali 
Mycobacterium bovis Mycobacteriumflavescens 
Mycobaclerium celatim Mycobacteriumfortuitum complex 
Mycobacteriumfarcinogenes Mycobacterium gadium 
Mycobacterium gastri Mycobacterium gilvum 
Mycobacterium genavense Mycobaclerium komossense 
Mycobacterium gordonae Mycobaclerium neoaurum 
Mycobacterium haemophilum Mycobacterium phlei 
Mycobacterium interjectum Mycobaclerium senegalense 
Mycobacterium intermedium Mycobaclerium smegmatis 
Mycobacterium intracellulare Mycobaclerium thermoresistibile 
Mycobacterium kansa. gii 
Mycobacterium leprae 
Mycobacterium malmoense 
Mycobacterium marinum 
Mycobacterium microti 
Mycobacterium nonchromogenicum 
Mycobaeterium parafortuitum 
Mycobacterium scrofulaceum 
Mycobaeterium shimoidei 
Mycobacterium simiae 
Mycobacterium szulgai 
Mycobacterium terrae 
Mycobaeterium triviale 
Mycobaeteriuni tuberculosis 
Mycobaclerium ulcerans 
Mycobacleriuni xenopi 
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1.2 Epidemiology of tuberculosis 
INTRODUCTION 
M tuberculosis has long been a major cause of mortality worldwide since the time of Robert 
Koch and no decrease has been observed in its prevalence since. The implementation of good 
sanitation and chemotherapy has drastically reduced TB in developed countries, but has had 
no major impact on the global problem (Bloom & Murray, 1992). 
Estimations suggest that about a third of the world's population, i. e. approximately 1.7 billion 
people are infected with M. tuberculosis with approximately 0.5 million of these cases being 
children under 15 years of age (Enarson & Murray, 1996) (Figure 1.2). The lifetime risk of 
developing active TB is 7 %. Individuals suffering from acquired immune deficiency 
syndrome (AIDS) however, have an increased risk of 7% per annum. Human 
immunodeficiency virus (HIV) infection is the greatest known risk factor for the progression 
of latent TB infection into active TB, the cause of 32 % of deaths among HIV-positive 
individuals (Narain et al., 1992). The frequency of MDR-TB in HIV patients is increasing, 
problems in drug absorption, especially RIF, in these patients accelerating the emergence of 
drug resistance (Narain et al., 1992). 
Several studies indicate that resistance to various anti-tubercular agents results from 
alterations to chromosomal targets (Cole, 1994). Thus, MDR does not stem from the 
acquisition of transposable elements or plasmids like in other bacteria, but by mutations of the 
antibiotic target (Fang et al., 1999) or pro-drug activating mechanisms. The inadequate 
prescription of chemotherapy and poor compliance to drug protocols has selected for 
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mutations. The advent of high incidence rates of HIV infection and the onset of AIDS, and the 
decline of socio-economic standards has contributed to the re-emergence of TB. 
Current data suggests that, under prevailing treatment practices, it appears that MDR-TB will 
remain a localised problem, rather than becoming a global obstacle to tuberculosis control. 
(Dye & Espinal, 2001). These data also indicate that, at present, MDR-TB strains are not in 
the process of replacing drug-susceptible strains. Statistical analysis of data illustrate that the 
ratio of resistance to susceptibility is greatest in the cases of INH and streptomycin. RIF 
resistance is also strongly associated with MDR-TB as it is one of the front-line agents against 
TB. The conclusions of the study suggested that TB resistance to INK or to INH plus RIF, is 
likely to remain low in most parts of the world, with trends showing that only 4 of the 
countries out of 25 studied, reported INH resistance. However, it is somewhat confusing that 
MDR-TB is prevalent in the Baltic States, India, Russia and China. 
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Figure 1.2 Global map showing the estimated new cases of TB in 1997, adapted from 
WHO, 1997 
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In the U. S. the rate of infection had been in constant decline, from 84,304 cases in 1953 to 
22,225 in 1984. However, between 1985 and 1992 a dramatic increase in cases was reported. 
The reason for these increases have been linked to a number of possible factors, namely the 
HIV/AIDS epidemic, increased immigration from high-prevalence countries and the 
deterioration of the primary health care system to combat TB. In a later study the Centre for 
Disease Control (CDC) recorded 93,449 cases of TB through the period 1993-96 with 1,457 
of these cases being identified as MDR-TB (CDC, 1995). Data from 1998 showed that 13 % 
of all new cases in the USA are resistant to front line drugs, with 1.6 % being resistant to both 
INH and RIF (CDC, 1995). Problems associated with diagnosis have been rectified by the 
implementation of BACTEC to quickly identify M. tuberculosis and the broad use of rapid 
methods for drug susceptibility testing leading to expanded use of preventive therapy and 
stronger infection control measures. Increased federal resources for state and local TB 
eradication programs have improved the situation, but problems still occur due to the 
introduction and spread of MDR-TB (CDC, 1995). 
In India about 13 million people, equating to 1.5 % of the total population, suffer from active 
pulmonary tuberculosis, showing no change since independence. The highest rate of incidence 
was observed in 1991 with 1,555,353 new cases, a steady decline has been observed since 
(Figure 1.3) (Corbett et al., 2003; WHO, 2003). The Revised National TB Control Program 
(RNTCP), configured by the Government of India in 1993 and implemented in 1997, 
introduced "directly observed therapy short course" (DOTS) and put TB control high on the 
public health agenda. This resulted in the allocation of more resources for TB control, 
improved laboratory diagnosis and the adoption of DOTS with standardised drug regimens 
and reporting methods. TB remains the leading cause of death in India, killing close to 
500,000 people each year. India has about 2 million new cases of TB each year, far more than 
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any other country, and accounts for nearly one-third of the global burden of TB. The treatment 
success rate for patients registered in 2000 was 84 %, with the estimated percentage of adults 
1549 years old with HIV and TB being recorded as 4% with a further 3.4 % of new cases 
being identified as MDR-TB (Dye et al., 2002; WHO, 2003). 
160 
1401 
0 
c 
1201 
0 10 lool 
80( 
60( 
Figure 1.3 Incidence rates of new active pulmonary M. tuberculosis infections in India 
from 1980-2001 adapted from WHO, 2003 
1.3 Genome project 
Since its discovery in clinical isolates from New York's Trudeau Sanatorium in 1905, the M. 
tuberculosis H37Rv strain has been the strain of choice for TB researchers. This is primarily 
due to the fact that it has retained full virulence in animal models, is still susceptible to anti- 
TB agents and amenable to genetic manipulation (Cole et al., 1998). Mycobacteria have been 
shown to contain a high GC content compared to that of other Gram-positive bacteria with M 
tuberculosis H37Rv possessing a GC content of 65.6 % (Cole et al., 1998; Hatfull, 1996; 
8 
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Parish & Stoker, 1999). The M. tuberculosis H37Rv genome project was completed in 1998. 
The single circular chromosome consists of 4.4 Mb (4,411,529 bp), 4,049 genes with 3,924 
open reading frames originally identified in the genome accounting for 91 % of its total 
potential coding capacity. By using various database comparative search techniques, 40 % of 
the proteins predicted have been assigned a function, with a further 44 % being assigned a 
putative function. It was shown that 16 % of the remaining genes encoded proteins of no 
known function or similarity to other proteins. One feature of the genome is the maintenance 
of a large number of genes apparently devoted to lipid metabolism; around 250 genes have 
been assigned thus, five-fold more than in E. coli. Such a high number is consistent with the 
diversity of lipids produced by M. tuberculosis ranging from simple palmitic acid and 
tuberculostearic acid, through to the more complex and characteristic long-chain mycolic 
acids. M. tuberculosis also contains a wide variety of polyketide synthases (PKS). 
The elucidation of the genome sequence of M. tuberculosis H37Rv has provided new avenues 
for the next generation of TB research. Genornic data is being used for a diverse range of 
purposes including the deduction of gene function by bioinformatics and reverse genetics. 
Together they should continue to increase our understanding of M. tuberculosis pathogenicity 
and hopefully prime new leads for chemotherapy and immunoprophylaxis (Cole et aL, 1998). 
The complete genome of the M. tuberculosis clinical strain CDC1551 is also available 
(Fleischmann et al., 2002). 
1.4 The mycobacterial cell wall 
There is an unusually high content of lipids in mycobacteria, comprising approximately 60 % 
of the dry weight, much higher than in other Gram-positive (0.5 %) and Gram-negative (3 %) 
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bacteria (Smith, 1982). The cell envelopes of mycobacteria exhibit low-permeability due to 
the high proportion of lipids and associated complex lipids. These are organised as a physical 
barrier to a variety of agents. This permeability barrier is thought to play a crucial role in the 
intrinsic resistance of M. tuberculosis to antibiotics, chemical injury and lytic enzymes. 
The first model of the mycobacterial cell wall incorporating an outer lipid bilyar was proposed 
by Minnikin (1982). This has been modified by McNeil and Brennan (1991) to incorporate 
complex lipids and further modified to incorporate novel insights into peptido, (, "Iycan (PG) 
organisation (Dmitriev el aL, 2000). Minnikin el aL (2002) combined all the theories as 
illustrated in Figure 1.4. 
SL T0 PDINI PAT 
Figure 1.4 The mycobacterial cell wall as proposed by Minnikin et A (2002) modified 
from (Dmitriev ef A, 2000). Sulphated tetra-acyl trehalose (SL), diacvl 
trehalose (DAT), phthiocerol dimycoccrosate (PDIM), pentaacyl trehalose 
(PAT), phosphoinositol hexamannoside (PIM6). mycolyl arabinogalactan 
(mAG), peptidoglycan (PG) and lipoarabinornannan (LAM) 
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In all of these models the cell bound mycolic acid residues which form the inner leaflet of the 
other membrane are esterified to a special branched arabinofuranose motif. This motif 
decorates the non-reducing end of a linear arabinan chain which is, in turn, linked to a linear 
galactan chain, together known as arabinogalactan. This whole assembly is attached to the 
glycan moiety of the peptidoglycan via a unique Rha-GIcNAc-phosphate linker. This 
covalenty linked structure is known as the mycolyl-arabinogalactan-peptidoglycan (mAGP) 
complex which has been the subject of much study in recent years. 
m 
Figure 1.5 Diagrammatic representation of PG lattice as proposed by Dover el al., 
(2004). The coiled galactan domains (yellow) of mAGP intercalate with the 
coiled glycan domains (burgundy) of peptidoglycan (PG), the chains being 
linked by the Rha-GleNAc-phosphate linker unit as shown. The glycan is 
arranged in a grid-like array perpendicular to the plane of the plasma 
membrane, cross-linked by the stem peptides (blue). The galactan is also 
oriented perpendicular to the plane of the membrane and between the 
stem peptide cross-links. The figure on the right represents the 
organisation of stem-peptide cross-linking during exponential phase (4-->3 
linked) (upper) and stationary phase (3-+3 linked) (lower) growth, the 
latter being associated with penicillin resistance. G and M represent the N- 
acetylglucosamine and muramic acid residues of the glycan respectively. 
(L-Ala (L-alanine), D-iGln (D-glutamate), DAP (meso-diaminopimelate), D- 
Ala (D-alanine)) 
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The PG layer consists of a highly cross-linked polymer of amino acids and amino sugars. The 
glycan is thought to be arranged in a grid-like array perpendicular to the plane of the plasma 
membrane, cross-linked by the stem peptides. Earlier models depicting the structural 
organisation of the mycobacterial cell wall assume PG and galactan strands to run in parallel 
to the cytoplasmic membrane forming several horizontal layers beneath perpendicularly 
oriented mycolic acids (Dmitriev et al., 2000). Dmitriev et al. (2000) re-evaluated the current 
chemical, biochemical and electron microscopical data and proposed a fundamentally distinct 
principle of the physical organisation and biosynthesis of the mycobacterial cell wall skeleton. 
According to this new concept, the cross-linked glycan strands which all run perpendicular to 
the plane of the cytoplasmic membrane and are found in a coiled conformation (Dmitriev et 
al., 2000). The organisation of stem-peptide cross-linking during exponential phase is meso- 
diaminopimelate (DAP) linked to D-alanine (D-Ala) and during stationary phase growth the 
link is in a DAP->DAP conformation, the latter being associated with penicillin resistance 
(Dover et aL, 2004). In addition, the coiled galactan domains of mycolyl-arabinogalactan- 
peptidoglycan (mAGP) intercalate with the coiled glycan domains of PG between the 
stempeptide cross-links, the chains being linked by the Rha-GIcNAc-phosphate linker unit 
(Dmitriev et aL, 2000). Mycolic acids are esterfied to the terminal arabinose motif of 
arabinogalactan (AG). This structural entity is known as the mAGP complex. An assortment 
of surface glycolipids complement the mAGP complex to provide an outer lipid bilayer, this 
configuration as mentioned earlier has been speculated to provide a protective barrier to drug 
permeation (McNeil & Brennan, 1991). The mycobacterial cell wall also contains a second 
unique molecule, termed lipoarabinomannan (LAM). It is speculated that LAM is linked to 
the interaction of the pathogen with the host, possibly leading to resistance mechanisms 
associated with macrophage killing. 
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1.4.1 Peptidoglycan 
From 1950 to 1970 there was a spate of investigations into the mAGP complex of M 
tuberculosis, but due to insolubility problems work was hampered and structural definition 
didn't arise until the 1980s when Petit & Lederer (1984) predicted mycobacterial PG to 
consist of alternating units of N-acetylglucosamine (GlcNAc) and modified muramic acid 
(Mur) residues. The accepted structure of the PG unit of the cell wall of M. tuberculosis is 
illustrated in Figure 1.6, N-glycoyl-MurNAc is linked to the 4-position of GIcNAc and to the 
stem polypeptide, which participates in PG cross-linking (Goffin & Ghuysen, 2002). The stem 
polypeptide consists of L-alanine (L-Ala), D-glutamate (D-iGln), meso-diaminopimelate 
(DAP) and finally two D-alanine (D-Ala) residues. The basic pathway for the biosynthesis of 
PG is similar in most bacteria with all the major enzymes being represented in the M 
tuberculosis H37Rv genome Figure 1.7 and Table 1.2. In E. coli the pathway is encoded by 
two major clusters, designated mra and mrb. In M. tuberculosis the mra cluster also contains 
genes thought to be involved in the synthesis of other aspects of PG biosynthesis. These genes 
encode high and low molecular weight penicillin binding proteins (PBPs) (van HeiJenoort, 
2001). The immediate precursor to polymerised PG in E. coli is Lipid 11, a polyisoprenoid- 
bound GIcNAc-MurNgly disaccharide (Higashi et al., 1967). 
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Figure 1.6 Structure of the basic PG unit of the mycobacterial cell wall. A singular 
disaccharide subunit of PG with N-acetylglucosamine bound via C4 to N- 
glycolymuramic acid and subsequently via its C3 to the stem polypeptide, 
which participates in PG cross-linking. The stem polypeptide consists of a 
L-alanine (L-Ala), D-glutamate (a-I)-iGln), meso-diaminopimelate (DAP) 
and finally two D-alanine (I)-Ala) residue. 
Table 1.2 PG biosynthetic enzymes found in M. tuberculosis (Belanger & Inamine, 
2000) 
Genes -- --- -------FM-. Function 
a1r Alanine racemase Rv3423c 
ddl D-Alanine-D-alanine ligase Rv2981c 
murl Glutarnate racemase R0338 
g1mu GIcNAc-l-P uridyltransferase RvlOl8c 
murA (murZ) UDP-GIcNAc enoylpyruvyl transferase R0315 
murB UDP-GlcNAc enoylpyruvy reductase Rv0482 
murC L-Alanine-adding enzyme Rv2l52c 
murD D-Glutarnate-adding enzyme Rv2l55c 
murE DAP-adding enzyme Rv2l58c 
murF D-Alanine-D-alanine-adding enzyme Rv2l57c 
murX Translocase Rv2l56c 
murG Transferase Rv2l53c 
ponA Transglycosylase/transpeptidase Rv0050 
ponA' Transglycosylase/transpeptidase Rv3682 
pbpA Transglycosylase/transpeptidase RvOO16c 
DbnR *, ft. R/ Trqn-, nlvr. n-, vin-, P/trnnQnizntiriqqp PV9163 
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Figure 1.7 Pathway of mycobacterial PG biosynthesis 
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1.4.2 Linker unit and arabinogalactan 
The linker unit (LU) of AG is believed to be the Achilles heel of the complex since the whole 
mAGP is attached to PG via this unique unit (McNeil et al., 1990). The galactan region of AG 
is linked to the C-6 of some of the MurNGly residues via the LU. The LU consists of a 
diglycosyl-P bridge, cc-L-Rhap-(l ->3)-cc-D-GlcNAc-(I ->P) (Figure 1.8). 
Figure 1.8 Linker unit of the mAGP complex 
There was much speculation about the structure of the galactan segment of the AG, whether it 
was 1->4-linked Galp or 1->5-linked Ga! f (Vilkas et al., 1973). Recent studies using gas 
chromatography-mass spectrometry (GS-MS) and fast-atom bombardment mass spectrometry 
(FAB-MS) established that: 
(i) The arabinose (Ara) and galactose (Gal) residues are both in the furanose (1) ring fonn 
(ii) The galactan region of AG is linked to the C-6 of some of the MurNGly residues of 
PG via a special diglycosyl-P bridge, a-L-Rhap-(I-->3)-D-GIcNAc-(I->P) (Figure 
1.8) 
(iii) The galactan region consists of a linear alternating 5- and 6-linked P-D-Ga! fresidues 
OV) The arabinan chains are attached to C-5 of some of the 6-linked Galf residues and 
approximately 2-3 arabinan chains are attached to each galactan strand 
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(V) The arabinan chains are mostly composed of cc-5-linked cc-D-Araf residues with 
branching introduced at 3,5-a-D-Arafresidues 
(vi) The non-reducing termini of arabinan consists of a hexa-saccharide motif 
[P-D-Araf-(I->2)-a-D-AraA2-3,5-(x-D-Araf-(I->5)-a-D-Araf 
(Vii) The mycolic acids are located in clusters of four on the terminal 
hexaarabinofuranoside with only two-thirds of these being mycolated 
These linkages are shown in Figure 1.9, which shows the full structure of the mAGP complex. 
1.4.2.1 Linker unit and arabinogalactan biosynthesis 
LU assembly is dependent on the transfer to GlcNAc- I -phosphate from UDP-GlcNAc to the 
lipid carrier decaprenyl moilophosphate catalysed by rfe (Mikusova et al., 2000). RmIA to 
RmID have been characterised as an cc-D-glucose-I -phosphate thymidylyltransferase, dTDP- 
D-glucose 4,6-dehydratase, dTDP-4-keto-6-deoxy-D-glucose 3,5 epimerase and dTDP-Rha 
synthase, respectively (Ma et al., 2002; Ma et al., 200 1). 
The inactivation of rmID in M. smegmatis was found to be lethal in the absence of a rescue 
plasmid carrying a functional copy of rmID (Ma et al., 2002), thereby demonstrating that 
dTDP-Rha is an essential component for mycobacterial growth and enzymes involved in its 
synthesis as novel chemotherapeutic targets. In E. coli wbbL has been identified as the 
rhammosyltransferase involved in Hpopolysaccharide biosynthesis (Rubires et al., 1997). 
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Similarily, Rv3265c of M. tuberculosis has been shown to exhibit rhamnosyltransferase 
activity and therefore possibly represents the rhamnosyltransferase involved in LU 
biosynthesis (McNeil, 1999). 
Galactan biosynthesis requires the provision of the sugar nucleotide UDP-Ga! f. The UDP- 
Galp mutase enzyme Glf (Rv3809c) (that converts UDP-Galp to UDP-Ga! /) has been 
identified in M. tuberculosis. It was predicted that four galactosyltransferase activities would 
be required for the synthesis of the galactan-segment of mAGP. One depositing the initial Ga! f 
residue, with two main activities polymerises the main chain of &(I ->5)Ga! f and P-D- 
(1->6)Ga! f restricted residues and another activity to transfer the terminal Gal residues. With 
two of these activities the P-D-(I->5)Ga! f andfl-D-(I->6)Ga! f transferase activities 
demonstrated as being associated with Glfr (Rv3808c) (Kremer et al., 2001b; Mikusova et 
al., 2000). 
HO, 
0 
Olp, 10 
OH 
OH 
Figure 1.10 Structure of DPA, the donor of Araf units of AG and LAM (Lee et aL, 
1998; Mikusova et aL, 1996) 
Biochemical studies using radiolabelled substrates and analysis of internal and external 
regions of [14C]arabinan, suggested that decaprenyl-monophosphoprenyl-Araf (DPA) is the 
major, and perhaps only donor of arabinosyl residues in mycobacteria (Xin et al., 1997). The 
enzymes that direct the formation of DPA in M. tuberculosis have not yet been identified. 
19 
CHAPTERI 
Cytosol 
INTRODUCTION 
Membrane 
Glo-l-P 
n"IA 
UDP-GIcNAc C, /Crp 
dTDP-GlC Me 
Dehydratase 
I 
tmlB 
dTDP4-keto-6-deoxy-Gle 
G]cNAc-P-P-C, /C,, (GL-1) 
Epimerase R"/C r7"/D dTDP-Rha 
I 
wbbL 
dTDP-keto-Rha 
dTDP UDP-Glcp alf-l-P 
A 
Epimerase galE Rha-GlcNAc-P-P-CdC, (GL-2) 
UDP-Galp gý- - UDP-Galf 
mutase gffr 
Rib-5-P 
UDP 
I 
prsA (Galý307RM-GlcNAO-P-P-C50C35 (GL-3; GL4; etc. ) 
pRpp CWP-Araf 
CW. P emb A-C 
11 
11 
1 (Araýý(Galý3eRha-GicNAcýP-P-Cw/Cm Pepbdogý/can 
AcetyýCoA 
iI 
Malon CoA r 
Man-P-C,, -, NN 
MycoV-ACP MycOyWan- - 35 antigen 85 
(Mycoly0l, -(AraO? O-(GalO3rRha-GIcNAe-P-Peptidogtycan 
Figure 1.11 Pathway for the biosynthesis of the mAGP complex of M. tuberculosis 
adapted from Baulard et aL (1999) 
The primary cellular targets of EMB were described as EmbAB in Mycobacterium avium and 
EmbCAB in M. tuberculosis (Belanger et al., 1996; Telenti et al, 1997). It was shown that 
they were responsible for the polymerisation of arabinose into the AG complex (Belanger et 
al., 1996) and LAM (Khoo et al., 1996). Disruption of either embA and embB in M 
smegmatis resulted in the impairment of the synthesis of P-D-Araf-l->2-p-D-Araf 
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disaccharide to the 3 position of the 3,5-linked Araf residue resulting in a linear terminal motif 
(Escuyer et al., 2001). Therefore EmbA and EmbB are crucial for the fonnation of the 
hexaarabinofuranosyl motif of AG, a important structure for the esterification of mYcolic 
acids to AG (Escuyer et aL, 200 1). Recently, it was shown that the synthesis of LAM, but not 
AG, ceases after inactivation of embC in M. smegmatis by insertional mutagenesis. LAM 
synthesis was also restored upon complementation with the embC wild-type gene. Thus the 
Emb proteins are capable of differential recognition of the galactan or mannan acceptors prior 
to appropriate arabinosylation (Zhang et al., 2003). 
1.4.3 Mycolic acids 
Mycolic acids are high molecular weight (C60 - C90) oc-alkyl, P-hydroxy fatty acids. In M 
tuberculosis they comprise approximately 40-60 % of the dry weight of the bacterium. As 
well as being found esterified to AG, mycolic acids are also present in lipids that are 
extractable with organic solvents. These are mainly in the form of trehalose 6,6'-dimycolate 
(TDM) and trehalose monomycolate (TMM) and account for 6% of the lipid population. 
Mycolic acids possess at least two chiral centres at positions cc and P to the carboxylic acid 
group (Figure 1.12). 
OH 0 
1a 11 
Rl- C-C-C -OH 
ß1 
R2 
Figure 1.12 Chemical structure of mycolic acids. Where R, is a meromycolate chain 
containing 50-56 carbons and R2 is a shorter cc-branch containing 22-26 
carbons 
21 
CHAPTERI INTRODUCTION 
Although the basic mycolate structure is well conserved there are a number of modifications 
at two mid-chain positions that identify different classes of mycolic acids as shown in Figure 
1.13 for M tuberculosis (Kremer et al., 2000a). 
Distal Proximal 
(x-mycolic acid 
cis 
methoxy- 
mycolic acid 
trans 
cis 
keto- 
mycolic acid 
trans 
Figure 1.13 Representative structures of M tuberculosis mycolic acids 
These modifications include the incorporation of both cis and trans cyclopropane rings, cis 
and trans double bonds, keto, methoxy, epoxy and wax-ester functional groups in addition to 
the characteristic P-hydroxy acid group. 51 % of the total mycolates are oc-mycolates, 36 % 
are methoxymycolates, and 13 % are ketomycolates (Yuan et al., 1997). cc-Mycolic acids 
contain no oxygen functionality groups at the proximal or distal positions (Minnikin, 1982). 
The polar oxygen containing functions are found at the distal position with non-polar 
cyclopropane modifications found at the proximal position keto and methoxymycolates have 
also been shown to possess trans-cyclopropane and cis-cyclopropane rings. Cyclopropane 
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rings and double bonds occurring in a trans conformation also possess an adjacent methyl 
group (Watanabe et al., 2001; Watanabe et al., 2002). Studies into mycolic acid composition 
revealed that oc-mycolates possess 76 to 82 carbons, whereas keto- and methoxymycolates 
contain 84 to 89 and 83 to 90 carbons, respectively (Watanabe et aL, 2001; Watanabe et aL, 
2002; Yuan et al., 1997). Both the cc- and methoxymycolates have only cis-cyclopropyl 
groups at the proximal position, while 17 % of the cyclopropyl groups at the proximal 
position in ketomycolates are trans (Liu et al., 1996). The molecular organisation of these 
mycolic acid residues may play an important role in nutrient uptake into the bacterium and 
confer resistance to a wide range of antibacterial agents (Brennan & Nikaido, 1995). 
1.4.3.1 Mycolic acid biosynthesis 
Mycolic acid biosynthesis can be divided into sequential steps; i) de novo fatty acid 
biosynthesis, ii) elongation, iii) modification of the meromycolate, iv) Claisen condensation 
and reduction. The synthesis of fatty acids involves the extension of the growing alkyl chain 
by a two-carbon unit via the repetition of a four-part cycle of reactions. The first reaction in 
each cycle is a condensation reaction in which a malonate residue is decarboxylated and 
undergoes a condensation reaction with a thioester-I inked fatty acyl chain (Heath & Rock, 
2002). This reaction achieves the extension of the acyl chain and the remaining three reactions 
involved in fatty acid biosynthesis remove the resulting P-keto-group of the product and 
return the chain to its aliphatic form. Firstly, the P-keto product is reduced to form a P- 
hydroxy intermediate which is then dehydrated to form an enoyl product which is 
subsequently reduced. The saturated aliphatic substrate is then passed on for the next round of 
chain extension (Figure 1.14). 
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Figure 1.14 Fatty acid biosynthesis. The fatty acid cycle is initiated by decarboxylation, 
of a malonate residue and undergoes a condensation reaction with the 
thioester of a growing fatty acyl chain. The 13-keto product is reduced to 
form a P-hydroxy intermediate which is then dehydrated to form an enoyl 
product which is subsequently reduced. The saturated aliphatic substrate 
is then passed on for the next round of chain extension. Red areas indicate 
the area of activity 
Two types of fatty acid synthases (FAS) are known, both containing similar enzymatic 
functions but differing in their Organisation. A single gene encodes fatty acid synthase-I 
(FAS-1), commonly found in mammals and the active homodimeric protein possesses all the 
necessary functions to perform de novo fatty acid biosynthesis (Howard, 1968; Smith et al., 
2003) from acetyl-CoA and malonyl-CoA. Most bacteria and plants, however, utilise fatty 
acid synthase-11 (FAS-II) in which the growing fatty acyl chain is shuttled between the active 
sites of disassociated enzymes as an acyl thioester of a small and highly acidic acyl carrier 
protein (ACP). Mycobacteria are unusual in that they contain both FAS-1 and FAS-11 (Figure 
1.15) (Table 1.3) (Kremer et aL, 2000a). FAS-I encoded by fas, is responsible for de novo 
fatty acid biosynthesis, producing a bimodal distribution Of C16-C26 fatty acids, mainly 
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thioesters of CoA. FAS-11 of M. tuberculosis is similar to other bacteria] FAS-11 synthases 
except for its primer specificity (Choi ei aL, 2000b). The M. tuberculosis FAS-11 extends 
relatively long acyl-chain thioesters of AcpM, aC -term ina I ly-extended homologue of other 
bacterial ACPs, to provide long-chain meromycolates leading ultimately to mature mycolic 
acids (Asselineau et aL, 2002; Barry et aL, 1998; Kremer et al., 2000a). 
Table 1.3 Genes involved in fatty acid biosynthesis in M. tuberculosis 
Known Gene M. tuberculosis 
Homologue 
Function 
AbG4 Rv0242c 3-oxoacyl-ACP reductase 
fabH Rv0533c P-Ketoacyl-ACP synthase III 
fabD2 Rv0649 Malonyl CoAACP transacylase 
accD3 Rv09O4c Acetyl/propionyl CoA carboxylase P-subunit 
Rv1344 Possible acyl carrier protein 
fabG2 Rv1350 3-oxoacyl-ACP reductase 
fabG1 (MabA) Rv1483 3-oxoacyl-ACP reductase 
inhA Rv1484 Enoyl-ACP reductase 
tesB1 Rv1618 Thioesterase 11 
Rv1722 Possible biotin carboxylase 
fabG3 Rv2002 3-oxoacyl-ACP reductase 
fabD Rv2243 Malonyl CoAACP transacylase 
acpM Rv2244 Acyl carrier protein 
kasA Rv2245 P-Ketoacyl-ACP synthase 
kasB Rv2246 P-Ketoacyl-ACP synthase 
accD6 Rv2247 Acetyl/propionyl CoA carboxylase P-subunit 
acpS Rv2523c CoA: apo-ACP pantethienephosphotransferase 
fas Rv2524c Fatty acid synthase I 
tesB2 Rv2605c Thioesterase 11 
fabG5 Rv2766c 3-oxoacyl-ACP reductase 
Rv3221c Possible biotin carboxyl carrier 
accD5 Rv3280 Acetyl/propionyl CoA carboxylase P-subunit 
accA3 Rv3285 Acetyl/propionyl CoA carboxylase P-subunit 
Rv3472 Possible acyl carrier protein 
accD4 Rv3799c Acetyl/propionyl CoA carboxylase 
25 
CHAPTER1 INTRODUCTION 
r P-OH -, **ý) 
P-keto FAS-1 trans-2 
ý, 
Acyl ') 
I 
Transacylase 
Phospholipids *-- Acyl-CoA Complex lipids 
mtFabH 
0 
apo-AcpM luS-CoA 
Phosphopantetheine 
Acotyl-CoA 
CoA. apo-ACP 
pantathiene AoetyVpmpmo 
phosphotransferase 
ýACPS 
CoA carboxylase 
I 
AccABCD 
holo-AcpM 
00 
'UýK HO S-COA 
Ma"-CoA 
FabD 
Malonyl COA. ACP transacylaw 
0 U 
HO S-AcpM 
Malonyl-AcpM 
0-ketoacyl-ACP wynftse III 
00 
MabA R'R'-ýS-AcpM rUstomc"Cp 
P-ketoacyl-AcpM 
. tase 
9H 9 
R"ýS-AcpM FAS-11 
P-hydroxyaCo-ACpM 
KasA 
KasB 
0-ketoacyl-ACP "hase I 
P*otoocyl-ACP syrAhose 11 
0 Desaturation 
R-'ýS-AcpM 
Cydopmponstons 
Acyl-AcpM Mothyitransformses 
t E= CP 
Dehydratase 0 re 1. InhA 
RýýS-AcpM 
trans-2-anoyi-AcpM 
w. -Ypw ýWnmuw 
my-Vtronef-- Ag85A, B, C 
Trehalose Mono- and Dimycolates 
Mycolyi-Arabinogalactan 
Figure 1.15 A schematic illustration of M. tuberculosis mycolic acid biosynthesis. The 
product of FAS-I (C16) is transacylated to CoA and utilised by mtFabH in 
the initiation of FAS-11. Malonyl-AcpM produced by Fabl) is used as the 
C2 donor for elongation. FAS-11 synthesises the long aliphatic acyl-chains 
which are further modified to produce the mature meromycolate chains of 
mycolic acids 
The 0-ketoacyl-ACP synthase 111, mtFabH (Rv0533c) (Choi et al., 2000b) has been proposed 
as the pivotal link between FAS-1 and FAS-11 mtFabH elongates acyl-CoA primers derived 
from FAS-1 forming P-ketoacyl-AcpM thioester products through condensation with malonyl- 
AcpM. In the proposed reaction mechanism, mtFabH is initially transacylated with the 
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incoming acyl-CoA forming a thioester with the active site cysteine residue (C122), its CoA 
moiety being released. The docking of malonyl-AcpM is followed by decarboxylation of the 
malonate residue. The resulting carbanion attacks the acyl-enzyme thioester linkage, thereby 
initiating the condensation reaction (Heath & Rock, 2002; Scarsdale et aL, 2001) (Figure 
1.16). 
000 
R"ýS-COA HO'4ý'ýS-AcpM 
Acyl-COA Malonyl-AcpM 
CoASH C02 
00 
R'^ý'ýS-Cys-FabH CH-'A'S-AcpM 2 
acyl-Cys-FabH Decarbo)cAated 
malonyl-AcpM 
00 
R-O'ýL'AS-AcpM 
A-ketoacyl-AcpM 
Figure 1.16 fý-Ketoacyl-ACP synthase III activity of mtFabH. (I) The initial 
transacylation of the acyl-CoA moiety to the cysteine of the catalytic triad 
followed by (11) decarboxylation of the donor unit of the malonyl-AcpM. 
The condensation of the two subunits (111) form the P-ketoacyl AcpM 
product 
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The reduction of the characteristic P-keto group to a hydroxyl function is carried out by the P- 
ketoacyl-ACP-reductase, MabA (Rv 1483). mabA has been cloned and expressed in E. coli and 
its NADPH-dependent P-keto-reductase activity biochemically characterised (Banerjee et al., 
1998; Marrakchi et al., 2002). The recent crystal structure of MabA has led to the recognition 
of structural differences that may distinguish M. tuberculosis MabA and several homologues 
suggested to have an affinity for long-chain substrates from most of the other known P- 
ketoacyl-ACP reductases (Marrakchi et al., 2002). In M tuberculosis, mabA lies adjacent to 
MhA (Rv1484) (Figure 1.17), which encodes an NADH-specific 2-trans-enoyl-ACP reductase 
involved in FAS-11 (Dessen et al., 1995). 
fabH mobA lnhA fabD sopm kssA kasS accA 
IVOM Rvl 483 Rvl 464 Rv2243 RM44 Rv2245 Rv2246 Rv2247 
Figure 1.17 Genomic organisation of open reading frames involved in long-chain fatty 
acid biosynthesis 
A detailed biochemical study demonstrated that InhA prefers long-chain substrates consistent 
with its involvement in long chain fatty acid biosynthesis (Quemard et al., 1995). The gene 
encoding the dehydratase function converting the P-hydroxyacyl-AcpM product of MabA into 
the enoyl-AcpM substrate for InhA has not yet been identified in M. tuberculosis. The 
subsequent rounds of acyl extension in FAS-Il are thought to be initiated by the highly 
homologous P-ketoacyl-ACP synthases, KasA (Rv2245) and KasB (Rv2246). Both enzymes 
have been expressed in E. coli, purified and characterised (Kremer et al., 2002c; Schaeffer et 
aL, 2001). Both extend acyl-ACP thioesters rather than acyl-CoA, condensing them with 
malonyl-ACP (Kremer et aL, 2002c; Schaeffer et aL, 2001). Both enzymes prefer acyl-ACPs 
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greater than 16 carbons long consistent with their proposed role in FAS-11 biosynthesis. 
Kremer et al. (2002) also demonstrated that over-expression of kasA from M tuberculosis in 
both M smegmatis and M. chelonae led to a decrease in the amount of shorter W-mycolates 
with an overall increase in oc-mycolates (Kremer et al., 2002c). The KasAB enzymes of M 
smegmatis are very similar to those of M tuberculosis and over-expression of M smegmatis 
kasA produced the same effect suggesting that the balance of cc'- and (x-mycolates is probably 
achieved by regulation of the amounts of the KAS proteins and associated enzymes (Kremer 
et al., 2002c). In M tuberculosis, KasAB are clustered with a series of genes implicated in 
fatty acid biosynthesis, which presumably form an operon. These include acpMandfabD, the 
latter encoding a malonyl-CoA acyltransferase responsible for the formation of the malonyl- 
AcpM which is used as a substrate by mtFabH, KasA and KasB (Kremer et al., 2001a) 
(Figure 1.17). Recently it was shown that M marinum mutants with a transposon insertion in 
kasB grew poorly in macrophages, although growth in vitro was unaffected (Gao et al., 2003). 
Detailed chemical analysis of mycolic acids from the kasB mutant found that they were 2-4 
carbons shorter than mycolic acids isolated from wild type M. marinum. The defect was 
localised to the proximal portion of the meromycolate chain. The kasB mutant also showed a 
significant reduction in the abundance of ketomycolates, with a slight compensatory increase 
in both cc- and methoxy mycolates. Despite these small changes in mycolate length and 
composition, the kasB mutants exhibited strikingly altered cell wall permeability, with 
increased susceptibility to lipophilic antibiotics and host antimicrobial molecules. 
Complementation experiments with M tuberculosis kasB reverted the phenotype to wild-type, 
whereas KasA complementation did not (Gao et al., 2003). 
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1.4.3.2 Meromycolate modification 
A range of monounsaturated and diunsaturated long chain fatty acids were extracted from 
M smegmatis that appeared to be related to the mero-chain of a-mycolates (Sathyamoorthy et 
al., 1985). Similar meromycolate-like C48-C56 fatty acids were synthesised using a palmitate 
precusor in an M tuberculosis-derived cell free system and [14C]-S-adenosyl-L-methionine 
(SAM) as a substrate (Qureshi et al., 1984). Recently, Barry and colleagues have provided 
strong evidence supporting the hypothesis that the meromycolate chain is modified during 
elongation prior to its condensation with the cc-alkyl chain (Yuan et al., 1998b). They 
observed that a range of long chain fatty acid residues derived from heat-inactivated extracts 
of M smegmatis act as acceptors of radiolabelled methyl groups from SAM. Labelling was 
strongly inhibited by an antiserum that specifically recognises AcpM implicating the protein 
as the acyl chain carrier throughout meromycolate elongation and modification (Yuan et al., 
1998b). Analysis of the M. tuberculosis genome has identified three potential desaturases 
DesAl, DesA2 and DesA3 (Cole et al., 1998; Jackson et al., 1997). These desaturases are 
speculated to form the double bonds of the meromycolate precursor allowing for the 
production of species-specific modification to form the range of mycolic acids (Jackson etal., 
1997). Cyclopropanation is a common modification in mycolic acids from slow-growing 
pathogenic mycobacteria, whereas fast-growing species (e. g. M smegmatis) do not produce 
cyclopropanated mycolates, but produce large amounts of unsaturated mycolic acids 
(Minnikin, 1982). The overproduction of a distal cyclopropanating encoded by cmal in M. 
tuberculosis was expressed in M. smegmatis resulting in hydrogen peroxide resistance being 
observed, thus suggesting that this is an important adaptation of pathogenic mycobacteria to 
oxidative stress (Yuan et al., 1995). The related cma42 was shown to cis-cyclopropanate the 
proximal position of the meromycolate chain (George et al., 1995). Recently, it was 
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demonstrated that the cmaA2 is actually required for the synthesis of trans-cyclopropane rings 
of both ketomycolates and methoxymycolates, defining cma, 42 as a mycolic acid proximal 
trans-cyclopropane synthase (Glickman et al., 2001). The systematic deletion of the 
cyclopropane modification enzymes in M tuberculosis identified PcaA, a homologue of 
cma, 42, as the enzyme involved in the synthesis of the proximal cis cyclopropyl group of 
mycolic acids (Glickman, 2003) (Figure 1.18). 
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Figure 1.18 Meromycolate modificatio n in M. tuberculosis. The proposed pathway and 
involvement of genes in the biosynthesis of methoxymycolates in M. 
tuberculosis adapted from Glickman, (2003); Huang et al., (2002); Yuan & 
Barry, (1996). 
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Through the use of a cmal gene probe, other meromycolate modifying enzymes were 
identified as mmal-4 encoding MMAS 1-4 (Yuan & Barry, 1996). It was subsequently shown 
that both the cma and mma genes have a high degree of homology and share a highly- 
conserved SAM binding region. The MMAS proteins are suggested to be involved in the 
biosynthesis of methoxymycolates, with MMAS-4 producing a distal hydroxyl group with a 
methyl branch on the adjacent carbon atom. MN4AS-3 appears to 0-methylate the hydroxyl 
group to form a methoxy group. MMAS-2 apparently possess proximal cis-cyclopropanation 
activity (Yuan & Barry, 1996) (Figure 1.18). Although the function of MMAS-I was not 
obvious, upon over-expression in M tuberculosis it was suggested that MMAS-I regulated a 
branch point between cis- and trans-cyclopropane containing oxygenated mycolates (Yuan et 
al., 1997). The over-expression of MMAS-3 in M. tuberculosis led to the total replacement of 
ketomycolates with methoxymycolates. This led to numerous effects, such as increased 
permeability properties of the cell wall consistent with the hypersensitivity to both ampicillin 
and RIF, impaired growth at low temperature and the inability to replicate in macrophage 
THP-I cells (Yuan et al., 1998a). A strain of M. tuberculosis devoid of mma4 activity was 
unable to synthesise oxygenated mycolates and was unable to grow in THP-I cells 
(Dinadayala et al., 2003). As there are no reported strains of M sinegmatis producing 
ketomycolates the existence of an mma4 homologue is unlikely, upon over-expression of the 
M. tuberculosis mma4 gene in M sineginatis it was expected that ketomycolates would be 
observed, but this wasn't the case (Yuan et aL, 1998a). Glickman et aL (2001) recently used 
gene deletion studies of CMAS-2 which clarified its role in mycolic acid modification. The 
deletion mutant no longer produced trans cyclopropane-containing mycolic acids suggesting 
that the previous assignment of CMAS-2 as a cis cyclopropane synthase was incorrect, this 
later data indicates that it is indeed a trans cyclopropane synthase. This result indicates that 
further studies of deletion are required for full determination of meromycolate metabolism, as 
many inconsistencies are observed in comparisons of over-expression data against deletion 
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results. Although there is no supporting experimental evidence, the coordination of 
meromycolate elongation and modification in multi-enzyme complexes seems a likely route to 
efricient meromycolate biosynthesis. Therefore the production of cis-cyclopropane rings in M. 
smegmatis over-expressing cma2 may reflect a mis-incorporation of CMAS-2 in such a 
complex (Dover et al., 2004). 
1.4.3.3 Claisen condensation type reactions 
The isolation of a mycolate-deficient mutant of M. smegmatis that accumulates novel long- 
chain fatty acids that correspond in structure to incomplete meromycolates provided strong 
evidence that the meromycolate chain and cc-branch are synthesised separately and fused by 
condensation (Liu & Nikaido, 1999). The mechanism for this carbon-carbon bond formation 
used in their biosynthesis is likely to occur via a decarboxylating Claisen-type condensation 
reaction (Heath & Rock, 2002). Various studies have proposed possible pathways for this type 
of reaction but with conflicting mechanisms, some involving an intermediate decarboxylation 
step (Figure 1.19, Theory 1) (Minnikin, 1982) and others proceeding directly without a 
decarboxylation step (Figure 1.19, Theory II) (Lee et al., 1997). 
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Figure 1.19 Claisen condensation step proposed in the production of mycolic acids. 
1.4.3.4 Deposition and export of mycolic acids 
The deposition and export of mycolates to the cell wall has been partially elucidated. A 
mycolated polyprenyl phosphate- I inked carrier described as Myc-PL (6-0-mycolyl-P-D- 
mannopyranosyl- I -monophosphoheptaprenol) from M. smegmatis (Besra et al., 1994) (Figure 
1.11) has been implicated in the final stages of mAG synthesis. The introduction Of[14C]MYC_ 
PL into a cell wall preparation from M smegmalis led to the transfer of [14C] mycolates into 
extractable TMM and TDM as well as insoluble mycolates esterified to AG (Besra el al., 
1994). Belisle et al. (1997) further demonstrated that three members of the M tuherculosis 
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antigen 85 complex, Ag85A, Ag85B and Ag85C2 (encoded by jbpA, jbpB and jbpC2 
respectively) were able to catalyse mycolyltransferase reactions involving TDM, TMM and 
mycolates of the cell wall AG (Belisle et al., 1997). Heterologous expression of FbpA, FbpC I 
and FbpC2 was perfon-ned in E. coli and recombinant proteins purified. In contrast to FbpA 
and FbpC2, recombinant FbpCI did not possess in vitro mycolyltransferase activity and was 
not recognised by two monoclonal antibodies to the native Ag85 (Kremer et al., 2002a). To 
aid functional characterisation of FbpCI the crystal structure was determined to 1.7 A 
resolution (Wilson et al., 2003). It was shown that FbpCI, like the Ag85 components Ag85B 
and Ag85C2, folds as an a/P hydrolase, but it does not contain any of the catalytic elements 
required for mycolyltransfetase activity. Moreover, the absence of a recognisable cc, a- 
trehalose monomycolate-binding site and the failure to detect an active site suggest that the 
function of FbpCI is of a non-enzymatic nature and that FbpCI may in fact represent a new 
family of non-catalytic alpha/beta hydrolases that might have a role in host tissue attachment, 
whereby ligands may include the serum protein fibronectin and small sugars (Wilson et aL, 
2004). 
1.4.4 Lipoarabinomannan 
LAM and its truncated form lipornarman (LM) are thought to be the primary plasma 
membrane-associated lipopolysaccharides in mycobacteria (Lee et al., 1996). LAM is present 
in the envelopes of pathogenic mycobacteria, such as M tuberculosis and M leprae, the 
vaccine strain M bovis BCG and opportunistic strains, such as M. avium, M. kansasil, M. 
fortuitum and M chelonae and finally the fast-growing non-pathogenic strain M. smegmatis 
(Besra & Chatterjee, 1994; Nigou et al., 2003). The biological and immunological properties 
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of LAM are significant and have been studied extensively. Mycobacterial LAMs are 
lipoglycans comprised of three distinctive domains, a mannosyl-phosphatidyl-myo-inositoI 
(MPI) anchor, a polysaccharide backbone and capping moieties. The structure of the MPI- 
anchor is illustrated in Figure 1.20. The anchor structure is heterogeneous, with variations in 
the number and location of fatty acid residues (Nigou el al., 1997). Its acylation with a 
combination of palmitic, stearic and tuberculostearic (10-methyl-octadecanoic) acids 
facilitates the interaction of the anchor and the plasma membrane (Guerardel et al., 2002). It 
has also been suggested that mycobacteria can escape intramacrophagic destruction by 
adapting the lipids of the MPI-anchor to reduce stimulation of the host cytokine response 
(Nigou et al., 1997). 
wn 
11 0 
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Figure 1.20 Structure of PIM2 illustrating the MPI-anchor common to LAM, LM and 
PIMs. The central myo-inositol moiety is linked to Manp residues at 
position 2 and 6 and to a glycerol moiety via a phosphate group linked to 
carbon 1. Two of the potential acylation sites are occupied by 
tuberculostearic (10-methyl-octadecanoic) and palmitic acid residues. 
Other potential acylation sites are marked with an asterisk (*) 
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The polysaccharide backbone is composed of two homopolysaccharides, D-mannan and D- 
arabinan. The structure of this backbone is highly conserved amongst different mycobacterial 
species. The mannan core is composed of around 30-35 mannose (Man) residues in the 
pyranose (p) form. These residues form a linear cc-(I 46)-Manp backbone with various single 
oc-(I42)-Manp side chains. The lipoglycans of M tuberculosis H37Rv, M. tuberculosis 
H37Ra and M. bovis BCG all have very similar mannan cores with 60-70 % of the backbone 
possessing side-chains (Nigou et al., 2002b) (Figure 1.21). The arabinan domain comprises 
around 60 arabinofuranose residues (Araj) linked in a linear oC-(I45)-Arqf fashion, with 
branching occurring via the 3-position of some residues. These lateral branches occur in two 
arrangements, a linear tetraarabinofiaranoside (Araf-(Pl->2)-Araf-((xl45)-Araf-(ccl->5)-Araf- 
((xl->) and a bi-antennary hexaarabinofuranoside ([Arqf-(PI42)-Arqf-(oCI412 43 and 45)- 
Arqf-(ccI45)- Arqf-(ccI4) (Chatterjee etal., 1991) (Figure 1.22). 
sn&, or 
Figure 1.21 Mycobacterial mannan core composed of a linear (%-(146)-Manp 
backbone with single a-(142)-Manp side chains (n and m=7,8) 
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Figure 1.22 Arabinan segment of LAM. Showing the linkages of the arabinose units in 
the following configuration (Araf-(0142)-Araf-(ccl45)-Araf-(ccl-->5)- 
Arqf-(ccI4) and (JArqf-(pl42)-Arqf-((xl4j2 43 and 45)-Araf-(ccl45)- 
(Araf-(al 4), the positions of the caps and mannan are indicated 
The terminal residues of the arabinan domains are decorated with various 'caps'. Two capping 
motifs have been identified for LAM (Nigou el al., 2003). Mannooligosaccharides cap the 
LAM of slow-growing mycobacteria, such as M. tuberculosis (Chatterjee ei al., 1992) which 
have now been termed as ManLAM. Phosphoinositide units cap LAM from fast-growing 
mycobacteria, such as M. sinegnialis. The LAM of M. chelonae has been shown to be devoid 
of any caps and has been termed AraLAM (Guerardel el al., 2002). ManLAM and phospho- 
myo- i nositol -capped LAM (PILAM) exhibit a broad spectrum of immunomodulatory 
activities (Chatterjee & Khoo, 1998. Nigou et al., 2002b, Strohmeier & Fenton, 1999). The 
main immune response activities of ManLAM derive from its ability to inhibit the activation 
of macrophages and to inhibit the production of the Thl pro-inflammatorýy cytokines IL-12 
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and TNF-cc. M. tuberculosis ManLAM is also able to induce apoptosis in macrophages (Nigou 
et al., 2003). Consequently, ManLAM has been linked to the longevity of slow-growing 
mycobacteria within the human reservoir through its contribution to the overall 
immunosuppressive effect. 
1.4.4.1 Lipoarabinomannan biosynthesis 
Recent studies have elucidated a number of the key steps in LAM biosynthesis, however, our 
knowledge of its complete synthesis is still somewhat fragmented. The biosynthetic scheme 
for the biosynthesis of this membrane molecule has been proposed as PI 4 PIM 4 LM 4 
LAM (Belanger & Inamine, 2000; Besra et al., 1997; Nigou et al., 2003) and is illustrated in 
Figure 1.23. Biosynthesis of the PI anchor involves a number of essential genes that have been 
identified in M. tuberculosis. Myo-inositol synthesis is achieved through (Nigou et al., 2003), 
an inositol-I -phosphate synthase in M tuberculosis (INOI, Rv0046c) (Bachhawat & Mande, 
1999). 
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Figure 1.23 Biosynthesis of LAM (Nigou el aL, 2003). Sugar donors are in blue and 
identified gh-cosyltransferases in red. AcvlT, acyltransferase; ManT(s), 
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Four related ORF's (R0137; suhB, Rv2701c; cysQ, Rv2l3lc; impA, Rvl604) in M 
tuberculosis have been suggested to encode inositol monophosphatases. Nigou et aL (2003) 
characterised suhB (Rv2701c) and demonstrated the release of phosphate from inositol-l- 
phosphate and, to a lesser degree other polyol phosphates (Nigou et al., 2002a). Recently an 
isolated impA mutant of M. smegmatis possessed altered permeability properties, indicating 
that the synthesis of the PI anchor and its upstream synthesis has subsequent effects on PIM, 
LM and LAM biosynthesis (Nigou et al., 2003; Parish et aL, 1997). PgsAI (Rv2612c) has 
been identified as an essential enzyme that catalyses the transfer of diacylglycerol from its 
activated cytosine diphosphate nucleotide donor to inositol (Jackson et aL, 2000). PIM 
synthesis is initiated by two distinct mannosyltransferases, both utilising GDP-mannose as a 
sugar donor. Mannose residues are first transferred to the 2-position of the myo-inositol ring 
of PI to form PIMI, which is then further mannosylated at the 6-position of the myo-inositol 
ring yielding PIM2. Recent studies have shown that pinzl (Rv2610) and pimB (Rv0557) 
encode mannosyltransferases involved in synthesis Of PIM2 (Kordulakova et al., 2002; 
Schaeffer et aL, 1999). The recently identified pimC of M. tuberculosis (gmt7625 in M. bovis), 
has been characterised as a GDP-Man-dependent a-mannosyltransferase that transfers Manp 
from GDP-Man to ACRIM2 to form AC3PIM3 (Kremer et aL, 2002b). Subsequent 
mannosyltransferases utilise the sugar donor polyprenolmonophosporylinannose (PPM), 
which is synthesised via PPM (Gurcha et al., 2002) to form linear ci(I 4 6) LM by extending 
PIM3 (Besra et aL, 1997). Mature LM is produced by further mannosylation to produce the 
cc(l->2) branches of Manp. The biosynthesis of the arabinan domain is speculated to be very 
similar to that of AG using EmbC (Chatterjee & Khoo, 1998; Zhang et aL, 2003). 
Furthermore, complementation of an embC mutant with a hybrid gene encoding the N- 
terminus of EmbC and the C-terminus of EmbB resulted in LAM with a lower molecular 
weight than wild-type LAM. Structural studies involving enzyme digestion and mass 
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spectrometry analyses revealed that the arabinan of the 'LAM' formed in the complemented 
strain was a hybrid of AG and LAM (Zhang et al., 2003). Finally, the synthesis of the 
mannose caps, a crucial feature of LAM, is still unresolved (Nigou et al., 2003). 
1.4.5 Other cell envelope lipids 
A number of the complex lipids of the cell envelope are key virulence factors and their 
structures are based upon very characteristic methyl-branched long-chain acids and alcohols 
(Minnikin et al., 2002). A variety of glycosylated forms of mYcolic acids exist in the outer 
layer of the cell wall and are composed of mainly trehalose monomycolates (TMM) and 
dimycolates (TDM) (Figure 1.24). TMM is involved in the transfer of mycolic acids into the 
cell wall (Belisle et al, 1997). TDM has been implicated in granuloma formation (Yamagami 
et al., 2001). M tuberculosis is characterised by a family of acylated trehalose molecules all 
based upon the basic structure of a diacyl trehalose unit with subsequent acylation at other 
sites to form the tri- (TAI) and penta- (PAT) forms of acylated trehaloses (Figure 1.24) 
(Besra et al., 1992). 
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Figure 1.24 Representation of characteristic glycolipids from M. tuberculosis adapted 
from Minnikin et A (2002). TDM, trehalose dimycolate; SLI, sulfated 
tetra-acyl trehalose; DATI, diacyl trehalose; TAT, triacyl trehalose; PAT, 
pentaacyl trehalose 
The dimycocerosates of the phthiocerol family (PDIM) are major waxes and are related to the 
phenolic glycolipids (Figure 1.25), which are found in M. tuberculosis strains and other 
related pathogenic mycobacteria (Minnikin et al., 2002). PDIM of M tuberculosis is 
composed of two mycocerosic acid chains attached to the phthiocerol backbone (Figure 1.25). 
These complex waxes are distinguished by their range of multimethyl-branched fatty acids 
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and have been proposed to covalently interact with the mycolic acids of the outer membrane 
(Daffe & Draper, 1998). 
Figure 1.25 Structure of M. tuberculosis phenolic glycolipids and PDIM (Besra 
Chatterjee, 1994; Watanabe et at, 1994) 
The biosynthesis of these complex lipids by a unique family of PKS (Minnikin et d, 2002) 
was reviewed recently (Brennan, 2003). 
1.5 Old and new drugs targeting M. tuberculosis 
In 1914 Selman A. Waksman began a systematic screening of soil bacteria and fungi. In 1939, 
he discovered the marked inhibitory effect of certain 'fungi', especially actinomycetes, on 
bacterial growth. In 1940, he and his team were able to isolate an effective anti-TB antibiotic, 
actinomycin, unfortunately it was shown to be toxic in humans and animals. The first success 
came when streptomycin was purified from Streptomyces griseus, and showed maximum 
inhibition of M tuberculosis with relatively low toxicity in animal tests. November 20,1944, 
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was a historic date in the fight against TB because on this day the antibiotic was first 
administered to a critically ill TB patient with great success. A rapid succession of anti-TB 
drugs appeared in the following years. These were important because with streptomycin 
monotherapy, resistant mutants began to appear within a few months, endangering the success 
of antibiotic therapy. However, it was soon demonstrated that this problem could be overcome 
with the combination of two or three drugs. Currently there are five major antibiotics that are 
essential in the treatment of M tuberculosis, RIF, INH, PZA, EMB and streptomycin. With 
the emergence of MDR-TB, new avenues for treatment are required. 
1.5.1 Isoniazid (INH) 
0 NHNH2 
INH is a synthetic, bactericidal agent that is used as a front-line drug against TB. INH was 
first used as an anti-tubercular agent in 1952, almost 50 years after its discovery it remains as 
one of the first lines of defence against TB (Heifets, 1994). Susceptible strains have an MIC of 
less than 0.05 pg/ml. Even though INH has been widely used against TB, little is known about 
the bacterial targets and mode of action of INH. In 1954 Middlebrook discovered that INH- 
resistant organisms had decreased catalase activity (Middlebrook, 1954). Recent genetic 
studies identified a catalase/peroxidase (katG) which restored susceptibility to INH-resistant 
strains of M tuberculosis. This study also showed that 50-70 % of INH-resistant strains 
contained at least one mutation in KatG (Zhang et al., 1992). Tberefore, it was suggested that 
INH is a prodrug and requires activation by KatG. The mode of action of INH was originally 
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thought to be related to cell wall disruption. It was shown to be a direct inhibitor of mycolic 
acid biosynthesis (Winder 1982). The mode of action of INH is still being studied but it is 
widely accepted that INH targets fatty acid biosynthesis, primarily the enoyl-ACP reductase 
(InhA) (Marrakchi et al., 2000). Activation of INH allows its product to mimic NADH and 
bind to InhA (Bemadou et al., 2001). Resistant strains of INH have shown A4G transversion 
at position 280, resulting in a mutation Ser94->Ala, which alters the affinity of INH to NADH 
binding, thus resulting in resistance (Pantano et al., 2002). As over-expression of kasA 
correlated with increased resistance to INE and the identification of single amino acid 
mutations in kasA conferring resistance to INH, led Slayden et al. to suggest KasA as a 
potential target for INH (Slayden et al., 2000). However, it has been recently demonstrated 
by in vitro assays using purified InhA and KasA that KatG-activated INH, triclosan, and 
diazaborine inhibit InhA, but not KasA activity (Kremer et al., 2003). It was also shown that 
neither kasA nor kasB over-expression influenced the MIC of INH against several 
mycobacteria (Kremer et aL, 2000b; Larsen et al., 2002). 
1.5.2 Triclosan 
OH 
cl-Ö-0 ci 
cl 
Triclosan (5-chloro-2-[2,4 dichlorophenoxy] phenol]) has also been shown to be an effective 
inhibitor of fatty acid biosynthesis (Kuo et al, 2003; Marcinkeviciene et al., 200 1; McLeod et 
al., 2001; Roberts et al., 2003; Sivaraman et al., 2003; Waller et al., 2003). Three M 
smegmatis mutants selected for resistance to triclosan all possessed mutations in InhA 
(McMurry et al., 1999). Two of the mutations also expressed INH resistance (McMurry et al., 
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1999). It was demonstrated that InhA, like its E. coli homolog Fabl, is a target for triclosan 
(Kuo et aL, 2003; McMurry el al., 1998; McMurry et al., 1999; Parikh et al., 2000). It is 
proposed to bind preferentially to the Enzyme-NAD+ binary complex, in which the triclosan 
phenolic hydroxyl interacts with the hydroxyl group of Lysl58 (Parikh etal., 2000). 
1.5.3 Ethionamide (ETH) 
NH2 
N 
ETH is believed to have a similar mode of action as INH due to their structural similarity 
(Winder et aL, 1971). However, significant differences in their mode of action have been 
observed. Mutations in KatG were found not to confer resistance to ETH, therefore an 
additional enzyme is required for the activation of ETH into an activated form (Baulard et aL, 
2000; DeBarber et al., 2000). Recently, it was shown that ETH is activated by an enzyme with 
homology to monooxygenases, EthA (Rv3854c) (Baulard et al., 2000; DeBarber et aL, 2000). 
When the neighbouring open reading frame, ethR (Rv3855), which is homologous to 
members of the TetR family of transcriptional repressors, was over-expressed in M. 
sinegmatis, ETH resistance was observed (Baulard et al., 2000; DeBarber et al., 2000). In 
addition, chromosomal inactivation of this gene by transposition led to ETH hypersensitivity 
and EthR was proposed to regulate the production of EthA, which subsequently activates ETH 
(Baulard et al., 2000). When the ethA promoter region was fused with a IacZ reporter gene 
over-expression of ethR in trans was found to cause a strong inhibition of ethA expression, 
independently of the presence of ETH in the culture media (Engohang-Ndong et al., 2004). 
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Vannelli et al. (2002) establish that EthA is an FAD-containing enzyme that oxidizes ETH to 
the corresponding S-oxide. The S-oxide, which has a similar biological activity as ETH, is 
further oxidized by EthA to 2-ethyl-4-amidopyridine, presumably via the unstable doubly 
oxidized sulfinic acid intermediate (Vannefli et al., 2002). It was found that purified EthA 
displays a remarkably low activity with the antitubercular prodrug ETH (Fraaije et al., 2004). 
1.5.4 Pyrazinamide (PZA) 
4 tN 
NH2 
The antitubercular activity of PZA was first detected in 1952 but its description was 
overshadowed by the use of INE. It is a structural analogue of nicotinamide that targets semi- 
dormant tubercle bacilli under acidic conditions (Tatar, 1974). In the acidic environment of 
phagosomes, M. tuberculosis produces pyrazinamidase (Pzase), which converts PZA into 
pyrazinoic acid, the active compound which kills M. tuberculosis. Notably, M tuberculosis 
isolates that show resistance to PZA have lost Pzase activity (Huang et al., 2003). The gene 
that encodes pyrazinamidase in M. tuberculosis is pncA (Huang et al., 2003). In clinical 
studies 72 % of PZA R isolates have pncA mutations (Huang et al., 2003). Point mutations and 
substitutions of Cys138 with Ser, Glnl41 with Pro, Asp63 with His, and also deletions of G 
nucleotide at position 162 and 288 have resulted in defective Pzase activity (Bamaga et al., 
2002). Naturally-resistant strains of M bovis lack Pzase activity (Raynaud et al, 1999). To 
date the cellular target for PZA has not been identified although the apparent similarity of 
PZA to nicotinamide suggests that enzymes involved in pyridine nucleotide biosynthesis or 
fatty acid biosynthesis are possible targets (Rattan et al., 1998). Recently, it has been found 
that FAS-I from M avium, M bovis BCG and M tuberculosis confers resistance to 5-Chloro- 
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PZA when present on multi-copy plasmids in M smegmatis (Zimhony et al., 2000). PZA was 
also shown to inhibit FAS-1 in M. tuberculosis therefore implying FAS-1 as a primary target 
of PZA (Zimhony et al., 2000). 
1.5.5 Ethambutol (EMB) 
CH20H H 
I 
NN 
I 
T"*ý 
H CH20H 
EMB ([S, S']-2,2'-[ethylenediimino])di-l-butanoI is one of the front line drugs used against 
TB. It has a bacteriostatic effect that is thought to be important in preventing the emergence of 
resistance to the front-line agents. Early studies reported that EMB inhibited incorporation of 
mycolic acids into the cell wall (Mikusova et at, 1995). The cellular target for EMB was 
sought using drug resistance, via target over-expression by a plasmid vector. This strategy led 
to the cloning of the M avium emb region which, on over-expression in M smegmatis 
rendered the otherwise susceptible host resistant to EMB. This data suggests that the main 
target of EMB in M tuberculosis may be emb which encode arabinosyltransferases involved 
in AG and LAM biosynthesis (Belanger et at, 1996). More recent genetic approaches in 
relation to M tuberculosis have revealed the products of three homologous open reading 
frames designated embC, embA, embB as EMB targets (Telenti et at, 1997). The EmbCAB 
proteins are believed to be membrane proteins involved in the synthesis of various motifs of 
AG and LAM (Escuyer et al., 2001; Telenti et al., 1997). Recently it has been shown that 
synthesis of LAM, but not AG, ceases after inactivation of embC in M smegmatis with LAM 
synthesis being restored upon complementation with embC (Section 1.4.2.1) (Zhang et al., 
2003). Mutations in codon 306 of embB producing Met to Ile or Val were found in 13 of 28 
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EMB-resistant strains. Strains with Met306->Leu or Met306-->Val were more resistant to 
EMB than those with Met30641le substitutions, consistent with the notion that amino acid 
substitutions in EmbB alter drug-protein interactions and thereby lead to resistance 
(Sreevatsan et al., 1997). In another study 70 % of EMB R isolates all had mutations in the 
EmbB protein. 
1.5.6 Rifampin (RIF) 
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Rifampin, a lipophilic ansamycin, was first introduced as a theraputic agent against TB in 
1967 after being discovered as a product of Streptomyces mediterrand (Clark & Wallace, 
1967). It was shown to be highly active, diff-using rapidly across the hydrophobic cell 
envelope. In most strains of M tuberculosis resistant to RIF, mutations were found in a short 
region of 27 codons situated near the centre of rpoB, which encodes the RNA polymerase 
P-sub-unit (Taniguchi et al., 1996). RNA polymerase is an oligomer of four sub-units 
designated cc, 0, P' and a (encoded by rpoA, rpoB, rpoC and rpoD). Double mutations and 
deletions were observed with 70 % of all mutations of clinical resistant M tuberculosis strains 
possessing mutations at His526 and Ser53 1, similar to those observed in E. coU (Taniguchi et 
aL, 1996) (Figure 1.26). 
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Figure 1.26 Region of rpoB gene involved in RIF resistance 
1.5.7 para-Aminosalicylic acid 
0 OH 
OH 
NH2 
para-Aminosalicylic acid displays high activity against M. tuberculosis but, not against other 
mycobacterial strains and bacteria in general. It is rarely used except in the case of MDR-TB. 
It has been suggested that it inhibits salicylate-dependent biosynthesis of iron-chelating 
mycobactins (Ratledge & Dover, 2000). 
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1.5.8 Streptomycin 
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Streptomycin was the first drug to be used effectively against TB in 1944 after its discovery 
by Selman Waksman in 1943 (Davies & Yew, 2003). Resistance to streptomycin was 
observed within a few months of its first use but the coupling of two or more anti-tubercular 
drugs solved the problem at the time. Due to its toxicity streptomycin was more or less 
excluded from front-line therapy, as less toxic and more active drugs were being discovered 
(Girling, 1989). The site of action of streptomycin is the small 30S subunit of the bacterial 
ribosome, which comprises the ribosome protein S12 and the 16S rRNA (Finken et al., 1993). 
Resistance to streptomycin has been investigated in a number of different bacterial systems 
resulting in three known mechanisms of resistance being established. 
The first mechanism involves mis-sense mutation in the rpsL gene, which encodes the S12 
protein in M tuberculosis (Heym et al., 1994; Musser, 1995; Ramaswamy & Musser, 1998). 
These mutations effectively change the binding site or the conformation of the ribosome so 
that streptomycin is ineffective. In about 70 % of resistant clinical isolates an A->G transition 
occurred in codon 43 replacing Lys with Arg (Heym et al., 1994). This same mutation was 
also observed in plant and other bacteria showing streptomycin resistance (Galili et al., 1989). 
These substitutions have also been observed in M tuberculosis rpsL but these mutations are 
less frequent. The second mechanism of resistance involves mutations in the rrs gene, 
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encoding 16S rRNA. A number of nucleotides substitutions have been implicated in this 
resistance mechanism but most abundant are at the 904 and 530 animo acids. Most common is 
the mutation of cytosine 904 to adenine or guanosine, or adenine 905 to guanosine (Heyrn et 
al., 1994). Little is known about the third and final mechanism of resistance, in these resistant 
isolates neither rrs nor rpsL are mutated. 
1.5.9 D-Cycloserine 
0 
H2N 
NH 
0 
D-Cycloserine a structural analogue of D-alanine, is used as a second-line agent in 
chemotherapy (Caceres et al., 1997). It inhibits biosynthesis of the mAGP complex and has 
been shown to target alrA, which encodes the D-alanine racemase involved in PG 
biosynthesis (Figure 1.7). Resistance has been correlated when a single transversion (G4T) 
located in the a1rA promoter region (Caceres et al., 1997). 
1.5.10 Cerulenin 
NH2 
Cerulenin ( (2R)(3S)-2,3-epoxy-4-oxo-7,10-dodecadienoly-amide ) is a fungal product isolated 
from Caephalosporium caerulens (Omura, 1976) which has been shown to be an irreversible 
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inhibitor of E. coli FabB and FabF (Magnuson et al., 1993). Cerulenin covalcritly modifies the 
KAS active site. The crystal structures of FabF (Moche et al., 1999) and FabB (Price et al., 
2001) co-crystallised with cerulenen provided evidence that cerulenin forms a covalent adduct 
with the active site cysteine residue. Incubation of KAS with acyl-ACP protects the enzyme 
from cerulenin therefore supporting the theory that a covalent adduct occurs with the key 
cysteine residue in the fatty acyl-binding site as seen in the E. coli co-crystallisation studies 
and therefore creates an irreversible interaction (Figure 1.27) (Moche et aL, 1999). 
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Figure 1.27 Interaction of FabF and cerulenin (left) and condenstation transition state 
of acyl-ACP (right) adapted from Price et ah (2001). Cerulenin mimics the 
condensation transition state and spans the two halves of the active site. 
The oxygen of cerulenin lies in the oxyanion hole formed by the Cys163 
and Phe392. The Cys163 rotates and forms a thioester bond with the 
carbon at position 2 carbon and the acyl-chain of cerulenin mimics the 
acyl chain of the donor and accommodates the hydrophobic pocket 
The tail of cerulenin occupies a long hydrophobic cavity, which normally contains the 
growing acyl chain of the natural substrate. This may explain why cerulenin does not inhibit 
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the E. coli 0-ketoacyl ACP synthase III (FabH), as this acetyl-CoA-primed enzyme lacks a 
fatty acyl-ACP binding site. The IC5o values of the purified E. coli KAS proteins were 
reported as 3 and 20 gM for FabB and FabF respectively (Price et al., 2001). Recently, it has 
been shown that the IC50 value of cerulenin against KasA is 0.67 JIM (Kremer et aL, 2002c). 
Cerulenin has been shown to be an effective inhibitor of KAS proteins but it has also been 
suggested that cerulenin inhibits the mammalian FAS-I enzymes and could therefore be toxic 
(Vance et al., 1972). 
1.5.11 Thiolactomycin 
Thiolactomycin ((4S)(2E, 5E)-2,4,6-trimethyl-3-hydroxy-2,5,7-ociatriene-4-thiolide ) (TLM) 
is a unique thiolactone antibiotic isolated originally from a Nocardia sp (Oishi et al., 1982) 
isolated from soil. It has proven to be an effective inhibitor of FAS-11, but does not inhibit 
FAS-1 (Slayden et al., 1996). This is a very attractive property as the drug should be able to be 
used as a chemotherapeutic agent against bacterial infections if it does not have any adverse 
effects on the human FAS-1. TLM and related thiolactones have been shown to be potent 
inhibitors of FAS-II and mycolic acid biosynthesis in mycobacteria (Slayden et al., 1996), as 
well as of chloroplast type 11 fatty acid synthesis in Plasmodiumfalciparum (Waller et al., 
2003). The use of M smegmatis cell extracts demonstrated that TLM specifically inhibited the 
mycobacterial FAS-11 but not the multifunctional FAS-1 (Slayden et al., 1996). The in vivo 
and in vitro data and knowledge of the mechanism of TLM resistance in E. coli suggests that 
two distinct TLM targets exist in mycobacteria, the P-ketoacyl-acyl carrier protein synthases 
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involved in the FAS-11-driven elongation steps leading to the synthesis of meromycolates 
(Slayden et al., 1996). The thiolactone ring of TLM mimics the bent conformation of 
thiornalonate. The oxygen forms a hydrogen bond with His-298 and His-333, and the carbons 
of the malonate are mimicked by the carbon ring of TLM. The oxygen of TLM points out of 
the active site tunnel that would be occupied by the pantetheine arm of the malonyl-ACP 
substrate (Figure 1.28) (Price et al., 2001). The E. coli strain CDM5 was derived as a TLM- 
resistant mutant but remained sensitive to cerulenin. The fatty acid synthase activity in 
extracts from strain CDM5 was sensitive to TLM inhibition therefore the TLM resistance was 
attributed to a different allele emrB. Disruption of the emrB gene converted strain CDM5 to a 
TLM-sensitive strain, and the over-expression of the emrAB operon conferred TLM resistance 
to sensitive strains. Thus, activation of the Emr efflux pump is the mechanism for TLM 
resistance in strain CDM5 (Furukawa et al., 1993). A similar strain with an efflux KO 
mutation remained resistant to TLM. Further investigation of this strain revealed another 
missense mutation in thefabB gene (TI 168G) that directed the expression of a mutant protein, 
FabB Phe390->Val. Structural modeling predicted that the CG2 methyl group of the valine 
side chain interfered with the positioning of the CI I methyl on the isoprenoid side chain of 
TLM in the binary complex, whereas the absence of a bulky methyl group on the leucine side 
chain permitted TLM binding (Jackowski et aL, 2002). 
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Figure 1.28 Schematic diagram illustrating how TLM mimics substrates in the active 
site of FabB. The thiolactone ring of TLM mimics the bent conformation 
of thiomalonate. The oxygen forms a hydrogen bond with His-298 and 
His-333, and the carbons of the malonate are mimicked by the carbon ring 
of TLM. The oxygen of TILM points out of the active site tunnel that would 
be occupied by the pantetheine arm of the malonyl-ACP substrate 
In bacteria] type 11 systems, as typified by that of E coli, the first step is catalysed by the 
condensation of acetyl-CoA and malonyl-ACP by P-ketoacyl-ACP synthase III (FabH). 
Recently, Choi et aL, (2000b) identified an open reading frame in M. luberculosis (Rv0553c), 
now termed mtFabH that contained the Cys-His-Asn catalytic triad signature (Choi et al., 
2000b). In contrast to E. coli FabH, mtFabH preferred long-chain acyl-CoA substrates, rather 
than an acetyl-CoA primer. In addition, mtFabH was sensitive to TLM and resistant to 
cerulenin in vitro. Interestingly, niýfabH over-expression in M. bovis BCG did not confer 
TLM resistance, suggesting that mtFabH may not be the primary target of TLM in vivo and 
surprisingly led to several unusual changes in the lipid composition of the cell wall. TLM is 
effective against these enzymes as they possess a malonyl-ACP binding site, which is targeted 
by TLM. It has been shown that the interaction between KAS and TLM is reversible (Price et 
Thiomalonate 
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His 29 
C 
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aL, 2001). Preliminary experiments have shown that the over-production of KasA and KasB 
increases the MIC from 30 ptg/ml to 150-200 ýtg/ml in M bovis BCG (Kremer et aL, 2000b). 
It was also shown that mycolate inhibition by TLM can be restored in the presence of 
overproduced KasA. This suggests KasA as one of the major targets for inhibition by TLM 
(Kremer el a/., 2000b). Schaeffer et aL (2001) showed that TLM was more effective against 
KasA than KasB; greater than 90 % of KasA activity was inhibited by TLM compared to only 
65 % for KasB. It was also shown that irrespective of the ACP used, inhibition was similar, 
suggesting that the mechanism for inhibition for each enzyme is similar and does not involve 
any interaction with the ACP but still inhibits the decarboxylation (Schaeffer el aL, 200 1 ). 
1.5.12 Isoxyl 
IN IN 
HH 
Isoxyl was first used in the clinical treatment of tuberculosis in the 1960s (Winder, 1982). 
Phetsuksiri et al. (1999) demonstrated that isoxyl has potent activity against M. aurum A', M. 
avium and M tuherculosis. In addition, 12 clinical isolates of M iuberculosis from different 
geographical areas and with various drug susceptibility profiles were found to be highly 
sensitive to isoxyl. In the same study a panel of 28 isoxyl analogues were synthesised with 
simple alkyl and alkoxy substituents which displayed various degrees of activity against M 
tuberculosis. Isoxyl's mode of action was thought to be similar to INH and ETH in that it 
inhibits both fatty acid and mycolic acid biosynthesis (Phetsuksiri et al., 1999). However, 
recent evidence suggests that isoxyl is able to interfere with oleic acid and tuberculostearic 
acid synthesis by inhibiting the acyl-CoA desaturase DesA3 (Phetsuksiri el al., 2003). 
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1.5.13 Diazoborine 
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Diazoborine (DZB) is a class of boron-containing compounds that are only used 
experimentally, due to the inherent toxicity of boron. DZB have been shown to inhibit 
polysaccharide biosynthesis in E. coli. This effect is thought to be due to inhibition of fatty 
acid synthesis (Grassberger et al., 1984) by blocking the active site of FabI (the NADH- 
dependent enoyl-ACP reductase) (Bergler et al., 1994; Turnowsky et al., 1989). Incubating a 
temperature-sensitive E. coli envMmutant at the nonpermissive temperature caused effects on 
the cells similar to those caused by treatment with diazaborine, i. e., inhibition of fatty acid, 
phospholipid, and lipopolysaccharide biosynthesis, induction of a 28,000-dalton inner 
membrane protein, and change in the ratio of the porins OmpC and OmpF (Tumowsky et al., 
1989). DZB forms a covalet linkage between the boron atom and the 2'-hydroxyl of the ribose 
cofactor in E. coli Fabl. Inhibition of this enzyme is associated with the orientation of the 
inhibitor within the channel that would normally allow the phosphopanthene of ACP to access 
the active site (Baldock et al., 1996). Homologues of the FabI of M. tuberculosis, such as 
InhA should be sensitive to DZB but further work is required to analyse this hypothesis. 
Although the MIC value of DZB for M smegmatis (pMV261) was significantly higher (MIC 
100 pg1ml) compared with that of other drugs, M smegmatis carrying pMV261-inh, 4 
showed a reproducible 2-fold increase in resistance against this drug over the strain carrying 
the empty vector. This suggests that InhA may be a target of DZB, in agreement with the fact 
that DZB inhibits the E. coli enoyl-ACP reductase encoded by the fabI gene (Kremer et al, 
2003). 
59 
CHAPTERI 
1.5.14 Hexachlorophene 
OH OH 
ci, ', ý>, , 
ci 
ZýN ; z_N 
ci ci 
1 ci 
INTRODUCTION 
The biphenyl inhibitor, hexachlorophene, has been shown to inhibit Fabl of Haemophilus 
influenzae with an IC50 of 2.5 +/- 0.4 ptM. Steady-state inhibition patterns did not allow the 
mode of inhibition to be unambiguously detennined, but binding kinetics suggested that free 
enzyme, enzyme-NAD+, and enzyme-crotonyl-CoA complexes have similar affinity for 
hexachlorophene. When the enzyme-NADH complex was mixed with hexachlorophene, 
concentration-independent fluorescence quenching at 480,,. was observed, suggesting at least 
partial competition between NADH and hexachlorophene for the same binding site 
(Marcinkeviciene et al., 2001). 
1.5.15 Summary of antimycobacterial agents and their targets 
Various antitubercular drugs of historical importance have proven to be effective inhibitors of 
M. tuberculosis cell envelope biosynthesis, but with the onset of MDR-TB, investigation of 
novel cellular targets is required. Table 1.4 summarises the current knowledge of several 
mycobacterial agents, their proposed targets and proposed activators. 
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Table 1.4 MIC for several inhibitors against various mycobacteria, na = not 
available. 
Inhibitor M. tuberculosis 
H37Rv MIC 
(pg/ml) 
M. smegmads 
MIC (Ag/ml) 
M. bovis BCG 
MIC (gg/ml) 
Known/proposed 
Target(s) 
Proposed 
Activator 
INH 0.1 5 0.05 InhA KatG 
TRC 7.5 5 na InhA 
ETH 10 20 10 InhA EthA 
PZA 20 25 25 FAS-1 PncA 
EMB 4 0.5 2 EmbCAB 
RIF 0.5 17 0.025 rpoB 
Para-Amino na na na MbtA 
STR 2 1 0.25 rpsL, rrs 
D-Cye na 75 na a1rA 
CER 3-6.25 0.5 1.5 KasA, KasB 
TLM 5 75 30 KasA, KasB, 
mtFabH 
ISO 2.5 600 1 DesA3 EthA 
DZB 50 100 na InhA 
HEX na 2 na InhA 
1.6 Project aims 
The major aims of the project are to investigate a number of enzymes involved in mycolic 
acid biosynthesis in M. tuherculosis by biochemical characterisation. More specifically we 
aimed to establish methods for the effective expression and purification and biochemical 
characterisation of. 
mtFabH - 0-ketoacyl-ACP synthase III, the pivitol link between FAS-1 and 
FAS-II 
KasA - P-ketoacyl-ACP synthase 1, involved in meromycolate extension via 
extension of acyl chains with malonyl-AcpM 
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e AcpM - Meromycolate extension ACP, essential carrier for lipid metabolism 
e AccD4 - Acyl-CoA carboxylase proposed to be one of the enzyme involved 
in carboxylation of acyl chains immediately before mycolic acid 
condensation 
* Pksl3 - Polyketide synthase 13, proposed to be the Claisen condensation 
enzyme involved in mycolic acid biosynthesis 
The biochemical properties of the purified proteins will be assessed in vitro along with the 
development of assays to investigate partial reactions, such as the decarboxylation and 
transacylation activites of P-ketoacyl-ACP synthases. In addition, their substrate specificity, 
targeting by various inhibitors and amino acid function will be examined by site-directed 
mutagenesis. Finally, the biochemical properties of Pksl3 will be assessed as a possible 
Claisen-condensation synthase involved in the production of mature mycolic acids. 
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2.1 Introduction 
The increase in drug-resistant pathogenic bacteria has created an urgent demand for new 
antibiotics. Among the more attractive targets for the development of new antibacterial 
compounds are the enzymes of fatty acid biosynthesis. Although a number of potent inhibitors 
of microbial fatty acid biosynthesis have been discovered, few of these are clinically useful 
drugs. Several of these fatty acid biosynthesis inhibitors have potential as lead compounds in 
the development of new antibacterials (Campbell & Cronan, 2001). P-Ketoacyl-acyl carrier 
protein synthase (KAS) III catalyses the first condensing step of the FAS-II reaction in plants 
and bacteria, using acetyl CoA and malonyl-ACP as substrates in most bacterial and plant 
systems (Abbadi et al., 2000; Clough et al., 1992; Dehesh et al., 2001; Revill et al., 2001; 
Tsay et al., 1992). The biochemical basis for the production of branched-chain fatty acids by 
Gram-positive bacteria was analysed using E. coli and Bacillus subtilis FabH proteins. 
Reconstitution of a complete round of fatty acid synthesis in vitro with purified E. coli 
proteins showed that ecFabH was the only enzyme incapable of using branched-chain 
substrates. Expression of either bsFabH I or bsFabH2 in E. coli resulted in the appearance of a 
branched-chain 17-carbon fatty acid. Thus, the substrate specificity of FabH is an important 
determinant of branched-chain fatty acid production (Choi et al., 2000a). It was also observed 
in Streptomyces glaucescens that FabH is responsible for initiating both straight- and 
branched-chain fatty acid biosynthesis in Streptomyces (Han et al., 1998). 
The accumulation of malonyl-ACP following the inhibition of a reconstituted fatty acid 
synthase system by acyl-ACP implicated ecFabH as a target for acyl-ACP regulation (Heath 
& Rock, 1996a). Kinetic analysis showed that acyl-ACP inhibition was mixed with respect to 
acetyl-CoA, but was competitive with malonyl-ACP, indicating that acyl-ACPs decrease 
64 
CHAPTER2 fWETOACYL-ACP SYNTHASE III (mtFabH) 
FabH activity by binding to either the free enzyme or the acyl-enzyme intermediate, thus 
Supporting the theory that the inhibition of chain initiation at the P-ketoacyl-ACP synthase III 
step contributes to the attenuation of fatty acid biosynthesis by acyl-ACP (Heath & Rock, 
1996b). 
An open reading frame in the M. tuberculosis genome (Rv0533c) now termed mVabH, 
encodes a 335 amino acid protein with a molecular mass of 34872.5 Da and has an amino acid 
identity of 37.3 % with ecFabH and contains the Cys-His-Asn catalytic triad signature 
characteristic of KASIII enzymes. The purified recombinant mtFabH clearly preferred long- 
chain acyl-CoA substrates rather than acyl-ACP primers but did not utilise acetyl-CoA as a 
primer, unlike ecFabH (Choi et al., 2000b). mtFabH catalyses a Claisen-type condensation of 
long chain acyl-CoA substrates, such as myristoyl-CoA (C14-CoA) and malonyl-AcpM 
(Scarsdale et al., 2001), consistent with a role for mtFabH as the pivotal link between the 
FAS-I and FAS-II fatty acid elongation systems in M. tuberculosis (Choi et al., 2000b). The 
elucidation of the structure of FabH is important for the understanding of its regulation by 
feedback inhibition and its interaction with drugs. The crystal structure of ecFabH was 
detertnined to 1.8 A resolution using a 12-site selenium multiwavelength anomalous 
dispersion experiment. The active site was shown to be formed by the convergence of two cc- 
helices and is accessed via a narrow hydrophobic tunnel (Qiu et al., 1999). Hydrogen-bonding 
networks that include two tightly bound water molecules fix the positions of His244 and 
Asn274, which are critical for the decarboxylation and condensation reactions. A 
His2444AIa mutation did not affect the transacylation reaction suggesting that His244 has 
only a minor influence on the nucleophilicity of Cys112. In ecFabH, these histidine and 
asparagine residues are both required for the decarboxylation of malonyl-ACP. The 
nucleophilicity of the active-site cysteine is enhanced by the cc-helix dipole effect, and an 
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oxyanion hole promotes the formation of the tetrahedral transition state (Davies et al., 2000). 
The first co-crystal structure of a bacterial FabH condensing enzyme and a small molecule 
inhibitor was reported by Daines et al. (2003). In S. pneumoniae it was identified that indole 
analogues were potential inhibitors of FabH (Figure 2.1). This indole subunit has a 2,6- 
dichlorobenzyl group attached which was shown to block the active site entrance in S. 
pneumoniae FabH. Analogues of this inhibitor were constructed and assessed against both S. 
pneumoniae FabH and E. coli FabH. Also in this study they co-crystallised acetyl-CoA 
showing that major determinants of the adenine-binding site were Trp32 and Argl5l. 
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Figure 2.1 Indole analogues that inhibit S. pneumoniae FabH, IC5o concentrations 
indicated to the right 
The Cys-His-Asn catalytic triad present in other FabH molecules is conserved in S. 
pneumoniae FabH (Khandekar et at, 2001). Dynamic light scattering, size exclusion 
chromatography, and mass spectrometry results indicated that selenomethionyl S. pneumoniae 
FabH is a noncovalent homodimer (Khandekar et al., 2000). In silico docking of the NMR 
derived solution structure of ACP with the crystal structure of ecFabH showed that ACP 
docked to a positively charged/hydrophobic patch adjacent to the active site tunnel on 
CcFabl-L which included a conserved arginine (Arg249) that was required for ACP docking. 
Kinetic analysis and direct binding studies between ecFabH and ACP confirmed the 
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identification of Arg249 as critical for ecFabH-ACP interaction (Zhang et al., 2001). In the 
ecFabH structure, this active site tunnel is blocked by a phenylalanine residue, which 
constrains specificity to acetyl-CoA, whereas in mtFabH, this residue is replaced by a 
threonine, which permits binding of longer acyl chains. This same channel in mtFabH is 
capped by an cc-helix formed adjacent to a 4-amino acid sequence insertion, which limits the 
bound acyl chain length to 16 carbons (Scarsdale et al., 2001). 
KAS enzymes are targets for two natural products, thiolactomycin (TLM) and cerulenin 
(CER). TLM mimics malonyl-ACP in the ecFabB active site. It forms strong hydrogen bond 
interactions with the two catalytic histidines, and the unsaturated alkyl side chain interacts 
with a small hydrophobic pocket stabilised by 7c stacking interactions. CER binding mimics 
the condensation transition state. The ecFabB His333->Asn protein was prepared to convert 
the FabB His-His-Cys active site triad into the FabH His-Asn-Cys configuration to test the 
importance of the two His residues in TLM and CER binding. This mutant was significantly 
more resistant to both antibiotics and had an affinity for TLM an order of magnitude less than 
the wild-type enzyme, illustrating that the two-histidine active site architecture is critical to 
protein-antibiotic interaction (Price et al., 2001). Purified mtFabH was sensitive to TLM and 
resistant to CER in an in vitro assay. However, mtFabH over-expression in M. bovis BCG did 
not confer TLM resistance, suggesting that mtFabH may not be the primary target of TLM 
inhibition in vivo leading to several changes in the lipid composition of the bacilli upon over- 
expression of FabH in the presence of TLM (Choi et al., 2000b). 
Although TLM does not inhibit Plasmodium falciparum KASIII (IC50 > 330 gM), three 
structurally-similar substituted 1,2-dithiole-3-one compounds did inhibit pfKASIII with IC5o 
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values between 0.53 ýM and 10.4 ýM These compounds also inhibited growth in culture 
(Prigge et al., 2003). 
2.2 mtFabH mechanism 
mtFabH performs the same type of condensation reaction observed with other P-ketoacyl- 
ACP sYnthase enzymes. The elongation condensing enzymes catalyse a three step ping pong 
reaction (Heath & Rock, 2002). The first substrate is acyl-CoA, which is covalently 
transferred to the active site cysteine. The active site Cys in E. coli FabH is situated at the 
NH2-terminus of an cc-helix where the microenvironment of the pH is affected by the cc-helix 
dipole effect and reduces the pH by 1.6 units. This in turn allows the Cys to remain in the 
thiolate form and thus the effective transfer of the acyl chain. The first product, reduced CoA, 
is released. Malonyl-ACP then binds and the decarboxylation of the malonyl moiety promotes 
the condensation of the two acyl chains. The final product is the released. The main difference 
between FabH enzymes and other P-ketoacyl-ACP synthase is that their first substrate is an 
acyl-CoA (usually acetyl-CoA) instead of acyl-ACP and CoASH is released (Figure 2.2). 
The pantotheinyl arm of acyl-CoA or acyl-ACP binds in a narrow tube leading to the active 
site from the surface (Davies et aL, 2000; Qiu et al., 2001; Qiu et al., 1999). As the tube is 
linked by hydrophobic residues it does not interact strongly with the pantothenal arm. This is 
consistent with the step wise mechanism of FabH as the CoA pantotheinyl arm must be 
removed after depositing the acyl chain at the active site cysteine to allow malonyl-ACP to 
interact via the same channel (Davies et aL, 2000). The ADP moiety of bound acyl-CoA is 
sandwiched between the side-chains of Trp32 and Argl5l and hydrogen bonded to the 
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carbonyl of Arg 151 and Thr28 in E. coli. This allows for the pantotheinyl arm to be inserted 
and the transfer of the acyl chain to the thiol of Cys 112 (Qiu ei al.. 200 1) (Figure 2.3a). 
Binding of ACP to FabH has been examined in detail (Zhang ei al., 2001). ACP and FabH are 
both highly negatively charged but there is a patch of positive and hydrophobic residues near 
the entrance to the Fabl-l active site channel. In silico modeling and docking experiments 
carried out with mutants indicated that Arg249 of ecFabH is critical for the electrostatic 
interaction with Glu41 on the surface of ACP (Zhang el aL. 2001). This predicted docking 
arrangement allows for the pantothenal arrn of the ACP to insert the malonate into the active 
site. 
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Figure 2.2 Proposed condensation reaction mechanism performed by mtFabH. (1) 
The initial acyl-CoA acylation of the catalytic triad cysteine is followed by 
(11) the decarboxylation of the donor unit of malonyl-AcpM. The 
condensation of the two subunits (111) form the fý-kctoacyl AcpM product 
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Figure 2.4 shows the proximity of acyl-CoA binding residues to the entrance to the active site. 
In E. coli FabH, His244 and Asn274 of the active site are both required for malonyl-ACP 
decarboxylation. Mutation of either of these residues to alanine almost eliminates 
decarboxylation activity (Davies et aL, 2000). The nitrogens of these two residues form strong 
hydrogen bonds with the malonyl thioester oxygen to stabilise its negative charge formed 
during catalysis (Figure 2.3b). 
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Figure 2.3 Proposed acylation (A) and decarboxylation (B) mechanisms of mtFabH 
adapted from (Davies et at, 2000). 
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Figure 2.4 Representation of mtFabH showing the binding site of acyl-CoA (blues) and the 
active site (Reds). The ADP moiety of bound acyl-CoA is sandwiched between the 
sidechains of Trp42 and Argl61 and hydrogen bonded to the carbonyl of Argl6l 
and Thr28 along with interations with Arg46. This allows for the pantotheinyl 
arm to be inserted and the transfer of the acyl chain to the thiol of Cysl 12 (122) 
(Red). This figure was generated using the crystal structure coordinates (1 MIM, 
Scarsdale el aL(2001)) and the Swiss-PdbViewer Deep view program. 
During the condensation reaction. the thioester oxygen atom of the malonyl-ACP interacts 
with the His244 and Asn274 during the enolisation to facilitate the formation of the carbanion 
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at the C2 position. Protons are probably pushed away from the leaving CoASH and C02 by 
the proximity of group to the active site Phe205. This intermediate is held in position by its 
interaction with the active site His and Asn. The nucleophilic carbonion formed attacks the 
acyl group attached to the Cysl 12 releasing the 0-ketoacyl-ACP product which is in turn 
released from the protein (Figure 2.5) (Heath & Rock, 2002). 
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Figure 2.5 mtFabH reaction scheme adapted from (Davies et at, 2000; Heath & 
Rock, 2002) 
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Structural analysis of the E. coli and M. tuberculosis Fabl-l proteins revealed that the side 
chain of residue 97 protruded into the hydrophobic canal. The ecFabH has a phenyalanine 
residue which blocks the canal whereas the mtFabH protein has a less bulky threonine residue; 
it is believed that this residue affects the substrate chain length of the proteins, changing the 
proteins specificity (Figure 2.6). 
Figure 2.6 Ribbon diagram of the active site and hydrophobic pocket of mtFabH. The 
aromatic ring of the phenylalanine (purple right) present in E. coli blocks 
the hydrophobic canal and selects for short acyl chains to bind to the 
sulphur of the catalytic cysteine (yellow). In M. tuberculosis FabH this 
residue is replaced with a threonine residue (purple left), allowing the 
binding of longer chains. At the terminus of the hydrophobic canal (green) 
is a loop formed by by 4 amino acid residues 213-216 (SGRP) (Green). 
This figure was generated using the crystal structure coordinates (IMIM, 
Scarsdale ef aL(2001)) and the Swiss-PdbViewer Deep view program. 
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2.3 Materials and methods 
2.3.1 Cloning 
Dr Laurent Kremer from Institut Pasteur de Lille, France, performed the molecular cloning of 
mtFabH. The mffiabH orf was amplified from genomic DNA isolated from M. tuberculosis. 
PCR primers (5'-AGCTAGGAATrCGCGCGCTCAACCC-3' and 5% 
GGACTAGTATGACGGAGA- 3') were used to create a hfal restriction site. The PCR 
product was ligated into plasmid pCR2.1 and E. coli INVaF9 were transformed with the 
ligation mix, and the insert DNA was sequenced to verify the absence of PCR artifacts. The 
resulting plasmid was isolated and digested with Bfal. This fragment was isolated and ligated 
into plasmid pEI28b (Novagen) digested with Mel. The construct was expressed in E. coli 
C41 (DE3). 
23.2 Site-directed mutagenesis 
Identification of candidate residues for site-directed mutagenesis were identified by sequence 
alignment and analysis of the crystal structure of ecFabH. The ORF was 37.3 % identical and 
46.8 % similar to E. coli FabH and 33.4 % identical and 42.9 % similar to Bacillus sublilis 
FabH2 (Figure 2.7). 
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Figure 2.7 Comparison of M. tuberculosis FabH (mtFabH) with E. coli FabH (ecFabH) 
and B. suhlifis FabH2 (bsFabH). Primary amino acid sequence of Gram- 
negative (E. colt) and Gram-positive (B. sublifis) FabH was compared with 
the predicted protein sequence of mtFabH. Identical amino acids common 
to any two of the FabH proteins are shaded. mtFabH possesses the 
hallmark features of 1ý-ketoacyl-ACP synthase III enzymes including the 
Cys-His-Asn active site triad (arrowhead), the oxyanion hole (*), and 
residues involved in acyl-CoA binding (+). 
A series of site-directed mutants were obtained using pET28a-mýfabH as the template for the 
QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer's 
instructions with the following primers: 
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C 122A UP YGAT CTT TCG GCG GGG GCC GCC GGA TTC GGA TAT GCG 3' 
DWN 5'CGC ATA TCC GAA TCC GGC GGC CCC CGC CGA AAG ATC 3' 
H258A UP YGAC GTG TrC GTC CCT GCT CAG GCC AAT AGC CGC ATC 3' 
MAN YGAT GCG GCT ATr GGC CTG AGC AGG GAC GAA CAC GTC 3' 
N289A UP YATC GAG CAC ACC GGA GCC ACC TCG GCG GCC TCC ATT 3' 
DWN 5'AAT GGA GGC CGC CGA GGT GGC TCC GGT GTG CTC GAT 3' 
W42A UP YGAC TCG TCC GAC GAG GCG ATC TAC ACC CGA ACC GCC 3' 
DMN 5' GGC GGT TCG GGT GTA GAT CGC CTC GTC GGA CGA GTC 3' 
R46A UP YGAG TGG ATC TAC ACC GCA ACC GGC ATC AAG ACC CGC 3' 
DWN 5'GCG GGT CTr GAT GCC GGT TGC GGT GTA GAT CCA CTC 3' 
R161A UP YATA GAC ATG TAC GAC GCC GGC AAC TGC TTC ATC TTC 3' 
DWN YGAA GAT GAA GCA GTT GCC GGC GTC GTA CAT GTC TAT 3' 
T97F UP YACC CAT TTC CTG CAA TrC CCG CCG GCC GCC CCA ATG 3' 
MN YCAT TGG GGC GGC CGG CGG GAA TTG CAG GAA ATG GGT 3' 
Using the R161A plasmid as the template, we were able to generate the double mutations 
R161A/R46A and R161A/W42A. The DNA was sequenced to assess the construct. 
2.3.3 Stratagene Quikchange site-directed mutagenesis 
The kit was used to make point mutations of pET28-mýfabH using the primers above. The 
PCR reaction and recipe follow, after the PCR reaction the methylated double stranded 
template DNA is removed by digestion with DpnI. Supercompetent XLl-Blue E. coli cells 
were transformed by heat shock with the digest mixture and plated on selective media 
containing kanamycin. 
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5 pl I Ox Reaction buffer 
I PI dsDNA template (pE728-mtfaffl) 
I PI 5' Mutant primer 
I gl 3' Mutant primer 
I gl dNTP mix 
40 gl ddH20 
I gl PfuTurbo DNA polymerase 
95"C 30 seconds 
95'C 30 seconds 
55*C I minute 16 cycles 
68'C I minute/kb 
2.3.4 Purification protocol 
E. coli C41 (DE3) expression host were transformed with pET28-mtfabH. The cells were 
cultured at 370C to an A. -=0.6 and then recombinant gene expression was induced with I 
mM IPTG. The cultures were grown for a further 4h at 371C followed by harvesting by 
centrifugation. The cell pellets were resuspended in buffer (20 mM phosphate buffer, pH 7.9, 
0.5 M NaCl, 10 mM imidazole) containing DNase and RNase. Bacteria were disrupted by 
sonication and the resulting lysate centrifuged at 27,000 xg for 60 min at 4'C. Hi-trap 
Chelating Sepharose TM fast flow matrix columns (I ml or 5 ml) equilibrated with 0.02 M 
phosphate buffer and 0.5 M NaCI pH 7.4. Columns were charged using 2 column volumes of 
0.1 M nickel chloride and washed with 4 column volumes of 0.02 M phosphate buffer and 0.5 
M NaCI pH 7.4 to re-equilibriate the column and remove excess nickel. The clarified 
supernatant was applied to the column (maximum of 10 ml for aI ml column and 50 ml for a 
5 ml column) and non-absorbed material collected for analysis. Proteins were eluted using 
varying concentrations of imidazole (10 mM - 500 mM). Fractions were collected and protein 
concentration determined by BCA (Pierce), 5 pg of each protein fraction was analysed by 12 
% SDS-PAGE. Purified protein samples were dialysed against 20 mM Tris-HCI pH 7.6,50 
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mM NaCI containing I mM P-mercaptoethanol and concentrated when required using a 
Centricon YM-10 filter unit (Millipore), and was stored in 50 % glycerol at -80T. Routinely, 
yields of approximately 20 mg pure recombinant protein were recovered from a2L culture by 
Ni2'-chelate affinity chromatography. Pure mtFabH were assessed by visualisation on SDS- 
PAGE (12 %). 
2.3.5 Assays and assay development 
2.3.5.1 MtFabH full Assay 
The filter disc assay developed for ecFabH (Heath & Rock, 1996b) was modified to measure 
the activity of mtFabH with long-chain radiolabelled acyl-CoA. The assays contained 50 tiM 
ACP/AcpM, I mM P-mercaptoethanol, 0.1 M sodium phosphate buffer, pH 7.0,50 PM 
malonyl-CoA, 100,000 cpm [2_14C] malonyl-CoA (specific activity 55 Ci/mole), 12.5 JIM 
substrate (acetyl-CoA, butyryl-CoA, hexanoyl-CoA octanoyl-CoA, decanoyl-CoA, lauroyl- 
CoA, myristoyl-CoA, palmitoyl-CoA, stearoyl-CoA, or arachidoyi-CoA) and mtFabD (0.3 mg 
of protein) in a final volume of 50 ml. The mtFabD protein was added to generate the 
malonyl-ACP substrate for the reaction. A mixture of ACP, I mM P-mercaptoethanol, and the 
buffer was incubated at 37'C for 30 min to ensure complete reduction of ACP, and then the 
remaining components (except mtFabH) were added. The mixture was then dispensed in 
aliquots into the assay tubes and any additions of antibiotics/analogues made prior to the 
initiation by the addition of mtFabH. The reaction mixture was incubated at 37'C for 40 min. 
The reaction was quenched by the addition of I ml 100 mM K2HP04,100 mM KCI, 30 % 
THF and 5 mg NaB114 converting the P-keto-acyl-AcpM product into a acyl-1,3-diol (Figure 
2.8). The radiolabelled fatty acids were extracted three times with I ml water saturated 
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toluene. Organic solvent extracts were pooled and washed with an equal volume of water. The 
solvent was then transferred to scintillation vials and dried, 5 ml EcoScint A was added prior 
to counting. 
-? 
0 
holo-AcpM + 0"ýS-COA 
Malonyl-CoA 
FabD Malonyl CoA ACP transacylase 
00 
0'4-"4S-ACPM 
Malonyl-AcpM 
0 
7 S-CoA 
C16-CoA 
mtFabH 
00 
-17'-ýýS-ACPM 
O-keto-C18-AcpM 
NaBH4 
OH OH 
7 
C18-1 
ý3-dol 
Figure 2.8 Schematic representation of the full mtFabH radiolabelled assay 
2.3.5.2 Transacylation assay 
The acylation assay for KAS I (McGuire el ul., 2001) was adapted for mtFabH. The acyl 
transferase assay measures the rate of formation of cys-acyl thioesters using a radiolabelled 
acyl-CoA. Acyl transfer was assessed using [3 H]-myristoyl-CoA. 
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The final reaction mixture consisted of 50 mM Tris-HCI pH 7.5 (Buffer A), 800 pmol [3 Hj- 
myristoyl-CoA (1.66 kBq), and I lig mtFabH/mutant mtFabH to a final volume of 60 Pd. The 
transfer was carried out at ambient temperature for 10 min. 200 ýd of N i21 charged chelating 
sepharose TM fast flow chromatography media (50 % '/, slurry in buffer A) was added and 
incubation continued for a further 5 minutes. The slurry was diluted by adding 300 ml buffer 
A and unbound myristoyl-CoA was then removed by filtration (cellulose nitrate, 0.45 gm). 
The beads were washed with 20 ml buffer A before the filters were removed to a scintillation 
vial for liquid scintillation counting using 5 ml EcoScintA (National Diagnostics). 
0 
S-CoA 
[3H]-myristoyi-CoA 
mtFabH 
0 
+ 
-1ý -+6 S-Cys-mtFabH 
PH]-myristoyl-cys-FabH 
Figure 2.9 Schematic representation of the mtFabH transacylation assay 
2.3.5.3 Malonyl-AcpM decarboxylation 
The method used by McGuire el al. (200 1) was adapted to measure the decarboxylation of 
malonyl-ACP by mtFabH. Here, nialonyl-ACP was synthesised from malonyl-CoA and holo- 
ACPs in situ using a malonyl-CoA: ACP transferase (MCAT), FabD. 
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The final reaction mixture used was as follows. The appropriate ACP and MCAT pre- 
incubated with dithiothreitol (DTT) for 15-60 min on ice. Synthesis of malonyl-ACP was 
accomplished using 25 mM KHP04 (pH 8), 12 ýtM ACP, [1_14C] malonyl-CoA (1.666kBq), I 
MM DT-F, and 5 ýtg of FabD per assay. After 5 min at 25'C, the reaction mixture, designated 
A, was transferred to ice. (ii) For a 100 ýd decarboxylation reaction, 83 VLI of A was al iquoted 
to an Eppendorf tube with 17 gl (4.25 gg monomer) of mtFabH wild-type or mutant protein. 
After 10 min at 25'C, the reaction was stopped by the addition of 800 pil of cold 10 % (w/v) 
trichloroacetic acid (4'C) and 50 ptl of 2 mg/ml BSA and incubated on ice for 30 min on ice. 
The solution was centrifuged at 14,000 rpm for 30 min, and the pelleted proteins were 
resuspended in 200 [d 50 mM Tris-HCI (pH 6.8); 20 gl samples were run on IM urea PAGE 
(13.3 % acrylamide), which separated acyl-ACPs on the basis of the chain length of the acyl 
substitution and the presence of functional groups (Post-Beittenmiller et al., 1991). The urea 
gel was dried and exposed for 72 hours. 
-00- holo-AcpM + O'Jý-AS-CoA 
Malonyl-CoA 
FabD Maionyl CoAACP transacylase 
00 
0 S-AcpM 
Malonyl-AcpM 
mtFabH 
Co 22 
1 
0 
"KIS-AcpM 
Acetyl-AcpM 
Figure 2.10 Schematic representation of the mtFabH decarboxylation radiolabelled 
assay 
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2.4 Results 
2.4.1 ACP preference of P-ketoacyl ACP synthase III activity of mtFabH 
The genome of M. tuberculosis H37Rv contains three putative ACP genes. One of these, 
AcpM, lies within a cluster of genes encoding several of the components of the FAS-11 system 
(Kremer et al., 2001) and has been suggested as the carrier for the growing meromycolate 
chain during FAS-11 (Besra et al., 1994). When we compared the rate of malonate 
incorporation into P-ketoacyl-ACP using both AcpM and the E. coli ACP (ecACP) we 
observed a shift in the acyl chain length specificity for mtFabH. When ecACP was used the 
optimal acyl-CoA substrate was C12-CoA. Both C8- and Clo-CoAs were efficiently extended 
but larger CoAs represented poor primers. However when AcpM was used as the carrier, 
malonate incorporation continued to rise with acyl chain length with an apparent optimum 
with octadecanoyl-CoA. As CLUSTALW alignments of the two ACPs show that AcpM 
carries a C-terminal extension (Figure 2.11), it is possible that this region may modulate the 
acyl-CoA chain length specificity of mtFabH allowing longer acyl chains to bind more 
efficiently (Figure 2.12). The apparent K.. calculated for C12-CoA was 2.23 mM, which is 
consistent with other FabH enzymes (Choi et al., 2000b). As longer chain length acyl-CoAs 
were not available to us we could not determine whether longer primers, emulating the C22- 
C24 FAS-I products thought to form the a-alkyl chain of the mature mycolates, are extended 
by mtFabH. 
ACP ---- MSTIEERVKKIIGEQLGVKQEEVTNNASFVEDLGADSLDTVELVMALEEEFDTEIP 56 
AcpM VPVTQEEIIAGIAEIIEEVTGIEPSEITPEKSFVDDLDIDSLSMVEIAVQTEDKYGVKIP 60 
ACP DEEAEKITTVQAAIDYINGHQA --------------------------------- 78 
AcpM DEDLAGLRTVGDVVAYIQKLEEENPEAAQALRAKIESENPDAVANVQARLEAESK 115 
Figure 2.11 CLUSTALW alignments of the E. coli ACP and M. tuberculosis AcpM, 
showing the C-terminal extension 
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Figure 2.12 Substrate specificity analysis of mtFabH, E. coli ACP vs M. tuberculosis 
AcpM. Comparison of E. coli ACP and AcpM as substrates for mtFabH 
with regards to substrate specificity using acyl-CoA chain lengths ranging 
from C2-C20. The mtFabH assay was performed in triplicate and activity 
assessed by scintillation counting. The method is described in detail section 
2.3.5.1. 
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2.4.2 fý-Ketoacyl ACP synthase III activity of mtFabH muteins 
The availability of the mtFabH crystal structure allowed us to target specific residues for site- 
directed mutagenesis thus facilitating a biochemical analysis of their individual contribution to 
KAS-111 activity. Three groups of amino acid residues were chosen for site-directed 
mutagenesis in order to determine their contribution to the KAS activity of mtFabH. These 
could be subdivided according to the predicted functions of the residue derived from our 
knowledge of the crystal structure of the enzyme; (i) the residues contributing the catalytic 
triad (Cys 12 1, His258 and Asn289), (ii) those implicated in acyl-CoA binding (Trp42, Arg46 
and Argl 61) and (iii) those apparently defining the acyl chain length specificity of the enzyme 
(Thr97 and A213-216). 
E. coli C41 (DE3) expression host transformed with pET28-mtfabH were cultured at 37'C to 
an A. - = 0.6 and then recombinant gene expression was induced with I mM IPTG. The 
cultures were grown for a further 4h at 37'C followed by harvesting by centrifugation. The 
cell pellets were resuspended in buffer and then the bacteria were disrupted by sonication and 
the resulting lysate centrifuged at 27,000 xg for 60 min at 4'C. The clarified supernatant was 
applied to a Hi-trap Chelating SepharoseTm (I ml). Fractions of purified mutated and wild 
type mtFabH were visualised by 12 % SDS-geI electrophoresis and Coomassie blue staining 
(Figure 2.13). Over-expression of these alleles in E. coli C41 (DE3) yielded large quantities of 
HiS6-tagged mutein (-10 mg/I culture). Purified proteins were dialysed into 20 mM Tris-HCI 
pH 7.9,50 mM NaCl. Pure protein was stored in 20 % glycerol and stored at -80'C. 
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Figure 2.13 SDS-PAGE gel of mutant protein purity. Produced by over-expression in 
E. coli C41 (DE3), 4 hours 1 mM IPTG and purification by His-trap 
chelating sepharose (1 mi). Fractions of purified mutated and wild type 
mtFabH were visualised by 12 % SDS-gel electrophoresis and coomassie 
blue staining 
The P-ketoacyl-ACP synthase III activity of each mutant protein was determined (Figure 
2.14). As expected, the mutations involving the catalytic triad residues completely inactivated 
the enzyme confirming that these residues are vital for the condensation reaction to occur. The 
single substitutions Trp42->Ala, Arg46->Ala and Argl 614AIa reduced activity to 44,13 and 
76 % of mtFabH activity, respectively suggesting a non-essential role in catalysis. This is 
wholly consistent with their predicted function of contributing to the binding of acyl CoA 
primers (Zhang et al., 2001). The two double muteins Trp42Argl6l->Ala and 
Arg46Argl6l-->Ala showed further reductions in activity to 0.5 and 0.6 %, respectively. To 
date we have not been able to construct a mutant containing substitutions at both codons 42 
and 46. 
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A Thr97->Phe substitution was created in an attempt to emulate the hydrophobic acyl-binding 
canal of ecFabH (Scarsdale et al., 2001), which is partially blocked by the acyl moiety of the 
Phe residue, and thus alter the substrate specificity of mtFabH. Unfortunately this mutation 
inactivated the enzyme completely, with none of the acyl-CoA chain primers (C2-C20) being 
elongated. The end of this hydrophobic canal is 'capped' by residues 213-216 at the surface of 
the protein. We investigated the possibility that removing these residues in order to analyse 
the effect of the mutation on substrate specificity. However, as with the Tbr974Phe 
mutation, this mutant also exhibited no activity with any of the acyl (C2-C20)-CoA primers 
used. 
With our collaborator J. C. Sacchettini we are at present producing crystals of the double 
mutant proteins to evaluate structural changes and to shed light on their effects in relation to 
CoA binding. 
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Figure 2.14 P-ketoacyl ACP synthase III activity of mutant mtFabH. 0.5 tig of 
mtFabII/mutein were assayed in triplicate. Palmitoyl-CoA was used as an 
acyl primer and malonyl-AcpM, which was provided in situ by Fabl)- 
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2.4.3 Transacylation activity of mutant mtFabH proteins 
The contribution of a particular amino acid residue to the overall KAS-111 activity can be more 
accurately defined by considering its performance in the component half-reactions. In the first 
transacylation reaction, the acyI chain is transferred from its acyl-CoA carrier to the active site 
residue Cys122 thus forming an enzyme-linked thioester. The subsequent decarboxylation of 
malonyl-AcpM produces a carbanion that initiates the condensation reaction by displacing the 
thioester and extending the ACP-bound primer. 
We analysed the transacylase activity of mtFabH and its various mutants by following the 
transfer of [3 H]-C14-CoA to Fabl-l. As expected, no transacylase activity was detected with 
the Cysl22->Ala substituted mutein, consistent with the loss of the active site sulphydryl 
group that forms the acyl thioester (Figure 2.15). Both of the other active site residues, 
His258->Ala and Asn289->Ala, were capable of transacylation but the reaction proceeded at 
a reduced rate suggesting that these residues are not essential for, but contribute, to the 
transfer of the acyl moiety. Somewhat surprisingly, these mutations had a more profound 
effect on acyl transfer than did individual substitutions in residues implicated in acyl-CoA 
binding (Trp42-->Ala, Arg46->Ala and Argl6l->Ala) and even the double-arginine mutant. 
The other double mutation, Trp42Arg I 614AIa demonstrated very low transacylation activity, 
presumably due to a poor affinity for the acyl-CoA substrate. Together these data suggest that 
TrP42 and Argl6l. both play a major role in acyl-CoA binding and thus influence the 
transacylation activity of the enzyme. The effect of the His258 and Asn289 alanine 
substitutions on the transacylation activity is less clear, although modification of active site 
geometry affecting acyl-CoA binding may occur, the possibility that these two polar residues 
may influence the binding of the CoA moiety cannot be ruled out. Again the A213-216 and 
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Thr97->Phe mutants were totally inactive in this assay system suggesting deleterious 
structural changes around the acyl-binding canal. 
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Figure 2.15 Transacylation activity of mtFabH muteins. Transfer of [3H]-myristoyl- 
CoA to the active site cysteine was followed for 15 mins. His6-tagged 
protein was sequestered using Ni2+ charged sepharose beeds and washed to 
remove unbound label. Activity was quantified by liquid scintillation 
counting 
2.4.4 Decarboxylation of malonyl-ACP by wild-type and mutant mtFabH proteins 
Confonnationally-sensitive, urea-containing SDS-PAGE gels have previously been used to 
separate variously substituted acyl-ACPs and was applied to analyse the ability of the mtFabH 
muteins to decarboxylate the donor substrate malonyl-AcpM to acetyl-AcpM. All the muteins 
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in this study exhibited decreased malonyl-AcpM decarboxylation activity. Both ACP or 
AcpM were used with the wild-type mtFabH but no change in activity was observed. The 
catalytic triad residues His258 and Asn289 had previously been implicated in the 
decarboxylation of the malonyl-AcpM. Consistent with this suggestion, the decarboxylation 
activity of His2584Ala was completely abrogated whereas that of the Asn2894Ala mutein 
was markedly reduced. This observation strongly suggests that His258 is essential for this 
half-reaction and that substitution of Asn289 merely influences the rate of the reaction. Again 
both Thr974Phe and the deletion mutation were inactive. All of the other mutant enzymes 
retain their decarboxylation activity but the reaction occurs at significantly reduced rates 
similar to that of the Asn2984Ala mutant. The reason for this reduced activity is not known 
but it is possible that even minor changes to the active site geometry brought about by these 
substitutions could significantly reduce the reaction rate. 
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Figure 2.16 Malonyl-ACP decarboxylation activity of mtFabH muteins. 4.25 Ag of the 
muteins was incubated with radiolabelled malonyl-ACP for 10 min at 
250C. After resolution of the ACP species by conformationally sensitive 
13.3 % acrylamide, IM urea gels, results were visualised by 
autoradiography using Kodak X-omat AR film for 3 days 
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2.4.5 Summary of mtFabH mutein activities 
Table 2.1 Activity of mIFabH muteins in P-ketoacyl-ACP synthase and part-reaction 
assays. 
Substitution mtFabH' 
nmol/min/mg 
Transacylation b 
nmol/min/mg 
Malonyl-AcpM 
decarboxylation 
mlFabH 194.44 4.17 100.00 
Trp42->Ala 41.92 3.72 30.08 
Arg464AIa 14.23 3.26 0.79 
Arg1614AIa 18.63 2.49 8.67 
Trp42 Arg 161 -->Ala 0.46 0.75 5.09 
Arg46 Arg I 614AIa 0.61 2.15 9.68 
Cysl224AIa 0.48 0.04 2.35 
His258->Ala 0.89 1.63 0.68 
Asn289->Ala 0.99 0.99 2.24 
Thr974AIa 0.91 0.02 0.84 
A213-216 0.60 0.00 0.97 
The assays were performed in triplicate using AcpM and a C16-CoA primer and activity 
assessed by scintillation counting method is described in detail section 2.3.5.1. 
b The transacylation activity of mtFabH and its muteins was deten-nined by quantifying the 
binding of [3 H]-C14-CoA to I gg protein by liquid scintillation counting of protein-bound 
radio-labelled acyl chains captured on Ni2'-Charged chelating Sepharose beads, as detailed 
in section 2.3.5.2. 
c Direct densitometric reading from autoradiogram (Figure 2.16) normalised to activity of 
mtFabH with AcpM and expressed as a percentage. 
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2.4.6 Analysis of compound sensitivities of wild-type mtFabH 
The susceptibility of the KASIII activity of mtFabH to various antibiotics were assessed by 
quantifying the effect of addition of each compound over a range of concentrations through 
their incorporation into the P-Ketoacyl-ACP synthase III assay. As previously observed (Choi 
el aL, 2000b) mtFabH is susceptible to thiolactomycin OC50 =5 pg/ml), triclosan (IC50 = 20 
gg/ml) and hexachlorophene (IC5o =6 gg/ml). No inhibition was seen with any of the other 
members of our panel antibiotics/inhibitors used in this study (Table 2.2). 
Table 2.2 Antibiotic sensitivity study of mtFabH. IC50 calculations were done using 
the direct assay method and assessed by scintillation counting method 
using palmitoyl-CoA. 
Antibiotic 
OC50 = 
Ag/ml) 
TLM 5 
HEX 6 
TRI 20 
CER >50 
ISO >50 
4-PY >bu 
P-ACID >50 
DIAZ >50 
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2.5 Discussion 
The genome of M tuberculosis H37Rv encodes several structurally and functionally related 
0-ketoacyl-ACP synthase enzymes/domains (Cole et at, 1998). These represent an important 
family of condensing enzymes that play key roles in the biosynthesis of fatty acids, 
polyketides and mycolic acids in mycobacteria (Cole et al., 1998; Kremer et al., 2000b). In 
terms of fatty acid biosynthesis, M tuberculosis H37Rv utilises FAS-1 (fas, Rv2524c) for de 
novo fatty acid synthesis and three KAS enzymes (Cole et al, 1998) encoded by m(fahH, kasA 
and kasB (Choi et at, 2000b; Kremer et al., 2002c; Mdluli et al., 1998; Schaeffer et at, 2001) 
for the further elongation of the acyl chain. The latter pair occupy neighboring loci (Rv2245- 
Rv2246) which are immediately downstream of acpM and are also clustered with jahD and 
accD6 consistent with a role in FAS-II (Cole et al., 1998; Kremer et al., 2000a). Similarly, 
the FAS-II employed by E. coli for de novo synthesis of fatty acids contains three KAS 
enzymes. Fabl-l initiates this synthesis by condensation of an acetyl-CoA primer with 
malonyl-ACP (Campbell & Cronan, 2001; Tsay et al., 1992). In contrast, FabB and FabF 
utilise acyl-ACP primers for condensation with malonyl-ACP (Campbell & Cronan, 2001; 
Magnuson et al., 1995). Choi et al. (2000b) showed that mtFabH corresponds to the E. coli 
KAS-111 enzyme (FabH), although its substrate specificity varies, preferring C12-CoA and C14- 
CoA rather than acetyl-CoA substrates. Thus, mtFabH is envisaged as a pivotal link between 
FAS-1 and FAS-11, condensing the CoA-bound products of FAS-1 with malonyl-AcpM, which 
following a complete cycle of FAS-11, provides the acyl-AcpM primers for further extension, 
presumably by KasA/B (Choi et al., 2000b). Consistent with this hypothesis KasA and KasB 
show a clear preference for AcpM-bound primers over acyl-CoA (4 % activity with C16-CoA 
of that with C16-AcpM) (Kremer et al., 2002c; Schaeffer et at, 200 1). 
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In this study, we sought to analyse the influence of the ACP partner on catalysis and to 
confirm the roles of several key residues suggested by the recent determination of the m1FabH 
Crystal structure. Analysis of mtFabH-catalysed malonate incorporation into P-ketoacyl-ACP 
using either AcpM or ecACP demonstrated an ACP-specific shift in the acyl-CoA chain 
length preference. The optimal acyl-CoA primer determined for ecACP was C12-CoA with 
both C8- and Clo-CoAs being efficiently extended and longer acyl-CoAs representing very 
poor substrates. In contrast, when AcpM was used as the acyl carrier, malonate incorporation 
continued to increase with the acyl-CoA chain length to an apparent optimum with C18-CoA. 
Sequence alignment of AcpM with ecACP revealed that the former bears a 33 amino acid- 
extended carboxy terminus (Wong et aL, 2002). It has been suggested that this extension may 
have an effect on protein: protein interactions and may also interact with the bound acyl chain 
(Wong et al., 2002). Molecular docking of E. coli ACP with ecFabH has been modelled 
(Zhang et al., 2001) and, consequently, amino acid residues contributing to this interaction 
were identified and confirmed by mutagenesis. However, many of the important residues are 
not conserved in AcpM, therefore suggesting that the KAS-111: ACP interaction differs 
between the mycobacterial and the E. coli counterparts. One possibility is that the carboxy 
terminal tail of AcpM interacts with a surface region of mtFabH to induce confon-national 
changes that might alter its substrate specificity. However, whether interaction with this C- 
terminal extension may manipulate the hydrophobic canal of mtFabH to allow successful 
interaction with longer acyl-CoA primers remains to be demonstrated. 
Analysis of muteins showed that Ala substitutions of catalytic triad residues (Cys 122, His258, 
Asn289) completely abrogated KAS-111 activity, thus confirming these as vital residues for the 
condensation reaction. The single substitutions of the acyl-CoA binding residues 
(Trp42->Ala, Arg46->Ala and Arg1614AIa) showed reduced KAS-111 activity, suggesting a 
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non-essential role for these residues in catalysis, consistent with their predicted function in 
binding of acyl-CoA primers (Scarsdale et al., 2001). The two double muteins 
(Trp42Arg 161 ->Ala and Arg46Arg I 614AIa), however, showed a more profound effect with 
almost complete loss of activity. We propose that the singly-mutated proteins interact with 
acyl-CoA substrate with reduced affinity. The combination of amino acid substitutions in the 
double mutants leads to loss of KAS-111 activity, suggesting that at least two of these three 
residues are required for efficient interaction of acyl-CoA and mtFabH. 
The Thr974Phe substitution was created in an attempt to emulate the hydrophobic acyl- 
binding canal of ecFabH, which is partially blocked by the side chain of a Phe residue 
(Scarsdale et al., 2001). We envisaged that this might alter the substrate specificity of 
mtFabH limiting the enzyme to the shorter primers C2- and C4-CoA. Unexpectedly, this 
substitution completely abolished the enzyme activity. Although this insertion of a Phe 
residue into the hydrophobic canal may have caused deleterious changes to the structure of the 
protein inactivating mtFabH, we can speculate that the acyl-CoA preference of mtFabH may 
be governed by the degree of hydrophobic interaction between the incoming acyl chain and 
the hydrophobic binding canal. In such a scenario, longer acyl chains may be preferred by 
virtue of a more extensive hydrophobic interaction. Introduction of the Phe residue may have 
precluded such an extensive interaction thus explaining the inactivity of the mutein. 
Consistent with this hypothesis, our results show that mtFabH possesses weak KAS-111 
activity with a C6-CoA primer; which may represent the shortest primer with an adequate Km 
to allow detectable activity. 
Previous studies suggested that the hydrophobic canal capping residues (A213-216) may limit 
the capacity of mtFabH to elongate acyl-CoA substrates bearing C16- and shorter acyl chains 
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(Scarsdale et al., 2001). However, deletion of this peptidic domain did not allow the 
extension of longer acyl-CoA primers, and as with the Thr97->Phe mutation, no activity was 
detected with any of the acyl (C2-C2o)-CoA primers. It remains possible that this mutation 
profoundly affects the overall folding of the protein. 
The contribution of a particular amino acid residue to the overall KAS activity can be more 
accurately defined by considering its performance in the component half-reactions (McGuire 
et al., 2001). In the first transacylation reaction, the acyl chain is transferred from its acyl- 
CoA carrier to the active site residue Cys 122, thus fori-n ing an enzyme-I inked th ioester (Figure 
2.4A). The subsequent decarboxylation of malonyl-AcpM produces a carbanion that initiates 
the condensation reaction by displacing the thioester and extending the ACP-bound primer 
(Figure 2.413). No transacylation activity was observed with the Cysl224AIa substituted 
mutein, consistent with the loss of the active site sulphydryl group that forms the acyl 
thioester. In contrast, both His258->Ala and Asn2894AIa muteins catalyse the transacylation 
reaction, although to a reduced rate compared to the mtFabH. This suggests that these residues 
are not essential, but do influence the transfer of the acyl moiety. Somewhat surprisingly, 
these mutations had a more profound effect on acyl transfer than did individual substitutions 
in residues previously implicated in acyl-CoA binding. The transacylation activity of muteins 
substituted at Trp42, Arg46 and Argl6l mirrored the effects seen in the KAS-Ill assay, thus 
confirming that these residues participate in acyl-CoA binding. Although modification of 
active site geometry may affect acyl-CoA binding, His258 and Asn289 are polar residues, 
which may also influence the binding of the CoA moiety or aid the transfer of the acyl chain 
to the active site Cys. Interestingly, Ala substitution of E. coli FabB at His289 also resulted in 
reduced transfer Of C14 acyl chains to the active site Cys (McGuire et aL, 2001). As the 
mtFabH His2584AIa mutein retains activity, it is unlikely that this active site residue 
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functions as a general base abstracting a proton from Cys122 to promote acyl transfer as has 
been shown for chalcone synthase (Jez & Noel, 2000). Rather, the stabilisation of the Cys122 
thiolate ion, which facilitates transacylation, appears to be promoted via the cc-helix dipole 
effect as in ecFabH (Davies et al., 2000). 
In ecFabI-L active site residues His244 and Asn274 are both required for decarboxylation of 
malonyl-ACP. The side-chain nitrogen atoms of these two residues form strong hydrogen 
bonds with the thioester carbonyl oxygen, effectively stabilising the negative charge it gains 
during catalysis. Mutation of either of these residues almost eliminated decarboxylation 
activity (Davies et al., 2000). The reduced ability of some of our mtFabH muteins to 
decarboxylate malonyl-AcpM implicated several residues in promoting efficient 
decarboxylation. Our results show that the His258->Ala and Asn289->Ala substitutions 
almost completely abrogated the decarboxylation activity of mtFabH. These observations 
strongly suggest that His258 is essential for this half-reaction and that substitution of Asn289 
merely influences the rate of the reaction. Nearly all of the other mutant enzymes retain their 
decarboxylation activity but the reaction occurs at significantly reduced rates similar to that of 
the Asn298->Ala mutant. The reason for this reduced activity is not known but it is possible 
that changes to the active site geometry brought about by these substitutions could 
significantly reduce the reaction rate. Surprisingly, Arg464AIa also drastically reduces the 
decarboxylation activity of mtFabH. In the absence of structural information regarding the 
mode of binding of AcpM by mtFabH, it remains possible that this residue plays a major role 
in the binding of AcpM, possibly interacting with the phosphopantetheine moiety of AcpM. 
Maybe incorporating interactions with such a residue may improve the efficacy of novel 
inhibitors of these enzymes. Interestingly, some recovery of malonyl-AcpM decarboxylation 
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activity relative to Arg46->Ala is seen in the Arg46Argl6l4AIa mutant, possibly indicating 
the importance of local charge distribution to efficient decarboxylation. 
The increasing incidence of MDR-TB intensifies the urgent need for novel targets and leads 
for anti-TB drug development. With this in mind, we examined the specific effect of several 
inhibitors of fatty acid synthesis on mtFabH. As previously observed (Choi et aL, 2000b; 
Jackowski et al., 1989) ecFabH and mtFabH are both susceptible to TLM inhibition (IC5o 5 
pg/ml), the data observed in this study supports these observations with identical ICso values 
being observed for the mtFabH. Our in vitro demonstration of CER resistance is consistent 
with current hypothesis; the Cys-His-Asn catalytic triad of the type III KAS (FabH) enzymes 
correlating with resistance and Cys-His-His catalytic triad of FabB/F and KasA/B enzymes 
correlating with sensitivity to cerulenin (Choi et al., 2000b). Interestingly TRC also inhibited 
the mtFabH in vitro (IC5o 20 Rg/ml) as no increased resistance against TRC in a strain 
overproducing mtFabH, suggesting that mtFabH is not a target in vivo (result provide by Dr L. 
Kremer, Institut Pasteur de Lille). 
Previous investigations had demonstrated M tuberculosis InhA, and its E. coli homolog Fabl, 
as targets of TRC (Kuo et al., 2003; McMurry et al., 1998; McMurry et al., 1999; Parikh et 
al., 2000). Likewise, the structurally-related HEX, another Fabl inhibitor (Marcinkeviciene et 
al, 2001), also inhibited mtFabH with an IC5o value of 6 pgIml. Taken together these data 
may suggest some cross over in terms of their modes of action with mtFabH and its FAS-11 
partner, InhA. The inhibition of mtFabH by TRC and HEX is exciting and further 
investigations are required to understand their modes of action and may prompt the 
development of new lead compounds as anti-mycobacterial drugs. 
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The first part of any new study would be that identification of AcpM specific binding 
residues, this would in turn allow a site-directed mutagenesis study of decarboxylation activity 
in relation to substrate binding via AcpM. Residues required for protein: protein interactions 
are attractive targets for investigation as these could in turn become targets of synthesised 
inhibitors and antibiotic analogues. The co-crystallisation of mtFabH with both malonyl- 
AcpM and E. coli ACP would aid the elucidation of the molecular basis for the substrate 
specificity changeswe presume to be dependent upon the extended regions of carrier proteins 
such as AcpM. This would indeed show the structural effects that the ACP has on the 
activated protein and in turn open new areas of interest with regards to inhibition, as this 
would hopefully identify residues that can be manipulated to allow the binding of blocker 
substrates or hinder substrate-binding altogether. The investigation of the function of specific 
amino acid residues in this study along with the identification of an mtFabH inhibitor may 
also aid the development of future antibiotics. 
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3.1 Introduction 
P-Ketoacyl ACP synthases (KAS) form new carbon-carbon bonds in a Claisen style 
condensation reaction performed in three steps. Firstly, transfer of an acYl-group from ACP to 
the enzyme, secondly decarboxylation of the elongation substrate, and finally condensation of 
the acyl primer with the elongation substrate. A number of key residues of E. coli KAS I 
(FabB) have been implicated in these partial reactions Cys163, His298, Asp306, Glu309, 
Lys328, and His333 (McGuire et al., 2001). Mutation of these residues revealed that the 
active site Cys163 is not required for decarboxylation, whereas His298 and His333 are 
essential. Neither of the histidine residues are essential for increasing the nucleophilicity of 
Cys163 to enable transfer of the acyl-group. Maintenance of the structural integrity of the 
active site by Asp306 and Glu309 is required for decarboxylation, but not for acylation 
(McGuire et al., 2000; McGuire et al., 2001). Another facet of catalysis revealed by 
mutational analysis was that the acylation activity of KAS I is inhibited by free ACP at 
physiological concentrations (McGuire et al., 2001). Differences in the inhibitory response by 
individually mutated KAS I proteins indicate that interaction of free ACP with Cys163, 
Asp306, Glu309, Lys328, and His333 might form a sensitive regulatory mechanism for the 
transfer of acyl groups (McGuire et al., 2001; Olsen et al., 2001). A detailed comparison of 
the active site of KAS enzymes using three-dimensional templates reveals differences in both 
the geometry and the catalytic role of key residues (Dawe et al., 2003). The template based on 
the catalytic cysteine and two histidines in KAS I and 11 is totally specific for this family. 
However, the role of the histidine residues in catalysis differs between KAS 1,11,111 and 
thiolase of chalcone synthases (Heath & Rock, 2002). The strucuture of KAS I Cysl634Ser 
mutant with covalently bound CIO and C12 acyl-ACP was elucidated to 2.40 and 1.85 A 
resolution, respectively (Olsen et al., 2001). In both structures the oxo group was orientated to 
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make hydrogen bonds to the main amides of Ser163 and Phe392. The acyl chain folds into an 
extended U-shape in the hydrophobic canal due to sidechain of Phe20 I, which points into the 
acyl binding pocket, thereby forcing the acyl chain to bend (Olsen et al., 2001). KAS I 
extracts of spinach leaves were highly active, elongating acyl-ACP's carrying from C2 to C149 
with C6-ACP being the most effective substrate. Interestingly, C16-ACP was far less effective 
and Ci8-ACP almost inactive (Shimakata & Stumpf, 1983). KAS I has been shown to be 
sensitive to the ACP released during the acyl transfase reaction, with 50 % inhibition 
occurring with 0.17 pM ACP which is close to the physiological concentration of holo-ACP 
(0-13 ptM) (McGuire et al., 2000). The KAS I dimer revealed an asymmetric binding of the 
two substrates (acyl-ACP and malonyl-ACP). 
The analysis of mutations of KAS I active site histidine residues involved in malonyl-ACP 
decarboxylation suggested that one donates a proton to the malonyl thioester group, and the 
other abstracts a proton from the leaving group (Olsen et aL, 2001). Decarboxylation does not 
take place readily unless an acyl group is positioned at the active-site cysteine residue 
(Witkowski et al., 1999). The crystal structure of the complex of E. coli KAS 1, and cerulenin 
revealed that the inhibitor is bound in a hydrophobic pocket formed at the dimer interface. 
Cerulenin is covalently attached to the active site cysteine through its C2 carbon atom (Figure 
1.27). The location of the inhibitor in the active site is not optimal, and there is thus room for 
improvement through structure-based drug design. TLM appears to mimic malonyl-ACP in 
the FabB active site by forming strong hydrogen bonds with the two catalytic histidines. The 
unsaturated alkyl side chain interacts with a small hydrophobic pocket stabilised by 7r stacking 
interactions (Moche et al., 1999). A FabB His333->Asn mutation was prepared to convert the 
FabB His-His-Cys active site triad into the FabH His-Asn-Cys configuration to test the 
importance of the two His residues in TLM and cerulenin binding. The mutant was 
101 
CHAPTER3 fý-KETOACYL-ACP SYNTHASE (KasA) 
significantly more resistant to both antibiotics than the wild-type, illustrating that the two- 
histidine active site architecture is critical to protein-antibiotic interactions (Price et aL, 2001). 
Mycolic acids are produced by successive rounds of elongation catalysed by FAS-11 as 
described in Chapter 1. A key feature in the elongation process is the condensation of a two- 
carbon unit from malonyl-acyl-carrier protein (ACP) to a growing acyl-ACP chain catalysed 
by a P-ketoacyl-ACP synthase A (KasA). KasA (Rv2245) from M. tuberculosis is a 416 
amino acid residue-containing enzyme of 43316 Da that elongates meromycolate precusors. It 
utilises prefers C16-ACP rather than short-chain acyl-ACP primers, unlike E. coli and other 
bacterial KAS enzymes that utilise C4-ACP (Magnuson et al., 1993; Schaeffer et al., 2001). 
Interestingly, the activities of KasA and KasB both increased with use of M. tuberculosis 
AcpM, suggesting structural differences between mycobacterial AcpM and E. coU ACP may 
affect their recognition by these enzymes (Schaeffer et al., 200 1). 
The design and synthesis of several TLM derivatives have led to the recognition of 
compounds more potent both in vitro against fatty acid and mycolic acid biosynthesis and in 
vivo against M tuberculosis (Senior et al., 2003). Genotypic analysis of resistance to INH in 
M tuberculosis showed that mutations in KasA were present in 16 out of 160 strains (10 %). 
However, Gly3l2->Ser was also present in 6 of 32 (19 %) susceptible strains (Lee et al., 
1999). Mdluli et al. (1998) have shown that INH treatment of M tuberculosis inhibits mycolic 
acid synthesis and is accompanied by a marked up-regulation of both AcpM and KasA, which 
are linked genetically. They also proposed KasA to be an INH target in M tuberculosis, on 
the basis of the detection of an interaction between INH and AcpM. A recent study suggests 
that KasA belongs to FAS-11 and participates in mycolic acid biosynthesis (Kremer et al., 
2000b). Therefore due to the importance of the FAS-11 elongation process and the possible 
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participation of KasA in relation to INH inhibition (Mdluli et aL, 1998), a number of studies 
were initiated to determine the role of KasA in mycolic acid biosynthesis. Firstly, the in vivo 
influence of KasA on mycolate production (cc versus oc'). Secondly, analysis in vitro of its 
overall effect on FAS-11 activity within an enriched cytosolic protein fraction, and thirdly, its 
precise enzymic activity in a classical condensation assay using highly purified recombinant 
KasA, as well as its sensitivity to cerulenin, a well-known KAS inhibitor (Campbell & 
Cronan, 2001). Our studies demonstrate that INH does not target KasA as observed in vitro, 
consistent with InhA being the primary target of INH (Kremer et al., 2003). KasA was 
assayed in vitro (Kremer et aL, 2002c) in the presence of various drugs and activated INH did 
not inhibit KasA activity, whereas CER was shown to be an effective inhibitor which 
demonstrated that INH does not target KasA (Kremer et al., 2003). 
The focus of the following study was to investigate the enzymological properties of KasA and 
analyse the role of particular residues by site-directed mutagenesis. 
3.2 Materials and methods 
3.2.1 Cloning 
KasA was cloned according to the conditions for PCR reported in Table 3.1. The kasA gene 
was amplified from genomic DNA isolated from M. tuberculosis H37Rv. PCR primers were 
created to allow the restriction of the PCR product followed by ligation into an appropriately 
digested expression vector. 
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Table 3.1 (A) PCR recipe and (B) PCR conditions for kasA 
(A) 
2 gI 5' Cloning Primer (100 pmol/ml) 
_2 
ýd 3' loning Primer (100 pmol/ml) 
.1 
gl Genomic DNA (H37Rv) (I ýLg/gl) 
_2 
gl dNTP's (25 mM each type) 
10 ýd Thermostable Buffer (I Ox) 
8 gl DMSO (optional) 
.2 
gl MgSO4 (optional) (100 mM) 
I PLI 
- 
Deep Vent " DNA polymerase 
(2000 U/ml) 
2 El ddH20 
I loo LI Final Volume 
(B) 
95*C 5 min 
84*C oo 
94*C I min 35 l 68*C I min 20 sec cyc es 
72*C 10 min 
4*C 1 00 
Cloning primers used in the PCR reactions can be found in Appendix 1. The PCR product was 
electrophoresed on I% agarose. DNA was visualised using EtBr. The appropriate DNA 
fragment was excised from the gel and extracted using the Qiagen Gel extraction kit. The PCR 
product purified using the Qiagen Gel extraction kit the cut DNA fragment was again 
extracted from the gel was digested. The concentration of the cut PCR product and similarly 
digested plasmid DNA was assessed by DNA electrophoresis and EtBr staining. The cut PCR 
product was ligated with the cut vector. The ligation mix was used to transformed E. coli TOP 
10 cells. Screening was performed by double digestion (pET28a, pET23b, pQE60) or PCR 
screening with orientation-specific primers and the lower cloning primer (pVV]6, pSD26) 
followed by analysis by electrophoresis on I% agarose and staining with EtBr. The DNA 
fidelity of the constructs were verified by sequencing. 
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3.2.2 Cloning of M. smegmatis kasA and expression in M. smegmatis 
PCR amplification of kasA was performed using M. smegmatis genomic DNA in the presence 
of the upstream primer 5'-TGA CCA GGC CTT CCA CTG CCA ACG GCG GTT AC-3, and 
the downstream primer 5'-GGA ATT CCG CTC TGG CCG TCG AGC AGC TTC TTC-3' 
under the conditions in Table 3.3. The downstream primer contains an EcoRl restriction site 
(underlined). The 1407 bp fragment corresponding to the kasA coding sequence was then 
digested with EcoRI and ligated with the previously ARuNIlEcoRI-restricted pMV261. The 
resulting plasmid, designated pMV261-kasA_MSG, was used to transform M. smegmatis. A 
further construct pMV261-kasA_mtb from Kremer et aL (2000b) was used to transform M. 
smegmatis. 
3.2.3 Expression and purification of M. tuberculosis AepM and mtFabD (malonyl-CoA 
: ACP transacylase) in E. coli 
Both pET28a-acpM and pET28a-mtfabD constructs by Kremer et aL (2001 a) were utilised in 
the production of the recombinant proteins. The vectors were used to transformed E. coU 
C41 (DE3) and purification of recombinant holo-AcpM, C16-AcpM and mtFabD was achieved 
using conditions described previously in Kremer et al. (2001 a). An overnight culture of E. coli 
C41 (DE3) carrying pET28a-acpM was used to inoculate IL of LB broth supplemented with 
25 pg/ml kanamycin and incubated at 37"C until OD600nm was 0.75. The culture was then 
induced with I mM IPTG. Growth was continued overnight at 16"C, and cells were harvested 
by centrifugation. The pellet was resuspended in 20 mM phosphate buffer (pH 7.4), 0.5 M 
NaCl, 50 mM imidazole, containing DNase, RNase. Bacteria were disrupted by passing twice 
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through a French pressure cell, and the resulting extract was clarified by centrifuged at 
27,000 xg for 60 min at 4 "C. The supernatant was collected and applied onto a Ni2+-charged 
His-Trap column (I ml). The column was extensively washed with phosphate buffer (pH 7.4), 
0.5 M NaCl, 50 mM imidazole and eluted with a stepwise gradient of imidazole (50-500 mM). 
I ml fractions were collected, and the presence of AcpM was detected by electropheresis on 
15 % SDS-PAGE and staining with coomassie blue stain. Fractions containing pure AcpM 
were pooled, dialyzed against 50 mM Tris-HCI (pH 7.4), 50 mM NaCl, 2 mM EDTA, 10 % 
glycerol, and stored at -20'C. The M. tuberculosis holo-AcpM obtained above was further 
purified using a Thiopropyl-Sepharose 6B column equilibrated with binding buffer (0.1 M 
Tris-HCI (pH 7.5), 0.5 M NaCl). The products obtained from the Ni2+-charged His-Trap 
column were loaded onto the column and after several washes with binding buffer; holo- 
AcpM was eluted using binding buffer containing 50 mM P-mercaptoethanol. Purified holo- 
AcpM was dialyzed against 50 mM Tris-HCI (pH 7.4), 50 mM NaCI, 2 mM EDTA, 10 % 
glycerol and stored at -20'C. pET28a-mffiabD was used to transforrn strain E. coli C41 (DE3) 
for overproduction of the recombinant protein. Recombinant mtFabD was purified using the 
same conditions as described above for AcpM, dialyzed against 50 mm Tris-HCI (pH 7.4), 
50 mm NaCI, 2 mm EDTA, 10 % glycerol, and stored at -20 'C. The purity of mtFabD was 
evaluated by electrophoresis on 12 % SDS-PAGE and staining with Coomassie blue stain. 
3.2.4 Preparation of cytosolic enzyme fraction 
M. smegmatis (30 g [wet weight]) was washed and resuspended in a buffer (30 ml) containing 
100 mM potassium phosphate (pH 7.0), 1 mM EDTA, 5 mM dithiothreitol, 5 MM MgC]2, and 
2 mM phenylmethylsulfonyl fluoride at 4'C and subjected to probe sonication (1-cm probe; 
Soniprep 150; MSE Ltd., Crawley, Sussex, United Kingdom) for 10 min in lOx 60-s pulses 
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with 90-s cooling intervals between pulses. The whole sonicate was centrifuged at 27,000 xg 
for 30 min at 41C, and the supernatant was recentrifaged at 100,000 xg for Ih to yield the 
soluble pale yellow cytosolic enzyme fraction with a typical protein concentration of 8 to 10 
mg/ml and containing FAS-1 and FAS-II enzyme activities. The 40-80 % saturated 
ammonium sulphate precipitate, containing FAS-1 and FAS-11 activities, was collected after 
centrifugation at 27,000 xg and dissolved in 3 ml of buffer A (100 mM potassium phosphate 
buffer, pH 7.0,1 mM EDTA I mM dithiothreitol 5 MM MgCl2) and dialysed overnight 
against 2L buffer A. 
3.2.5 FAS-I and FAS-11 assays 
The standard reaction mixture for the incorporation of radioactivity from [2- 14C]malonyl-CoA 
into C16 to C24 fatty acids catalysed by FAS-1 was composed as follows: 100 mM potassium 
phosphate pH 7.0,5 mM EDTA, 5 mM dithiothreitol, 300 ýM acetyl-CoA, 100 gM NADPH, 
100 gM NADH, I pLM flavin mononucleotide, 500 pM cc-cyclodextrin, 20 piM malonyl-CoA, 
100,000 cpm of [2- 14C] malonyl-CoA, and 100 pil of the cytosolic enzyme preparation (I to 2 
mg of protein) in a total volume of 500 ld. Similarly, the standard reaction mixture for 
incorporation of radioactivity from [2_14C]malonyl-CoA into C24 to C30 fatty acids catalysed 
by FAS-11 contained the following: 100 mM potassium phosphate buffer (pH 7.0), 5 mM 
EDTA, 5 mM dithiothreitol, 100 pM palmitoyl-CoA, 140 gM NADPH, 140 pM NADH, 180 
Ag of ACP, 40 pM malonyl-CoA, 200,000 cpm of [2- 14C]malonyl-CoA, and 100 pLI of the 
cytosolic enzyme preparation (I to 2 mg of protein) in a total volume of 500 pl. 
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In both the FAS-I and FAS-II assays, reactions were performed in triplicate at 37'C for 30 
min and terminated by the addition of 500 gl of 20 % potassium hydroxide in 50 % methanol 
at IOOT for 30 min. Following acidification with 300 gI of 6M HCl, the resultant 14c- 
labelled fatty acids were extracted three times with petroleum ether. The organic extracts were 
pooled, washed once with an equal volume of water, and dried in a scintillation vial prior to 
counting. 
3.2.6 KasA assay 
Mycobacterial KasA assays were perfortned according to the condensation assays developed 
for E. coli KAS enzymes (Garwin et aL, 1980). Initially, assay components were mixed 
together in a batch fashion. The amounts stated correspond to those of a single reaction, which 
are scaled up proportionately to the number of assays performed. Holo-AcpM (40 gg) was 
incubated on ice for 30 min with P-mercaptoethanol (0.5 ýLmol) in a total volume of 40 gl. [2- 
14C]malonyl-CoA (6.78 nmol, 1.66 kBq; Amersham), mtFabD (40 ng) and 25 gl of IM 
potassium phosphate buffer, pH 7.0, were added. The reaction mixture was held at 37*C for 
20 min to allow the mtFabD-catalysed transacylation of holo-AcpM using [2-1 4 C]malonyl- 
CoA to reach equilibrium. C16-AcpM (22.5 pLg) was added to obtain a final volume of 89 gl. 
The reaction mixture was then dispensed into 1.5 ml microcentrifuge tubes and a 10 gI aliquot 
of KasA (0.25 gg) was added. The reaction was held at 37'C for I h, after which the reaction 
was quenched by the addition of 2 ml of a NaBH4 reducing solution (5 mg/ml NaBH4 in 0.1 
M K2HP04,0.4 M KCI and 30 % (v/v) THF) to convert the P-keto-Cig-AcpM into Cis-1,3- 
diol. This reaction was held at 37'C for at least I h. The completely reduced product was 
extracted twice with 2 ml of water-saturated toluene. The combined organic phases from both 
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extractions were pooled and washed with 2 ml of toluene-saturated water. The organic layer 
was removed and dried under a stream of nitrogen in a scintillation vial. The 14C, 8-1,3-diol 
product was then quantified by liquid scintillation counting using 5 ml of EcoScintA (National 
Diagnostics, Hull, U. K. ). 
3.2.7 Site-directed mutagenesis 
3.2-7.1 QuikChange site-directed mutagenesis 
The QuikChange site-directed mutagenesis kit is used to make point mutations, switch amino 
acids, and delete or insert single or multiple amino acids. It utilises a PfuTurbo DNA 
polymerase to replicate both plasmid strands with high fidelity and without displacing the 
mutant oligonucleotide primers. The basic procedure utilises a supercoiled double-stranded 
DNA vector with the insert of interest and two complementary synthetic oligonucleotide 
primers containing the desired mutation. The oligonucleotide primers are extended during 
temperature cycling by PfuTurbo DNA polymerase using the vector as a template, generating 
a mutated plasmid containing staggered nicks. The Dpn I endonuclease (target sequence: 5'- 
GM6ATC-3') treatement of the PCR reaction digests the parental DNA template and selects 
for the mutation-containing DNA which can be selected for asper the normal plasmid. 
Possible interesting functional amino acid residues for site-directed mutagenesis were 
identified by sequence alignments and structural analysis of KasA homologues. The 
QuikChange site-directed mutagenesis kit was used to make point mutations of pE'1'28-kasA 
using the primers described in Table 3.2. and the PCR reaction and recipes as shown below in 
Table 3.3. 
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Table 3.2 Site directed mutagenesis primers for kasA catalytic triad mutations. 
Mutagenic substitutions are highlighted in bold 
Cysl7l->Ala I UP 151 JCCC CGG TGT CGG CCG CTT CGT CGG GCT CGG 31 
1 D)WN 1 31 GGG GCC ACA GCC GGC GAA GCA GCC CGA GCC 51 
His3ll4AIa ýP 
-! 
ýp 1 51 GAC CAC GTC AAC GCG GCC GGC ACG GCG ACG 31 
ID'WN 1 31 J CTG GTG CAG TTG CGC CGC CCG TGC CGC TGC 51 
Lys340->Ala I up- 1 51 J GCG GTG TAC GCG CCG G-CG TCT GCG CTG GGC CAC 31 
J DMN 1 31 J CGC CAC ATG CGC GGC CGC AGA CGC GAC CCG GAG 51 
His3454AIa 1 1 51 1 GAA GTC TGC GCT GGG CGC CTC GAT CGG CGC G 31 
1 DVrN_ L3, I CTT CAG ACG CGA CCC GCG GAG CTA GCC GCG C 51 
Table 3.3 PCR recipe (A), PCR conditions (B) for QuikChange site-directed 
mutagenesis of KasA 
(A) 
-5 
gi I Ox Reaction buffer 
I RI dsDNA template (pET28-kasA) 
I A] 5' Mutant primer (100 pmol/ml) 
I gl 3' Mutant primer (100 pmol/ml) 
I ýLl dNTP mix (25mM each type) 
40 gl ddH20 
I gi I PfuTurbo DNA polymerase (25 
(B) 
95'C 30 seconds 
95'C 30 seconds 
55'C I minute 
- 
I 
16 cycles 
68'C I rninute/Ký 
After the PCR reaction, the methylated double stranded template DNA was removed by 
digestion with DpnI. The digest mixture was transformed into supercompetent E. coli XLI- 
Blue cells by heat shock and plated on selective media containing the relavent antibiotic. 
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3.2.7.2 Megaprimer mutagenesis 
The mega primer method involved amplification of a "mega primee, which contained the 
required point mutation. Using the upper cloning primer and the lower mutagenic primer, a 
standard PCR reaction was used to create the "megaprimee' (Sarkar & Sommer, 1990). In 
cases where the PCR reaction did not yield significant quantities of product, the opposite 
primers were used, i. e. the lower cloning primer and the upper mutagenic primer. The 
products from this "Phase I" PCR were separated on I% agarose, and visualised with EtBr 
staining. DNA was extracted from an excised block of agarose using the Qiagen Gel 
extraction kit. The PCR mix in Table 3.3 was modified for the "Phase 11" reaction. The 
extracted mega primer (24 gl) and I ýd of the opposite cloning primer was used in the 
reaction. Electrophoresis of the Phase 11 PCR products confirmed the generation of full- 
length kasA alleles, which were purified and digested with EcoRI and NheI and assessed by 
DNA electropheresis. The cut DNA fragment was again extracted from the gel, and ligated 
with cut pET28a vector. The ligation reaction was carried out at 16"C overnight and the 
products were used to transform E. coli Top 10 cells. Transformants were cultured in liquid 
media containing kanamycin overnight at 370C and plasmid DNA extracted using the Qiagen 
Miniprep Plasmid extraction kit. Screening for recombinant plasmids was performed by 
double digestion with EcoRI and NheI and analysis by electrophoreses on I% agarose and 
visualisation with EtBr. The DNA insertions were sequenced to verify the absence of PCR 
anomalies and to verify the fidelity of the construct. The primers used in the mega primer 
method with mutations (bold) and cloning indicated in Table 3.4. 
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Table 3.4 Site directed mutagenesis primers for kasA further mutations. Mutagenic 
substitutions are highlighted in bold 
Asp664Asn GC 3' 
JDWN 131 1CCC CCA GTG GAG TTC TTA GGC CAG CTG TCG 51 
Glyl 154AIa U T U L GTC GGC ACC GCT CTA GGT GGA GCC 31 
D N 131 1CAA CAA CAG CCG TGG CGA GAT CCA CCT CGG 51 
Lys] 164AIa JUP 15 1 JGTT GTC GGC ACC GGT GCA GGT GGA GCC GAG 31 
IDWN 131 1CAA CAG CCG TGG CCA CGT CCA CCT CGG CTC 51 
Alai 194Trp JUP 15 1 JGGC ACC GGT CTA GGT GGA TGG GAG AGG ATT GTC GAG 31 
ID" 13' ICCG TGG CCA GAT CCA CCT ACC CTC TCC TAA CAG CTC 5' 
Arg]214Lys GGT GGA GCC GAG AAG ATT GTC GAG AGC 31 
OWN 131 1GAT CCA CCT CGG CTC TTC TAA CAG CTC TCG 51 
_ 
Ala]41-->Trp TG 3' 
AGG GGC GAC ACC CAA GTC TAC TAG TAC 5' 
Pro2064AIa JUP 15 1 ICCC ATC GAG GCG CTG GCC ATC GCG GCG TTC 3' 
_ 
JDWN 131 1GGG TAG CTC CGC GAC CGG TAG CGC CGC AAG 51 
Phe2lO-->Ala JUP 15 1 JCTG CCC ATC GCG GCG GCC TCC ATG ATG CGG 31 
ID" 131 1GAC GGG TAG CGC CGC CGG AGG TAC TAC GCC 51 
Val 1424AIa JUP 15 JGTG TCC CCG CTG GCC GCT CAG ATG ATC ATG 31 
D" "VVI -4 13D I CAC AGG GGC GAC CGG CGA GTC TAC TAG TAC 51 
Gly269-->Ser UP 51 CGA TTG CTG GGT GCC AGT ATC ACC TCG GAC 31 
J DWN 1 
U 
311 GCT AAC GAC CCA CGG TCA TAG TGG AGC CTG 51 
Gly3124Ser UP CAý AAC GCG CAC AGC ACG GCG ACG CCT 31 
J DWN TTG CGC GTG TCG TGC CGC TGC GGA 51 
Gly387-->Asp J UP 1 5I GAC GTC GTC GCC GAC GAA CCG CGC TAT GGC 31 
_I 
DWN 1 3J CTG CAG CAG CGG CTG CTT GGC GCG ATA CCG 51 
Phe404-->Ala l up 1 5J GTC AAC AAC TCG TTC GGG GCC GGC GGC CAC AAT GTG 31 
J DWN 1 3I CAG TTG TTG AGC AAG CCC CGG CCG CCG GTG TTA CAC 51 
Phe41341-eu l up I 5'I CAC AAT GTG GCG CTT GCC TTG GGG CGT TAC 31 
J DWN 1 3J GTG TTA CAC CGC GAA CGG AAC CCC GCA ATG 51 
Asp2314AIa l up 1 5J GCC TCC CGC CCG TTC GCC AGG GAC CGC GAC 31 
I DWN 1 3J CGG AGG GCG GGC AAG CGG TCC CTG GCG CTG 51 
TW154A]a J UP 1 5J GCG CAC GGC ACG GCG GCG CCT ATC GGC GAC 31 
J DWN 1 3J CGC GTG CCG TGC CGC CGC GGA TAG CCG CTG 51 
- - ý he4134Leu D WN TT GAT CGA TCG AAT TCT TAG TAA CGC CCC AAG GCA AGC 
GCC ACA TG TG 3 1 
-- - Fh e4O24Val D WN 5ý'[ EAT CGA TCG AAT TCT TAG TAA CGC CCG AAG GCA AGC 
lr -r ACA TTG TGG CCG CCG AAC CCG TGC GAG TTG TTG ACT GC 31 
Phe4044Val DWN 5' GAT CGA TCG AAT TCT TAG TAA CGC CCG AAG GCA AGC 
I GCC ACA TTG TGG CCG CCG TGC CCG AAC GAG TTG TTG ACT GC 31 
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3.2.8 FAMEs and MAMEs analysis 
For the expression study, M. smegmatis MC21 55 and M. chelonae were transformed by 
electroporation with the pMV261 constructs and cultured to mid-log phase in 50 ml of 
Sauton's medium containing 50 ýtg/ml hygromycin, 50 pCi of [1,2- 14 C]acetate (50-62 
mCi/mmol, Amersham. Pharmacia Biotech) was added to the cultures followed by further 
incubated at 370C for 4-6 hrs for M smegmatis MC2 15 5 and 3 O'C for 8 hrs for M chelonae. 
The [14C]-labelled cells were harvested by centrifugation and washed successively with PBS. 
The [14C]-labelled cells were then subjected to alkaline hydrolysis using 15 % aqueous 
tetrabutylammonium hydroxide at I 001C overnight. 4 ml of CH2CI2,300 Al Of CH31 and 2 ml 
of water was added to the reaction mixture followed by mixing for 30 min. The upper aqueous 
phase was discarded, and the lower, organic phase was washed twice with water and 
evaporated to dryness. Methyl esters were re-dissolved in diethyl-ether, and then the solution 
evaporated to dryness. The final residue was dissolved in 200 ul of CH2CI2 and the 
incorporation [1,2- 14 C]acetate was quantified by liquid scintillation counting of a5 ýd of the 
resulting solution of FAMEs and MAMEs. Approximately 100,000 cpm of the 
FAMEs/MAMEs mix were subjected to TLC using silica gel plates (5735 silica gel 6017254; 
Merck, Darmstadt, Germany), developed in petroleum ether-acetone (95: 5). Autoradiograms 
were produced by overnight exposure of Kodak X-Omat AR film to reveal [14C]-labelled fatty 
acid and mycolic acid methyl esters. 
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3.2.9 Anaylsis of recombinant protein solubility 
The pET28a-kasA and pET23b-kasA plasmids were used to transform the expression host E. 
coll C41 (DE3). However pQE60-kasA was expressed in E. coli M 15 (pREP4). The pVV 16- 
kasA and pSD26-kasA vectors were expressed in M smegmatis MC21 55. An overnight pre- 
culture of the transformed cells was used to inoculate I litre of Terrific broth (E. coli) or I 
litre of Sautons broth (M. smegmatis), which was incubated at 37'C until A60o nn, = 0.6 and 
then recombinant protein production was induced with I mM isopropyl-P-D-thiogalactoside 
(E. coli) or 0.02 % acetamide (M. smegmatis pSD26-kasA). The E. coli cultures were grown 
either for a further 4h at 37'C or 16 h at 161C, and then harvested by centrifugation. The E. 
coli cell pellets were resuspended in 4 ml/g of cells (wet weight) in 20 mM phosphate buffer, 
pH 7.9,0.5 M NaCl, 10 mM imidazole containing DNase and RNase, whereas the M. 
smegmalis cell pellets were resuspended in 4 ml/g of cells (wet weight) in 50 mM MOPS, pH 
7.9,50 mM MgCl, 5 mM P-mercaptoethanol and 10 mM imidazole. Bacteria were disrupted 
by sonicaton or French press and the resulting extracts clarified by centrifuged at 27,000 xg 
for 60 min at 41C. The supernatants were stored on ice and the pellet was resuspended in 
buffer containing 8M urea, and then centrifuged at 27,000 xg for 60 min at VC. Protein 
concentrations were estimated by BCA assay kit (Pierce) and purity assessed by 
electrophoresis of 25 pg of protein on 12 % SDS-PAGE, visualised by Coomaisse blue-stain. 
3.2.10 Purification of KasA and muteins 
Purification of protein extracts was performed using Ni2+ Hi-trap Chelating Sepharose TM fast 
flow matrix columns (I ml or 5 ml). Columns were charged using 2 column volumes of 0.1 M 
nickel chloride and washed with 4 column volumes of 0.02 M sodium phosphate and 0.5 M 
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NaCl pH 7.4 to remove excess nickel chloride to equilibriate the column. The clarified lysate 
was applied to the column (maximum of 10 ml for aI ml column and 50 ml for a5 ml 
column) and non-absorbed material collected for post-column analysis. Bound proteins were 
eluted using a step gradient of imidazole concentrations (10 mM - 500 mM). Fractions were 
collected and protein concentration deten-ninded by BCA (Pierce), 5 gg of each protein 
fraction was analysed by 12 % SDS-PAGE. Purified protein samples were dialysed against 20 
mM Tris-HCI pH 7.6,50 mM NaCI containing I mM P-mercaptoethanol. 
3.3 Results 
The initial work on the biochemistry of KasA was done in conjunction with Dr. Lynn Dover 
and Dr. Laurent Kremer in the first year of my PhD program, which I further developed 
through identification and construction of additional site-directed mutants of KasA. 
3.3.1 Over-expression of KasA from M. tuberculosis is associated with a decrease in a'- 
mycolate production 
To further clarify whether KasA participates in meromycolate elongation, M. smegmatis was 
transformed with pMV26l-kasA from M. tuberculosis H37Rv. The effect of KasA 
overproduction on mycolic acid composition was analysed by TLC after in vivo labelling of 
_14C mycobacterial FAMEs and MAMEs with [1,2 ]acetate. TLC analysis revealed a significant 
reduction of the cc-subclass in M. smegmatis over-expressing mtKasA (pMV26 I -kasA_MTB) 
when compared with the control strain carrying pMV261 (Figure MA). In a compensatory 
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fashion, over-expression of KasA led to an increase of a- and epoxymycolates (Figure 3.1 A). 
The ratio of cc' to long chain (combined cc and epoxy) was 24 and 76 % in the control strain, 
whereas the ratio was 10 and 90 % in the strain overproducing KasA. To determine whether 
this effect was restricted only to M. smegmatis as a host or extended to other mycobacterial 
species, M. chelonae was transformed either with the control plasmid pMV261 or with 
pMV26 I -kasA_MTB. As shown in Figure 3.1 B, over-expression of mtKasA in M. chelonae 
resulted in an increase of the m/cO ratio, the strain carrying pMV261 being approximately 1: 2, 
and that carrying pMV261-kasA approximately 1: 3.5. These results suggest that over- 
expression of the M. tuberculosis KasA protein consistently increases the cc/cCratio in 
different mycobacterial species, suggesting that KasA participates in the in vivo elongation 
process of the meromycolic chain. Although, W-mycolic acids can be considered as 
precursors of the cc-mycolic acids, it is not known why these precursors accumulate in some 
mycobacterial species, such as M. smegmatis. Possible explanations could be that KasA 
activity may be deficient in these species due to the absence of kasA, which seems unlikely, or 
possibly due to a defect in KasA expression or regulation. 
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Figure 3.1 Normal-phase TLC of FAMEs and MAMEs in mycobacteria over- 
producing KasA from M. tuberculosis or M. smegmatis. Visualisation of 
the incorporation of 114C Jacetate into lipids to produce radiolabelling 
FAMEs and MAMEs. The radio-labelled lipids were extracted with 15 % 
tetra butyla m moniu m hydroxide at IOOOC overnight. The corresponding 
fatty acid methyl esters (FAMEs), a-mycolates, a'-mycolates and epoxy- 
mycolates were prepared and subjected to TLC (5735 silica gel 60F2.1.4. 
Merck), followed by exposure to Kodak X-Omat film. (A) M. smegmatis 
harbouring pMV261 containing KasA from M. tuberculosis 
(B) M. chelonae harbouring pMV261 containing KasA from M. 
tuberculosis (C) M. smegmatis harbouring pMV261 containing KasA from 
M. smegmatis 
The genomic organisation of this operon is well conserved in M. smegmatis and with a high 
homology of KasA in both species (Kremer et al., 2002c), it seemed reasonable to assume that 
over-expression of kavA from M. smegmatis would have the same effect as over-expression of 
the M. luberculosis gene. As shown by TLC analysis in Figure 3.1 C, M. smegmatis over- 
expressing its homologous gene (pMV26l-kasA_MSG) presents a significant reduction of the 
(x'-subclass when compared with the control strain. This suggests that the gene product from 
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M. smegmatis exhibits the same activity as its M. tuberculosis counterpart. Thus KasA 
participates in meromycolate chain extension in vivo. 
3.3.2 FAS-11 activity in a KasA-enriched cytosolic fraction 
It was shown previously that KasA was present in 40-80 % saturated ammonium sulphate 
fraction isolated from M. bovis BCG over-expressing KasA (Kremer et aL, 2000b). When 
enriched fractions derived from M. smegmatis pMV261 were assayed for FAS-I and FAS-11 
activity, the optimum reaction conditions were obtained in the presence Of C14-CoA and C16- 
CoA, presumably following transacylation to AcpM, mtFabH converts the acyl-CoA followed 
by a complete cycle of FAS-11 into acyl-AcpM, the preferred substrates for further elongation 
via KasA and FAS-11. It is clear long-chain acyl-ACP substrates (C18 or C2o) do not enter 
FAS-II as efficiently, and almost no activity was seen with short-chain acyl-ACPs (Figure 
3-2). The FAS-11 elongation activity was also assessed with the enriched cytosolic fraction 
isolated from M. smegmatis (pMV261-kasA_MTB). As shown in Figure 3.2, although the 
substrate specificity was conserved, the specific activity was enhanced significantly regardless 
of the primer used. This indicates that KasA produced in M. smegmatis is active enzymically 
and represents a key enzyme within FAS-II. To characterize the compounds synthesised by 
FAS-11, FAMEs were analysed by C18 reversed-phase TLC. The inset (Figure 3.2) illustrates 
the chain-length distribution of the FAMEs produced for primers C12-CoA/ACP and C14- 
COVACP and shows that the yield decreases sharply with increasing chain length, an 
observation also made by others (Marrakchi et al., 2000). 
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Figure 3.2 FAS-11 enzymatic assay analysis of M. smegmalis extracts containing over- 
expressed M. wherculosis KasA. The FAS-11 assay was performed using 
different primers (C2_C26_CoA) E. coli ACP and the enriched soluble- 
cytosolic fraction from M. smegmatis harbouring either pMV261 or 
pMV261-kasA_MTB. The inset shows the chain length distribution of 
FAMEs synthesised from C12-CoA and CWCoA in the FAS-11 assay. 
Radiolabelled FAMEs (7000 c. p. m. ) were loaded on to C, 8 reverse-phase 
TLC in each lane, developed in CHCI, /CHOH (2 : 3, v/v), and the 
products were revealed by exposure to Kodak X-Omat film after a period 
of 4 days. Methyl [1- 
14 CIpalmitate was used as a reference standard. 
In light of the recent results the primer-specific activity profile observed in this assay system 
is wholly consistent with the substrate specificity of pure recombinant mtFabH with malonYl- 
ACP and strengthens the argument that mtFabH links FAS of mycobacteria (Figure 2.12). 
Repetition of this experiment using AcpM instead of E. coli ACP would be interesting, maybe 
longer acyl-CoA primers could be elongated efficiently by FAS-11. 
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3.3.3 KasA activity and biochemical analysis of active site mutants 
To determine directly the nature of the enzyme activity of KasA, it was a requirement that the 
key recombinant proteins holo-AcpM, C]6-AcpM, mtFabD and KasA were produced in E. coli 
to develop an in vitro elongation-condensation assay (Kremer et al., 2002c). We were able to 
obtain the pure KasA enzyme by loading the clarified soluble lysate onto a Ni2+-charged His- 
Trap column (Amersham). KasA was obtained as a pure protein migrating at approximately 
45 kDa, which is in agreement with the theoretical molecular mass. 
When incubated together with other key components, KasA elongated C16-AcpM via a 
condensation reaction with [2- 14C]malonyl-AcpM, which was generated in situ by the action 
of mtFabD on holo-AcpM and [2- 14C]malonyl-CoA. Within the linear range of a KasA dose- 
response curve, we observed a specific activity of 96 nmol-i-min-l-mg -1 for the elongation- 
condensation reaction (Figure 4.2A). To test the specificity of KasA with regard to acylated 
primers (acyl-CoA versus acyl-AcpM), we compared its activity with C16-CoA and C16- 
AcpM. When C16-CoA was incorporated (in equimolar concentrations to C16-AcpM) into the 
condensation assay, product formation was reduced dramatically (Figure 4.2A) to 4% of that 
observed with C16-AcpM. This is consistent with our current understanding of mycobacterial 
FAS-11 and the notion that KasA is a KAS involved in meromycolate extension, which utilises 
acyl-AcpM bound precursors. 
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Figure 3.3 (A) KasA active site mutant analysis. kasA and its various mutants were 
expressed as His-tagged recombinant proteins in E. coli C41 (DE3) and 
purified as described in the materials and methods section. They were 
assayed for KAS activity as described in the section 4.2.2. The 
condensation rates for KasA were tested with equimolar amounts of either 
C16-AcpM or C16-CoA as acyl sources. The activity of each of the mutants 
was assayed using C16-AcpM. (B) The condensation rates for KasA using 
C16-AcpM as a substrate in the normal KasA assay were determined in the 
presence of increasing concentrations of cerulenin. 
Previously it was shown that ccrulenin exhibits potent in vivo anti-mycobacterial activity 
(Kremer et al., 2000b). Although over-expression of kasA in M. bovis BCG did not generate 
an increased resistance against cerulenin, it was suggested that the in vivo anti-mycobacterial 
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activity of cerulenin was primarily via inhibition of de novo fatty acid synthase catalysed by 
FAS-I (Kremer et al., 2000b). Earlier studies have shown that cerulenin is a potent inhibitor of 
both FAS-I and FAS-II (Omura, 1976). In addition, the in vitro inhibition of E. coli KAS 
FabB and FabF by cerulenin has also been well documented for cerulenin (Campbell & 
Cronan, 2001). It was thus reasonable to assume that cerulenin may also inhibit the P- 
ketoacyl-AcpM synthase activity of KasA. Increasing concentrations of cerulenin were added 
to the in vitro condensation assay. As shown in Figure 3.313, a marked dose-response 
inhibition of KasA activity was observed with cerulenin providing an IC5o value of 0.15 Pg/ml 
(0.67 pM). The IC5o values of the purified E. coli Kas proteins were reported as 3 and 20 PM 
for FabB and FabF, respectively (Price et aL, 2001), suggesting that the mycobacterial 
condensing enzyme is more susceptible to cerulenin inhibition in vitro than the related E. coli 
enzymes. 
Siggaard-Anderson has identified a number of important amino acid residues in the E. coli 
FabB protein (Siggaard-Andersen, 1993). For instance, Cys163 constitutes one of the active- 
site catalytic residues. Other residues, such as His298, Lys328 and His333 were also 
identified and when replaced by Ala, decarboxylation and the overall elongation activity were 
abolished completely suggesting the importance of equivalent amino acids in catalysis. The 
recently presented structural model of the M. tuberculosis KasA generated by homology 
modelling (Kremer et al., 2000b) based on the determined X-ray structure of the E. coli FabF 
protein by Huang et al. (1998) allowed the identification of these residues in KasA. The three- 
dimensional structural model showed Cysl7l, His3ll, Lys340 and His345 as likely 
candidates for the catalytic residues of the active site of KasA (Kremer et al., 2000b). Site- 
directed mutagenesis was used to determine the role of these four residues in KasA activity by 
replacing them individually with alanine. The mutated KasA proteins were purified and CD- 
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spectral analysis were performed to confirm that the overall secondary structure of the mutant 
proteins did not differ significantly from that of the wild-type enzyme 
KasA activity of all the mutant proteins (Cys 17 1, His3l. 1, Lys340 and His345 to Ala) was 
abolished (Figure 33A), confin-ning the importance of these amino acids in KasA activity. It 
is likely that the His3ll->Ala, Lys340->Ala and His345-->Ala muteins were unable to 
decarboxylate the malonyl-AcpM and therefore in the absence of the C2 carbanion the 
condensation event would not be completed. The intermediate is proposed to be held in 
position by its interaction with His311 and His345 of the active site via interactions with the 
oxygen of the malonyl-AcpM. In the case of the muteins this interaction is likely reduced thus 
abrogating activity. It has been proposed that the equivalent amino acids facilitate the 
transacylation event in the E. coli homolog FabB (McGuire et aL, 2001). Therefore not only 
may these muteins be deficient in decarboxylation activity but may also have reduce 
transacylation activity. The transacylation of C, 6-AcpM to the active site cysteine would not 
be able to occur in a Cys 1714AIa mutein as the thio group required for the transfer would not 
be present when substituted for an alanine. Although this mutein might be able to 
decarboxylate malonyl-AcpM, but it could not condense the decarboxylate malonyl-AcpM 
with the acyl-protein intermediate as it would not be present. 
3.3.4 Sequence derived KasA mutational analysis 
To gain a more detailed understanding of KasA we initiated a more extensive mutagenesis 
study. We hoped that a simultaneous biochemical and crystal structure determination would 
provide further insight. The low yields of KasA muteins means that we required a more 
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effective purification or expression system as highly concentrated protein preparations are 
required for the crystallography study. As for mtFabH it was decided that four major areas of 
the enzyme properties would be assessed by site-direceted mutagenesis; 'substrate specificity, 
catalytic triad, protein-protein interaction and antibiotic sensitivity (Table 3.5). 
Table 3.5 KasA targets for site-directed mutagenesis, listed by class. 
Substrate 
Specificity/Binding 
Catalytic 
Triad 
Other Active 
Site 
Protein-protein 
Interaction 
Antibiotic 
Sensitivity 
Glyl 15 Cys171 Lys340 Asp231 Asp66 
Lysl 16 His311 Thr315 Arg 121 
Ala 119 His345 Gly269 
AIa141 His311 
Val142 Gly312 
Pro206 His345 
Phe2l 0 Gly387 
Asp231 Phe402 
Thr315 Phe404 
Phe413 
The crystal structure of mtKasA has not yet been solved and therefore the identification 
residues to be mutated would be identified by sequence alignments and the literature on 
homologs of KasA. The development of a series of site-directed mutants of KasA depended 
greatly on previous work done on E. coll FabB, and FabF. 
The sequence alignments of related KAS proteins was compiled to allow for the identification 
of amino acids which were potential candidates for mutagenesis and have been previously 
shown to be important residues (Figure 3.4). The majority of the mutations selected were 
based on previous studies with E. coli FabB (Olsen et aL, 200 1), with several key amino acids 
being identified, Va1134, Gly107, Va1135, Pro202 and Phe201(01sen et al, 1999). Residues 
Gly107, Va1134, Va1135 and Phe201 line the cavity of the active site and may play a role in 
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the substrate specificity, therefore it was assumed that these residues play a major role in 
transacylation of the acyl chain of acyl-AcpM to the active site Cys. The active site in KASI 
dimer are accessible at the bottom of a narrow tunnel defined with Pro202 being located at the 
entrance. The possibility that mutation of this residue affects the kinetics of the catalysis is 
interesting and requires further investigation. Asp223 and Thr307 of FabF were identified as 
parts of the binding site of the acyl-ACP substrate (Huang ei al., 1998). Thi-307 together with 
the N-terminal end of the preceding cc-helix form a binding site at the top of the binding cavity 
for the hydroxyl and phosphate of the phosphopantetheine group of the acyl-ACP. Some 
distance from the active site pocket is the Asp223 residue which is located on the surface of 
the enzyme and could be involved in the interaction with ACP (Huang el al., 1998). Therefore 
it was decided to analyse these mutant enzymes with substitutions at these residues for overall 
KAS, transacylation and decarboxylation activites. 
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RCRKEKKXH. KKKN: NE', 'NSKRYAFl KRG: PG: SKNYFKC, rKLYNSREIMEN LCE'l S RV 
ScFabB -------------------------------------------- MSPRHAAGPAPGERAA 
mtKa3A --------------------------------------------- MSQPSTANG-GFP3V 
mbKasI ---------------------------------------------- MQPSTANG-GFPSV 
msgl<asA --------------------------------------------- MTRPSTANG-GYPSV 
miKasI --------------------------------------- MIARLMTTSPELVTGKAFPNV 
ecFabE3 VITGLGIVSSIGNNQQEVLASLREGRSGITFSQELKDSGMRS ---- HVWGNVXLDTTGLI 
pfFabB VCTGVGVVTGLGIGIEH7WNNIINGYTSIDKITKFDITGMSCGIGSEIKKSDFNPSDYYT 
scFabB VVTGLGLTTSLGGDVPSTWRALLDGGCGVERV-DFGEPAGPAQV--YLAAPAAVDPGTVL 
mtKasA VVTAVTATTSISPDIESTWKGLLAGESGIHALEDEFVTKWDLAV--KIGGHLKDPVDSHM 
mbKasI V-VTAVTATTSISPDIESTWKGLLAGESGIHALEDEFVTKWDLAV--KIGGHLKDPVDSHM 
msgKasA VVTAVTATTSIAPDIESTWKGLLAGESGIRVLEDEFVTKWDLPV--RIGGHLVDNIDDHM 
mlKasI VVTGIAMTTALATDAETTWKLLLDNQSGIRMLDDPFIEEFNLPV--RIGGHLLEEFDHQL 
ecFabB DRKVVRFMSDASIYAFLSMEQAIADAGLSPEAYQ--NNPRVGLIAGSGGGSPRFQVFGAD 
pfFabB NKKDVNRNDDCTHYAVAATRLATýDDAKLNLEKL --- DKDKTGTIIGSGIGGLRFLEKEMK 
scFabB SSAKAAHCDRSAQFALVAAREAVRDAGFPDPSALAGDGSRVAVV-VGVGLGGLTSVLEQDH 
mtKasA GRLDMRRYSYVQRMGKLLGGQLWESAGSPEV ----- DPDRFAVVVGTGLGGAERIVESYD 
mbKasI GRLDMRRýMSYVQRMGKLLGGQLWESAGSPEV ----- DPDRFAVVVGTGLGGAERIVESYD 
. sgKasA TRLDMRRMSYVQRMSKFLSKQLWENAGAPEV ----- DPDRFAV-VIGTGLGGGEKIVETYD 
. lKasI TRVELRRMGYLQRMSTVLSRRLWENAGSPEV ----- DTNRLMVSIGTGLGSAEELVFSYD 
ecFabB AMRGPRGLKAVGPYVVTKAMASGVSACLATPFKIHGVNYSISSA: ATSAHCIGNAVEQIQ 
pfFabB TMY-EKGHKRITPYLIPAMIANTPSGYVSIENNIRGISLGMLSACATSGNTIGEAYRYIK 
scFabB RLR-TQGAGRVSPRTIPVMLPNHAAAEVGLMVGAKAGVHAPVSACAAGAEALAQALGMIR 
mtKasA LMN-AGGPRKVSPLAVQMIMPNGAAAVIGLQLGARAGVMTPVSAýSSGSEAIAHAWRQIV 
mbKa, gl LMN-AGGPRK-VSPLAVQMIMPNGAAAVIGLQLGAPAGVMTPVSACSSGSEAIAHAWRQTV 
msgKasA AMN-EGGPRKVSPLAVQMIMPNGAAAVVGLELGARAGVITPVSACSSGSEAIAHAWRQIV 
mlKasI DMR-ARGMKAVSPT-AVQKYMPNGAAAAVGLEHHAKAGVMTPVSACASGSEAIAHAWQQIV 
ecFabB LGKQDIVFAGGGEELCWEMA-CEFDAMGALSTKYNDTPEKASRTYDAHRDGFVIAGGGGM 
pfFabB YKEYDVMICGGTEASITPISFAGFNSLKALCTGYNDNPKKGCRPFDLKRSGFVMGEGSGI 
scFabB DGPADIVVAGGTEAALHPLVLAGFARLR-ALSRRHDDPKGASRPFDADRDGFVMGEGAGM 
mtKasA MGDADVAVCGGVEGPIEALPIAAFSMMR-AMSTRNDEPEPASRPFDKDRDGFVFGEAGAL 
. bKasl MGDADVAVCGGVEGPIEALPIAAFSMMR-AMSTRNDEPERASRPFDKDRDGFVFGEAGAL 
msgKasA MGDADFAVCGGVEGGIEALPIAAFSMMR-AMSTRNDDPQGASRPFDKDRDGFVFGEAGAM 
mIKasI LGEADSAICGGVETKIEAVPIAGFSQMRIVMSTKNDNPAGACRPFDRDRDGFVFGEAGAL 
ecFabB VVVEELEHALARGAHIYAEIVGYGATSDGADMVAP--SGEGAVRCMKMAMHGVD --- TPI 
pfFabB LILESYEHAIKRNAPIYGEIISYSSECDAYHITAPEPNGKGLTNSIHKALKNANINTNDV 
scFabB LVVESAAHAAARGARVHGRLTGAGITNDSHHVAQPAPGGPGCAAAVDAALRDAGLVPEQI 
. tKasA MLIETEEHAKARGAKPLARLLGAGITSDAFHMVAPAADGVRAGRAMTRSLELAGLSPADI 
mbKasI MLIETEEHAKARGAKPLARLLGAGITSDAFHMVAPAADGVRAGRAMTRSLELAGLSPADI 
mSqKaSA MIIETEEHAKARGAKPLARLMGAGITSDAFHMVAPAADGVRAGQAmKRAMETAGLDPKDI 
mlKasl MLIETEDSAKARSANILARIMGASITSDGFHMVAPDPNGERAGHAIARAVHLAGLSPSDI 
ecFabB DYLNSHGTSTPVGDVKELAAIREVFGD--KSPAISATKAMTGHSLGAAGVQEAIYSLLML 
pfFabB KYINA. '. ýGTSTNLNDKIETKVFKNVFKDHAYKLYISSTKSMTG; ICIGAAGAIESIVCLKTM 
scFabB QHVNAHATATPLGDLGEAQALHSVFAKGVDDVTVSATKGAFGý,, TLGAAGAIEAVLTVLAL 
mtKasA DHVNAHGTATPIGDAAEANAIRVAGCD --- QAAVYAPKSALGHSIGAVGALESVLTVLTL 
mbKasI DHVNA-ýGTATPIGDAAEANAIRVAGCD --- QAAVYAPKSALGHSIGAVGALESVLTVLTL 
msgKasA DHVNAI: ATATPIGDTAEANALRVAGVE --- HAAVYAPKSALGHSIGAVGALESILTVLAL 
mlKasl DHVNAýýýATSTQVGDLAEAKAINKALCN--NRPAVYAPKSALGHSVGAVGAVESILTVLAL 
ecFabB EHGFIAPSTNIEELDEQAAGLNIVTETT --- DRELTTVMSNSFGFGGTNATLVMRKLKD 
pfFabB QTNIIPPTINYEYKDPDC-DLNYTPNKYIHAKENIDISLNTNLGFGGHNTALLFKKIVK 
scFabB RDRTAPPACSLERVDPEI-GLNV-VGRDPATLPCGPLAAVSTSMGFGGHNVALAFADAS- 
MtKasA RDGVIPPTLNYETPDPEI-DLDV-VAGEPR--YGDYRYAVNNSFGFGGHNVALAFGRY-- 
mbKasI RDGVIPPTLNYETPDPEI-DLDVVAGEPR--YGDYRYAVNNSFGFGGHNVALAFGRY-- 
msgKaSA RDGVIPPTI, NYE7PDPEI-DLDTVAGEPR--YGEYKYAINNSFCFGGHNVAI, AFGRY-- 
7 R"ý'V: I' -1ý1, IýI i%', . V, F; Fý1: 2,,: A Fý:, 'ý 
Figure 3.4 Comparison of M. luberculosk KasA (mtKasA) with E. coli FabB (ecfabB), 
Plasmodium falciparum FabB (pfFabB), Slreptonycev coelicolor A3(2) 
FabB (scFabB), M. boviN Kasl (mbKasi), M. s~gmafiv KasA (msgKasA) 
and M. leprae Kasl (mlKasl). Primary amino acid sequences of all the 
KasA homologues were compared with the predicted protein sequence of 
KasA. KasA possesses the hallmark features of synthase I including the 
Cys-His-His and Lys of the active site (Red), new mutation sites identified 
are indicated (yellow) 
126 
CHAPTER3 f3-KETOACYL-ACP SYNTHASE (KasA) 
INH resistance has been observed in clinical isolates from Singapore with residues 
Argl2l--)Lys, Gly269-->Ser, Gly387-->Asp and Gly3l2-->Ser involved in INH resistance (Lee 
et aL, 1999). Furthennore these substitutions plus Asp66->Asn and Phe4l3-->Leu were 
identified to confer INH resistance in vitro (Mdluli et al., 1998). Gly269->Ser and 
Phe4l3->Leu were single mutations and no other alterations were observed in KatG, InhA or 
AhpC. The mis-sense Phe404->Ala Phe402->Val and Phe4044Val mutations in KAS of E. 
coli lead to resistance to TLM with the IC50 increasing from wild-type FabB of 20 tiM to 200 
gM (Jackowski et al., 2002). 
Table 3.6 Summary of proposed mutations of KasA and their homologs; A, Exo1i 
FabB; B, E. coli FabF; C, clinical isolates of KasA 
Proposed M. tuberculosis 
Function KasA Homolog 
Residue Residue 
Substrate Glyl 15 Gly107 A 
Specificity/Binding Lys116 Gly108 A 
Ala'119 Prol 11 A 
Ala 141 VaI134 A 
VaI142 VaI135 A 
Pro206 Pro202 A 
Phe21O Phe20 1A 
Asp231 Asp223 B 
Thr315 Thr307 B 
Lys340 Lys328 A 
Catalytic Cys171 Cys163 A 
Triad His311 His328 A 
His345 His333 A 
Protein-protein Asp231 Asp223 B 
Interaction Thr315 Thr307 13 
Antibiotic Asp66 c 
Sensitivity Arg'121 c 
Gly269 c 
His311 His328 A 
Gly312 c 
His345 His333 A 
Gly387 c 
Phe402 Phe390 A 
Phe404 Phe392 A 
Phe413 c 
127 
CHAPTER3 fWETOAcn-ACP SVNTIIASE (KasA) 
The additional generation of these mutants of KasA was attempted using the Stratagene 
QuikChange site-dirccted mutagenesis Kit. Despite our initial four success' with the catalytic 
triad mutants using this method the production of further mutations was not successful after 
several attempts. Manipulation of the standard protocol was attempted. Firstly the annealing 
and melting temperatures %%, ere investigated to see if products were produced under different 
PCR conditions. I'lie melting temperature was increased from 95*C to 97C and it was also 
reduced to 94*C, the annealing temperature was changed over aI OT range from 63C to 73C 
but with no mutants being observed it was decided that we should increase the number of 
cycles in the PCR reaction from 16 to 20,24 and 28. Yet again with no success our attention 
was redirected towards the recipe of the PCPL TIIrcc areas were assessed in the recipe of the 
PCR reaction; template concentration, primer concentration and DMSO/MgSO4 additions. 
The template was diluted 1: 20 and 1: 50 and tested at the range of conditions stated above, no 
mutants were observed so the primer concentration was change by the addition of extra I pl of 
the 100 pmol/Al primer. With still no mutations we finally turned our attentions to the 
additions of DMSO and MgS04, the MgS04 was added to the standard reaction in increasing 
concentrations with and without DMSO but still no mutants were generated. The main 
disadvantage with the QuikChange site-dirccted mutagcnesis method was that we were unable 
to find out exactly at %%hat point the method was failing therefore it was decided that other 
methods Of site-directed mutagenesis should be tried. 
After all the unsuccessful attempts at producing mutants using the QuikChange site-directed 
mutagenesis Kit a new method was utilised. It required two separate PCR reactions followed 
by digestion, ligation with the vector and screening, known as the megaprimer method (Figure 
3.5). The mega primer method involved cloning of a -mega primer" which contained the 
required point mutation. The PCR conditions were as stated in section 4.2.7.2, the further 
128 
CHAPTER3 fl-KETOACI'L-ACP SYNTHASE (KasA 
extension of the megaprimer to the full length gene allowed the identification of PCR 
conditions that have been successful (Figure 3.6). The advantage of this system was that it 
allowed the identification of the problems in the production of the mutation, and therefore 
allowed for development of the technique to achieve our goal. Due to the two primers required 
for the QuikChange site-dirccted mutagcnesis method the mega primer preparation could be 
performed in both directions. In some cases the PCR reaction did not yield significant 
quantities of product so the opposite primers were used, i. e. the upper cloning primer and the 
lower mutagcnic primer. This method allowed for the production of either the front or the 
back segment of the gene containing the mutation. In some cases neither of the fragments 
would cxend to the full length of the gene. In these situations both mega primers were used in 
the Phase II reaction. A number of the mutants didn't extend in either direction so new 
primers were designed. With regards to the mutants at the terminus of the gene (Phe402, 
Phe404, Phe413) it was difficult to see any change in the length of the mega primer after the 
phase 11 PCP, therefore new extended primers %%, ere designed Ahich included the mutation, 
the end of the gene and the cloning site (Phe4O4 Phe404, Phe413). 
The cut DNA fragmentswere then ligated with cut pET28a vector. In some cases the fragment 
wouldn't ligate into the vector. Tbereforc it was necessary to vary the usual ligation reaction 
which was carried out at 16*C overnighL So other conditions were tried including storage on 
ice overnight and a step gradient of temperatures starting at 40C increasing to 200C over 16 
hours. 
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Figure 3.5 Schematic representation of the Ategaprimer method used in the 
Production of site-directed mutants of KasA adapted from Sarkar & 
Sommer(1990) 
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Figure 3.6 Agaro%c gel (of phase I and phase If site-directed mutagenesis of kas4 
After all the problems of PCR and ligatiom not all the proposed mutations were able to be 
constructed. The following mutations were created. Glyl 154AIa. Arg12141-ys, 
Ala]414Trp. Val]424AIa. Pro2G64AIa. Phe2104A[a. Thr3]5-*ala, Gly2694Ser, 
Gly3124Ser, Gly387--)Asp, Phe402-*Val. Phe4044Val and Phe41341-ys. 
3.3.5 Protein purification and further analysis of KasA and muteins 
Along side the production of the mutant KasA plasmids it was essential that protein was 
obtainable for analysis and in large enough quantities for analysis by circular dichroism and. 
more importantly, by crystallography. The purification of the new mutant, non-denatured 
proteins by Ni2' Hi-trap Chelating SepharoseTm fast flow matrix column yielded less protein 
than Previously observed with the catalytic triad muteins. So the attention of the study 
reverted to the wild-q, pe KasA in order to tfý to develop a method to increase the yield and 
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solubility of the wild-qpc as the mutants would theoretically react the same. Tbcrcforc 
analysis of the solubility of the protein was implemented as per the solubility analysis 
protocol, F- coli C41 (DE3) transformed with the pET28b-kas, 4 was culture and induced with 
0.1-1.0 mM IPTG for 4 hours. The cells %%, crc harvested and lysed by sonication. The SDS- 
PAGE analysis demonstrated that the majority of the recombinant KasA protein was 
insoluble, shown by the presence of a dominant 45 kDa protein in the crude and urea-trcated 
samples. Production of KasA muteins at lower temperature, i. e. 16*C was attempted. Lower 
temperatures would slow the overall protein production and may favour correct folding 
reducing aggregation of intermediates therefore theorectically increasing its solubility. 
Unfortunately this still produced poor protein recovery. F. coli C41 (DE3) transformed with 
PET'28-kasA was used to prepare KasA His-tagged recombinant proteins. Tbc expression was 
Performed in triplicate and each I)sed by French pressure cell and clarified by centrifugation, 
the first clarified supernatant was run as normal through the column, the second was run in the 
Presence of 500 mXf arginine and finally the last was run in the presence of 2M urea. The 
SDS-PAGE analysis demonstrated that the majority of the recombinant KasA protein was 
insoluble, shown by the presence of a dominant 45 kDa protein in the urea purified KasA 
(Figure 3.7). Protein concentrations were estimated by BCA assay and their enzyme activity 
analysed by assay as per section 3.2.6. As previously observed the recombinant protein could 
be purified in small quantities and remained active. However, to develop a structural biology 
investigation larger yields were required. Our investigation thus far produced low yields of 
soluble protein but a band corresponding to a 45 kDa protein, consistent with the predicted 
molecular weight of the recombinant KasA was evident in insoluble aggregates solubilised by 
urea treatment. On attempted refolding, this protein did not exhibit KasA activity (Figure 3.7). 
I'lle development of other purification methods including Q-sepharose (anion exchange) and 
Phenyl-sepharose (Hydrophobic interaction) purification did not yield significant quantities of 
KasA. 
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Figure 3.7 SDS-PAGE (12 %) of purified KasA, arginine and urea. KasA 
Preparation His-tagged recombinant proteins expressed in E. coli C41 
(DE3) were expressed as described in the materials and methods section. 
Cellular lysates were centrifugation at 27,000 xg followed bv Ni2+ column 
purification (Normal). this was repeated but with the presence of 5OOmM 
arginine (Arginine), a further preperation resuspension in 0.02 M Sodium 
Phosphate and 0.5 M NaCl pH 7.4 containing 2M urea followed by 
centrifugation at 27,000 xg (Urea) was analysed. KasA activity shown 
below'. 
As the high levels of protein were purified using the urea-based method. it was decided to 
investigate the refolding of this denatured protein. Schaeffer et al., (2001) purified M. 
tuberculosis KasA via Ni. '. chelating column system followed by refolding using an 8M urea 
dialysis refolding methocL whereas Saini et al., (2002) refolded a M. tuberculosis histidine 
Protein kinase (DevS) by a matrix-assisted method. Both methods were adapted to try to 
refold our KasA His-tagged recombinant protein after expression in E coli C41 (DE3) (Figure 
3-8). These methods were developed to include arginine which was added to mediate native 
structure formation and to reducing aggregation. 
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Figure 3.8 Methods for the refolding of KasA. Two methods of purification and 
refolding -a-ere Investigated, one in solution phase and the other bound to a 
Ni+2-chelating agarose bound matrix. Methods 2 and 4 are further 
modified by the addition of 500 mAl arginine 
All four Preparation protocols yielded protein in large quantities similar to that observed in 
Figure 3.7. When these purified proteins were assayed using the in vitro KasA assay, no 
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Catalytic activity was exhibited. Tbc development of the pET'28 expression system had now 
become exhausted and it %%-as decided that other expression systems may prove more fruitful. 
Four expression vectors pET-23b, pVV16, pSD26 and pQE60 were considered. pET23b was 
used to utilise the C-terminal His-tag as opposed to the pET28a constructs which contain a N- 
r +2 terminal His-tag. The change in the position of the His-tag may aid puri Ication via the Ni 
Hi-trap system and therefore yield greater quatities of enzymatically active protein. The 
pQE60 expression system utilises an E coli N115 (pREP4) expression host. It has previously 
been shown that F_ coli FabB and FabF are both soluble in this system in contrast to the pET 
expression systems (Edwards et al., 1997). Due to the similarity between KasA and FabB it is 
feasible that KasA will behave in a similar manner to FabB. The pVV16 expression system 
utilises AL smegmalis as the expression host, but also produces C-terminal His-tagged 
proteins. This system is not inducible and as the vector is constitutively expressed via the 
hsp60 promoter. The downfall of this expression system is that it is based on a low copy 
number plasmid therefore only small yields of protein might be obtained. The pSD26 
expression system, however, also contains a C-terminal His-tag but is based on an acetamide 
inducible promoter for use in AL smegmalis. This vector has all the same properties as the 
PVV16 system butaffords a higheryield of protein. 
3.3.5.1 pET23b-A-as. 4 an2lySiS 
PET'23b production of the C-terminal His-tag KasA was first assessed for solubility by first 
culturing the E coli C41 (DE3) containing the plasmid to an 013,46m nm = 0.6 followed with 
induction with IPTG at varying conditions as per section 3.2.9. The cells were harvested 
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followed by sonication and clarification b,. centrifugation at 27.000 x g. The pellet was 
resuspended in buffer containing 8M urea. The samples were then visualised by 12 % SDS- 
PAGE (Figure 3.9). 
01 mM IPTG 10 rnk4 IPTG 1.0 MM IPTG 
KaßA 
35 c mm MM' «IMP 
im 
37"C. 4h leýC leh 
Figure 3.9 Analysis of recombinant KasA production and solubility. E. coli C41 
(DE3) pET23b-A-asA was cultured to O-D-6oo.,. = 0.7 at 370C when 
recombinant protein production was induced by addition of IPTG- 
Different concentrations and induction temperatures were assessed for the 
production of soluble protein. Induction at 37'C was carried out for a4 
hour period using IPTG at either 0.1 mM or I mM. Some cultures were 
cooled to 161C before protein production was induced by addition of IPTG 
to IMM for a period of 16 h. Crude lysates (crude) were centrifuged at 
27,000 xg for 30 min at 4*C and the pelleted insoluble material was 
dissolved in buffered 8M Urea (urea) before comparison with the 
supernatant and crude samples on 12 % SDS-PAGE. 
It was proposed that changing the position of the His-tag may affect the purification properties 
of the wild-type KasA via the Ni'2 Hi-trap system and therefore produce greater quantities of 
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enzymatically active protein. The supernatant fractions were taken and purified as per the 
Materials and methods (section 31.10). As for the pET28 system the protein failed to bind to 
the column and was observed in the flow through or eluting early in the imidazole 
concentration gradient (10-20 m, \f) washes prior to the clution washesý therefore no protein 
was cffectively purified via this system. After the two failed attempts using the E. coli 
expression system we decided to utilise AL smegmads as the expression host. It was 
hypothesised that due to KasA being a mycobacterial enzyme there was the possibility that 
over-production within AL smegmatis would produce more soluble protein. 
3.3.5.2 pVV16-lasA analysis 
The production of the soluble C-terminal His-tag KasA was assessed by first culturing M. 
smegmatis containing the pVV16-kasA plasmid to an OD . 46oo nm = 1.2. Tlie cells were 
harvested followed by sonication and clarification by centrifugation at 27,000 x g. T'lle pellet 
was resuspended in buffer containing 8 NI urea and the samples visualised by Coomaisse 
blue-staining after electrophoresis on 12 % SDS-PAGE gels (Figure 3.10). This system is not 
inducible and as the vector is constitutively expressed via the hsp60 promoter different 
expression conditions were unavailable. 'Me downfall of this expression system is that it is 
based on a low copy number plasmid therefore only small yields of protein were observed. 
As observed on SDS-PAGE there was relatively high expression of a protein with a molecular 
weight of 45 kDa consistent with pure recombinant KasA as predicted by the protein 
sequence. Purification was required in this system to assess levels of expression due to the 
host being Af smegmaris a similar 45 kDa would natively be expressed possibly masking any 
results. Therefore the clarified lysate was applied to a Ni+2 charged Hi-trap column. The 
Protein bound much better to the column and was purified to high degree after clution; 
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visualisation by Coomaisse blue-staining after electrophoresis on 12 % SDS-PAGE gels 
showed that this system yielded large quantities of recombinant KasA (Figure 3.11). 
kDa 
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Figure 3.10 Analysis of recombinant KasA production and solubility. M. smegmalis 
me 2 155 pVV16-kasA was cultured to O. D. 6m. = 0.7 at 37C of the C- 
terminal His-tagged recombinant proteins prepared as described in the 
materials and methods section. Crude lysates (crude) were centrifuged at 
27,000 xg for 30 min at 40C and the pelleted insoluble material was 
dissolved in buffered 8M Urea (urea) before comparison with the 
supernatant and crude samples on 12 % SDS-PAGE. 
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35.0 
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2 Figure 3.11 Purified recombinant KasA production in M. smegmalis MC 155. 
2 M. smegmatis MC 155 pVV16-kasA were grown to O. D. 6w.. = 0.7 at 37'C 
and pelleted by centrifugation. Followed by lysis by sonication and 
clarification by centrifugation at 27,000 x g. Clarified lysates were and 
subjected to Ni2+-chelating agarose chromatography and elution in 
imidazole (10-500 mM imidazole). 
The protein concentration of the pVV 16-kasA produced recombinant KasA was estimated by 
BCA assay kit (Pierce). In vitro radio-chemical assaying of this recombinant protein in the 
KasA assay unfortunately did not produce any activity, therefore suggesting that this enzyme 
preparation method is uneffective for recombinant KasA. The system as stated previously is 
constitutively expressed via the hsp60 promoter therefore it was proposed that an inducible 
expression vector may change expression levels and possibly the overall folding and therefore 
the activity of the protein. The pSD26 expression vector is inducible via additions of 
acternamide. Over-production within M. smegmatis might produce more soluble protein, as 
observed in the pVV]6 system. But allowing the production of protein by induction and 
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therefore allowing it to be produced in an active form due to a more susceptible cellular 
environment. 
3.3.5.3 pSD26-kasA analysis 
The production of the C-terminal His-tag KasA using M. smegmatis containing the pSD26- 
kasA was assessed for solubility by first culturing to an OD A600 = 0.6 followed by 
induction with 0.2 % acetamide for 4h at 370C. The cells were harvested by centrifugation 
followed by sonication and clarification by centrifugation at 27,000 x g. The pellet was 
resuspended in buffer containing 8M urea and the samples visualised by Coomaisse blue- 
staining after electrophoresis on 12 % SDS-PAGE gels (Figure 3.12). As observed on the 
SDS-PAGE there was relatively high expression of a protein with a molecular weight of 45 
kDa in comparison with uninduced celluar lysate consistent with the production of 
recombinant KasA. As with the pVV16 system purification was required due to the host M. 
smegmatis having a similar 45 kDa natively expressed protein which may possibly mask 
results. Therefore the clarified lysate (Super) was applied to a Ni+2 charged Hi-trap column. 
The protein bound much like the two pET expression systems and was not purified; 
visualisation by Coomaisse blue-staining after electrophoresis on 12 % SDS-PAGE gels 
showed that this system yielded large quantities of contaminating protein along with the 
recombinant KasA (Figure 3.13). The protein purification also showed little affinity as 
observed with the pET systems with a protein with a molecular weight of 45 kDa consistent 
with pure recombinant KasA as predicted by the protein sequence being eluted in 20 mM 
imidazole therefore not allowing for effective purification. 
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Figure 3.12 Solubility analysis of pSD26-kasA expressed in M. smegmalis me 21 55. C- 
terminal His-tagged recombinant proteins expressed were expressed as 
described in the materials and methods section. Cellular lysates were 
sampled (Crude) then subjected to centrifugation at 27,000 xg (Super), 
followed by pellet resuspension in 0.02 M MOPS, pH 7.9,50 mM MgCl, 5 
mM P-mercaptoethanol and 10 mM imidazole containing 8M urea 
followed by centrifugation at 27,000 xg (Urea) 
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Figure 3.13 Purified recombinant KasA production in M. smegmatis MC2155. 
M. smegmalis MC2155 pSD26-kasA were grown to O. D-600nm = 0.7 at 37'C 
followed by induction with 0.2 % acetamide and pelleted by 
centrifugation. Followed by lysis by sonication and clarification by 
centrifugation at 27,000 x g. Clarified lysates were and subjected to N i2+_ 
chelating agarose chromatography and elution in imidazole (10-500 mM 
imidazole). 
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Unfortunately the preparation of recombinant KasA in M. smegmatis failed again to produce 
an active protein. Further investigation into the homologs of KasA showed that the E. coli 
FabB and FabF were shown to be soluble from another E. coli expression system. The pQE60 
expression system utilises an E. coU M15 (pREP4) expression host and had been shown to be 
an effective preparation system for E. coli FabB and FabF (Edwards et al., 1997). Due to the 
similarity between KasA and FabB it is feasible that KasA will behave in a similar manner to 
FabB, therefore as before in the E. coli expression systems solubility and purification potential 
were assessed. 
3.3.5.4 pQE60-kasA analysis 
pQE60 production of the C-terminal His-tag KasA was first assessed for solubility by 
culturing the E. coli M15 (pREP4) containing the plasmid to an OD A60o ,=0.6 followed 
with induction with IPTG at varying conditions as per section 3.2.9. The cells were harvested 
followed by sonication and clarification by centrifugation at 27,000 x g. The pellet was 
resuspended in buffer containing 8M urea. The samples were subjected to electrophoresis on 
12 % SDS-PAGE and visualised by staining with Coomaisse blue-staining (Figure 3.14). 
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Figure 3.14 Analysis of recombinant KasA production and solubility. E. coli M15 
(pREP4) pQE60-kasA was cultured to O. D-600nm = 0.7 at 37'C when 
recombinant protein production was induced by addition of IPTG. 
Different concentrations and induction temperatures were assessed for the 
production of soluble protein. Induction at 37'C was carried out for a4 
hour period using IPTG at either 0.1 mM or I mM. Some cultures were 
cooled to 16*C before protein production was induced by addition of IPTG 
to ImM for a period of 16 h. Crude lysates (crude) were centrifuged at 
27,000 xg for 30 min at 40C and the pelleted insoluble material was 
dissolved in buffered 8M Urea (urea) before comparison with the 
supernatant and crude samples on 12 % SDS-PAGE. 
In contrast to the expression profile we observed with the pET vectors (Figure 3.9) no 
significant IPTG-dependent induction of a protein with a molecular weight consistent with 
recombinant KasA at 37'C was observed. However, significant quantities of such a protein 
were observed in the cultures induced with I mM IPTG at 160C for 16 h. Purification of this 
protein was implemented using aN if2 charged Hi-trap column as described as per materials 
and methods (section 3.2.10). The purified protein was dialysed against 20 mM phosphate 
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buffer, pH 7.9,0.5 M NaCl. Final protein preparations were visualised on 12 % SDS-PAGE 
(Figure 3.15). 
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Figure 3.15 Purified recombinant KasA production in E. coli M15 (pREP4). 
E. coli M15 (pREP4) pQE60-kavA were grown to O. D. 600.. = 0.7 at 371C 
and induced with I mM IPTG followed by pelleted by centrifugation. 
Followed by lysis by sonication and clarification by centrifugation at 
27,000 x g. Clarified lysates were and subjected to Ni2+-chelating agarose 
chromatography and elution in imidazole (10-500 mM imidazole). 
The pure protein was of insufficient quantities for assaying therefore further preparation 
would be required to produce more recombinant kasA from the pQE60 expression system. 
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3.4 Discussion 
KAS of the FAS-11 system belong to an important family of condensing enzymes that are 
related both structurally and functionally. It play key roles in the biosynthesis of fatty acids, 
polyketides and mycolic acids in mycobacteria (Cole et al., 1998; Kremer et al., 2000b). 
Analysis of the M. tuberculosis genome database shows that there are only three potential 
KAS enzymes (Cole et al., 1998). One of these is KasA which has a substrate specificity for 
acyl-AcpM or acyl-CoA with KasA favouring AcpM, but still active with acyl-CoA (4 % 
activity of that with AcpM). This is consistent with the current understanding of 
mycobacterial FAS-11 and that KasA is involved in the extension of acyl-AcpM as a part of 
FAS-II involved in meromycolate extension, which utilises AcpM-bound precursors (Kremer 
et al., 2002c). 
Over-expression of kasA from M tuberculosis was associated with a decrease in cc'-mYColate 
production and an increase in cc-mycolates, both in M. smegmatis and in M. chelonae, 
suggesting that KasA is able to elongate the short cc'-mero-chain into full-length 
meromycolates (Kremer et al., 2002c). Overproduction of M smegmatis KasA in M. 
smegmatis resulted in similar changes in the cdcc' ratio. Therefore the absence of kasA cannot 
be inferred by the presence of a'-mycolates in some mycobacterial species, or by an alteration 
of KasA activity via point mutations, since it was very similar to KasA from M. tuberculosis. 
The cc' composition may be simply due to different regulation levels of kasA expression 
and/or of other genes involved in the mycolic acid biosynthetic pathway in M. smegmatis 
(Kremer et al., 2002c). Analysis of the FAS-11 activity of the cytosolic fraction of M. 
smegmatis using a set of acyl primers ranging from C2- to C2o-CoA, observed that FAS-11 
145 
CHAPTER3 P-KETOACYL-ACP SYNTHASE (KasA) 
activity was optimal with C14/C16-acyl-CoA/AepM precursors. By comparing the FAS-11 
activity with a recombinant strain overproducing KasA, it was shown that although the same 
substrate preference was followed, the specific activity was enhanced significantly. This 
supports the notion that KasA is part of the mycobacterial FAS-11 system. Recombinant KasA 
purified under non-denaturating conditions was assayed and found to catalYse the transfer of a 
two-carbon unit from [2- 14C]malonyl-ACP to C16-AcpM, thus confirming KasA as a 
condensing enzyme involved in FAS-11 and meromycolate extension. To improve our 
understanding of the catalytic site of KasA, Cysl7l, His3ll, Lys340 and His345 were 
mutated to alanine. All mutations impeded the enzymic activity, suggesting that these residues 
play a critical role in condensation activity mediated by KasA. 
The described expression system and culture conditions that allow the generation of soluble 
KasA mutants were published by Kremer et al., (2002c). The Cysl7l, His3l I, Lys340, 
His345 and wild-type KasA produced varying amounts of protein and yields of soluble were 
low. 
The production of the subsequent mutants showed little soluble protein for some and no 
soluble protein for others, therefore halting protein production until a more effective method 
was developed. Refolding of the insoluble proteins was attempted using several methods but 
to little success. Despite using techniques identified by Schaeffer et al. (2001) to produce 
soluble active protein, in our hands the wild-type protein remained insoluble and inactive after 
several attempts at refolding. 
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Mutations in KasA (mutated at Asp664Asn, Gly2694Ser, Gly3l2->Ser and Phc4l3->Leu), 
which also correlate with low levels of INH resistance, were reported to inhibit the forination 
of a trimolccular complex consisting of KasA, INH and AcpM (Mdluli el al., 1998). 
Interestingly, these mutations do not reside within the catalytic site, suggesting that these 
mutations may rather influence the degree of binding of the acyl-AcpM or the stability of the 
KasA dimer. Clearly, the generation of substrates, such as C16-AcpM and purified KasA, now 
allows the possibility to study key interactions between KasA and long-chain acyl-ACPs, in 
addition to how these mutations affect the KasA-INH-AcpM complex (Kremer et al,, 2000b), 
but the ongoing problem of efficient and consistent production of mutated proteins remains an 
issue. Other residues of interest like Gly107, Va1134, Va1135 and Phe201 which line the 
cavity of the active site and may play a role in the substrate specificity of the acyl-chain, 
therefore it was assumed that these residues play a major role in transacylation of the acyl- 
AcpM to the active site Cys and pose viable candidates for investigation (Olsen et al., 1999). 
The active site in the FabB dimer is accessible at the bottom of a narrow tunnel defined by a 
number of residues, but Pro202 was shown to be present at the entrance. The possibility that 
this mutation will have an effect on the kinetics of catalysis is interesting and requires further 
investigation. Asp231 and Tbr315 were identified in FabF to be part of the binding site of the 
acyl-ACP substrate (Huang et aL, 1998). Thr307 together with the N-terminus of the 
preceding a-helix form a binding site at the top of the binding cavity for the hydroxyl and 
phosphate of the phosphopantetheine group of the acyl-ACP. Some distance from the active 
site pocket is the Asp223 residue which is located on the surface of the enzyme and could be 
involved in the interaction with ACP (Huang et al., 1998). This study set out the groundwork 
for the further investigation of significant amino acid residues within the KasA enzyme, upon 
elucidation of a viable purification protocol. 
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The type II KAS enzymes are commonly separated into two classes based on their sensitivity 
to cerulenin. In E. coli, cerulenin binds irreversibly to KAS proteins (Campbell & Cronan, 
2001). The mechanism of inhibition involves covalent cross-linking of the KAS active-site 
cysteine to cerulenin (Chapter 1.5.11). The crystal structures of the FabB and FabF active sites 
(Huang et al., 1998; Moche et al., 2001; Olsen et al., 1999; Price et aL, 2001) show that a 
hydrophobic binding pocket is present and occupied by the inhibitor. Structural analyses of 
KAS4cerulenin complexes suggest that cerulenin mimics the transition state of the 
condensation reaction effectively (Price et al., 2001). Cerulenin-sensitive KAS enzymes have 
a catalytic triad, which in FabB consists of Cys163, His298 and His333 (Price et al., 2001). 
Protein alignments among FabB, FabF and KasA reveal a full conservation of these three 
residues (Kremer et aL, 2000b), which may explain the sensitivity of KasA to cerulenin. In 
contrast, mtFabH, another KAS, has been shown to be resistant to cerulenin (Choi et aL, 
2000b). It was shown previously that cerulenin exhibits potent in vivo anti-mycobacterial 
activity (Kremer et al., 2000b). Although over-expression of KasA in M. bovis BCG did not 
generate an increased resistance against cerulenin, it was suggested that the in vivo anti- 
mycobacterial activity of cerulenin was primarily via inhibition of earlier events catalysed by 
de novo FAS-I, thus masking inhibition of FAS-11. The in vitro inhibition of the E. coli, FabB 
and FabF, has also been well documented for cerulenin (Campbell & Cronan, 2001). 
Therefore it was reasonable to assume that cerulenin may also inhibit the P-ketoacyl-AcpM 
synthase activity of KasA. Increasing concentrations of ceruicnin were added to the in vitro 
condensation assay. A marked dose-response inhibition of KasA activity was observed with 
cerulenin providing an IC50 value of 0.15 pg/ml (0.67 pM). The IC50 values of purified E. coli 
KAS proteins were reported as 3 and 20 gM for FabB and FabF respectively (Price et al., 
2001), suggesting that the mycobacterial condensing enzyme is more susceptible to cerulenin 
inhibition in vitro than the related E. coli enzymes. 
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Recent studies by Schaeffer et al. (2001) and Kremer et al. (2002b) contribute to the 
understanding of the condensation-reaction mechanism mediated by KasA leading to mycolic 
acids via FAS-II and now allows for the development of new anti-mycobacterial agents that 
target this key condensation step in M wherculosis. 
Two new possible methods for further investigation of recombinant KasA production have 
recently been elucidated, firstly the use of quiescent-cells. The quiescent-cell expression 
system is a radical alternative to conventional fermentation for protein overproduction in E. 
coli (Rowe et al., 1999). It is dependent on the controlled over-expression of a small RNA 
called Rcd in hns mutant strains to generate non-growing, quiescent cells which are not 
nutrient limited. Quiescent cells no longer produce biomass and have their metabolic 
resources channelled toward the expression of plasmid-based genes. The biosynthetic capacity 
of the system has been demonstrated in their ability to express chloramphenicol 
acetyltransferase to more than 40 % of total cell protein (Rowe & Summers, 1999). Therefore 
quiescent cells may provide an ideal environment for the expression of KasA. Toxicity 
problems are negated by this system and with extremely high levels of protein expressed it 
would hopefully produce some active recombinant KasA. The second method would be the 
use of chaperones. Takara Bio Inc. have produce a set of five chaperone plasmids developed 
by HSP Research Institute which have been designed to enable efficient expression of 
multiple molecular chaperones that are known to work in cooperation as aids of protein 
folding processes. The have shown that these chaperones have the ability to reduce inclusion 
body formation and allow for the effective recovery of soluble folded protein. Development of 
such a system in the production of recombinant KasA would be very beneficial as the majority 
of expressed protein in any of the systems tested in this study had high levels of insoluble 
protein. 
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The following outlines the future work on KasA when the problems of expression, solubility 
and purification have been solved: 
KasA assay analysis of mutated proteins 
* Chain length specificity with a range of acyl-AcpM substrates (C8, C129 C161 
C20% C24 and C26) 
4, Decarboxylation activity of wild-type and mutated proteins with malonyl- 
AcpM 
o Transacylation OfCI6-AcpM 
e Antibiotic sensitivity of wild type KasA 
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4.1 Introduction 
AcYL-COA CARBOXYLASE (ACCD) 
The Corynebacterianeae represent a distinct and unusual group within Gram-positive bacteria, 
with the most prominent members being the human pathogens M. tuberculosis and M. leprae 
(Brennan & Nikaido, 1995; Stackebrandt et al., 1997). In addition, non-pathogenic bacteria 
belong to this taxon, such as Corynebacterium glutamicum, which is used in the industrial 
production of amino acids (Eggeling et al., 2001). A common feature to all these bacteria is that 
they possess unusual lipids, for instance mycolic acids (Brennan & Nikaido, 1995). 
Mycolic acids are long chain a-alkyl-p-hydroxylated fatty acids (R-CH[OH]-CH[R']-COOH), 
where R represents the meromycolate chain consisting in M tuberculosis of up to 56 carbons 
possessing additional structural modifications, and R' a shorter aliphatic branch possessing 22-26 
carbons. These two chains are then condensed together via a specialised Claisen condensation 
enzyme, followed by reduction to yield mature mycolic acids (Kremer et al., 2000a). In contrastý 
mycolic acids from Corynebacterium species, like C. glutamicum, represent the simplest fortri of 
these lipids, whereby two C16 fatty acids condense together followed by reduction to afford a C32 
mycolic acid. These a-branched, P-hydroxy fatty acids are found, primarily, as esters of the non- 
reducing arabinan terminus of arabinogalactan (McNeil et al., 1991). In addition, mycolic acids 
can also been found as extractable "free" lipids within the cell wall, mainly linked to glucose and 
trehalose (Minnikin, 1982). These mycolic acids and their derivatives are believed to play a 
crucial role in the architecture of the cell envelope (Brennan & Nikaido, 1995). 
Interestingly, M. tuberculosis is characterised by an exceptionally high number of additional 
lipids and glycolipids, which are thought to aid in the persistence of the bacterium thereby 
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fuelling the promise of the identification of new drug targets in the context of tuberculosis 
(Kremer & Besra, 2002). The rich diversity of lipids present in M. tuberculosis is reflected at the 
genomic level by possessing a panoply of genes involved in lipid biosynthesis (Cole et al., 1998), 
some of them constituting sets of paralogous genes. For instance, M tuberculosis has 35 JadD 
genes, annotated as fatty-acid-CoA ligases, 16 pks genes annotated as PKS, and 6 accD genes 
annotated as acyl-CoA carboxylases, whilst their detailed function in lipid biosynthesis and 
relevance for persistence is only now emerging (Cole et al., 1998; Glickman & Jacobs, 2001). 
Importantly, Corynebacterium species are considered the archetype within Corynebacterianeae, 
including M tuberculosis due to a low frequency of gene duplications and structural alterations 
giving rise to a strong conservation at the genomic level within this sub-group of the 
Corynebacterianeae (Nakamura et al., 2003). Together with their simpler chemical composition 
- as outlined above for mycolic acids - it can therefore be assumed that species of 
Corynebacterium have at their disposal just the core set of genes and reactions characteristic for 
the Corynebacterianeae. Indeed, C glutamicum possesses just 3 JadD, I pks and 4 accD genes 
(Kalinowski et al., 2003). As a result comparative studies using C. glutamicum have been 
employed in understanding the role of several M tuberculosis proteins, for instance Ppm I /D2 in 
lipoarabinomannan (LAM) biosynthesis (Gibson et al., 2003) and the "antigen 85" 
mycolyltransferases in cell wall mycolylation (Belisle et al., 1997; Brand et al., 2003; De Sousa- 
D'Auria et al., 2003; Kacem et al., 2004). 
The group of 4 accD genes in C glutamicum is interesting, and little is known of the function 
of these genes in Corynebacteriamae. These genes encode polypeptides with similarities to 
the P-subunits of acetyl-/propionyl-CoA carboxylases, and basically only one of them would 
be sufficient for the carboxylation of acetyl-CoA to provide malonyl-CoA for fatty acid 
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biosynthesis. This suggests additional and specific carboxylations, probably involved in the 
synthesis of unusual lipids. 
In this context the still controversial issue of mycolic acid synthesis is very attractive to 
consider carboxylation reactions. Cell-free extracts of Corynebacterium have been shown to 
utilise [I _14C]-labelled palmitic acid (Shimakata et aL, 1984; Shimakata et aL, 1985), with the 
newly synthesised mycolic acid exclusively labelled at C- I and C-3 (Walker et aL, 1973). The 
Claisen condensation reaction was hypothesised to involve a carboxylation step since it was 
inhibited by avidin, an inhibitor of biotin dependent enzymes in extracts-of C. diphtheriae 
which produced the putative precursor of mycolic acids, 2-tetradecyl-3-oxo-octadecanoic acid 
(Ahibo-Coffy et al., 1978; Walker et aL, 1973). In contrast, avidin had no effect on the 
Claisen condensation reaction in a cell-free extract of C matrucholii that synthesises mature 
mycolic acids (Shimakata et al., 1984; Shimakata et al., 1985). What seems to support this 
last observation came from the incorporation of [2,2_2H] palmitic acid in whole cells of C 
matruchotH (Lee et al., 1997). During the studies carried out in this thesis a polyketide 
synthase from C glutamicum (Cg-pks), the equivalent of M. wherculosis pkS13, was 
identified which apparently plays a key role in mycolic acid biosynthesis (Portevin et al., 
2004). 
The studies in this thesis are centered on the 4 accD genes located downstream of Cg-pks. As 
a result this study presents a systematic study on lipid and mycolic acid biosynthesis based on 
defined C glutamicum mutants, focusing on the relevance of the accD genes along with a 
phylogenomic analyses of these genes in Corymbacterium and Mycobacterium species whose 
genomes are established (Cerdeno-Tarraga et aL, 2003; Cole et al., 1998; Cole et al., 2001; 
Gamier et al., 2003; Kalinowski el al., 2003). 
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4.2 Materials and methods 
4.2.1 Bacterial strains and growth conditions 
Escherichia coli DH5ccmcr and C glutamicum ATCC 13032 (the wild type strain, and 
referred for the remainder of the text as C. glutamicum) were grown in Luria-Bertani (LB) 
broth (Difco) at 37*C and 30'C, respectively. The mutants generated in this study were grown 
on complex medium LBHIS (5 g tryptone, 5g NaCl, 2.5 g yeast extract, 18.5 g brain heart 
infusion (Difco), and 90.1 g sorbitol per litre). Kanamycin and ampicillin were used at a 
concentration of 50 pg/ml. The minimal medium CGXII was used for C. glulamicum 
(Keilhauer et al., 1993) with 30 mg/I protocatechuic acid included as a chelating agent. 
Samples for lipid analyses were prepared by harvesting cells at an OD 10-15, followed by a 
saline wash and freeze drying. Growth comparisons of the four accD-mutants were performed 
on un-supplemented CGXII and LBHIS plates, as well as LBHIS plates supplemented with 
0.03 % Na-oleate (w/v), 0.03 % Tween 40 (w/v), 0.04 % Brij-35 (w/v) and 0.03 % butter 
hydrolyzate (w/v). 
4.2.2 Construction of plasmids 
To enable chromosomal inactivation of the four acc genes of C glulamicum internal 
fragments were amplified by PCF, and blunt end ligated using the Sure Cloning Kit 
(Amersham) into the Smal-site of the non-replicative vector pkl8mob (Schafer et aL, 1994). 
The primers used were: accDlMuFlO (5'-GCA TGT GCA GGT GGC AAC GC-3'), 
accDlMuRI I (51-GGT AAT CTT TGG AAC GGT TGC-3'), accD2MuF30 (5'-GTC ACG 
TGT ACT CCC CT-3'), accD2MuR31 (5'-CAA GCG AAT ACG AGG TC-3'), 
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accD3MuF40 (5'-GTT GTA GGC GTC GCA GAT AC-3'), accD3MuR41 (5'-GCG TCC 
TCT GAA GAA GAG-3'), paccD4intfor (5'-TGG GGT TCA TCT GGG CAT CTC AC-3'), 
paccD4intrev (5'-TGC CCC CAA CGT TTC CAT AAT CTC-3'). The inactivation vectors 
derived were ten-ned pKl8mobaccDl-int, pK18mobaccD2-int, pKl8mobaccD3-int and 
pKl8mobaccD4-int. 
The in-frame deletion of Cg-pks in C glutamicum was achieved with pKl9mobsacBApks. 
Cross-over PCR was used to enable one-step integration of fragments containing upstream 
and downstream sequences of Cg-pks into pKl9mobsacB. In the first PCR-round two separate 
amplification products were generated by using the primer pairs pCipks (5'-TGT TTA AGT 
TTA GTG GAT GGG AGT CGC CGC ATT GAT GAG ATT TC-3'), with pCopks (5'-GGA 
ATT CGA CAG CGG AAG CTG ACG ACG -3') and pNopks (5'-GGA ATT CCG TTG 
GCA CTG CAC ACG GTG-3'), with pNipks-2 (5'-CCC ATC CAC TAA ACT TAA ACA 
CTT CTG ATC CGA CGA TTG GCT CTG-3'). Both PCR products subjected to 
electrophoresed on I% agarose and DNA visualised using EtBr. The appropriate DNA 
fragment was excised from the gel and extracted using the Qiagen Gel extraction kit. The PCR 
product purified using the Qiagen Gel extraction kit was used as a template to amplify with 
primers pCopks and pNopks a fragment devoid of Cg-pks that was treated with EcoRl and 
ligated with EcoRl-cleaved pKl9mobsacB to afford pKl9mobsacBApks. The inserts in 
constructs used in this study were verified by sequencing. 
4.2.3 Genomic mutations 
The non-replicative integration and deletion vectors were usually introduced via 
electroporation but conjugation was used when electroporation failed. Conjugation used E. 
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coli S-17-1 as the donor, and its sensitivity to nalidixic acid (50 pg/ml) was used after plating 
for counterselection. Selection of recombinant C glutamicum strains for the integration of the 
four pKl8mob-int vectors used 15 pg/ml kanamycin. The correct integration of sequences 
into the chromosome and absence of sequences, respectively, in the resulting recombinants 
was verified by PCR using two different primer pairs and by Southern analysis. 
To achieve deletion of Cg-pks, plasmid pKl9mobsacBApks was introduced into C 
glulamicum by electroporation. Selection for resistance to kanamycin in at least 20 
independent assays yielded regularly a number of clones indicating integration of the vector in 
the chromosome by homologous recombination. At least 100 clones derived from independent 
electroporation experiments were subjected to the subsequent selection for the second 
homologous recombination event. In this round the presence of sacB (together with addition 
of 10 % sucrose to the medium) resulted in a positive selection of clones where vector 
sequences were lost. Small colonies picked after 10 days were analysed for deletion of Cg- 
pks. Of 60 colonies analysed, 19 exhibited the loss of Cg-pks. One of these was further 
analysed by Southem-blot analysis and the resulting strain, C glutamicumApks was used in 
all subsequent studies. 
4.2.4 Southern blot analysis 
Genomic DNA was extracted from accDI-D4 mutants and the Cg-pks mutant and cleaved 
with BstEll. The resulting fragments were separated on aI% agarose gel and blotted onto a 
Nytran NY13N nitrocellulose membrane, with subsequent washings according to standard 
protocols. Detection was carried out with fragments of the acc-genes as probes which were 
labelled with digoxygenin (Roche Dig Labeling and Detection Kit). For accD], accD2, accD3 
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and accD4 the Sacl-BgIll, Pvull-SgrAl, Clal-&W and Sful-Pvul fragments were used, 
respectively. For the C glutamicumApks analysis the 645 bp-fragment used was generated by 
PCR with primers pNopks (5'-GGA ATT CCG TTG GCA CTG ACA ACG GTG-3') and 
ppksACPintrev (5'-CAA CAT CGC GAG AGG AAA GG-3'). 
4.2.5 Extraction and analysis of 114CI-labelled lipids 
LBHIS (5 ml) was inoculated with a single colony of the accD], accD2, accD3, accD4 and 
Cg-pks mutant, respectively, and shaken at 120 rpm overnight at 30'C. An aliquot (I ml) of 
this culture was used to inoculate 5 ml CGIII and grown again overnight. This second pre- 
culture was used to inoculate 5 ml of CGXII to give a starting OD600". of about 0.2. Cells 
were incubated at 30'C until an 0136oon of 0.4 at which point 5 ýtCi/ml of [ 14 C]acetate (62 
mCi/mmol, Amersham) was added followed by overnight incubation with shaking at room 
temperature. Cells were harvested by centrifugation followed by wash in a saline wash and 
freeze-dried. 
Free lipids were extracted by two consecutive extractions with 2 ml of CHC13/CH30H/H20 
(10: 10: 3, v/v/v) for 3h at 500C. These lipidic extracts were combined with 1.75 ml of CHC13 
and 0.75 ml of water, mixed and centrifuged. The lower organic phase was recovered, washed 
twice with 2 ml of CHC13/CH30H/H20 (3: 47: 48, v/v/v) and the resulting organic phase dried 
and resuspended in 200 pl of CHC13/CH30H/H20 (10: 10: 3, v/v/v). An aliquot (20,000 cpm) 
from each strain was subjected to thin-layer chromatography (TLC) using silica gel plates 
(5735 silica gel 6017254, Merck), developed in CHC13/CH30H/H20 (60: 16: 2, v/v/v). 
Autoradiograms were produced by 2-3 day exposure to Kodak X-Omat AR film to reveal 
[14C]-labelled lipids and compared to known standards (Puech et al., 2000). 
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The bound lipids from the de-lipidated extracts were released by the addition of 2 ml of 5% 
aqueous solution of tetra-butyl ammonium hydroxide (TBAH), followed by overnight 
incubation at 95'C. After cooling, water (2 ml), CH202 (4 ml) and CH31 (500 gl) were added 
and mixed thoroughly for 30 min. The lower organic phase was recovered following 
centrifugation and washed three times with water (4 ml), dried and resuspended in diethyl 
ether (4 ml). After centrifugation the clear supernatant was again dried and resuspended in 
CH2CI2 (200 gl). An aliquot (10,000 cpm) from each strain was subjected to TLC using silica 
gel plates (5735 silica gel 6017254, Merck), and developed in petroleum ether/acetone (95: 5, 
v/v). Autoradiograms were produced by overnight exposure to Kodak X-Omat AR film to 
reveal [14C]-labelled fatty acid methyl esters (FAMES) and mycolic acid methyl esters 
(MAMES) and compared to known standards (Lee et al., 1997). 
4.2.6 Acyl carboxylation assay 
To assay acyl carboxylase activity we adapted the method of Rainwater et al. (1982). Briefly, 
a clarified lysate of the appropriate strain was prepared by resuspending the bacterial cultures 
to a density of 0.5 g wet weight/ml in 0.1 M potassium phosphate buffer pH 8.0 with 5 mM 2- 
mercaptoethanol. The cell paste was lysed by two passages through a French pressure cell 
(19000 p. s. i., cell pre-chilled to 4'Q and the lysate clarified by centrifugation at 27000 xg for 
30 minutes at 40C. The supernatant was removed and stored on ice until assayed. Assay 
mixtures (100 gl) contained 100 mM potassium phosphate pH 8.0,5 mM ATP, 5 MM MgC12, 
2% DMSO, 0.9 mM acyl substrate (either acetyl-CoA, palmitoyl-CoA or palmitic acid), 65 
mg bovine serum albumin, 0.5 pCi NaH[14C]CO3 ( 0-1 Ci/mol; AP Biotech CFA42 1) and 250 
pg total protein from the lysate. All of the components of the assay excluding the enzyme 
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extract were pre-mixed, and then mixed with the enzyme extract to initiate the reaction, which 
was held at 30'C for 30 minutes. The reaction was quenched by the addition of 50 Al of 
concentrated HCL This mixture was then held at 95'C under a stream of air to remove non 
fixed [14CIC02- After evaporation to dryness, the residue was dissolved in I ml of water and 
added to 10 ml EcoscintA (National Diagnostics) prior to liquid scintillation counting. 
4.2.7 Acetyl-CoA carboxylation assay 
To assay for acetyl-CoA dependent malonyl-CoA formation, cells grown on complex medium 
CGIII were washed twice with 0.9 % NaCl, resuspended in 60 mM Tris-HCI pH 7.2 and 
disrupted as described above. Assay mixtures (250 pl) contained 60 mM Tris-HCI pH 7.2,65 
mM KHC03. I mM ATP, 1.5 MM M902 and 135 pl of cell extract. The mixture was pre- 
incubated at 30 T for I minute, and the reaction initiated by adding acetyl-CoA (Lithium salt, 
Roche) to give a final concentration of 2 mM and further incubated at 30"C. Samples were 
taken at the given time intervals and mixed immediately with 5 PI of 30 % perchloric acid to 
quench the reaction. The assay tubes were centrifuged subsequently (14000 x g, 4"C, 5 
minutes), 50 pI of the supernatant withdrawn, neutralised with 12.5 PI Na2CO3 and analysed 
via HPLC. The acyl-CoA synthesis was monitored by reversed-phase chromatography using a 
column (125 x4 mm) filled with LiChrospher 1000 RP 18-EC-5p (Merck KGaA, Darmstadt, 
Germany) on an Agilent 1100 Series HPLC (Palo Alto, California, USA). Samples (12 pl) 
were automatically injected, and separated by an increasing gradient consisting of 50 mM Na- 
phosphate buffer pH 5.0 containing 2% acetonitrile, increasing up to 26 % acetonitrile in the 
same buffer at a flow rate of 0.3 ml/min, and monitored at 254 nm. Reactions were compared 
to known standards of acetyl-CoA, malonyl-CoA, and CoA in concentrations of 0.1 to I MM 
dissolved in 200 mM Na-phosphate buffer pH 3.0. 
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4.3 Results 
4.3.1 The accD genes of Corynebacterianeae 
From the recent Himarl-based transposon mutagenesis in M. tuberculosis (Sassetti et al, 
2003) accD4 and accD6 were found to be essential genes, whereas accD1 and accD3 are non- 
essential. In terms of accD1 (previously dtsR]) of C glutamicum an involvement in L- 
glutamate formation was demonstrated which is related to fatty acid synthesis (Kimura et al., 
1997). To address the problem on functional similarities of the carboxyltransferase proteins 
we performed a phylogenomic analysis of the accD genes present in the genomes of the 
sequenced Corynebacterianeae (Cerdeno-Tarraga et al., 2003; Cole et al., 1998; Cole et al., 
200 1; Gamier et al., 2003; Kalinowski et al., 2003; Nishio et al., 2003). 
In fatty acid biosynthesis, malonyl-CoA is required for each elongation step, which is 
generated by carboxylation of acetyl-CoA. The process is catalysed by an enzyme consisting 
of a biotinylated cc-subunit and a P-subunit, the latter being the actual carboxyltransferase. In 
E. coli and Bacillus subtilis each of these subunits consists of two polypeptides, whereas in all 
Corynebacterianeae analysed, we have found that the cc- and the P-subunits consist of a single 
polypeptide. C. glutamicum has four putative carboxyltransferase P-subunits (accD genes) its 
close relatives C. efficiens and C diphteriae possess five, whereas M tuberculosis, M bovis, 
as well as M marinum possess as many as 6 carboxyltransferases. The sequence identities of 
the polypeptides within one organism are also in part exceptional. For instance, AccDI and 
AccD2 of M tuberculosis have identities of 49 %, and even the most distant paralogous, 
which are AccDI and AccD3 still share 22 % identity. The primary structures of 35 
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polypepticles were analysed using ClustalW (Pearson, 1990), with the results presented in 
Figure 4.1. 
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Figure 4.1 Phylogenomic analysis of mycobacterial and corynebacterial acc genes. 
Groups of orthologous carboxyltransferases are boxed in grey and labelled 
1-111. The organism key is as follows: Cg, C glutamicum; Ce, C effIciens; 
Cd, C: diptheriae; Mt, M. Wherculosis; Mb, M. hovis; Mm, M. marin"HI; 
MI, M. leprae. Diagram provided by Lothar Eggeling, (Gande et at, 2004) 
There are several remarkable features. Firstly, there are two distinct groups (I and 11) of 
closely related proteins, where each organism analysed is represented only once with one 
carboxyltransferase. Group III is clearly distant from groups I and 11, whereas the latter two 
are more closely related. The distinct clustering of these groups suggests that members of 
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these groups are orthologues in each group with an identical function. Secondly, there are 
three additional clusters, where M. hovis and M. tuberculosis are represented once. Also, M 
marinum is present in two of these clusters. These results indicate that these 
carboxyltransferases serve more specialised functions within the mycobacterial branch of 
Corynehacterianeae, whereas that of clusters I and 11, represent fundamental core functions 
specific for lipid biosynthesis in all bacteria. In addition, M. leprae possesses 3 pseudogenes 
sharing in part identities with the other carboxyltransferases (Cole et at, 200 1). However, the 
fact that in M leprae the two single carboxyltransferases fully retained are members of group 
I and 11, strengthens the view that these members encode essential functions in lipid 
biosynthesis, as is the case with mycobacterial mycolic acid biosynthesis (Kremer et at, 
2000a). Since, carboxyltransferase activity requires an activated carboxy group derived from a 
biotinylated a-subunit we searched the genomes for the corresponding proteins. The three 
Corynehacterium species, as well as M leprae have only one such subunit, whereas M 
tuberculosis, M bovis and M. marinum possess three. 
4.3.2 Inactivation of the corynebacterial P-subunit genes 
To systematically investigate the function of the accD genes each of them was inactivated in 
C. glutamicum. For this purpose we constructed non-replicative vectors to enable their 
specific disruption by use of internal fragments of accD], accD2, accD3, and accD4, 
respectively (Figure 4.2A). After transformation kanamycin resistant clones were assayed for 
vector integration by PCR with two different primer sets. 
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Their correct chromosomal integration was further confirmed by a scrupulous Southern-blot 
analysis, with the final result shown for each mutant in Figure 4.2B. The three chromosomal 
fragments derived from the accD] inactivation mutant hybridised with the accDI-probe 
(Figure 4.213, upper left panel), which is in agreement with the correct integration and 
inactivation of accDL The fact that a shift occurs with the same accDI-probe with DNA 
prepared from the accD2 mutant is due to the immediate proximity of both accD] and accD2 
separated by 344 bp (Figure 4.2A). One of these genes probably originated by a recent gene 
duplication event since the paralogues share more than 74 % identical nucleotides over 75 % 
of their length. With the accD2, accD3 and accD4-probes the chromosomal fragment of each 
respective mutant carrying the inactivation vector was shifted to the expected fragment 
increased by the vector length (3.99 - 4.35 kb) (Figure 4.213). These results confirm the 
specific inactivation of each accD gene and the integrity of the gene locus in the mutants 
generated. 
For control, the four inactivation mutants were made competent and transformed with either 
pEC7-accD], accD2, accD3, or accD4, respectively. Resulting recombinants were confirmed 
by plasmid preparations and PCR analysis to have the chromosomal locus disrupted with an 
intact copy of the respective gene plasmid encoded. Growth of these complemented mutants 
was undistinguishable from that of wild type C. glutamicum either on LBHIS or minimal 
medium CGXIL This makes it unlikely that the accD disruptions result in any polar effects. 
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4.3.3 Phenotypic characterisation of mutants 
As shown in Figure 4.3 the accD4 mutant (compare left and right panels) did not exhibit a 
phenotype, whereas growth of the accD], accD2 and accD3 mutants were strongly reduced 
on salt medium CGXII (upper row). The worst growth was in fact seen with the accD] 
inactivation mutant, and the colonies visible in Figure 4.3 are due to revertants. 
wt 
cgxll 
Ra 
LBHIS 
LBHIS 
+ FA 
:: accD I :: accD2 :: accD3 ::, iccD4 
Figure 4.3 Growth of accD mutants of C. glujamicum. The aceD mutants of C 
glulamicum and the wild type (wt) were grown for three days at 30'C. The 
plates used were salt medium with glucose (CGXII), complex medium 
(LBHIS), and complex medium supplemented with Na-oleate (300 mg/1), 
and butter hydrolysate (300 mg/1) together with the detergents Tween 40 
(300 mg/1) and Brij-35 (400 mg/1) 
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Also on complex medium LBHIS growth of the three mutants was still impaired illustrating 
that these mutants are not rescued by specific components supplied from yeast extract and 
tryptone, which are present in LBHIS. However, when this complex medium was 
supplemented with Na-oleate together with butter hydrolysate (and detergents for 
emulsification) growth of the accD] mutant was markedly improved, whereas the accD2 and 
accD3 mutants were still impaired, indicating a direct relation of accD] with fatty acid 
biosynthesis, and confirming previous observations with a dtsR] deletion mutant (Kimura et 
al., 1997). The colony surface of both the accD2 and the accD3 mutants were rougher than 
that of wild type colonies and these two mutants inclined to clump in liquid culture CGXIL 
Overall, the accD4 mutation has no apparent phenotype, whereas accDI appears to be 
involved in lipid biosynthesis, as it is rescued by Na-oleate suggesting that it may be involved 
in the synthesis of oleate from malonyl-CoA. The accD2 and accD3 mutants are likely to be 
very specific and essential carboxyltransferase P-subunits, as also illustrated from the 
phylogenomic analysis. 
4.3.4 Lipid analysis of the accD mutants 
In order to relate the phenotypic changes of the accD mutants to their cellular composition, 
the mutants and wild type bacteria were grown on salt medium CGXII for 4 hours and then 
labelled with [14C] -acetate. After further incubation the cells were harvested, dried and 
analysed for their lipid composition. The free lipids were extracted with chloroform-methanol- 
water and analysed by TLC as shown in Figure 4.4A. The accD] and accD4 mutation did not 
change considerably the relative amounts of phospholipids, trehalose monomycolates (TMM) 
and dimycolates (TDM), and glucose monomycolates (GMM). However, the consequences of 
the accD2 and accD3 mutations were dramatic. Surprisingly, both mutations resulted in the 
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complete loss of "free" and extractable mycolates (TMM, TDM and GMM), without effecting 
phospholipid synthesis, and the possible accumulation of an unknown intermediate. The 
extracted lipids were also hydrolysed and their methyl esters separated by TLC confirming 
that the synthesis of fatty acids was not affected in the accD2 and accD3 mutants. 
The remaining cell wall bound lipids were analysed by hydrolysis and the preparation of 
methyl esters. The profile of the extracted FAMES and MAMES is shown in Figure 4.413. In 
the accD2 and accD3 mutant cell wall bound mycolic acids were absent, whereas the relative 
amounts of fatty acids and mycolic acids in the accD] and accD4 mutants were comparable. 
These results illustrate the specific involvement of both accD2 and accD3 in mycolic acid 
synthesis, and that neither of these two genes themselves can complement each other, nor 
accD] or accD4. 
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Figure 4.4 Lipid analysis of accD mutants of C glulamicum. A) Free lipids were 
extracted and an aliquot (20,000 cpm) from each strain subjected to TLC 
analysis using silica gel plates (5735 silica gel 60F254, Merck), developed in 
CHC13/CH30HIH20 (60: 16: 2, v/v/v). Autoradiograms were produced by 2- 
3 day exposure to Kodak X-Omat AR film to reveal 114C I-labelled lipids 
and compared to known standards (TMM, TDM, and GMM, (Puech et al., 
2000)). B) The bound lipids from the de-lipidated extracts were released 
by the addition TBAH followed by overnight incubation at 95*C. 
Following preparation of methyl esters an aliquot (10,000 epm) from each 
strain was subjected to TLC analysis using silica gel plates (5735 silica gel 
60F2'54, Merck), developed in petroleum ether/acetone (95: 5, v/v). 
Autoradiograms were produced by overnight exposure to Kodak X-Omat 
AR film to reveal 114CI-labelled FAMES and MAMES, and compared to 
known standards 
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4.3.5 Carboxylation reactions in the accD mutants 
In order to assess the validity of the assignment of the Accl) family members as acyl 
carboxylase components, we assayed the fixation of [14C] from radio-labelled bicarbonate in 
extracts of the C. glutamicum mutants. In these assays we used acetyl-CoA and palmitoyl- 
CoA as these were the obvious substrates for de novo fatty acid biosynthesis and 
corynomycolate condensation, respectively. The recent demonstration that the product of M. 
tuberculosis fadD32, which occupies the locus adjacent to pks]3, activates fatty acids by 
adenylation (Trivedi et al., 2004) led us to incorporate palmitic acid into our experiments to 
detennine whether, in the absence of commercially available palmitoyl-ADP, it may generate 
a suitable substrate for carboxylation. When assaying acyl carboxylase activity in clarified 
lysates of the parent strain, we detected carbon fixation was 40-fold higher when using acetyl- 
CoA than with palmitoyl-CoA and palmitic acid as acyl substrates yielding specific activities 
of 2.45,0.06 and 0.06 nmol min-' mg- , respectively. The following reaction rates were 
normalised to these values. Basically, with each accD mutant and overexpressing strain, a 
significant influence on carbon fixation was apparent (Figure 4.5). 
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The most distinct effect was present for the accD4 mutant where inactivation resulted in 
uniform and significant decrease in [14C]carbon fixation, and over-expression of accD4 led to 
an uniform increase in activity, in both cases independent of the substrate used. The accD] 
mutant also possessed lower levels of carboxyltransferase activity with respect to acetyl-CoA 
and palmitoyl-CoA effects, however extracts prepared from the AccD I overexpressing strain 
possessed similar levels of activity in comparison to the wild type. When analysing extracts 
from AccD2 and AccD3, we observed substrate specific variations in acyl carboxylase 
activity. With the accD2 inactivation mutant, acyl carboxylase activity with acetyl-CoA 
present was slightly reduced, whereas it was most pronounced with the C16 substrates. A 
similar activity profile was observed with the extract of the accD3 inactivation mutant; both 
observations being wholly consistent with roles for AccD2 and AccD3 specific to 
corynomycolate biosynthesis. When we assayed extracts from bacteria overexpressing accD2 
or accD3, we observed clear differences in their substrate preference. The extract enriched in 
ACCD3, [14C]carbon fixation detected using acetyl-CoA was similar to the wild-type extract, 
whilst activity with C16 substrates was increased. In contrast, over-expression of accD2 
coincided with increased [14C]carbon fixation when using acetyl-CoA rather than the longer 
acyl chain length substrates. 
4.3.6 Acetyl-CoA carboxylation by AccDl 
We inferred from the growth response of the accD] inactivation mutant (Figure 4.3) that 
accD] might encode the P-subunit of the carboxylase transfering the carboxyl group from the 
P-subunit onto acetyl-CoA to yield malonyl-CoA. Therefore a HPLC assay was used to follow 
malonyl-CoA formation. 
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Figure 4.6 Malonyl-CoA formation with extracts of recombinant C. glufamicum. 
Malonyl-CoA synthesis shown in nmol per mg protein of recombinant C. 
glulamicum strains derived from the wild type strain and with the 
genotypes Apyc pJCIaccBC pEC7accDI (E), Apyc pJCIaccBC pEC7 (*), 
Apyc pJC1 pEC7accD] (A), and Apyc as control (X) after incubation at 
30'C at given time intervals. The inset shows comparable analyses using a 
separate accDI overexpressing strain pVWEx2accD/ (0) compared to 
control with empty vector pVWEx2 (0). 
As shown in Figure 4.6, use of extracts derived from wild type C. gluiamicum results in a 
constant increase in malonyl-CoA formation over time that is dependent upon acetyl-CoA and 
ATP. The derived specific activities were 23.1 nmol min" mg-1, which is in the range of that 
determined for M. tuberculosis and M. bovis (Rainwater & Kolattukudy, 1982). When accD] 
was overexpressed (pJC I accDI), the specific activity increased 2-fold to 40.7 nmol min-] mg- 
This significant increase was confirmed in a separate experiment using a separate construct 
(pVWEx2accDl), see inset in Fig. 4.6, where the specific activity was increased from 15.1 to 
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27.2 nmol min-' mg-1. Unexpectedly, the over-expression of the biotin-containing cc-subunit of 
C. glutamicum (pJClaccBC) resulted in a sharp rise in acetyl-CoA carboxylation activity, 
yielding a specific activity of 132.8 nmol min-' mg-1. These results indicate a possible limiting 
availability of this subunit for sufficient carboxylation to occur. This was reconfirmed by the 
mutual over-expression of accBC and accD] (pJC I accBC paccD 1) where the specif ic activity 
was additionally increased to yield a specific activity of 180.3 nmol min-' mg-1. These results 
were confirmed in several independent experiments. A low activity of malonyl-CoA 
formation was observed in the accD] inactivation mutant (specific activity 8 nmol min" mg, 
1), where poor growth in liquid culture and malonyl-CoA detection at the threshold level 
prevented a more detailed quantification in this mutant 
In summary, the acyl carboxylase assays described above for AccD 1 -4 demonstrate that these 
enzymes possess carboxylase activity, with AccD3 (and possibly AccD2) preferring long- 
chain substrates consistent with their involvement in mycolic acid biosynthesis, and that 
AccD I uses acetyl-CoA as a substrate. 
4.3.7 The pks locus of Corynebacterianeae 
Inspection of the chromosomal organisation of the accD genes in C glulamicum revealed the 
localisation of accD3 close to the single Cg-pks gene in this bacterium (Figure 4.7). The Cg- 
pks has high identity to pks]3 of M wherculosis and is located in a locus strictly conserved in 
all Mycobacteria and Corynebacteria species (Figure 4.7), as it is also in Rhodococcus 
(Portevin et al., 2004). It consists of at least six genes, all of them transcribed in the same 
direction and extending over more than 12 kb. 
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Figure 4.7 The pks locus of mycolic acid containing bacteria responsible for mycolic 
acid biosynthesis 
In M tuberculosis, the first two genes arejbpA andjbpC], which encode mycolyltransferases, 
respectively (Belisle et al., 1997). These mycolyltransferases are followed by an essential 
gene (Sassetti et al., 2003), whose product is predicted to be anchored in the membrane by 
one transmembrane spanning helix. The remaining segment (cccc 35-336) is probably directed 
towards the periplasm and is predicted to possess an esterase acitivity. Further, located 
downstream is fadD32, recently shown to activate long chain fatty acids as acyl-adenylates 
(Trivedi et al., 2004), followed by polyketide synthase phs. 13. The gene locus is completed 
with the P-chain of the acyl carboxylase accD4 (accD3 in C glutamicum). The overall 
organisation of the entire locus in all species analysed is almost identical, although a slight 
difference is apparent in the mycolyltransferase region (grey arrows in Figure 4.7). In C 
glutamicum a transposase is located between cmytA and cmylB. The strong conservation of 
this entire locus, the known mycolyltransferase activities in M. tuberculosis (Belisle et aL, 
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1997) and C glutamicum (Brand et aL, 2003; De Sousa-DAuria el aL, 2003), the absence of 
mycolic acids in accD3 and Cg-pks mutants (see below and (Portevin et aL, 2004) and the 
acyl-AMP ligase identified (Trivedi et al., 2004) suggests a fundamental and essential role of 
these genes in mycolic acid biosynthesis and translocation of mature mycolic acids to the cell 
wall and the outer lipid layer. 
4.3.8 Deletion ofpks]3 
In order to examine the phenotype of a Cg-pks mutant, whilst preserving the entire gene locus 
we attempted to delete the pks gene. For this purpose the upstream and downstream sequences 
adjacent to Cg-pks where fused, with the in-frame deletion in the construct verified by 
sequencing. The construct was used in two rounds of positive selection. The original clones 
obtained after 3 days were all shown to have the wild type locus restored. This indicates a 
strong disadvantage of cells deleted of pks. However, when we analysed the small colonies 
that appeared after 10 days, these had lost Cg-phs. One of these clones was chosen, verified by 
PCR (Figure 4.8) and Southern-blot analysis confirmed a Cg-pks deletion. 
This strain, C glutamicumApks, exhibited poor growth and a rough colony surface. Lipid 
analysis revealed that C glutamicumApks, is devoid of extractable mycolic acids (Figure 4.8) 
and bound cell wall mycolic acids, although fatty acids are still present in phospholipids. 
Since the Cg-pks deletion has virtually the same consequences on mycolic acid synthesis as 
accD2 and accD3, this illustrates that these genes are equally important and possibly act in 
concert in the final assembly of mature mycolic acids. 
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Figure 4.8 Analysis of the pks deletion mutant of C glulamicum. A) The panel shows 
the PCR analysis of the Cg-pk. v locus of the wild type (wt) and the in-frame 
deletion mutant (C. glutamicumApks). A standard is applied in the middle 
(standard), with the molecular weights given on the right. Whereas, with 
the primers annealing upstream and downstream of Cg-plts the expected 
amplification product of 1.11 kb is obtained with chromosomal DNA from 
C. glulamicumApks, no product can be formed under the conditions used 
with wild type DNA due to the length of Cg-pks. B) TLC analysis of 
extractable lipids from C. glulamicum (wt) and the deletion mutant (C. 
glutamicumApks), illustrate the absence of the dominant lipids, TDM and 
GMM, upon Cg-pks deletion 
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4.4 Discussion 
Our combined mutational and functional analysis on the accD genes, which we propose are 
key to lipid biosynthesis, revealed that growth of the accD] mutant of C glutamicum on 
minimal medium is severely restricted as compared to the other mutants. This mutant was 
extremely unstable, and the phospholipids derived from the mutant culture are, in all 
likelihood, due to revertants. The recovery of growth by Na-oleate addition is strong evidence 
that AccDI is a constituent of the acetyl-carboxyltransferase enzyme generating oleate from 
malonyl-CoA. This is further substantiated by the increased malonyl-CoA fortnation when 
accD1 is overexpressed yielding a higher specific activity of 40.7 nmol min" mg"' as 
compared to wild type extracts (23.1 nmol min" mg-1). In addition, when over-expression of 
accD1 is combined with accBC, an 8-fold increase in specific activity is observed indicating 
that both polypeptides are components of acetyl-CoA carboxyltransferase, which is in 
agreement with an acyl-CoA carboxylase isolated from M bovis (Rainwater & Kolattukudy, 
1982), and a propionyl-CoA carboxylase from M. smegmatis (Haase el al., 1982), both of 
which are composed of 2 individual polypeptides, with one being biotinylated. 
Extracts of the accD4 mutant possessed lower levels of acyl carboxylase activity and extracts 
from the overexpressing accD4 strain possessed increased levels of acyl carboxylase activity, 
suggesting that AccD4 is a carboxylase enzyme. However, the absence of a phenotype for the 
AccD4 mutants, as well as their unaltered lipid profiles led us to conclude that AccD4 is not 
directly involved in lipid biosynthesis. In sharp contrast are the AccD2 and AccD3 mutants 
where the lipid analyses revealed that both proteins are essential for corynomycolate 
biosynthesis. We cannot be sure whether the general carboxylation assays reported here 
represent an indication of relative acyl-carboxylase activity or if it simply reflects the half-life 
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of the carboxylated products, which we presume, are readily decarboxylated in a Claisen-type 
condensation reaction. However, the assays revealed a profound decrease in carboxylation 
activity for the accD2 and accD3 inactivation mutants with respect to the C16 substrates. The 
data would appear wholly consistent with the proposed function of AccD2 and AccD3 in the 
later stages of corynomycolate biosynthesis. As expected, over-expression of accD3 led to a 
similar increase in acyl-carboxylase activity with both C16 substrates, whereas when using 
acetyl-CoA, carboxylation activity was comparable to extracts from the parent strain. 
Intriguingly, over-expression of accD2 led to an increase in the acyl-carboxylase activity with 
acetyl-CoA only. Maybe the peculiar substrate specificities implied by the above in vitro data 
indicate the formation of heterooligomeric assemblies whose composition defines substrate 
specificity. However, as both AccD2 and AccD3 are required for corynomycolate 
biosynthesis we can rule out any complementation by AccD1 and may speculate that AccD2 
and AccD3 operate as a heterodimer. Furthermore, our in vitro analyses of accD2 and accD3 
over-expression are highly suggestive that AccD3 might define the strict substrate specificity 
of such a complex. Sequence analysis of the AccD paralogues support this hypothesis as 
AccD2 is more closely related to AccD I than AccD3. 
The M. tuberculosis antigen 85 complex, which possess mycolyltransferase activity are 
located outside of the cytoplasm in the cell envelope and often found in the culture medium 
(Belisle et al., 1997) as observed for C glutamicum (Brand et al., 2003; De Sousa-DAuria et 
al, 2003). The localisation of these enzymes suggests that they use mature mycolic acids once 
they are synthesised to transfer them to their final destination (Belisle el al., 1997; Brand el 
al, 2003; De Sousa-DAuria et al., 2003; McNeil et al., 1991). The mycolyltransferase locus 
is slightly different in the related Corynebacterium species (Figure 4.7). CmytA in C. 
glutamicum is fused to a larger polypeptide with a domain of unknown function. In addition a 
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small open reading frame is present downstream (166 ccoc). A distinct possibility exists that 
cmytA and cmytB have different specificities as they are conserved in Corynebacterianeae. 
Interestingly, downstream of the mycolyltransferase locus is a gene essential for M. 
tuberculosis (Sassetti et al., 2003). The Pro-rich protein encoded is predicted to be membrane 
anchored with the remaining segment directed towards the periplasm, and exhibiting identity 
with an acetylxylan esterase from Penicillium purpurogenum possessing the characteristic 
serine esterase motif. A tempting hypothesis is that this particular gene may be responsible for 
the first steps of mature mycolic acid transfer from a putative carrier molecule, such as 
ACP/CoA or from an intermediate polyprenol carrier (Besra et al., 1994) to possibly either 
trehalose or to the cell wall arabinogalactan. This seems meaningful as it is located in close 
conjunction with the mycolyltransferases and together with the fadD-pk; s-accD3 locus, and 
warrants further investigation as a possible specific mycolyltransferase. Another structural 
characteristic is the gene arrangement of pks and its downstream accD3 gene. In the three 
Corynebacterium species analysed the genes are separated by less than 20 nucleotides, 
however both genes overlap by 4 nucleotides in M tuberculosis, M. bovis and M leprae. 
Such, intimate structural organisation has also been observed for other important genes in the 
Corynebacterianea, like for instance Ppml, where even protein fusion has occurred (Baulard 
et al, 2003; Gibson et al., 2003; Gurcha et al., 2002). 
The P-ketoacyl synthases catalyse the forination of new carbon-carbon bonds by condensation 
of a variety of acyl-chain precursors with an elongation substrate, usually malonyl or 
methylmalonyl residues, that are covalently attached in a thioester linkage to an acyl carrier 
protein (ACP). The data obtained in this paper, along with the structural characteristics of the 
fadD-Pk, T-accD3 locus, and recent findings on FadD32 (Trivedi et al., 2004) and pkS13 
(Portevin et al., 2004) yields three distinct features, which are very likely to represent the 
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basis of discrete steps in the mechanism of mycolic acid biosynthesis. (i) FadD, recently 
shown to constitute a new class of fatty acyl-AMP ligases, activates long-chain fatty acids as 
acyl-adenylates, which are loaded onto multifunctional PKS for further chain extension 
(Trivedi et al., 2004), (ii) PKS possess a P-ketoacyl synthase domain with 2 
phosphopantetheinyl binding sites and a thioesterase domain, and (iii) the carboxyltransferase 
activity of the Acc enzymes, with AccD2 and AccD3 in C glutamicum directly linked to 
mycolic acid biosynthesis. An explanation for the two phosphopantetheinyl arms is that one 
site is occupied by the acyl-chain forming the mero-chain and the other by the acyl-chain 
resulting in the incoming cc-branch. The role of AccD3 as shown in these studies would be to 
generate an activated carboxylated acyl-derivative which would then react with the bound 
acyl-chain to form a 3-oxo inten-nediate which would be reduced to form mature mycolic 
acids (Figure 4.9). The experimental data as well the phylogenomic analysis indicate that in 
addition to AccD3 in C glutamicum, a second Acc protein (AccD2) is also apparently 
required for mycolic acid biosynthesis. One possibility is that after the fixation of carbon by 
AccBC, this is not directly transferred via AccD3 (AccD4 in M. tuberculosis) but transmitted 
via AccD2 (AccD5 in M. tuberculosis). The carboxylating transferase might fall into a group 
of multienzyme complexes, such as transcarboxylases from Propionibacterium shernianii 
(Hall et al., 2003) which is a 1.2 MDa multienzyme complex that couples two carboxylation 
reactions, transferring COj- from methylmalonyl-CoA to pyruvate, yielding propionyl-CoA 
and oxaloacetate. Cg-AccD3 also exhibits a high degree of identity with the 12S subunit of 
this enzyme. Shuttling via intermediates between different catalytic subunits provides a 
complex and intriguing mechanism for regulation and modulation of this specificity. 
181 
CHAPTER4 ACYL-COA CARBOXYLASE (AccD) 
ATP Poý 
Cg-FadD 
AD 
(3) 
KAS 
li[ýD 
(5) 
S. 
"XtI KAS 
(1) 
FAS-la 
AcetN I CoA +7 malonyl CoA 0 palmitoyl CoA +7 CoA 
Ili KtA7, S 
(6) 
KS 
(7) 
I KAS 
(8) 
INIM. D%. (; M, %l 1, 
KAS 
182 
CHAPTER 4 AcYL-COA CARBOXYLASE (AccD) 
Clearly further experiments and in particular an in vitro system for the Claisen condensation 
reaction involved in mycolic acid biosynthesis is required. The mechanism proposed (Figure 
4.9) for the Claisen condensation could well be a general mechanism of relevance for other 
lipids or antibiotics produced via PKS. 
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5.1 Introduction 
Polyketides form a large family of natural products found in bacteria, fungi and plants, which 
includes many clinically-important drugs such as tetracycline, daunorubicin, erythromycin 
(antibacterial), rapamycin (immunosuppressant) and lovastatin (anti-hypercholesterolemic). 
Their unparalleled range of biological activities drives current research into polyketide 
biosynthesis and enormous commercial value as promising candidates for future drug 
discovery. Also the structure, mechanism and catalytic reactivity of PKS synthases provide an 
opportunity to further investigate the molecular mechanisms of enzyme catalysis, molecular 
recognition and protein-protein interactions (Shen, 2003). Both PKS and FAS employ 
repeated Claisen-type condensations with acyl residues, typically derived from acetyl-CoA 
and malonyl-CoA. In contrast with fatty acid biosynthesis, the assembly of polyketides does 
not always employ a complete cycle (P-ketoacyl reduction, dehydration and enoyl reduction) 
after each chain extension (Child & Shoolingin-Jordan, 1998). 
There are three types of bacterial PKS known. Type I and 11 PKS utilise ACP domains to 
activate acyl-CoA substrates and allow the binding and manipulation of polyketide 
intermediates, whereas type III PKS, are not ACP-dependent acting directly on the acyl-CoA 
substrates. Type I PKS are multifunctional enzymes that are organised into modules that are 
further sub-divided into active regions. An example of a type I PKS product is 6- 
deoxyerythromycin B synthases (DEBS) which is involved in the biosynthesis of reduced 
polyketides product, such as erythromycin A (Reeves el al., 2001). Type 11 PKSs are 
multienzyme complexes that carry only a single module, for instance Streptomyces 
glaucescens tetracenomycin C synthesis. The genes tcniJIKILIMIN encode 5 modules of the 
tetracenomycin C PKS. These have been shown to be highly specific. In the absence of any 
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one module significantly diminished activity is observed, implicating formation of a 
multienzyme complex (Shen & Hutchinson, 1993). Type III PKS are also characterised as 
chalcone synthase-like PKS, they are homodimeric enzymes that are essentially condensing 
enzymes. Recent literature on polyketide biosynthesis suggests that PKS have much greater 
diversity in both mechanism and structure than the current type 1,11 and III paradigms (Shen, 
2003). In some incidences type I PKS lack a domain which is essential for complete function 
like in the biosynthesis of leinamycin. The biosynthetic gene cluster from Streptomyces 
atroolivaceus S-140 lacks the acyl transferase (AT) domain, whose missing activity instead is 
provided in trans by a discrete protein, LnmG. This PKS has the majority of the type I PKS 
properties but also has type 11 characteristics therefore in some incidences there may be call 
for sub-typing to occur (Cheng et al., 2003). 
In M. wherculosis several families of polyketide and non-ribosomal peptide synthases exist 
(Figure 5.1), for instance, ppsABCDE and mas, which are involved in the biosynthesis of 
PDIM, an important factor in pathogenicity (Betts et al., 2002; Camacho et al, 200 1). Lipids 
derived from in vivo labeling experiments using [1_14C]propionic acid showed that pks2 
mutant of M. wherculosis was incapable of producing hepta- and octamethyl phthioceranic 
acids and hydroxyphthioceranic acids, the major acyl constituents of sulfolipids (Sirakova et 
a1,2002; Sirakova. et al., 200 1). 
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Figure 5.1 Domain organisation among pks families from M. luberculosis. (A) Known 
pks genes (B) pks genes of unkown function. The domain organisation 
consists of the subunits 0-ketoacyl synthase (KS), acyl transferase (AT), 
dehydratase (DH), enoyl reductase (ER), 0-ketoreductase (KR), acyl 
carrier protein (ACP), thioesterase (TE), and chalcone synthase-like 
(CHS? ). 
Interestingly labelling studies also showed in both pk. v2 and pks12 mutants using [I- 
14 Clpropionate that the mutants were deficient in the synthesis PDIM. Disruption of ?? I. VI5 
(pkv8 plus pks17) in M. luberculosis H37Rv generated a mutant incapable of producing 
monomethy I -branched C16-C20 fatty acids that are minor constituents of acyltrehaloses and 
sulfolipids (Dubey el aL, 2003). Two further mas-like PKS genes pk. v5 and pk. V7 were 
disrupted in M. mberculosis. Disruption of pk. v7 resulted in a mutant deficient in PDIM 
production. However, the cell envelope composition of the pk. v5 mutant was fiound to be 
187 
CHAPTER 5 POLVKETIDE SNATHASE 13 (pA-sl.? ) 
identical to that of the parental strain. Both pk. v5 and pkv7 mutants displayed severe growth 
defects in mice (Rousseau et al., 2003). 
Interestingly, nucleoticle sequence analysis of pk. vl3 predicted a 1733 amino acid product with 
a molecular weight of 186445.6 Da consisting of P-ketoacyl synthase (KS), acyl transterase 
(AT) and thioesterase (TE) domains (Minnikin el al., 2002) (Figure 5.2), which was flanked 
by a gene encoding a probable propionyl-CoA carboxylase 0 chain (accl)4) and a probable 
tatty-acid-CoA ligase (fadD32) (Figure 5.3). 
25-91 
117366 37+543 
713-1039 D-- 1236-1292 
1469-IS61 
11733 mOklesl 
Figure 5.2 Domain organisation of Pksl3 of M. Wherculosis 
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Figure 5.3 pksl3 region of M. tuberculosis H37Rv chromosome 
The locus occupied by pkvl3 lies in a 48.5 kb region in which several key genes involved ill 
cell wall assembly and biosynthesis are located. The modular organisation and genetic linkage 
with act-D4 andfadD32 suggest that Pks 13 is involved in I ipid biosynthesis and their location 
within this region suggests that Pks 13 is involved in the biosynthesis oflipids of the cell wall. 
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The cluster of ORF, Rv3789-3792 are all involved in cellular metabolism and possibly 
involved in transmernbrane functions. Alongside these ORFs lies the embCAB cluster, these 
genes are predicted to encode mycobacterial arabinosyltransferases involved in the synthesis 
of AG and LAM (Telenti et al., 1997). FadE32 has been predicted to encode an acyl-CoA 
dehydrogenase. FbpA has been characterised and shown to encode a mycolyltransferase 
implicated in the deposition of mycolates allowing the synthesis of TMM and TDM cord 
factor (Kremer et al., 2002a). FbpD has recently been shown to be inactive in 
mycolyltransferase activity (Kremer et al., 2002a). gYT has been shown to encode a novel 
UDP-galactofuranosyltransferase. This enzyme possesses dual functionality in performing 
both (145) and (146) galactofuranosyltransferase reactions implicating its involvement in 
AG biosynthesis (Kremer et al., 2001b). The clustering of functionally related genes within 
genomes isn't uncommon therefore hypothetically it is possible that the cluster offadD32 to 
accD4 is involved in cell wall biosynthesis. We propose that pkS13 is involved the Claisen 
condensation of the meromycolate chain to the cc-chain forming the a-alkyl P-hydroxy fatty 
acid (mycolic acids) (Figure 5.4) from the fatty acids from FAS-I and the meromycolates 
produced by FAS-11 and further modification (Figure 5.5). 
The aim of this project was to investigate the functionality of AccD4, Pksl3 and FabD32 by 
further characterisation of the enzymes and elucidate their function as proposed in Figure 5.4. 
Although it is not clear how the covalently sequestered biosynthetic intermediates are 
transferred from one enzymatic complex to another it was assumed that it would be either be 
by an ACP or CoA adduct. 
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Trivedi et al. (2004) recently showed that some of the 36 annotated fiull) genes, located 
adjacent to the PKS genes in the M. tuberculosis genorne, constitute a new class of long-chain 
fatty acyl-AMP ligases. These proteins activate long-chain fatty acids as acyl-adenylates, 
which are then transferred to the multifunctional PKSs for further chain extension. This mode 
of activation and transfer of fatty acids is contrary to the previously described universal 
mechanism involving the formation of acyl-CoA thioesters (Trivedi el al., 2004). The 
identification of the acyl-carrier was essential as studies on Pks 13 using acyl-CoA and AcpM 
substrates might indicate negative results. 
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5.2 Materials and methods 
5.2.1 Cloning of Pks13, FadD32 and AccD4 
pks]3, pks]3-KAS domain, fadD32 and accD4 were all cloned into the expression vector 
pET23b to create His6-tagged fusion proteins to simplify purification. pks]3, pks]3-KAS 
domain and anti-pks]3 were cloned into the acetamide-inducible mycobacterial expression 
vector pSD26 so that in vivo studies could be carried out in M. smegmatis. The main purpose 
of the study was to assess any changes in mycolate composition within the host upon over- 
expression of the gene. 
5.2.1.1 pET23b system 
Pksl3 and the KAS domain were cloned using the recipe in Table 5.1. The conditions for the 
PCR reaction are found in Table 5.2. For the KAS domain the normal upper primer was used 
but a different lower primer was used. The DNA encoding pks]3 was amplified from Af 
tuberculosis H37Rv genomic DNA. PCR primers upper (5'- 
GATCGATCCATATGGCTGACGTAGCGGATTC-3') and Full lower (5'- 
GACTGATCAAGCTTCTGCTrGCCTACCTCACTTG- 3') kas lower (5'- 
GATCGATCAAGCTTGGCGGGTTCGGCGGCCGCC-3') were used to create NdeI and 
HindIff restriction sites (underlined), respectively. The PCR product was separated from 
primers and nucleotides by electrophoresis on I% agarose, and after visualisation with EtBr, 
fragments consistent with the size of the gene were extracted using the Qiagen Gel Extraction 
Kit. The PCR product was then digested with NdeI and HindIff and yield was assessed by 
DNA electrophoresis, along side a similar digest of pET23b. The cut DNA fragment was 
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again extracted from the gel, and ligated with the cut vector and transformed into E. coli Top 
Ten. Plasmid DNA was isolated from transformants showing ampcillin resistance. Screening 
was performed by double digest with and analysis on I% agarose and visualisation by 
staining with EtBr. The integrity of the DNA construct was confinned by nucleotide 
sequencing. 
Table 5.1 PCR recipe 
Volume 
2 gl 5' Cloning Primer (100 pmol/ml) 
2 gl 3' Cloning Primer (100 pmol/ml) 
I Al Genomic DNA (I pg/gl) 
2 gi dNTP's (25 mM each type) 
10 gl Thermostable Buffer (I Ox) 
8 til DMSO 
2 ul M9SO4 
(100 MM) 
I gl Deep Vent " DNA polymerase (2000 U/ml) 
72 gl ddH20 
I 
I Final volume of 100 ptl with the addition of ddH20 
Table 5.2 PCR conditions for Pks13 
Full Pksl3 KAS Domain 
94*C 3 min 94*C 3 min 
94*C 30 ýec 94*C 30s -C 
1 
68*C 10 min 
1 
35 cycles 68*C 3 min 
35 cycles 
68*C 10 min 68*C 10 min 
4*C 00 4*C 00 
accD4 and fadD32 were cloned by the same method using the recipe in Table 5.1 and the 
following primers, under the PCR conditions in Table 5.3. Both DNA fragments were 
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separated from primers and nucleotides by electrophoresis on I% agarose, and after staining 
with EtBr, relevant bands excised from the gel and extracted using the Qiagen Gel Extraction 
Kit. The PCR fragment was then digested with both restriction enzymes incorporated in the 
primer and assessed by DNA electrophoresis, along side a similar digest of pET23b. The cut 
DNA fragment was again extracted from the gel, and ligated with the cut vector and 
transformed into E. coli Top Ten. Screening was performed by double digest with and 
analysis on I% agarose. The DNA was then sequenced to assess the viability of the construct. 
AcCD4 Upper 5'GATCGATCCATATGACCGTCACCGAGCCGG 3' 
Lower 5'GATCGATCAAGCTTCTAGACCGGGATCAGGCCG 3' 
FadD32 Upper 5'GATCGATCCATATGTTTGTGACAGGAGAGAGTGGG 3' 
Lower 5'GATCGATCAAGCTTGTCCGAAGTGGCGAAGACCGTC 3' 
Table 5.3 PCR conditions for AccD4 and FadD32 
AccD4 FadD32 
94*C 
- - 
3 min 94*C 3 min 
94i; C 30 see 35 c C es 
94*C 30 sec 35 cycles 68*C y 4 min 68*C 3 min 
68*C 10 min 68*C 10 min 
4*C 00 4*C 00 
5.2-1.2 pSD26 system 
Pks13 and KAS domain were cloned using the recipe and conditions as for the pET23b 
system Table 5.1 and Table 5.2. For the KAS domain the normal upper primer was used but 
with a different lower primer. The pks]3 gene was amplified from M tuberculosis 1137RV 
genomic DNA using the following primers to clone the genes of interest and create BamHI 
restriction sites upper (5'-GATCGATC-GGA-TCCATGGCTGACGTAGCGGATTC-3') and 
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lower (5-GACTGATCGGATCCCTGCTTGCCTACCTCACTrG- Y) Kas lower (5'- 
GATCGATCGGATCCGGCGGGTTCGGCGGCCGCC-3'). The PCR product was separated 
from primers and nucleotides by electrophoresis on I% agarose, and after visualisation with 
EtBr, was extracted using the Qiagen Gel Extraction Kit. The PCR fragment was then 
digested with BamHI and assessed by DNA electropheresis, alongside a similar digest of 
PSD26. The cut DNA fragment was again extracted from the gel, and ligated into the cut 
vector and transformed into E. coli Top Ten. Screening was performed using an orientation 
PCR method. Normal PCR conditions, an orientation primer (5'- 
ATGCCCGAGGTAGT'=ATCCATGG-3') and the lower primer were used to access the 
plasmid. The pSD26-antipks]3 was created via the normal cloning regime but with the gene 
ligated in the incorrect orientation. The DNA was then sequenced to verify the construct. 
5.2.2 Culturing and purification 
An induction protocol yielding good quantities of soluble protein was sought by varying the 
concentration of IPTG and the induction temperature used. E. coli C41 (DE3) expression host 
were transformed with the pET23b-pks]3 and pET23b-pksl3KAS constructs. The cells were 
cultured at 370C to an A,,. = 0.6 and then recombinant gene expression was induced with 
varying concentrations of IPTG (0.1 mM, 0.5 mM and 1.0 mM). The cultures were grown for 
a further 4h at 370C. Another culture was cooled to 160C before I mM IPTG was added and 
was grown for a further 16 h at 16"C and harvested by centrifugation. The cell pellets were 
resuspended in buffer (20 mM phosphate buffer, pH 7.9,0.5 M NaCI, 10 mM imidazole) 
containing DNase and RNase. Bacteria were disrupted by sonication and the resulting lysate 
centrifuged at 27,000 xg for 60 min at 40C (Table 5.4). Samples were analysed by 
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electroPhoresis on 8% SDS-PAGE followed by staining with Coomassie brilliant blue 
staining. 
Table 5.4 Induction Protocol for pksl3 
JPTG (mM) Time (hours) Temp (C) 
0.1 4 37 
0.5 4 37 
1.0 4 37 
1.0 16 16 
Solubility of the recombinant protein was assessed by comparing the amount of the protein 
seen in the crude and clarified lysates. If the protein was soluble then purification was 
performed. Hi-trap Chelating Sepharose, TM fast flow matrix columns (I ml or 5 ml) were 
washed with 4 column volumes of Hi-Trap running buffer (0.02 M Sodium Phosphate, 0.5 M 
NaCl pH7.4). The column was charged using 2 column volumes of 0.1 M nickel chloride. The 
column was then washed with 4 column volumes of running buffer to equilibriate the column 
and remove excess nickel. The clarified lysate was applied to the column (maximum of 10 ml 
for aI ml column and 50 ml for a5 ml column) and non-absorbed material collected for 
analysis. Absorbed proteins were eluted using varying concentrations of imidazole (10 mM - 
500 mM). Fractions were collected and analysed by SDS-PAGE following protein level 
assessment. Pure protein samples were dialysed against large volumes (100-200 fraction 
volumes) of dialysis buffer (20 mM Tris-HCI pH 7.6,50 mM NaCl, I mM P- 
mercaptoethanol) 
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5.2.3 FAMEs and MAMEs analysis 
For the expression study M. smegmatis MC2 155 were transfortned by electroporation with the 
pSD26-based constructs and cultured to mid-log phase in 50 ml. of Sauton's medium 
containing 50 gg/ml hygromycin, 50 pCi of [1,2- 14 C]acetate (50-62 mCi/mmol, Amersharn 
Pharmacia Biotech) was added to the cultures followed by acetamide at various 
concentrations, then incubated at 37'C for 4 hrs. 
Investigation of the effects of TLM on the production of fatty acid methyl esters (FAMEs) and 
mycolic acid methyl esters (MAMEs) was performed using M. smegmatis MC21 55 
transformed by electroporation with pSD26 and the pSD26-pks]3 construct. As before, they 
were cultured to mid-log phase in 50 ml of Sauton's medium containing 50 ýIg/ml 
hygromycin, the cultures were induced with 0.2 % acetamide followed by incubation at 37'C 
for 4 hrs. 50 jiCi of [1,2- 14C]acetate (50-62 mCi/mmol, Amersharn Pharmacia Biotech) was 
added along with various concentrations of TLM, followed by a further incubation at 37T for 
4 hrs. 
The [14C]-labelled cells were harvested by centrifugation and washed successively with 0.9 % 
aqueous NaCl and water. The [14C]-labelled cells were then subjected to alkaline hydrolysis 
using 15 % aqueous tetrabutylammonium hydroxide at I 001C overnight. 4 ml Of CH202,300 
Al of CH31 and 2 ml of water was added to the reaction and mixed for a further 30 min. The 
upper aqueous phase was discarded, and the lower, organic phase was washed twice with 
water and evaporated to dryness. Methyl esters were re-dissolved in diethyl-ether, and then 
the solution evaporated to dryness. The final residue was dissolved in 200 111 Of CH2C12 and 
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the incorporation [1,2_14C]acetate was quantified by liquid scintillation counting of a5 ptl of 
the resulting solution of FAMEs and MAMES. Approximately loo, 000 cpm of the 
FAMEs/MAMEs mix were subjected to TLC using silica gel plates (5735 silica gel 6017254; 
Merck, Darmstadt, Germany), developed in petroleum ether-acetone (95: 5). Autoradiograms 
were produced by ovemight exposure of Kodak X-Omat AR film to reveal [14C]-labelled fatty 
acid and mycolic acid methyl esters. 
5.2.4 Growth Curve and induction of Pksl3 in M. smegmalis 
Investigation of the effects of Pks13 on M. smegmatis growth was analysed along with the 
expression of the plasmid. M. smegmatis MC2 155 transformed by electroporation with the 
empty pSD26 vector and the pSD26-pky]3 construct. They were cultured to OD6w = 0.2 in 
100 ml of Sauton's medium containing 50 pg/mI hygromycin, the cultures were induced with 
0.2 % acetamide followed by incubation at 371C. Regular OD readings were taken along with 
I ml samples every 2-4 hrs. Samples were harvested by centrifugation and resuspensed in 50 
mM MOPS pH 7.9,50 mM MgCl, 5 mM P-mercaptoethanol. Cells were lysed by sonication 
and debris removed by centrifugation (27,000 x g). Clarifled lysate were visual ised on 10 % 
SDS-PAGE. 
5.2.5 Minimum inhibition concentration analysis (MIC) 
The MIC of TLM was performed using M. smegmatis mc? 155 transformed by electroporation 
with the pSD26 and the pSD26-pks]3 construct. Cultures were grown to OD6oo = 0.4 in 50 ml 
of Sauton's medium containing 50 pg/ml hygromycin, they were induced with 0.2 % 
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acetamide followed by further incubation at 37*C for 4 hrs. Serial dilutions (10-14 10 -6 ) of the 
cultures were plated on LB agar containing 50 pg/ml hygromycin, with and without 0.2 % 
acetamide and increasing concentrations of TLM followed by incubation at 37*C for 34 days. 
5.2.6 Lipid Analysis 
5.2.6.1 Culturing and labelling 
Investigation of the effects of TLM on lipid production was performed using M. smegmalls 
mc2155 transformed by electroporation with the pSD26 and the pSD26-pks]3 construct. 4 
cultures (2x pSD26,2x pSD26-pks]3) were grown to mid-log phase in 50 ml of Sauton's 
medium containing 50 pglml hygromycin, induced with 0.2 % acetamide followed by 
incubation at 37'C for 4 hrs. 50 jiCi of [1,2- 14 C]acetate (50-62 mCi/mmol, Amersharn 
Pharmacia Biotech) was added to each culture along with 15 jag/mI of TLM, followed by a 
ftirther incubation at 37'C for 4 hrs. Radiolabelled cells were harvested by centrifugation. 
5.2.6.2 Extraction 
Cells were transferred to glass PTFE-capped tubes and resuspended in 2 ml MeOH-0.3 % 
NaCl (100: 10 v/v) and I ml petroleum ether (high boiling point), followed by mixing on a 
rotator for 15 minutes. The cellular suspension was centrifuged at 3,500 xg for 5 minutes. 
The upper petroleum ether layer was removed and a further I ml of petroleum ether added, 
followed by a further mixing on the rotator for 15 minutes. Again the petroleum ether was 
removed and pooled with the previous extraction and evaporated under nitrogen using a 
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heathing block (<370C). This extract known as the "non-polar lipids" was dried and 
resuspended in 200 ptl dichloromethane prior to use. 20 gI of the non-polar lipids were dried 
in scintillation vials and counted after the addition of 10 ml of EcoscintA with 25,000 cPm of 
the sample run on TLC using systems A-D. The methanolic-saline extract (lower layer) was 
heat treated in a boiling-water bath for 30 minutes and allowed to cool to room temperature. 
chloroforin-methanol-0.3 % NaCI (2.3 ml; 9: 10: 3) was added, followed by mixing for 60 
minutes. The solvent extract and biomass were separated by centrifugation at 3,500 xg and 
retained. A further 2 extractions were performed using chloroforin-methanol-0.3 % NaCl (750 
pl; 5: 10: 4) followed by mixing for 30 minutes, and centrifugation at 3,500 xg with extracts 
combined. The combined extracts were then mixed with chloroform (1.3 ml) and 0.3 % NaCI 
(1.3 ml) followed by mixing for 5 minutes. ne fraction was centrifuged at 3,500 xg for 10 
minutes to separate the lower-organic layer and the upper aqueous layer discarded. The lower 
layer was evaporated to dryness yielding the "polar lipids" which were resuspended in 200 111 
of chlOrOfonn/methanol (2: 1) prior to analysis. The polar lipids (20 PI) were dried in 
scintillation vials and counted after the addition of 10 ml of EcoscintA, with 25,000 cpm of 
the sample was run on each TLC using systems D and E. 
5.2-6.3 Analysis of the non-polar and polar lipids by TLC 
The non-polar and polar lipid fractions are further analysed by two-dimensional TLC using 
the developing systems in Table 4.5, using aluminium backed silica gel plates (5735 silica gel 
6017254; Merck, Darmstadt, Germany). Autoradiograms were produced by 2-3 day exposure 
of Kodak X-Omat AR film to reveal [14C]-labelled lipids. 
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Table 5.5 Polar and non-polar TLC developing systems 
System Direction I No. Runs 
A Petroleum ether/ethyl acetate (98: 2) 3 
B Petroleum ether/acetone (92: 8) 3 
C Chloroform/methanol (96: 4) 1 
D Chlorofomi/methanol/water (100: 14: 0.8) 1 
E Chlorofomi/methanol/water (60: 30: 6) 1 
. 
EX! jern Direction 2 No. Runs 
A Petroleum ether/acetone (98: 2) 
B Toluene/acetone (80: 20) 
c Toluene/acetone (95: 5) 
D 
-- ý 
Chlorofomi/acetone/methanol/water (50: 60: 2.5: 3) 1 r 
E 
thloroforin/acetic 
acid (glacial)/methanol/water (40: 25: 3: 6)1 1 
5.2.7 Construction of apA-s]3 knockout mutant inM. smegmads 
Regions of DNA flanking pks]3 corresponding to I kb upstream and downstream of the ORF 
were amplified from the M smegmatis MC2 155 genome using the recipe (Table 5.1) but using 
M. smegmalis mc2l. 55 genornic DNA and conditions in Table 5.6 along with the following 
cloning primers; 
Upstream 5' primer (5'-GATCGATCACTAGTTGTGCCGAAGCCGGGCTCAC-3') 
SpeI 
Upstream 3' primer (5'-GATCGATCGATATCATGTGCGCAGCCACTCCCGC-3') 
EcoRV 
Downstream 5'primer (5'-GATCGATCTCTAGAAGGCGCTCAACCGCATCGAGGCTC-3') 
XbaI 
Downstream 3'primer (5'-GATCGATCCTTAAGTCGCGCCCGACAACACCAT-3') 
Aflff 
The PCR products were cloned into Smal-cut pUC18. The recombinant plasmids were then 
digested SPeI / EcoRV for the upstream and Xhal / API for the downstream and the pkvl3 
flanking DNA were purified by extraction from agarose gels. The uptstream region was first 
ligated into SpeI / EcoRv cut pJSC347 KO vector and transformed into E. coll HBIOI. 
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Screening by restriction digestion with SpeI / EcoRV was used to identify constructs 
containing the upstream fragment. The construct was then digested with XhaI I Aflff to allow 
the ligation of the downstream fragment. Screening of plasmid DNA extracted from 
transformants of E. coli HB 10 1 derived from the ligation products by two separate double 
digests yielded the I kb upstream (SpeI / EcoR V) and the I kb downstream fragments (XbaI / 
AflIJ). 
Table 5.6 PCR conditions forpA-s]3 knockout fragments 
I kb Fragments 
94*C 3 min 
94*C 30 sec 
68*C I min 20 sec 
H 
35 cycles 
68*C 10min 
4*C 00 
As it was possibile that a pkvl3 KO might be lethal, pSD26-pks]3 construct could be used as 
an inducible survival vector. The KO pJSC347 vector was sent to Dr Aproova Bhatt (Albert 
Einstein Institute, New York). Who then packaged the vector into phage and prepared high 
titre of phage suspensions. Cultures of M smegmatis and m smegmatis pSD26-pks]3 were 
grown until OD 6oon, = 0.8-1.0. The pellet was washed twice with MP buffer (50 mM Tris- 
HCI pH 7.5,150 mM NaCl, 10 MM MgS04,2 mM CaC12). The cells were then resuspended 
in 0.5 ml of MP buffer and sterile culturing tubes followed by addition of 250 pI of the phage 
(1010 PFU/ml), the suspension was incubated at 37'C for 3 hours, 3 ml of 7H9 media (7H9, 
OADC, Tween) was added to the cells follwed by growth for 3 hours at 37T. The cells were 
then harvested and washed once in 10 ml of 7H9 media before resuspension in 0.5 ml. The 
culture was spread on plates (7HIO, OADC, Hyg 75 pg/ml) with and without acetamide (0.2 
%) and Tween (0.5 %). Screening for KO-pks]3 was performed by PCR using the 5' upstream 
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primer and a 3' hygromycin cassette primer. The PCR should yield a fragment size of 
approximately 1.5 kb with screening confirmed by southern blotting as described 
in the 
materials and methods (Appendices). 
5.3 Results 
5.3.1 Cloning and expression of Pksl3, AccD4 and FadD32 
5.3.1.1 pET23b system 
The cloning and preparation of the gene or gene fragment required for the construction of the 
pET23b construct allowed for the utilisation of the C-terminal His-tag aiding purification of 
recombinant protein via the Ni'2 Hi-trap system. 
op 
. 4- 5.2 Kb 
*- 2.1 Kb 
Figure 5.6 DNA electrophoresis (I % agarose) of pET23b pksl3 PCR product. 
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pET23b constructs of pks]3 and pks, 13KAS domain were created using PCR products from 
H37Rv template DNA in specific PCR reactions (Figure 5.6) followed by digestion and 
ligation into the empty vector. Screening was performed by double digest followed by 
electrophoresis of the cut plasmid on I% agarose and staining with EtBr. 
37'C 16"C 37"C 16"C 
kDe 
mom 
116.0 
66.2 
45.0 000 
35.0 lot 
Full pks13 pksl 3 Kas Domain 
Figure 5.7 Solubility and expression analysis of Pks13 and Pks13-KAS by 8% SDS- 
PAGE. E. coli C41 (DE3) transformed with the pET23b constructs were 
culture in 50 ml LB broth to OD600 ý 0.5.3 cultures induced with varying 
lPTG concentrations (0.1 mM, 0.5 mM and 1.0 mM) whereas another was 
cooled to 16'C and induced with I mM IPTG for 16 h. A further 
uninduced culture was used as a control. Cells were harvested by 
centrifugation and resuspended in 3 volumes of 20 mM sodium phosphate 
pH7.9,500 mM NaCl. The cell suspension was lysed using a French 
Pressure cell and cell debris removed by centrifugation at 27,000 x g. 
Equal amounts of protein were added to the gels after protein 
concentration determination using a BCA assay kit (Pierce) 
p 
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E. coli C41 (DE3) were transformed with the pET23b constructs and analysed for the 
expression and solubility. Pksl3 and Pksl3KAS were analysed by varying conditions of' 
induction as stated in section 5.2.2. Analysis of extracts on 12 % SDS-PAGE demonstrated 
novel polypeptides in the order of - 180 kDa and 60 kDa in molecular weight consistent with 
the predicted molecular weight of Pks 13 and Pks I 3KAS were observed in induced cultures 0 
MM IPTG, 37C) but not in the uninduced equivalents. The analysis of the expression 
conditions firstly showed that both proteins are expressed in high yields and secondly that the 
protein is soluble under all the conditions of expression tested. The optimal conditions were 
observed with 0.1 mM IPTG for both the full Pksl3 protein and the Pksl3-KAS domain 
(Figure 5.7). 
pET23b constructs of fadD32 (Rv3801c, 637 amino acids, 69232.0 KDa) and (jc-cD4 
(Rv3799c, 522 amino acids, 56647.7 Kda) were created using PCR products from 1137Rv 
template DNA specific PCR reactions (Figure 5.8) followed by digestion and ligation into the 
empty vector. Screening was performed by double digest followed by electrophoresis ofthe 
cut plasmid on I% agarose and staining with EtBr. 
Figure 5.8 DNA clectrophoresis of pET23b accD4 andfadD32 JlCR product. 
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An expression study and extensive analysis of the solubility of both proteins was carried out 
as before, but FadD32 was insoluble under all conditions tested. AccD4 was expressed well 
with high yields being observed in the crude lysate but clarification of the crude lysate by 
centrifugation showed that the majority of the protein was insoluble when induced at 37'C for 
4 hours. The solubility problem was overcome by induction with I mM IPTG at 16'C for 16 
hours (Figure 4.10). The crude lysate contain large yields of the recombinant protein and after 
clarification soluble protein was still visible. 
370C for 4h1 (PrC for 
EI --1 
16 h 
0.1 mm 1 Omm I Omm 
IPTG IPTG IPTG 
kDa 1 
116.0 mmm 
662 
450 
35.0 
9Ip 
ii 
Figure 5.9 AccD4 expression study. E. coli C41 (DE3) transformed with the pET23b- 
accD4 construct were culture in 50 ml LB broth to 01)(, (, (, = 0.5.3 cultures 
induced with varying IPTG concentrations (0.1 mM and 1.0 mM) whereas 
another was cooled to 16'C and induced with I mM IPTC for 16 h. A 
further uninduced culture was used as a control. Cells were harvested I)-, - 
centrifugation and resuspended in 3 volumes of 20 mM sodium phosphate 
pH7.9,500 mM NaCI. The cell suspensions were lysed b., French press and 
samples taken (crude) followed by removal of the cell debris bý 
centrifugation at 27,000 xg (Supernatant). Equal volumes of protein were 
added to the gels after protein concentration determination using a IICA 
assay kit (Pierce) 
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5.3-1.2 pSD26 system 
The successful cloning and preparation of the gene or gene fragment required for the 
production of the pSD26 expression systems was necessary for the over-expression of the M. 
luberculosis protein in M. smegmatis. The pSD26 expression system also contains a C- 
terminal His-tag which would aid purification via the Ni Q Hi-trap system and is also based on 
an acetamide inducible promoter for use in M smegmalis allowing for the controlled 
expression of the protein. 
.. 
4. 
/' lZey 
5.2 Kb 
2.1 Kb 
Figure 5.10 DNA electrophoresis (1 % agarose) of pSD26pk. v/3 PCR products. 
pSD26 constructs of pkv13 and pksl3KAS domain were created using PCR products 
from 
H37Rv template DNA in specific PCR reactions (Figure 5.10) followed by digestion and 
ligation into the empty vector. Screening was performed by double digest flollowed 
by 
electrophoresis of the cut plasmid on I% agarose and staining with EtBr. 
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M. smegmatis MC2 155 were transformed with the fully sequenced vectors pSD26-pkv/3, 
pSD26-anti-pks]3, pSD26-Kas-pks]3 and empty pSD26 for in vivo analysis. No significant 
change in the colony morphology was observed when the gene expression was induced with 
0.2 % acetamide on 7H 10 agar containing Hyg5o. 
5.3.2 Purifleation 
Recombinant proteins were synthesised for purification using transformants of E coli C41 
(DE3) containing the pET23b-based constructs of Pksl3 and Kas-Pksl3. Proteins were 
purified as described in materials and methods (Appendices). SDS-PAGE was used to analyse 
the protein to assess their purity (Figure 5.11). 
b25 
Ela 
18 0 kDa 
116.0 «W 
66.2 im um - 60 kDa 
45.0 OW 
35.0 #0 
Figure 5.11 Purification of pks]3 and Kas-pks13 by Ni2+ chelating sepharose column 
(1 ml) and visualised by 8% SDS-PAGE 
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Recombinant protein with molecular weights of 180 kDa and 60 kDa consistent with the 
predicted molecular weigth of Pksl3 and Pksl3KAS were purified. The production of this 
recombinant protein would allow for in vitro biochemical analysis, but first the production of 
the substrates via FadD32 and AccD4 are required. 
A single polypeptide of -57 kDa consistent with the predicted molecular weight of AccD4 
was visualised on 12 % SDS-PAGE after the clarified lysate was subjected to liquid 
chromatography using Ni2+ chelating His-trap columns. This procedure yielded approximately 
3.0 mg of pure AccD. Purified proteins were dialysed 3 times for 4 hours against 100 volumes 
of 20 mM Tris-HCI, 50 mM NaCl, pH 7.5 then flash frozen in liquid nitrogen and stored at - 
80'C. Attempts at radiobiochemical assays involving pure AccD4, palmitoyl-CoA and radio- 
labelled bicarbonate proved to be ineffective. AccD4 is thought to utilise long-chain acyl- 
CoA's (C24-C26) and therefore the reaction rate with the shorter chains may be undetectable. 
As previously stated the substrate is most likely to be an acyl-AMP as shown in a recent study 
therefore these experiments will have to be repeated with this newly identified substrate 
(Trivedi et al., 2004). 
5.3.3 FAMEs and MAMEs Analysis 
Radiolabelled FAMEs and MAMES were separated by TLC and visualiscd by 
autoradiography using cell lines expressing pSD26-pks]3, pSD26-anti-pks13, pSD26- 
pks13KAS and pSD26 to assess in vivo overproduction of Pksl3 on FAMES and MAMES. 
After expression and extraction (section 5.2.3) the FAMEs and MAMEs TLC showed that 
little or no change when the plasmids were over-expressed (Figure 5.12). In cells bcaring the 
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antisense construct it was hypothesised that this mRNA produced by the expression of the 
antisense vector would bind the mRNA of the M. smegmatis and therefore cease Pks13 
production changing the profile of the FAMEs and MAMEs, unfortunately no change was 
observed on the TLC. The control samples showed that the vector had no effect on lipid 
synthesis upon induction. Hypothetically the over-expression of pks]3 should increase the 
production of mycolates if indeed involved in the Claisen condensation. The study of the 
over-expression of the pks]3 had little effect on the composition of the MAMEs, as did the 
over-expression of the KAS domain therefore this isn't a rate limiting step in mycolate 
biosynthesis. 
PKS13 
Control Anti-sense PKS13 KAS Domain 
F_ -f -_ --- I 
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FAMEs o 0064DO06004MO& 
, ct ir MAMEs 4 
«0 (X, 
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Figure 5.12 The effect of over-expression of Pksl3 constructs in M. smegmatis 
visualised by the incorporation of 114C Jacetate into lipids to produce 
FAMEs and MAMEs in the presence of increasing concentrations of 
acetamide. The reaction was terminated by the addition of 1_5 % 
tetrabutylammonium hydroxide at IOOOC overnight. The corresponding 
FAMEs, a-mycolates, (x'-mycolates and epoxy-mycolates (MAMEs) were 
isolated, subjected to TLC (5735 silica gel 60F254, Merck), and exposed to a 
Kodak X-Omat film. 
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Further analysis of the FAMEs and MAMEs composition of M sineginalis extracts was 
assessed in the presence of TLM as it was theorised that Pksl3 over-expression would 
overcome the effects of TLM by increasing the mycolate composition of the cell wall thus 
making the wall less permeable to TLM. Radiolabelled FAMEs and MAMES were separated 
by TLC and visualised by autoradiography using cell lines expressing pSD26-I)ks/3 and 
PSD26 to assess in vivo effects of Pksl3 on FAMES and MAMES and resistance to TI. M. 
After expression and extraction (section 5.2.3) the TLC was exposed to film and developed. 
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Figure 5.13 The effect of over-expression of Pksl3 construct in M. vmeg"taIA in the 
presence of increasing concentrations of TLM. Followed by visualisation 
by the incorporation of 11"Clacetate into lipids to produce FAMEs and 
MAMEs. The reaction was terminated by the addition of 15 % 
tetrabutylammonium hydroxide at 100'C overnight. The corresimn(linp. 
FAMEs, ot-mycolates, a'-mycolates and epoxy-mycolates (MAMEs) were 
isolated, subjected to TLC (5735 silica gel 60F254, Merck), and cxlx)sc(l 141 a 
Kodak X-Omat film. 
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Interestingly, the overproduction of Pksl3 in the presence of TLM changed the lipid profile 
more significantly than the WT strain. The MAMES profile of the Wr is as previously 
observed with increasing concentration of TLM (Kremer et al., 2000b) with less epoxy- and 
a-mycolates being observed as the TLM concentration increases. The over-expression of 
Pks13 reduced the overall MAMEs observed with increasing concentration of TLM, resulting 
in the over-expression strain becoming more sensitive to mycolate inhibition. This would 
suggest that the over-expression of Pks 13 increases the sensitivity of Af smegniatis to TLNI. 
5.3.4 Expression ofpks]3 in M. smegmatis 
M. smegmatis MC2 155 transformed by electroporation with pSD26 and the pSD26-pkSI3 
construct were cultured to OD600 ý 0.2. Upon induction with 0.2 % acetamide followed by 
incubation at 370C, regular OD readings were taken along with 1 ml samples cvcry 24 hours 
to assess the effects of Pks13 over-expression on growth. It was proposed that the o%, cr- 
expression of the pks]3 gene from M. tuberculosis in M. smegnialis may incrcasc the 
synthesis of mycolates and accelerate growth. 
The SDS-PAGE Gel in Figure 5.14 shows that expression of the pSD26-pksl3 within Al 
smegmatis throughout the time course experiment produced large quantities of protein. 
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the increased expression of Pksl3 would infact increase the resistance of M. snkgmaliv to 
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when grown in the absence or presence of acetamide. The expression of Pks 13 showed that no 
obvious change in the sensitivity of the organism to TLM. 
pSD26 
Pks 13 pSD26 
Ak: cIallilde , 
TLM 0 
pSD26 
Pks]3 pSD26 
Ný: ctamidc - 
TLM 0 
pSD26 
Pks 13 pSD26 
Acetamide 
TLMIO 
pSD26 
Pksl 3 pSD26 
TLM 10 
pSD26 
Pk sl 3 pSD-16 
Acetamide, 
TLM 20 
pSD26 
PksJ3 pS D2 6 
TLM 20 
pSD26 
Pksl3 pSD26 
Acetamide + 
TLM 30 
pSD26 
Pks 13 pS D21 6 
A 
Accuumde - 
TLM 30 
MC215r, n Figure 5.15 MIC of TILM using M. smegmalis - transformed 
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with pSD26 and pSD26-pks]3. Cultures were grown to OD600 = 0.4 in 50 
ml of Sauton's medium containing 50 jig/ml hygromycin, they were 
induced with 0.2 % acetamide followed by further incubation at 37'C for 
4 hrs. Serial dilutions (results shown are the 10-3 dilution) of the cultures 
were plated on LB agar containing 50 jig/ml hygromycin, with and 
without 0.2 % acetamide and increasing concentrations of TLM followed 
by incubation at 370C for 3-4 days. 
214 
CHAPTER 5 POLYKETIDE SYNTHASE 13 (pks]3) 
5.3.6 Lipid analysis ofM. smegmadsover-expressingPlisI3 in the presence of TLM 
Investigation of the effects of TLM on overall lipid production using M. smegmatis mc'155 
transformed by electroporation with pSD26 vector and pSD26-phS13 was assessed. 
Radiolabelled cells were produced as per section 4.2.6.1 and non-polar and polar lipids 
extracted as per section 4.2.6.1. Previously it was hypothesized that the up regulation of 
multiacylated trehalose in M. bovis BCG on mtfabH over-expression led to the observed TLM 
hypersensitivity of this strain via changes in cell wall pertneability (Choi et al., 2000b). 
Similarly, the hypersensitivity to TLM observed on over-expression ofpb]3 in M smegmatis 
may have an effect on not only mycolate synthesis but also other lipids within the cell wall. 
Analysis of the non-polar lipids showed that little change in the lipid profiles upon over- 
expression of Pksl3. The system D profiles changed in the presence of TLM showing an 
increase in the overall GMM but with no change being observed between the two strains. Also 
with the polar lipids, little or no changes were observed on TLC's developed with systems D 
and E. 
5.3.7 Deletion ofpks]3 in M. smegmatis 
The over-expression ofpksl3 which resulted in the reduction on the overall MAMEs observed 
in the presence of increasing concentration of TLM resulted in the over-expression strain 
becoming more sensitive to mycolate inhibition. This indicates that futher experiments 
especially a knockout of the gene would prove more useful in understanding the role Pksl3 
plays in the production of mycolates. Regions of DNA flanking pks]3 corresponding to I kb 
upstream and downstream of the ORF were amplified from the M. smegmatis mc2l55 genome 
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DNA and cloned into the pJSC347 vector, screening was performed by double digest 
followed by electrophoresis on I% agarose and visualisation by staining with EtBr (Figure 
5.16). 
- pJSC347 
Upstream Fragment 
Downstream Fragment 
Figure 5.16 Double digested pJSC347-pk. vI3KO- Spel / EcoRV digest yielding the 
upstream fragment and XbaI / AflII for the downstream. The upstream 
fragment was slightly larger than the downstream fragment as the region 
cloned was required to contain a larger proportion of the upstream gene 
so as not to inactivate not only the Pksl3 but also the AccD4. 
The construct was successfully packaged into the phage but as of yet any screening of 
possible knockouts has not been achieved. 
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5.4 Discussion 
The alignment study of the M tuberculosis pks]3 region and the Corynehacterium 
diph1heride pks]3 homologue region showed a highly conserved region (Dover et al., 2004). 
In the previous chapterpks]3 was speculated to encode the Claisen condensation enzyme 
required for mycolic acid biosynthesis. Therefore the M. tuberculosis genes in this study were 
successfully cloned into the relevant expression vector but the insolubility problems of 
FadD32 halted the in vitro testing. The prefered substrate of AccD4 was proposed to be C24- 
C26-CoA and may be the reason why no activity was observed with shorter acyl-CoAs. The 
observation that FadD's located adjacent to PKS genes in the M. tuberculosis genome, 
constituted a new class of long-chain fatty acyl-AMP ligases was timely (Trivedi et al., 2004). 
More specifically, they demonstrated that FadD32 possessed acyl-AMP substrate specificity, 
which would suggest this as the carrier for AccD4. The AccD4 in vitro assay could not 
proceed further without FadD32 and the acyl-AMPs. 
PKS present an exciting area for the controlled manipulation of complex natural product 
structure. In particular, regioselective modification of polyketide structure is possible by 
alterations in either intracellular acyl-CoA pools or, more commonly, by manipulation of acyl 
transferases that act as the primary gatekeepers for building blocks (Liou & Khosla, 2003). A 
Computational protocol has been used to predict the domain organisation and substrate 
specificity for PKS clusters from various microbial genomes. A searchable computerized 
database (PKSDB) was produced that would serve as a valuable tool for identification of 
polyketide products biosynthesised by uncharacterised PKS clusters. This database can also 
provide guidelines for rational design of experiments to engineer novel polyketides (Yadav et 
al., 2003). 
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A mutant strain of M. smegmatis defective in the biosynthesis of mycolic acids was recently 
isolated (Liu & Nikaido, 1999). This mutant failed to synthesise full-length mycolic acids and 
accumulated a series of long chain P-hydroxymeromycolates. Wang et al. (2000) further 
characterised this mutant and revealed that the meromycolates were covalenty attached to AG 
at the 5-OH position of the terminal arabinofuranosyl residues, therefore demonstrating that 
mutants devoid of mycolic acids could be produced. However, the permeability barrier of this 
mutant was significantly compromised (Liu & Nikaido, 1999). The attempt at down- 
regulating Pksl3 activity using an 'antisense' transcript of M. tuberculosis pks]3 in M. 
smegmatis in this study did not produce similar changes to lipid profiles as seen with the 
mutant strain. The experiment carried out here was not optimised; ideally an antisense 
transcript of the native gene should be used to maximise homology and promote the formation 
of a duplex with the phs. 13 mRNA in vivo. Furthermore, such constructs are often more 
effective if the antisense construct contains the reverse complement of the ribosome binding 
site. Despite these inadequacies, the experiment was warranted given that a mis-oriented 
construct was discovered during recombinant plasmid screening. 
The alternative strategy, in which Pks13-was overproduced in vivo, resulted in no noticeable 
changes in the mycolic acid or lipid compositions of M. smegmatis MC2 155 but this is an 
acceptable result as the recombinant protein may only facilitate mycolic acid production but is 
tightly regulated by limiting substrates. The increased sensitivity of M. SMegMatiS MC2155 to 
TLM in the presence of over expressed Pks13 could in turn be explained by the same theory. 
Over-production of Pks13 may bind up small quantities of either the meromycolate or the ct- 
branch subunits which would not be produced in vast quantities therefore slowing mycolate 
production enough to increase the sensitivity of the organism to TLM. As with MMAS and 
CMAS over-production studies, the results could differ from the KO studies therefore for true 
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investigation of the M tuberculosis Pksl3's involvement in mycolic acid biosynthesis a 
disruption or KO mutation is required. As stated previously it is believed that Pksl3 is 
essential therefore a survival vector is required. 
As an exciting and new area of work all the basic biochemical and physiological properties of 
pks]3 are still to be established. With the production of M. bovis BCG and M. smegmatis 
KOs, in vivo investigation into Pksl3 can take place, ranging from FAMES and MAMES 
analysis to more complex mycolate separation and characterisation. Determination of the 
Crystal structure will in turn, allow us to compute possible binding sites and therefore identify 
amino acid residues which are essential for catalysis and can be studied by site-directed 
mutagenesis. Finally antibiotic sensitivity can be assessed and new drug analogues can be 
designed from the structural and biochemical data achieved from the work. Pksl3 looks like a 
very exciting target for new drugs, as its possible role in the production of mycolates is key to 
cell survival and as no mycobacteria have been shown to survive without their mycolates 
other than the mutant mentioned above, therefore it's potentially an excellent one. 
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The mycolic acids are the dominant feature of the Mycobacterium tuberculosis cell wall, 
providing the basis for its lipid-rich permeability barrier. Throughout this thesis a number of 
fundamentally important proteins involved in the biosynthesis of these characteristic a-alkyl, 
P-hydroxy fatty acids have been analysed to allow a greater understanding of their properties 
and functions. Mycolic acids are thought to be formed by the Claisen-type condensation of a 
long meromycolic acid and a shorter C24-C26 fatty acid. These component fatty acids are 
produced via a combination of type I and II fatty acid synthase (FAS) systems. The C16-C24 
fatty a cyl products of FAS-I are elongated by F AS-II to form meromycolic acids. The P- 
ketoacyl ACP synthase (KAS) mtFabH links FAS-I and FAS-II, catalyzing the condensation 
of acyl-CoA derivatives of FAS-I products with malonyl-AcpM. Two discrete KAS enzymes, 
which are encoded by kasA and kasB, located in tandem within a five-gene operon, perform 
subsequent decarboxylation condensation within FAS-II. Finally, enzymology of the mycolic 
condensation, in which the meromycolate and C24-C26 fatty acid are ligated, was addressed. 
Investigation of the acyl-CoA chain length specificity of mtFabH in vitro using either E. coli 
ACP (ecACP) or the M. tuberculosis AcpM revealed altered substrate specificity. It was 
observed that the acyl-CoA chain length specificity of mtFabH was similar to that previously 
described by Choi et al. (2000) when ecACP was utilised in the in vitro assay. However with 
M. tuberculosis AcpM, which bears a 33 residue carboxy terminal extension relative to 
ec: ACP, the enzyme was able to utilise longer acyl-CoA chains. The recent elucidation of the 
crystal structure of mtFabH facilitated a detailed study of the roles of key amino acid residues 
in catalysis (Scarsdale etal. 2001). Selected residues thought to be involved in acyl-CoA 
chain length specificity, substrate binding and residues proposed to represent the catalytic 
triad of the enzyme were mutated. Substitution of residues implicated in acyl-CoA chain 
length specificity totally abrogated overall KAS activity. Alanine substitution of residues 
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implicated in acyl-CoA binding led to a reduction in the transacylation activity of the enzyme; 
a double aIanine substitution of Trp42 and Argl6l drastically reduced transacylation activity. 
On investigation of the proposed catalytic triad residues, Cys122 was confirmed to be an 
essential residue for transacylation and His258 was essential for malonyl-AcpM 
decarboxylation, whilst mutation of Asn289 resulting in reduced decarboxylation activity. 
In this study, evidence was provided that demonstrated kasA from M. tuberculosis to encode 
an enzyme that elongates the meromycolate chain of both M. smegmatis and M. chelonae, in 
vivo. Investigation of KasA substrate specificity identified the enzyme as a key component of 
the FAS-11 system, which utilises primarily palmitoyl-ACP rather than short-chain acyl-ACP 
primers. An in vitro condensing assay using purified recombinant KasA, palmitoyl-AcpM and 
malonyl-AcpM, demonstrated that KasA unequivocally possess KAS activity in the presence 
of the ACP thioesters and is significantly less active using acyl-CoA precursors. Purified 
KasA was highly sensitive to cerulenin, a well-known inhibitor of KAS activity, which may 
lead to the development of novel anti-mycobacterial drugs targeting KasA. 
Alanine substitutions of key amino acids of KasA allowed the functional analysis of these 
residues importance in terms of KAS activity of KasA. The mutation of Cysl7l, His3l I, 
Lys340 and His345 completely abrogated the condensation activity of KasA in vitro, 
suggesting that these residues play a critical role in the condensation reaction. Furthermore, 
analysis of further key residues required the production of further substitutions hence mutant 
kasA allele production was facilitated by the development of a mutagenesis system termed the 
"mega primer method". This system provided more success than the Stratagene QuikChange 
system and allowed for the production of 13 of the 21 mutations identified as candidates for 
investigation. The production of soluble enzymematically-active protein became a major 
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obstacle in this study, hence the elucidation of a viable protein purification protocol is still 
required and is vital for the further analysis of key amino acid residues within KasA. 
Like M. tuberculosis, C glutamicum possess mycolic acids but these corynomycolates are 
much shorter in chain length (C32). Although the function of a number of genes involved in 
fatty acid and mycolic acid biosynthesis have been identified, information relevant to the 
condensation event within these biosynthetic pathways is relatively sparse. Analysis of these 
Corynebacterianeae genomes showed that they possess a high number of accD genes, whose 
gene products resemble the P-subunit of the acetyl-CoA carboxylase of E. coli, providing the 
activated intermediate for fatty acid synthesis. In this study four putative accD genes found in 
C glutamicum were analysed. Although growth of the accD4 mutant remained unchanged, 
growth of the accDl mutant was strongly impaired and partially recovered by the addition of 
exogenous oleic acid. Over-expression of accD1 and accBC, encoding the carboxylase cc- 
subunit, resulted in an 8-fold increase in malonyl-CoA formation from acetyl-CoA in cell 
lysates, providing evidence that accDl encodes a carboxyltransferase involved in the 
biosynthesis of malonyl-CoA. Interestingly, fatty acid profiles remained unchanged in both 
accD2 and accD3 mutants. However a complete loss of mycolic acids, either as organic 
extractable trehalose and glucose mycolates or as cell wall-bound mycolates was observed. 
These two carboxyltransferases are also retained in all Corynebacterianeae, including M. 
leprae, constituting two distinct groups of orthologs. Furthermore, carboxyl fixation assays, as 
well as a study of a Cg-pks deletion mutant, led us to conclude that accD2 and accD3 are key 
to mycolic acid biosynthesis, thus providing a carboxylated intermediate during condensation 
of the mero-chain and cc-branch directed by the pks-encoded polyketide synthase. This study 
illustrates that the high number of accD paralogs have evolved to represent specific variations 
on the well known basic theme of providing carboxylated intermediates in lipid biosynthesis. 
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Further analysis of the pks]3 encoded polyketide synthase identified it as a homolog of the 
Cg-pks recognized in the previous study and is the most likely candidate to perform the 
Claisen condensation event involved in mycolate biosynthesis. Successful expression and 
purification of Pks; 13 may allow for the development of in vitro assays and therefore validate 
the results found in the C glutamicum system. The identification and careful characterisation 
of the key biosynthetic partners of the mycobacterial Pksl3, will allow for the production of 
the high molecular weight fatty acid 2-carboxy-derivatives, which would otherwise be 
difficult to synthesis chemically. 
Overall, the increased understanding of the roles played by these key enzymes of mycolic acid 
biosynthesis will future development of existing inhibitors and identification of new 
inhibitors, eventually leading to novel anti-tubercular agents, which might target the 
production of meromycolates or the final Claisen condensation event to produce the mature 
mycolate. 
224 
CHAPTER 7 
References 
225 
CHAPTER 7 REFERENCES 
Abbadi, A., Brummel, M. & Spener, F. (2000). Knockout of the regulatory site of 3- 
ketoacyl-ACP synthase III enhances short- and medium-chain acyl-ACP synthesis. Plant J 24, 
1-9. 
Ahibo-Coffy, A., Aurelle, H., Lacave, C., Prome, J. C., Puzo, G. & Savagnac, A. (1978). 
Isolation, structural studies and chemical synthesis of a'palmitone lipid' from 
Corynebacterium diphtheriae. Chem Phys Lipids 22,185-195. 
Asselineau, C., Asselineau, J., Laneelle, G. & Laneelle, M. A. (2002). The biosynthesis of 
mycolic acids by Mycobacteria: current and alternative hypotheses. Prog Lipid Res 41,50 1- 
523. 
Bachhawat, N. & Mande, S. C. (1999). Identification of the INOI gene of Mycobacterium 
tuberculosis H3 7Rv reveals a novel class of inositol- I -phosphate synthase enzyme. J Mol Biol 291,531-536. 
Baldock, C., Rafferty, J. B., Sedelnikova, S. E., Baker, P. J. & Stuitje, A. R. (1996). A 
mechanism of drug action revealed by structure studies of enoyl reductase. Science 274,2107- 
2110. 
Bamaga, M., Wright, D. J. & Zhang, H. (2002). Selection of in vitro mutants of 
pyrazinamide-resistant Mycobacterium tuberculosis. InIJAntimicrob Agenis 20,275-281. 
Banerjee, A., Sugantino, M., Sacchettini, J. C. & Jacobs, W. R., Jr. (1998). The mabA 
gene from the inh, 4 operon of Mycobacterium luberculosis encodes a 3-ketoacyl reductase that 
fai Is to confer isoniazid resistance. Microbiology 144 ( Pt 10), 2697-2704. 
Barry, C. E., 3rd, Lee, R. E., Mdluli, K., Sampson, A. E., Schroeder, B. G., Slayden, R. 
A. & Yuan, Y. (1998). Mycolic acids: structure, biosynthcsis and physiological functions. 
Prog DpIdRes 37,143-179. 
Baulard, A. PL, Gurcha, S. S., Engohang-Ndong, J., Gouffi, YL, Locht, C. & Besra, G. S. 
(2003). In vivo interaction between the polyprenol phosphate mannose synthasc Ppm I and the 
integral membrane protein Ppm2 from Mycobacterium smegmalis revealed by a bacterial two- 
hybrid system. JBiol Chem 278,2242-2248. 
Baulard, A. R., Betts, J. C., Engohang-Ndong, J., Quan, S., McAdam, R. A., Brennan, P. 
J., Locht, C. & Bcsra, G. S. (2000). Activation of the pro-drug ethionamide is regulated in 
mycobacteria. JBiol Chem 275,28326-2833 L 
Belanger, A. E. & Inamine, J. M. (2000). Genetics of Cell Wall Biosynthesis. In Molecular 
Genetics qfMycobacteria, pp. 191-202. Edited by G. F. Hatfull & W. R. Jacobs, Jr. 
Washington D. C.: ASM Press. 
Belanger, A. E., Bcsra, G. S., Ford, M. E., Mikusova, K, Belisle, J. T., Brennan, 11. J. & 
Inamine, J. M. (1996). The embAB genes of Afycobacterium avium encode an arabinosyl 
transfcrase involved in cell wall arabinan biosynthesis that is the target for the 
antimycobacterial drug cthambutol. Proc Nail AcadSci USA 93,11919-11924. 
226 
CHAPTER 7 REFERENCES 
Belisle, J. T., Vissa, V. D., Sievert, T., Takayarna, K, Brennan, P. I& Besra, G. S. 
(1997). Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276,1420-1422. 
Bergler, H., Wallner, P., Ebeling, A., Leitinger, B., Fuchsbichler, S., Aschauer, H., 
Kollenz, G., Hogenauer, G. & Turnowsky, F. (1994). Protein EnvM is the NADH- 
dependent enoyl-ACP reductase (Fabl) of Escherichia coli. JBiol Chem 269,5493-5496. 
Bernadou, J., Nguyen, M. & Meunier, B. (2001). [The mechanism of action of isoniazid. A 
chemical model of activation]. Ann Pharm Fr 59,331-337. 
Besra, G. S. & Chatterjee, D. (1994). Lipids and carbohydrates of Mycobacterium 
tuberculosis. In Tuberculosis: pathogenesis, protection andcontrol, pp. 285-306. Edited by B. Bloom. Washington D. C.: American Society for Microbiology. 
Besra, G. S., Morehouse, C. B., Rittner, C. M., Waechter, C. I& Brennan, P. J. (1997). 
Biosynthesis of mycobacterial lipoarabinomannan. JBiol Chem 272,18460-18466. 
Besra, G. S., Sievert, T., Lee, R. E., Slayden, R. A., Brennan, P. J. & Takayarna, YL 
(1994). Identification of the apparent carrier in mycolic acid synthesis. Proc NadlcadSci U 
SA 91,12735-12739. 
Bcsra, G. S., Bolton, R. C., McNeil, M. R., Ridell, M., Simpson, K E., Gluska, J., van 
11albeek, H., Brennan, P. I& Minnikin, D. E. (1992). Structural elucidation of a novel 
family of acyltrehalose from Mycobacterium tuberculosis. Biochemistry 31,9832-9837. 
Betts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A. & Duncan, YL (2002). Evaluation 
of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein 
expression profiling. Mol Microbiol 43,717-73 1. 
Bloom, B. R. & Murray, C. J. (1992). Tuberculosis: commentary on a rcemcrgent killer. 
Science 257,1055-1064. 
Brand, S., Niehaus, K., Puhler, A. & Kalinowski, J. (2003). Identification and functional 
analysis of six mycolyltransferase genes of Corynehacterium glulamicum ATCC 13032: the 
genes copl, cmtl, and cmt2 can replace each other in the synthesis of trchalose 
dicorynomycolate, a component of the mycolic acid layer of the cell cnvelope., 4rch Aficroblol 
180,3344. 
Brennan, P. J. (2003). Structure, function, and biogcncsis of the cc] I wall of Afycobacterium 
tuberculosis. Tuberculosis (Edinb) 83,91-97. 
Brennan, P. J. & Nikaido, 11. (1995). The envelope of mycobactcria. Annu Rev Biochem 64, 
29-63. 
Caceres, N. E., Harris, N. B., Wellchan, J. F., Feng, Z., Kapur, V. & Barletta, It. G. 
(1997). Overexpression of the D-alanine racemase gcne confers resistance to D-cycloýcrine in 
Afycobaclerium smegmatis. JBacleriol 179,5046-5055. 
Camacho, L. It, Constant, P., Raynaud, C., Lancelle, M. A., Triccas, J. A., Gicqucl, B., 
Daffe, M. & Guilhot, C. (2001). Analysis of the phthiocerol dimycoccrosatc locus of 
227 
CHAPTER 7 REFERENCES 
Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability 
barrier. JBIol Chem 276,19845-19854. 
Campbell, J. W. & Cronan, J. E., Jr. (2001). Bacterial fatty acid biosynthesis: targets for 
antibacterial drug discovery. Annu Rev Microbiol 55,305-332. 
CDC (1995). Tuberculosis morbidity--United States. MMWR 45,365-370 
Cerdeno-Tarraga, A. M., Efstratiou, A., Dover, L. G. & other authors (2003). The 
complete genome sequence and analysis of Corynebacterium diphtheride NCTC 13129. 
Nucleic Acids Res 31,6516-6523. 
Chatterjee, D. & Khoo, K. H. (1998). Mycobacterial lipoarabinomannan: an extraordinary 
lipoheteroglycan with profound physiological effects. GlycobioloV 8,113-120. 
Chatterjee, D., Bozic, C. M., McNeil, M. & Brennan, P. 1 (1991). Structural features of the 
arabinan component of the lipoarabinomannan of Mycobacterium tuberculosis. JBiol Chen? 
266,9652-9660. 
Chatterjee, D., Lowell, K., Rivoire, B., McNeil, M. R. & Brennan, P. 1 (1992). 
Lipoarabinomarman of Mycobacterium tuberculosis. Capping with mannosyl residues in some 
strains. JBiol Chem 267,6234-6239. 
Cheng, Y. Q., Tang, G. L. & Shen, B. (2003). Type I polyketide synthase requiring a 
discrete acyltransferase for polyketide biosynthesis. ProcNallAcadSci USA 100,3149- 
3154. 
Child, C. J. & Shoolingin-Jordan, P. M. (1998). Inactivation of the polyketide synthase, 6- 
methylsalicylic acid synthase, by the specific modification of Cys-204 of the beta-ketoacyl 
synthase by the fungal mycotoxin cerulenin. Biochem J330 ( Pt 2), 933-937. 
Choi, K If., Heath, R. J. & Rock, C. 0. (2000a). beta-ketoacyl-acyl carrier protein synthase 
III (Fabil) is a determining factor in branched-chain fatty acid biosynthesis. JBacleriol 182, 
365-370. 
Choi, K. 11., Kremer, L., Besra, G. S. & Rock, C. 0. (2000b). Identification and substrate 
specificity of beta -ketoacyl (acyl carrier protein) synthase III (mtFabII) from Mycobacterium 
tuberculosis. JBiol Chem 275,28201-28207. 
Clark, J. & Wallace, A. (1967). The susceptibility of mycobactcria to rifamide and 
rifampicin. Tubercle 48,144-148. 
Clough, R. C., Matthis, A. L., Barnum, S. I; L & Jaworski, J. G. (1992). Purification and 
characterization of 3-ketoacyl-acyl carrier protein synthase III from spinach. A condensing 
enzyme utilizing acetyl-coenzyme A to initiate fatty acid synthesis. JBiol Chem 267,20992- 
20998. 
Cohn, D. L., Bustreo, F. & Raviglione, M. C. (1997). Drug-rcsistant tuberculosis: review or 
the worldwide situation and the W11O/lUATLD Global Surveillance Project. International 
Union Against Tuberculosis and Lung Disease. Clin Infect Dis 24 Suppl 1, S 121-130. 
228 
CHAPTER 7 REFERENCES 
Cole, S. T. (1994). Mycobacterium tuberculosis: drug-resistance mechanisms. Trends Microbiol 2,411-415. 
Cole, S. T., Brosch, R., Parkhill, I& other authors (1998). Deciphering the biology of Afycobacterium tuberculosis from the complete genome sequence. Nature 393,537-544. 
Cole, S. T., Eigimeier, K., Parkhill, I& other authors (2001). Massive gene decay in the leprosy bacillus. Nature 409,1007- 1011. 
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C. & 
Dye, C. (2003). The growing burden of tuberculosis: global trends and interactions with the 111V epidemic. Arch Intern Med 163,1009-102 1. 
Daffe, M. & Draper, P. (1998). The envelope layers of mycobacteria with reference to their 
pathogenicity. Adv Microb Physiol 39,131-203. 
Daines, R. A., Pendrak, I., Sham, YL & other authors (2003). First X-ray cocrystal 
structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved 
using rational design and homology modeling. JMed Chem 46,5-8. 
Davies, C., Heath, R. J., White, S. W. & Rock, C. 0. (2000). The 1.8 A crystal structure 
and active-site architecture of beta-ketoacyl-acyl carrier protein synthase III (Fabll) from 
Escherichia coli. Structure Fold Des 8,185-195. 
Davies, P. D. & Yew, W. W. (2003). Recent developments in the treatment of tuberculosis. 
Expert Opin Investig Drugs 12,1297-1312. 
Dawe, I H., Porter, C. T., Thornton, I M. & Tabor, A. B. (2003). A template search 
reveals mechanistic similarities and differences in beta-ketoacyl synthases (KAS) and related 
enzymes. Proteins 52,427435. 
De Sousa-D'Auria, C., Kacem, R., Puech, V., Tropis, M., Leblon, G., Houssin, C. & 
Daffe, M. (2003). New insights into the biogenesis of the cell envelope of corynebacteria: 
identification and functional characterization of five new mYcoloyltransferase genes in 
Corynebacterium glutamicum. FEMS Microbiol Lett 224,3544. 
DeBarber, A. E., Mdfuli, K., Bosman, M., Bekker, L. G. & Barry, C. E., 3rd (2000). 
Ethionamide activation and sensitivity in multidrug-resistant Afycobacterium tuberculosis. 
Proc Nall Acad Sci U SA 97,9677-9682. 
Debesh, K., Tai, 11., Edwards, P., Byrne, J. & Jaworski, J. G. (2001). Ovcrexprcssion of 3- 
ketoacyl-acyl-carrier protein synthase III in plants reduces the rate of lipid synthesis. Plant 
Physiol 125,1103-1114. 
Dessen, A., Quemard, A., Blanchard, I S., Jacobs, W. It, Jr. & Sacchettini, J. C. (1995). 
Crystal structure and function of the isoniazid target ofAfycobacterium tuberculosis. Science 
267,1638-1641. 
Dinadayala, P., Laval, F., Raynaud, C., Lemassu, A., Lancelle, M. A., Lancelle, G. & 
Daffe, M. (2003). Tracking the putative biosynthctic precursors of oxygenated mycolatcs of 
229 
REFERENCES CHAPTER 7 
Mycobacterium tuberculosis. Structural analysis of fatty acids of a mutant strain deviod of 
methoxy- and ketomycolates. JBiol Chem 278,7310-7319. 
Dmitriev, B. A., Ehlers, S., Rietschel, E. T. & Brennan, P. 1 (2000). Molecular mechanics 
of the mycobacterial cell wall: from 
horizontal layers to vertical scaffolds. IWJMedMicrobiol 290,251-258. 
Dover, L. G., Cerdeno-Tarraga, A. M., Pallen, M. J., Parkhill, I& Besra, G. S. (2004). 
Comparative cell wall core biosynthesis in the mycolated pathogens, Mycobacterium 
tuberculosis and Corynebacteriurn diphtheriae. FEMS Microblol Rev 28,225-250. 
Dubey, V. S., Sirakova, T. D., Cynamon, M. H. & Kolattukudy, P. E. (2003). Biochemical 
function of msl5 (pks8 pluspksl7) in Mycobacterium tuberculosis H37Rv: biosynthesis of 
monomethyl branched unsaturated fatty acids. JBacteriol 185,46204625. 
Dye, C. & Espinal, M. A. (2001). Will tuberculosis become resistant to all antibiotics? Proc 
R Soc Lond B B161 Sci 268,45-52. 
Dye, C., Espinal, M. A., Watt, C. J., Mbiaga, C. & Williams, B. G. (2002). Worldwide 
incidence of multidrug-resistant tuberculosis. JInfect Dis 185,1197-1202. 
Edwards, P., Nelsen, I S., Metz, I G. & Dehesh, K. (1997). Cloning of thefabF gene in an 
expression vector and in vitro characterization of recombinantfabF andfabB encoded 
enzymes from Escherichla coli. FEBS Leit 402,62-66. 
Eggeling, L., Pfefferle, W. & Sahm, 11. (2001). Amino acids. In Basic Biolechnolo'v, pp. 
281-302. Edited by C. Ratledge & B. Kristiansen: Cambridge University Press. 
Enarson, N. D. & Murray, J. F. (1996). Global epidemiology of tuberculosis. In 
Tuberculosis, pp. 57-75. Edited by W. N. Rom & S. Garay. Boston: Little, Brown and Co. 
Engohang-Ndong, J., Baillat, D., Aurnercier, M., Bellefontaine, F., Bcsra, G. S., Locht, C. 
& Baulard, A. R. (2004). EthR, a repressor of the TctR/CamR family implicated in 
ethionamide resistance in mycobacteria, octamerizcs cooperatively on its operator. Afol 
Microbiol 51,175-188. 
Escuyer, V. E., Lety, M. A., Torrelles, I B. & other authors (2001). The role of the embA 
and embB gene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of 
Mycobacterium smegmatis arabinogalactan. JBiol Chem 276,4885448862. 
Fang, Z., Doig, C., Rayner, A., Kenna, D. T., Watt, 11. & Forbes, Ka 1 (1999). Molecular 
evidence for heterogeneity of the multiple-drug-rcsistant Alycobacterium tuberculosis 
population in Scotland (1990 to 1997). J Clin Aficroblol 37,998-1003. 
Finken, M., Kirschner, P., Meier, A., Wrede, A. & Bottger, E. C. (1993). Molecular basis 
of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein 
S 12 gene and point mutations within a functional 16S ribosomal RNA pscudoknot. Afol 
Aficroblol 9,1239-1246. 
230 
CHAPTER 7 REFERENCES 
Fleischmann, R. D., Alland, D., Eisen, J. A. & other authors (2002). Whole-genome 
comparison of Mycobacterium tuberculosis clinical and laboratory strains. JBacteriol 184, 
5479-5490. 
Fraaije, M. W., Kamerbeek, N. M., Heidekamp, A. J., Fortin, R. & Janssen, D. B. (2004). 
The prodrug activator EtaA from Mycobacterium tuberculosis is a Baeyer-Villiger 
monooxygenase. JB1ol Chem 279,3354-3360. 
Furukawa, H., Tsay, J. T., Jackowski, S., Takamura, Y. & Rock, C. 0. (1993). 
Thiolactomycin resistance in Escherichia coll is associated with the multidrug resistance 
efflux pump encoded by emrAB. JBacteriol 175,3723-3729. 
Galili, S., Fromm, H., Aviv, D., Edelman, M. & Galun, E. (1989). Ribosomal protein S12 
as a site for streptomycin resistance in Nicoliana chloroplasts. Mol Gen Genet 218,289-292. 
Gande, R., Gibson, V- J., Brown, A. K& other authors (2004). Acyl-CoA carboxylases 
(accD2 and accD3), together with a unique polyketide synthase (Cg-pks), are key to mycolic 
acid biosynthesis in Corynebacterianeae such as Corynebacterium glutamicum and 
Mycobacterium tuberculosis. JB/ol Chem 279,4484744857. 
Gao, L. Y., Laval, F., Lawson, E. H., Groger, R. K., Woodruff, A., Morisaki, J. IT., Cox, 
J. S., Daffe, M. & Brown, E. J. (2003). Requirement for kasB in Afycobacterium mycolic 
acid biosynthesis, cell wall impermeability and intracellular survival: implications for therapy. 
MOIMicrobiolO, 1547-1563. 
Garnier, T., Eiglmeicr, K., Camus, J. C. & other authors (2003). The complete genome 
sequence of Mycobacterium bovis. Proc NatlAcadSci USA 100,7877-7882. 
Garwin, J. L., Klages, A. L. & Cronan, J. E., Jr. (1980). Structural, enzymatic, and genetic 
studies of beta-ketoacyl-acyl carrier protein synthases I and 11 of Escherichia coli. JBiol 
Chem 255,11949-11956. 
George, V. M., Yuan, Y., Sherman, D. R. & Barry, C. E., 3rd (1995). The biosynthcsis or 
CYClopropanated mycolic acids in Afycobacterium tuberculosis. Identification and functional 
analysis of CMAS-2. JBiol Chem 270,27292-27298. 
Gibson, K. J., Eggeling, L., Maughan, W. N., Krumbach, K., Gurcha, S. S., Nigou, J., 
Puzo, G., Sahm, 11. & Besra, G. S. (2003). Disruption of Cg-Ppm I, a polyprcnyl 
monophosphomannose synthase, and the generation of lipoglycan-Icss mutants in 
Corynebacterium glulamicum. JBiol Chem 278,4084240850. 
Girling, D. J. (1989). The Chemotherapy of Tuberculosis. In 77; e b1oloV ofAfycobacterla' 
pp. 285-323. Edited by C. Ratlcdge, J. Stanford & J. M. Grange. London: Academic Press. 
Glickman, M. S. (2003). The mmaA2 gene of Af)vobacterium tuberculosis encodes the distal 
cyclopropane synthase of the alpha-mycolic acid. JBIol Chem 278,7844-7849. 
Glickman, M. S. & Jacobs, W. R., Jr. (2001). Microbial pathogenesis ow)-cobacteriuln 
tuberculosis: dawn of a discipline. Cell 104,477485. 
231 
CHAPTER 7 REFERENCES 
Glickman, M. S., Cahill, S. M. & Jacobs, W. R., Jr. (2001). The Mycohacterium 
tuberculosis cma, 42 gene encodes a mycol ic acid trans-cyclopropane synthetase. J Biol Chem 276,2228-2233. 
Goffin, C. & Ghuysen, J. M. (2002). Biochemistry and comparative genomics of SxxK 
superfamily acyltransferases offer a clue to the mycobacterial paradox: presence of penicillin- 
susceptible target proteins versus lack of efficiency of penicillin as therapeutic agent. Microbiol Mol Biol Rev 66,702-738. 
Grassberger, M. A., Turnowsky, F. & Hildebrandt, 1 (1984). Preparation and antibacterial 
activities of new 1,2,3-diazaborine derivatives and analogues. JMed Chem 27,947-953. 
Guerardel, Y., Maes, E., Elass, E., Leroy, Y., Timmerman, P., Besra, G. S., Locht, C., 
Strecker, G. & Kremer, L. (2002). Structural study of lipomannan and lipoarabinomannan 
from Mycobacterium chelonae. Presence of unusual components with alpha 1,3- 
mannopyranose side chains. JBiol Chem 277,30635-30648. 
Gurcha, S. S., Baulard, A. PL, Kremer, L. & other authors (2002). Ppm 1, a novel 
Polyprenol monophosphomannose synthase from Mycobacterium tuberculosis. Biochem J 
365,441-450. 
Haase, F. C., Henrikson, YL P., Treble, D. H. & Allen, S. If. (1982). The subunit structure 
and function of the propionyl coenzyme A carboxylase of Mycobacterium smegmalis. JB! ol 
Chem 257,11994-11999. 
Hall, P. R., Wang, Y. F., Rivera-Hainaj, R. E., Zheng, X., Pustai-Carey, M., Carey, P. R. 
& Yee, V. C. (2003). Transcarboxylase 12S crystal structure: hexamer assembly and substrate 
binding to a multienzyme core. Embo J 22,2334-2347. 
Ilan, L., Lobo, S. & Reynolds, K. A. (1998). Characterization of beta-kctoacyl-acyl carrier 
protein synthase III from SireptomycesgIducescens and its role in initiation of fatty acid 
biosynthesis. JBacleriol 180,4481-4486. 
I latfull, G. F. (1996). The molecular genetics of Afycohacteriuni tuberculosis. Curr Top 
Aficrobiol Immunol 215,29-47. 
Heath, R. J. & Rock, C. 0. (1996a). Regulation of fatty acid elongation and initiation by 
acyl-acyl carrier protein in Escherichia coli. JBiol Chen: 271,1833-1836. 
Heath, R. J. & Rock, C. 0. (1996b). Inhibition of bcta-ketoacyl-acyl carrier protein synthasc 
III (FabII) by acyl-acyl carrier protein in Escherichia coli. JBiol Chem 271,10996-11000. 
I Icath, R. J. & Rock, C. 0. (2002). The Claiscn condensation in biology. Alai Prod Rep 19, 
581-596. 
1 Iclfcts, L. 13. (1994). Expedited detection of drug resistance in tuberculosis patients. Ann 
EniergAW24,457461. 
Heym, B., Ilonore, N., Truffot-Pernot, C., Banerjec, A., Schurra, C., Jacobs, W. It, Jr., 
van Embden, J. D., Grosset, J. 11. & Cole, S. T. (1994). Implications of multidrug resistance 
232 
CHAPTER 7 REFERENCES 
for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 344, 293-298. 
Higashi, Y., Strominger, I L. & Sweeley, C. C. (1967). Structure of a lipid intermediate in 
cell wall peptidoglycan synthesis: a derivative of a C55 isoprenoid alcohol. Proc Nail Acad 
Scl USA 57,1878-1884. 
Howard, C. F., Jr. (1968). De novo synthesis and elongation of fatty acids by subcellar fractions of monkey aorta. JLipid Res 9,254-26 1. 
Huang, T. S., Lee, S. S., Tu, H. Z., Huang, W. K., Chen, Y. S., Huang, C. K, Wann, S. 
R., Lin, H. H. & Liu, Y. C. (2003). Correlation between pyrazinamide activity andpncA 
mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob Agents Chenlother 
47,3672-3673. 
Huang, W., Jia, J., Edwards, P., Dehesh, V-, Schneider, G. & Lindqvist, Y. (1998). 
Crystal structure of beta-ketoacyl-acyl carrier protein synthase 11 from Exo1i reveals the 
molecular architecture of condensing enzymes. Embo J 17,1183-1191. 
Jackowski, S., Murphy, C. M., Cronan, J. E., Jr. & Rock, C. 0. (1989). Acetoacetyl-acyl 
carrier protein synthase. A target for the antibiotic thiolactomyc in. JBiol Chem 264,7624- 
7629. 
Jackowski, S., Zhang, Y. M., Price, A. C, White, S. W. & Rock, C. 0. (2002). A missensc 
mutation in thefabB (beta-ketoacyl-acyl carrier protein synthase 1) gene confcrs tiolactomycin 
resistance to Escherichia coli. AnlimicrobAgents Chemother 46,1246-1252. 
Jackson, M., Crick, D. C. & Brennan, P. J. (2000). Phosphatidylinositol is an essential 
phospholipid of mycobacteria. JBiol Chem 275,30092-30099. 
Jackson, M., Portnoi, D., Catheline, D., Dumail, L., Rauzicr, J., Legrand, P. & Gicquel, 
13. (1997). Mycobacterium tuberculosis Des protein: an immunodominant target for the 
humoral response of tuberculous patients. Infect Immun 65,2883-2889. 
Jez, J. M. & Noel, J. P. (2000). Mechanism of chalcone synthasc. pKa of the catalytic 
cysteine and the role of the conserved histidine in a plant polykctide synthasc. JBiol Chem 
275,39640-39646. 
Kaccm, R., De Sousa-D'Auria, C., Tropis, M., Chami, M., Gounon, P., Leblon, G., 
Houssin, C. & Daffe, M. (2004). Importance of mycoloyltransfcrascs on the physiology of 
Corynebacterium glulamicum. Microbiology 150,73-84. 
Kalinowski, J., Bathe, B., Bartels, D. & other authors (2003). The complete 
Corynebacterium glutandcum ATCC 13032 gcnomc sequence and its impact on the 
production of L-aspartate-derived amino acids and vitamins. JBIotechnol 104,5-25. 
1 
Keilliauer, C., Eggeling, L. & Sahm, 11. (1993). Isolcucine synthesis in Cor), nebacterium 
glulamicum: molecular analysis of the flvB-flvN-iIvCopcron. JBacteriol 175,5595-5603. 
233 
CHAPTER 7 REFERENCES 
Khandekar, S. S., Konstantinidis, A. V-, Silverman, C. & other authors (2000). Expression, purification, and crystallization of the Escherichia Coli selenomethionyl beta- ketoacyl-acyl carrier protein synthase Ill. Biochem Biophys Res Commun 270,100-107. 
Khandekar, S. S., Gentry, A R., Van Aller, G. S. & other authors (2001). Identification, 
substrate specificity, and inhibition of the Streptococcuspneumoniae beta-ketoacyl-acyl 
carrier protein synthase III (FabH). JBiol Chem 276,30024-30030. 
Khoo, K. H., Douglas, E., Azadi, P., Inarnine, J. M., Besra, G. S., Mikusova, YL, Brennan, 
P. J. & Chatterjee, A (1996). Truncated structural variants of lipoarabinornannan in 
etharnbutol drug-resistant strains of Mycobacterium smegmatis. Inhibition of arabinan biosynthesis by etharnbutol. JBiol Chem 271,28682-28690. 
Kimura, E., Abe, C., Kawahara, Y., Nakamatsu, T. & Tokuda, H. (1997). A dIsR gene- 
disrupted mutant of Brevibacterium lactofermentum requires fatty acids for growth and 
efficiently produces L-glutarnate in the presence of an excess of biotin. Biochem Biophys Res Commun 234,157-161. 
Kordulakova, J., Gilleron, M., Mikusova, K, Puzo, G., Brennan, P. J., Gicquel, B. & 
Jackson, M. (2002). Definition of the first mannosylation step in phosphatidylinositol 
mannoside synthesis. PirnA is essential for growth of mycobacteria. JBiol Chem 277,31335- 31344. 
Kremer, L., Baulard, A. I- & Besra, G. S. (2000a). Genetics of MYCOlic Acid Biosynthesis. 
In Molecular Genetics ofMycobacteria, pp. 173-190. Edited by G. F- Hatfull & W. R. Jacobs, Jr. Washington D. C.: ASM Press. 
Kremer, L., Maughan, W. N., Wilson, PL A., Dover, L. G. & Besra, G. S. (2002a). The Af 
iuberculosis antigen 85 complex and mycolyltransferase activity. Lejj, 4ppj 1croblol 34,233- M 
237. 
Kremer, L., Gurcha, S. S., Bifani, P., Hitchin, P. G., Baulard, A., Morris, If. It, Dell, A., 
Brennan, P. J. & Besra, G. S. (2002b). Characterization of a putative alpha- 
mannosyltransferase involved in phosphatidylinositol trimannoside biosynthesis in 
MYOCbacterium Wherculosis. Biochem J 363,43 7-447. 
Kremer, L., Nampoothiri, K. M., Lesjean, S. & other authors (2001a). Biochemical 
characterization of acyl carrier protein (AcpM) and malonyl-CoA: AcpM transacylase (MtFabD), two major components of Mycobacterium tuberculosis fatty acid synthase 11. JBIoI 
Chem 276,27967-27974. 
Kremer, L., Dover, L. G., Carrere, S. & other authors (2002c). Mycolic acid biosynthcsis 
and enzymic characterization of the beta-ketoacyl-ACP synthase A-condensing enzyme 
from 
Mycobacterium tuberculosis. Blochem J364,423430. 
Kremer, L., Douglas, J. D., Baulard, A. R. & other authors (2000b). Thiolactomycin and 
related analogues as novel anti-mycobacterial agents targeting KasA and 
KasB condensing 
enzymes in Mycobacterium tuberculosis. JBiol Chem 275,16857-16864. 
234 
CHAPTER 7 REFERENCES 
Kremer, L., Dover, L. G., Morehouse, C. & other authors (2001b). Galactan biosynthesis in Mycobacterium tuberculosis. Identification of a bifunctional UDP- 
galactofuranosyltransferase. JBiol Chem 276,26430-26440. 
Kremer, L., Dover, L. G., Morbidoni, H. R. & other authors (2003). Inhibition of InhA 
activity, but not KasA activity, induces fonnation of a KasA-containing complex in 
mycobacteria. JBiol Chem 278,20547-20554. 
Kremer, L. S. & Besra, G. S. (2002). Current status and future development of antitubercular 
chemotherapy. apert Opin Investig Drugs 11,1033-1049. 
Kuo, M. R., Morbidoni, H. R., Alland, A& other authors (2003). Targeting tuberculosis 
and malaria through inhibition of Enoyl reductase: compound activity and structural data. J 
Biol Chem 278,20851-20859. 
Larsen, M. H., Vilcheze, C., Kremer, L. & other authors (2002). Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionarnide in Mycobacteriurn stnegmatis, 
M. bovis BCG and A tuberculosis. Mol Microbiol 46,453466. 
Lee, A. S., Lim, 1. H., Tang, L. L., Telenti, A. & Wong, S. Y. (1999). Contribution of kasA 
analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. 
AntimicrobAgents Chemother 43,2087-2089. 
Lee, R. E., Brennan, P. J. & Besra, G. S. (1996). Mycobacterium tuberculosis cell envelope. 
In Tuberculosis, pp. 1-27. Edited by T. M. Shinnick: Springer. 
Lee, R. E., Brennan, P. I& Besra, G. S. (1998). Synthesis of beta-D-arabinofuranosYl-l- 
monophosphoryl polyprenols: examination of their function as mycobacterial arabinosyl 
tranSferaSe donors. Biborg Med Chem Lett 8,951-954. 
Lee, R. E., Armour, I W., Takayama, K, Brennan, P. I& Besira, G. S. (1997). Mycolic 
acid biosynthesis: definition and targeting of the Claisen condensation step. Biochim Biophys 
, 4cta 1346,275-284. 
Liou, G. F. & Khosla, C. (2003). Building-block selectivity of polyketide synthascs. Curr 
Opin Chem Biol 7,279-284. 
Liu, I& Nikaido, H. (1999). A mutant of Mycobacterium smegmalis defcctive in the 
biosynthesis of mycolic acids accumulates meromycolates. Proc Natl, 4cadSci US, 4 96, 
4011-4016. 
Liu, J., Barry, C. E., 3rd, Besra, G. S. & Nikaido, H. (1996). Mycolic acid structure 
determines the fluidity of the mycobacterial cell wall. JBIoI Chem 271,29545-2955 1. 
Ma, Y., Pan, F. & McNeil, M. (2002). Formation of dTDP-rhamnose is essential for growth 
Of mycobacteria. JBacteriol 184,3392-3395. 
Ma, Y., Stern, R. J., Scherman, M. S. & other authors (2001). Drug targeting 
Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic 
enzymes and development of a microtiter plate-based screen for inhibitors of conversion of 
dTDP-glucose to dTDP-rhamnose. Antimicrob Agents Chemother 45,1407-1416. 
235 
CHAPTER 7 REFERENCES 
Maglrlus0n, X, Carey, M. R. & Cronan, J. E., Jr. (1995). The putative fabJ gene of Escherichia coli fatty acid synthesis is the fabF gene. JBacteriol 177,3593-3595. 
Magnuson. V-, Jackowski, S., Rock, C. 0. & Cronan, J. E., Jr. (1993). Regulation of fatty 
acid biosynthesis in Escherichia coli. Microbiol Rev 57,522-542. 
Marcinkeviciene, J., Jiang, W., Kopcho, L. M., Locke, G., Luo, Y. & Copeland, % A. 
(2001). EnOYI-ACP reductase (Fabl) of Haemophilus influenzae: steady-state kinetic 
mechanism and inhibition bytriclosan and hexachlorophene., 4rchBiochem Bioplys390 10 108. 
Marrakchi, H., Laneelle, G. & Quemard, A. (2000). InhA, a target of the antitubcrculous 
drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-11. Microbiologv 146 ( Pt 2), 289-296. 
Marrakehi, H., Ducasse, S., Labesse, G., Montrozier, H., Margeat, E., Emorine, L, 
Charpentier, X., Daffe, M. & Quemard, A. (2002). MabA (FabG 1), a Mycobacterium 
tuberculosis Protein involved in the long-chain fatty acid elongation system FAS-11. Microbiologv 148,951-960. 
McGuire, V- A., McGuire, J. N. & von Wettstein-Knowles, P. (2000). Acyl carrier protein (ACP) inhibition and other differences between beta-ketoacyl synthase (KAS) I and 11. BiOchem Soc Trans 28,607-610. 
McGuire, K. A., Siggaard-Andersen, M., Bangera, M. G., Olsen, I G. & von Wettsfein- 
Knowles, P. (2001). beta-Ketoacyl-facyl carrier protein] synthase I of Escherichia coli: 
aspects of the condensation mechanism revealed by analyses of mutations in the active sitc 
pocket. Biochemistry 40,9836-9845. 
McLeod, R., Muench, S. P., Rafferty, J. B. & other authors (2001). Triclosan inhibits the 
growth Of Plasmodiumfalciparum and Toxoplasma gondii by inhibition of apicompic. xan Fab I- Int JParasitol 31,109-113. 
McMurry, L. M., Oethinger, A& Levy, S. B. (1998). Triclosan targcts lipid synthcsis. 
Nature 394,531-532. 
McMurry, L. M., McDermott, P. F. & Levy, s. B. (1999). Genetic evidence that InhA of 
Mycobacterium smegmatis is a target for triclosan. Antimicrob Agenis ClIenjoiller 43,711 713. 
McNeil, M. (1999). In Genetics ofbacterialpolysaccarides, pp. 207-223. 
Editcd by J. B. 
Goldberg. Washington D. C.: CRC Press. 
McNeil, M., Daffe, M. & Brennan, P. J. (1990). Evidence for the naturc of tile link bct%%-cen 
the arabin0galactan and peptidoglycan of mycobacterial cell walls. JBiol 
Client 265,18200- 
18206. 
McNeil, M., Daffe, M. & Brennan, P. 1 (1991). Location of the m)'cOIYI csicr substitucnts 
in the cell walls of mycobacteria. JBiol Chem 266,13217-13223. 
236 
CHAPTER 7 REFERENCES 
McNeil, M. PL & Brennan, P. 1 (1991). Structure, function and biogenesis of the cell 
envelope of mycobacteria in relation to bacterial physiology, pathogenesis and drug 
resistance; some thoughts and possibilities arising from recent structural information. Res 
Microbiol 142,451463. 
Mdluli, K, Slayden, R. A., Zhu, Y., Ramaswamy, S., Pan, X., Mead, D., Crane, D. D., 
Musser, J. M. & Barry, C. E., 3rd (1998). Inhibition of a Mycobacterium tuberculosis beta- 
ketoacyl ACP synthase by isoniazid. Science 280,1607-1610. 
Middlebrook, G. (1954). Isoniazid-resistance and catalase activity of tubercle bacilli; a 
preliminary report. Am Rev Tuberc 69,471-472. 
Mikusova, YL, Slayden, R. A., Besra, G. S. & Brennan, P. J. (1995). Biogenesis of the 
myrobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother 
39,2484-2489. 
Mikusova, YL, Mikus, M., Besra, G. S., Hancock, 1. & Brennan, P. J. (1996). Biosynthesis 
of the linkage region of the mycobacterial cell wall. JBiol Chem 271,7820-7828. 
Mikusova, K, Yagi, T., Stern, R., McNeil, M. R., Besra, G. S., Crick, D. C. & Brennan, 
P. 1 (2000). Biosynthesis of the galactan component of the mycobacterial cell wall. JBiol 
Chem 275,33890-33897. 
Minnikin, D. E. (1982). Lipids: complex lipids, their chemistry, biosynthesis and roles. In 
The Biology of the Mycobacteria: Physiology, Identification and Classification. Edited by C. 
Ratledge & J. Stanford. London, UK: Academic Press. 
Minnikin, D. E., Kremer, L., Dover, L. G. & Besra, G. S. (2002). The methyl-branched 
fortifications of Mycobacterium tuberculosis. Chem Biol 9,545-553. 
Moche, M., Dehesh, V-, Edwards, P. & Lindqvist, Y. (2001). The crystal structure of beta- 
ketoacyl-acyl carrier protein synthase 11 from Synechocystis sp. at 1.54 A resolution and its 
relationship to other condensing enzymes. JMol Biol 305,491-503. 
Moche, M., Schneider, G., Edwards, P., Dehesh, K. & Lindqvist, Y. (1999). Structure of 
the complex between the antibiotic cerulenin and its target, beta-ketoacyl-acyl carrier protein 
synthase. JBiol Chem 274,6031-6034. 
Musser, I M. (1995). Antimicrobial agent resistance in mycobacteria: molecular genetic 
insights. Clin Microhiol Rev 8,496-514. 
Nakamura, Y., Nishio, Y., Ikeo, V- & Gojobori, T. (2003). The genome stability in 
Corynebacterium species due to lack of the recombinational repair system. Gene 317,149- 
155. 
Narain, I P., Raviglione, M. C& Kochi, A. (1992). HIV-associated tuberculosis in 
developing countries: epidemiology and strategies for prevention. Tuber Lung Dis 73,311. 
321. 
237 
CHAPTER 7 REFERENCES 
Nigou, J., Dover, L. G. & Besra, G. S. (2002a). Purification and biochemical 
characterization of Mycobacterium tuberculosis SuhB, an inositol monophosphatase involved in inositol biosynthesis. Biochemistry 41,4392-4398. 
Nigou, J., Gilleron, M. & Puzo, G. (2003). Lipoarabinomannans: from structure to bi0synthesis. Biochimie 85,153-166. 
Nigou, J., Gilleron, M., Rojas, M., Garcia, L. F., Thurnher, M. & Puzo, G. (2002b). 
Mycobacterial lipoarabinomannans: modulators of dendritic cell function and the apoptotic 
response. Microbes Infect 4,945-953. 
Nigou, J., Gilleron, M., Cahuzae, B., Bounery, I D., Herold, M., Thurnher, M. & Puzo, 
G. (1997). The phosphatidyl-myo-inositol anchor of the lipoarabinomannans from Mycobacterium bovis bacillus Calmette Guerin. Heterogeneity, structure, and role in the 
regulation of cytokine secretion. JBiol Chem 272,23094-23103. 
Nishio, Y., Nakamura, Y., Kawarabayasi, Y. & other authors (2003). Comparative 
Complete genome sequence analysis of the amino acid replacements responsible for the 
thermostability of Corynebacterium effiWens. Genome Res 13,1572-1579. 
Oishi, H., Noto, T., Sasaki, H., Suzuki, YL, Hayashi, T., Okazaki, If., Ando, K. & 
Sawada, M. (1982). Thiolactomycin, a new antibiotic. 1. Taxonomy of the producing 
organism, fermentation and biological properties. JAnfibiot (Tokyo) 35,391-395. 
Olsen, I G., Kadziola, A., von Wettstein-Knowles, P., Siggaard-Anderscn, At. & Larsen, S. (2001). Structures of beta-ketoacyl-acyl carrier protein synthase I complexed with fatty 
acids elucidate its catalytic machinery. Struclure (Camb) 9,233-243. 
Olsen, J. G., Kadziola, A., von Wettstein-Knowles, P., Siggaard-Andersen, M., 
Lindquist, Y. & Larsen, S. (1999). The X-ray crystal structure of bcta-kctoacyl [acyl carricr 
protc in] synthase 1. FEBS Lett 460,46-52. 
Omura, S. (1976). The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor or fatty acid synthesis. Bacteriol Rev 40,681-697. 
Pantano, S., Alber, F., Larnba, D. & Carloni, P. (2002). NADI I intcractions with %VT. and 
S94A-acyl carrier protein reductase from Afycobacterium tuberculosis: an ab 11111io study. 
Proteins 47,62-68. 
Parikh, S. L., Xiao, G. & Tonge, P. J. (2000). Inhibition of InhA. the cnoyl mductase from 
Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 39,7645-7650. 
]Parish, T. & Stoker, N. G. (1999). Mycobactcria: bugs and bugbears (two steps forward and 
one step back). Mol Biolechnol 13,191-200. 
Parish, T., Liu, J., Nikaido, If. & Stoker, N. G. (1997). A Afycobacteriuln sineginall. 1 
mutant with a defective inositol monophosphatc phosphatasc gcnc lioniolog has aftcrcd cell 
envelope pen-neability. JBacleribl 179,7827-7833. 
Pearson, W. R. (1990). Rapid and sensitive scquencc comparison with FASTI, and FASTA. 
Afeihods Enzymol 183,63-98. 
238 
CHAPTER 7 REFERENCES 
Petit & Lenderer (1984). In The mycobacteria sourcebook, pp. 301-322. Edited by G. P. Kubica & L. G. Wayne. New York: Marcel Dekker. 
Phetsuksiri, B., Baulard, A. R., Cooper, A. M., Minnikin, D. E., Douglas, J. D., Besra, G. 
S- & Brennan, P. J. (1999). Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Antimicrob Agents Chemother 43,1042- 1051. 
Phetsuksiri, B., Jackson, M., Scherman, H. & other authors (2003). Unique mechanism of 
action of the thiourea drug isoxyl on Mycobacterium tuberculosis. JBiol Chem 278,53123- 53130. 
Portevin, D., De Sousa-D'Auria, C., Houssin, C., Grimaldi, C., Chami, M., Daffe, M. & 
Guilhot, C. (2004). A polyketide synthase catalyzes the last condensation step of mycOlic 
acid biosynthesis in mycobacteria and related organisms. ProcNatlAcadSci USA 101,314- 319. 
POst-Beitten Miller, D., Jaworski, I G. & Ohlrogge, I B. (1991). In ViVO Pools of free and 
acylated acyl carrier proteins in spinach. Evidence for sites of regulation of fatty acid biosynthesis. JBiol Chem 266,1858-1865. 
Price, A. C., Choi, YL H., Heath, R. J., Li, Z., White, S. W. & Rock, C. 0. (2001). 
Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism. JBiol Chem 276,6551-6559. 
Prigge, S- T-, He, X, Gerena, I..,, Waters, N. C. & Reynolds, K. A. (2003). The initiating 
steps of a type 11 fatty acid synthase in Plasmodiumfalciparum are catalyzed by pfACP, 
PfMCAT, and pfKAslll. Biochemistry 42,1160-1169. 
Puech, V., Bayan, N., Salim, K., Leblon, G. & Daffe, M. (2000). Characterization of the in 
vivo acceptors of the mycoloyl residues transferred by the corynebacterial PSI and the related 
mycobacterial antigens 85. Mol Microbiol 35,1026-104 1. 
Qiuq X. ) Janson, C. A., Smith, W. W., Head, M., Lonsdale, J. & Konstantinidis, 
A. IC 
(2001). Refined structures of beta-ketoacyl-acyl carrier protein synthase 111. JAfol M61307, 341-356. 
Qiu, X., Janson, C. A., Konstantinidisq A. K., Nwagwu, S., Silverman, C., Smith, NV- NV-, 
Khandekar, S., Lonsdale, J. & Abdel-Meguid, S. S. (1999)- Crystal structure of bct3- 
ketoacyl-acyl carrier protein synthase 111. A key condensing enzyme in bacterial 
fattY acid 
biosynthesis. JBiol Chem 274,36465-3647 1. 
Quemard, A., Sacchettini, J. C., Dessen, A., Vilcheze, C., Bittman, R., Jacobs, W. PL, Jr. 
& Blanchard, J. S. (1995). Enzymatic characterization of the target for isoniazid 
in 
Mycobacterium tuberculosis. Biochemistry 34,8235-824 1. 
Qureshi, N., Sathyamoorthy, N. & Takayama, K. (1984). Biosynthesis of C30 to C56 fatty 
acids by an extract of Mycobacterium tuberculosis H37Ra. JBacteriol 157,46-52. 
239 
CHAPTER 7 REFERENCES 
Rainwater, A L. & Kolattukudy, P. E. (1982). Isolation and characterization of acyl 
coenzyme A carboxylases from Mycobacterium tuberculosis and Mycobacterium bovis, which 
produce multiple methyl-branched mycocerosic acids. JBacteriol 151,905-911. 
Rarnaswarny, S. & Musser, J. M. (1998). Molecular genetic basis of antimicrobial agent 
resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 79,3-29. 
Ratledge, C& Dover, L. G. (2000). Iron metabolism in pathogenic bacteria. Annu Rev 
Microbiol 54,881-94 1. 
Rattan, A., Kalia, A. & Ahmad, N. (1998). Multidrug-Resistant Mycobacterium 
tuberculosis: Molecular Perspectives. Emerg Infect Dis 4,195-207. 
Raynaud, C, Laneelle, M. A., Senaratne, YL H., Draper, P., Laneelle, G. & Daffe, M. 
(1999). Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake 
in addition to lack of pyrazinamidase activity. MicrobioloýV 145 ( Pt 6), 1359-1367. 
Reeves, C. D., Murli, S., Ashley, G. W., Piagentini, M., Hutchinson, C. R. & McDaniel, 
R. (2001). Alteration of the substrate specificity of a modular polyketide synthase 
acyltransferase domain through site-specific mutations. Biochemistry 40,15464-15470. 
Revill, W. P., Bibb, M. J., Scheu, A. K, Kieser, H. J. & Hopwood, D. A. (2001). Beta- 
ketoacyl acyl carrier protein synthase III (FabH) is essential for fatty acid biosynthesis in 
Streptomyces coelicolor A3(2). JBacteriol 183,3526-3530. 
Roberts, C. W., McLeod, R., Rice, A W., Ginger, M., Chance, M. L. & Goad, L. J. 
(2003). Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and 
trypanosomatid parasitic protozoa. Mol Biochem Parasifol 126,129-142. 
Rousseau, C., Sirakova, T. D., Dubey, V. S., Bordat, Y., Kolattukudy, P. E., Gicquel, B. 
& Jackson, M. (2003). Virulence attenuation of two Mas-like polyketide synthase mutants of 
Mycobacterium tuberculosis. Microbioloýv 149,1837-1847. 
Rowe, A C. & Summers, D. V_ (1999). The quiescent-cell expression system for protein 
synthesis in Escherichia coli. AppI Environ Microbiol 65,2710-2715. 
Rubires, X, Saigi, F., Pique, N., Climent, N., Merino, S., Alberti, S., Tomas, I M. & 
Regue, M. (1997). A gene (wbbL) from Serratia marcescens N28b (04) complements the 
rfb-50 mutation of Escherichia coli K-12 derivatives. JBacleriol 179,7581-7586. 
Saini, D. V-, Pant, N., Das, T. K. & Tyagi, I S. (2002). Cloning, overexpression, 
purification, and matrix-assisted refolding of DevS (Rv 3132c) histidine protein kinasc of 
Mycobacterium tuberculosis. Protein Expr Puri(25,203-208. 
Sarkar, G. & Sommer, S. S. (1990). The "megaprimer" method of site-dirccted mutagenesis. 
Blotechniques 8,404407. 
Sassetti, C. M., Boyd, D. H. & Rubin, E. J. (2003). Genes required for mycobacterial 
growth defined by high density mutagenesis. Mol Aficrobiol 48,77-84. 
240 
CIL4, PTER 7 REFERENCES 
Sathyamoorthy, N., Qureshi, N. & Takayama, K. (1985). Purification and characterization 
of C28-55 fatty acids from Mycobacterium smegmatis. Can JMicrobiol 31,214-219. 
Scarsdale, J. N., Kazanina, G., He, X., Reynolds, V- A. & Wright, H. T. (2001). Crystal 
Structure of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase 111. J 
Biol Chem 276,20516-20522. 
Schaeffer, M. L., Agnihotri, G., Volker, C., Kallender, H., Brennan, P. J. & Lonsdale, J. 
T. (2001). Purification and biochemical characterization of the Mycobacterium tuberculosis 
beta-ketoacyl-acyl carrier protein synthases KasA and Kasl3. JBIoI Chem 276,47029-47037. 
Schaeffer, M. L., Khoo, V- H., Besra, G. S., Chatterjee, D., Brennan, P. J., Belisle, J. T. 
& Inamine, J. M. (1999). ThepimB gene of Mycobacterium tuberculosis encodes a 
mannosyltransferase involved in lipoarabinomannan biosynthesis. JBiol Chem 274,31625- 
31631. 
Schafer, A., Tauch, A., Jager, W., Kalinowski, J., Thierbach, G. & Puhler, A. (1994). 
Small mobilizable multi-purpose cloning vectors derived from the Escherichia coli plasm ids 
pKI8 and pK19: selection of defined deletions in the chromosome of Corynebacterium 
glutamicum. Gene 145,69-73. 
Senior, S. J., Illarionov, P. A., Gurcha, S. S., Campbell, 1. B., Schaeffer, M. L., Minnikin, 
D. E. & Besra, G. S. (2003). Biphenyl-based analogues of thiolactomycin, active against 
Mycobacterium tuberculosis mtFabH fatty acid condensing enzyme. Moorg Aled Chem Lell 
13,3685-3688. 
Shen, B. (2003). Polyketide biosynthesis beyond the type 1,11 and III polyketide synthase 
paradigms. Curr Opin Chem Biol 7,285-295. 
Shen, B. & Hutchinson, C. R. (1993). Enzymatic synthesis of a bacterial polyketide from 
acetyl and malonyl coenzyme A. Science 262,1535-1540. 
Shimakata, T. & Stumpf, P. K. (1983). Purification and characterization of beta-ketoacyl- 
ACP synthetase I from Spinacia oleracea leaves. Arch Biochem Biophys 220,3945. 
Shimakata, T., Iwaki, M. & Kusaka, T. (1984). In vitro synthesis of mycolic acids by the 
fluffy layer fraction of Bacterionema matruchoW. Arch Biochem Biophys 229,329-339. 
Shimakata, T., Tsubokura, V, Kusaka, T. & Shizukuishi, YL (1985). Mass-spectrometric 
identification of trehalose 6-monomycolate synthesized by the cell-free system of 
Bacterionema matruchoW. Arch Biochem Biophys 238,497-508. 
Siggaard-Andersen, M. (1993). Conserved residues in condensing enzyme domains of fatty 
acid synthases and related sequences. Protein Seq DaIaAnal 5,325-335. 
Sirakova, T. D., Fitzmaurice, A. M. & Kolattukudy, P. (2002). Regulation of expression of 
mas andfadD28, two genes involved in production of dimycocerosyl phthioccrol, a virulcncc 
factor of Mycobacterium tuberculosis. JBacteriol 184,6796-6802. 
Sirakova, T. D., Thirumala, A. V-, Dubey, V. S., Sprecher, H. & Kolattukudy, 1". E. 
(2001). The Mycobacterium tuberculosis pks2 gene encodes the synthase for the hepta- and 
241 
CHAPTER 7 REFERENCES 
octarnethyl-branched fatty acids required for sulfolipid synthesis. JBiol Chem 276,16833- 
16839. 
Sivaraman, S., Zwahlen, J., Bell, A. F., Hedstrom, L. & Tonge, P. 1 (2003). Structure- 
activity studies of the inhibition of Fabl, the enoyl reductase from Escherichia coli, by 
triclosan: kinetic analysis of mutant Fabls. Biochemistry 42,4406-4413. 
Slayden, F- A., Lee, R. E. & Barry, C. E., 3rd (2000). Isoniazid affects multiple 
components of the type 11 fatty acid synthase system of Mycobacterium tuberculosis. Afol 
Microbiol 38,514-525. 
Slayden, R. A., Lee, F- E., Armour, I W., Cooper, A. M., Orme, 1. M., Brennan, P. J. & 
Besra, G. S. (1996). Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and 
Mycolic acid synthesis. Antimicrob Agents Chemother 40,2813-2819. 
Smith, A W. (1982). Mycobacteria. In Microbiology. Edited by A. J. Braude, A. C. E. Davies 
& J. Frierer: W. B. Saunders Co. 
Smith, S., Witkowski, A. & Joshi, A. K. (2003). Structural and functional organization of 
the animal fatty acid synthase. ProgLipidRes 42,289-317. 
Southern, E. M. (1975). Detection of specific sequences among DNA fragments separated by 
gel electrophoresis. JMol Biol 98,503-517. 
Sreevatsan, S., Stockbauer, YL E., Pan, X., Kreiswirth, B. N., Moghazeh, S. L, Jacobs, 
W. R., Jr., Telenti, A. & Musser, J. M. (1997). Ethambutol resistance in Afycohacterium 
tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother 41,1677-168 1. 
Stackebrandt, E., Sproer, C., Rainey, F. A., Burghardt, J., Pauker, 0. & Hippe, If. 
(1997). Phylogenetic analysis of the genus Desul(olomaculum: evidence for the 
misclassification of Desutfotomaculum gulloideum and description of Desulrolonlaculun; 
Orienfis as Desulfosporosinus ofientis gen. nov., comb. nov. Int JSyst Bacleriol 47,1134- 
1139. 
Stratton, M. A. & Reed, M. T. (1986). Short-course drug therapy for tuberculosis. Clin 
Pharm 5,977-987. 
Strohmeier, G. R. & Fenton, M. J. (1999). Roles of lipoarabinomannan in the pathogcncsis 
of tuberculosis. Microbes Infect 1,709-717. 
Taniguchi, H., Aramaki, H., Nikaido, Y., Mizuguchi, Y., Nakamura, Al., Koga, T. & 
Yoshida, S. (1996). Rifampicin resistance and mutation of the rpoB gcne in At)-cobacterium 
tuberculosis. FEMSMicrobiolLett 144,103-108. 
Tatar, J. (1974). [Sensitivity of tubercle bacilli to pyrazinamide determined on the basis of 
their sensitivity to nicotinam ide]. Gru-zlica 42,765-77 1. 
Telenti, A., Philipp, W. J., Sreevatsan, S., Bernasconi, C., Stockbauer, K. E., Wicles, B., 
Musser, J. M. & Jacobs, W. R., Jr. (1997). The emb opcron, a gcnc cluster of 
Mycobacterium tuberculosis involved in resistance to ethambutol. Alai AW3.567-570. 
242 
CHAPTER 7 REFERENCES 
Trivedi, 0. A., Arora, P., Sridharan, V., Tickoo, PL, Mohanty, D. & Gokliale, R. S. 
(2004). Enzymic activation and transfer of fatty acids as acyl-adenylates in mycobacteria. 
Nature 428,441445. 
Tsay, J. T., Oh, W., Larson, T. J., Jackowski, S. & Rock, C. 0. (1992). Isolation and 
characterization of the beta-ketoacyl-acyl carrier protein synthase III gene (fabH) from 
Escherichia coli K-12. JBiol Chem 267,6807-6814. 
Turnowsky, F., Fuchs, V-, Jeschek, C. & Hogenauer, G. (1989). envAf genes of Salmonella 
typhimurium and Escherichia coll. JBacteriol 171,6555-6565. 
van Heijenoort, J. (2001). Formation of the glycan chains in the synthesis of bacteria] 
peptidoglycan. GlycoblolpSy 11,25R-36R. 
Vance, D., Goldberg, I., Mitsuhashi, 0. & Bloch, K. (1972). Inhibition of fatty acid 
synthetases by the antibiotic cerulenin. Mochem Biophys Res Commun 48,649-656. 
Vannelli, T. A., Dykman, A. & Ortiz de Montellano, P. R. (2002). The antituberculosis 
drug ethionamide is activated by a flavoprotein monooxygenase. JBI61 Chem 277,12824. 
12829. 
Vilkas, E., Amar, C., Markovits, J., Viiegenthart, I F. & Kamerling, J. P. (1973). 
Occurrence of a galactofuranose disaccharide in immunoadjuvant fractions orAfycobacterium 
tuberculosis (Cell walls and wax D). Biochim BiophysActa 297,423435. 
Walker, PL W., Prome, I C. & Lacave, C S. (1973). Biosynthesis of mycolic acids. 
Formation of a C32 beta-keto, ester from palmitic acid in a ccil-free system of 
Corynebacterium diphtheride. Biochim BiqphysActa 326,52-62. 
Waller, R. F., Ralph, S. A., Reed, M. B., Su, V., Douglas, J. D., Minnikin, 1). E., 
Cowman, A. F., Besra, G. S. & McFadden, G. 1. (2003). A type 11 pathway for fatty acid 
biosynthesis presents drug targets in Plasmodiunifalciparunt. Anfindcrob Agents Chentother 
47,297-301. 
Watanabe, M., Yamada, Y., Iguchi, V, & INfinnikin, 1). E. (1994). Structural elucidation of 
new phenol ic glycol ipids from Afycobacterium tuberculosis. Biochim BiophjsAcla 12 10, 
174-180. 
Watanabe, M., Aoyagi, Y., Ridell, M. & Minnikin, D. E. (2001). Separation and 
characterization of ' 
individual mycolic acids in representative mycobactcria. Aficrobioloff 
147,1825-1837. 
Watanabe, M., Aoyagi, Y., Mitome, If., Fujita, T., Naokl, 11., Ridell, 51. & Alinnikin, 1). 
E. (2002). Location of functional groups in mycobacterial mcromycolate chains; thc 
recognition of new structural principles in mycolic acids. Aficrobiolov 148,1881-1902. 
WHO (2003). Global TB control. 7,1-192. 
Wilson, R. A., Maughan, W. N., Kremer, L., Besra, G. S. & Fulterer, K. (2004). 711C 
structure of Afycobacterium tuberculosis MPT51 (FbpC 1) defincs a new ramiiy ornon. 
catalytic alpha/bcta hydrolascs. JAJol Blol 335,519-530. 
243 
CHAPTER 7 REFERENCES 
Wilson, FL A., Rai, S., Maughan, W. N., Kremer, L., Kariuki, B. M., Harris, V_ D., 
Wagner, T., Besra, G. S. & Futterer, V_ (2003). Crystallization and preliminary X-ray 
diffraction data of Mycobacterium tuberculosis FbpC I (110803c)-Acta Crystallogr D Biol CrYstallogr 59,2303-2305. 
Winder (1982). Mode of action of the antimycobacterial Agents and Associated Aspects of 
the Molecular Biology of the Mycobacteria. In The BioloSy ofthe Mycobacteria, pp. 354442. Edited by C. Ratledge & J. Stanford. London: Academic Press. 
Winder, F. G., Collins, P. B. & Whelan, D. (1971). Effects of ethionamide and isoxyl on 
mYcolic acid synthesis in Mycobacterium tuberculosis BCG. JGen Microbiol 66,379-380. 
Witkowski, A., Joshi, A. K., Lindqvist, Y. & Smith, S. (1999). Conversion of a beta- 
ketoacyl synthase to a malonyl decarboxylase by replacement of the active-site cysteine with 
glutamine. Biochemistry 38,11643-11650. 
Wong, H. C., Liu, G., Zhang, Y. M., Rock, C. 0. & Zheng, J. (2002). The solution 
structure of acyl carrier protein from Mycobacterium tuberculosis. JBiol Chem 277,15874- 15880. 
Xin, Y., Lee, R. E., Scherman, M. S-9 Khoo, K. H., B6sra, G. S., Brennan, P. J. & McNeil, 
K (1997). Characterization of the in vitro synthesized arabinan of mycobacterial cell walls. 
Biochim Biophys Acta 1335,231-234. 
Yadav, G., Gokhale, % S. & Mohanty, D. (2003). Computational approach for prediction of 
domain organization and substrate specificity of modular polyketide synthases. JMOl Biol 
328,335-363. 
Yamagami, H., Matsumoto, T., Fujiwara, N., Arakawa, T., Kaneda, K., Yano, 1. & 
Kobayashi, K. (2001). Trehalose 6,6'-dimycolate (cord factor) of Mycobacterium 
tuberculosis induces foreign-body- and hypersensitivity-type granulomas in mice. Infect 
Immun 69,810-815. 
Yuan, Y. & Barry, C. E., 3rd (1996). A common mechanism for the biosynthesis of 
methoxy and cyclopropyl mycolic acids in Mycobacterium tuberculosis. Proc NatlAcadSci U 
SA 93,12828-12833. 
Yuan, Y., Zhu, Y., Crane, A D. & Barry, C. E., 3rd (1998a). The effect of oxygenated 
mycolic acid composition on cell wall function and macrophage growth in Mycobacterium 
tuberculosis. Mol Microbiol 29,1449-1458. 
Yuan, Y., Lee, R. E., Besra, G. S., Belisle, J. T. & Barry, C. E., 3rd (1995). Identification 
of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Afycobacteriuni 
tuberculosis. Proc NatlAcadSci USA 92,6630-6634. 
Yuan, Y., Crane, D. C., Musser, J. M., Sreevatsan, S. & Barry, C. E., 3rd (1997). MMAS- 
1, the branch point between cis- and trans-cyclopropane-containing oxygenated mycolates 
in 
Mycobacterium tuberculosis. JBiol Chem 272,10041-10049. 
244 
CHAPTER 7 REFERENCES 
Yuan, Y., Mead, D., Schroeder, B. G., Zhu, Y. & Barry, C. E., 3rd (1998b). The 
biosynthesis of mycolic acids in Mycobacterium tuberculosis. Enzymatic methy](ene) transfer 
to acyl carrier protein bound meromycolic acid in vitro. JBiol Chem 273,21282-21290. 
Zhang, N., Torrelles, I B., McNeil, M. R., Escuyer, V. E., Khoo, K. H., Brennan, P. J. & 
Chatterjee, D. (2003). The Emb proteins of mycobacteria direct arabinosylation of 
lipoarabinomannan and arabinogalactan via an N-terminal recognition region and a C-tenninal 
synthetic region. Mol Microbiol 50,69-76. 
Zhang, Y., Heym, B., Allen, B., Young, D. & Cole, S. (1992). The catalase-peroxidase gene 
and isoniazid resistance of Mycobacterium tuberculosis. Nature 358,591-593. 
Zhang, Y. M., Rao, M. S., Heath, R. J., Price, A. C., Olson, A. J., Rock, C. 0. & White, S. 
W. (2001). Identification and analysis of the acyl carrier protein (ACP) docking site on beta- 
ketoacyl-ACP synthase 111. JBiol Chem 276,8231-8238. 
Zimhony, 0., Cox, J. S., Welch, J. T., Vilcheze, C. & Jacobs, W. R., Jr. (2000). 
Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium 
tuberculosis. Nat Med 6,1043-1047. 
245 
Appendices 
246 
APPENDICES 
8.1 General materials and methods 
8.1.1 Culture media 
LB (Luria-Bertani) Broth 
Amount per Litre (g) 
Bacto-tryptone 10 
Bacto-yeast extract 5 
NaCl 5 
Sauton's Broth (12H 7.2) 
AmountperLitre 
K2HP04 0.5 g 
MgS04 0.5 g 
Asparagine 4g 
Fe Ammonium Citrate 0.05 g 
GlYcerol 60 ml 
Citric Acid 2g 
ZnS04 (I % w/v) 0.1 ml 
Triton (Tyloxapol) (5 %) 5 ml 
LB agar was purchased from Sigma and prepared using manufacturers directions. All media is 
to be autoclaved at 1210C for 15 minutes. 
Terrific Broth 
Solution I 
Bacto-tryptone 
Bacto-yeast extract 
Glycerol 
Solution 2 
KH2PO4 
K2HP04 
Amount per 900 m1 
12 g 
24 g 
4 ml 
Amount per 100 mI 
2.3 g 
12.5 g 
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The above solutions were autoc laved at 12 1 IC for 15 m inutes. Sol ution 2 for terri fic broth was 
added to solution I prior to use, with the appropriate antibiotic. 
8.1.2 Growth of bacterial strains 
Batch culturing of the E. coli stains used in the project were carried out at 37T or 16*C in an 
orbital incubator at a speed of 180 rpm; length of incubation varied depending on the 
experiment. In broth and solid medium the following antibiotics were used: 
0 Kanamycin (25 ptg/ml) to select for E. coli containing the pET28a plasmid vector. 
0 Ampicilin (100 gg/ml) to select for K coli containing the pET23b plasmid vector. 
0 Ampicilin (100 gg/ml) to select for E. coli containing the pQE60 plasmid vector. 
Ampicilin(100 pg/ml) to select for E. coli containing the pUC18 plasmid vector. 
9 Hygromycin (200 jig/ml) to select for E. coli containing either pSD26 or pVV16 
plasmid vectors. 
Hygromycin (50 pg/ml) to select for M smegmatis containing either pSD26 or pVV 16 
plasmid vectors. 
8.1.3 Cell lines 
Escherichia coli C41 (DE3) 
Escherichia coli TOP 10 
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Escherichia coli HB 10 1 
Escherichia coli XL-1 Blue Super competent (Stratagene) 
Escherichia coli M 15 (pREP4) 
Mycobacterium smegmatis mc 21 55 
8.1.4 Plasmid extraction 
40 ml of LB broth was inoculated with the appropriate glycerol stock. After incubation at 
37'C overnight 5 mls of the cells were harvested by centrifugation at 12,500 xg for 15 mins at 
4'C. Plasmid DNA was prepared using the Qiagen Plasmid purification kit. 
8.1.5 Polymerase chain reaction (PCR) 
The recipe for PCR was similar for all the genes cloned but slight variations are used in each 
case to create the best yield. Four PCR mixtures are possible and are shown below. 
Each PCR reaction has a final volume of 100 pl made up with H20, one reaction contains the 
following ingredients with the addition of one of the methods making a final volume of 99 pl. 
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2 pd 5' Cloning Primer 
2 pI 3' Cloning Primer 
I Al Genomic DNA 
2 jil dNTP's 
10 PLI Thermostable Buffer (I Ox) 
Method I Method 2 Method 3 Method 4 
0 pl DMSO 8 pl DMSO 0 pl DMSO 8 pl DMSO 
0 PI MgS04 0 PI MgS04 2 PI MgS04 2 pl MgSO4 
82 ptl H20 74 pl H20 80 pl H20 72 pl H20 
M9S04 ý 100 MM 
I pI of the Vent' was added prior to starting the PCR followed by gentle mixing. 
8.1.6 Gel electrophoresis 
8.1.6.1 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein levels were assessed using a bicinchoninic protein assay (BCA) Kit (Pierce). Protein 
fractions (crude 25 pg, purified 5 pg) were analysed by electrophoresis on 10 - 15 % SDS 
polyacrylamide gels by the method of Laemmli (1970) using a Hoefer "mighty smal I" SE200 
vertical slab gel system. The gels were made with the following ingredients: - 
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4x Resolving gel buffer 
Acrylamide / bis / water mix 
TEMED 
10 % ammonium persulphate 
Amount required for 2 gels 
3.75 ml 
11.25 ml 
30 pLI 
75 gl 
(Resolving gel buffer 1.5 M Tris-HCI, 0.4 % SDS pH 8.8). The acrylamide / bis / water mix 
contained the following concentrations depending on the percentage acrylamide required, 
normally percentages used ranged from 10 % to 15 %: - 
% 8 10 1 12 15 
Acrylamide ('50 %, 37.5: 1 acrylamide/bis-acrylamide) 4.0 
d. 
5 
Water 7.25 I . 75 _2.75 
The stacking Gel contained the following ingredients: - 
Amount required for 2 gels 
4x stacking gel buffer 1.25 ml 
Acrylamide 0.65 ml 
Water 3.05 ml 
TEMED 15 pl 
10 % ammonium persulphate 75 pl 
(Stacking gel buffer 0.5 M Tris-HCI, 0.4 % SDS pH 6.8). Protein samples were added to 115 
of SDS loading buffer (360 mM Tris-HCI, pH 8.8,9 % (w/v) SDS, 0.9 % (w/v) bromophenol 
blue, 15 % (w/v) P-mercaptoethanol and 30 % glycerol) and boiled for 5 minutes. Samples 
were loaded onto the gel and run at 20 mA for 60 minutes. The running buffer (25 mM Tris, 
190 mM Glycine, 4 mM SDS) were applied as per the manufacturers instructions. 
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The proteins were visualised by staining the gels in 50 ml of Coomassie brilliant blue R 
(CBB) stain (5 % glacial acetic acid, 0.025 % CBB (w/v), 50 % methanol) and left for 0.5-1.0 
hour on an oscilating platform. Excess stain that was not bound was removed by rinsing in 
destaining solution (10 % glacial acetic acid in 30 % methanol). 
8.1.6.2 Electrophoresis of DNA 
DNA fragments from restriction reactions and PCR products were analysed by horizontal slab 
agarose gel electrophoresis (Hoefer). I% (w/v) Agarose gels were prepared by dissolving 
electrophoresis grade agarose in TAE. DNA samples were prepared by mixing with one-fifth 
the volume of 5X DNA loading buffer (0.25 % bromophenol blue, 0.25 % xylene cyanol FF, 
40 % (w/v) sucrose in water). All agarose gels were run in IX TAE (40 mM Tris-acetate, I 
mM EDTA) buffer. The samples were run at 100 volts until marker dye migrated the required 
distance. The gel was then stained with a 0.5 gg/ml solution of ethidium bromide for 20 mins, 
then viewed by UV transillumination and photographed using a gel documentation system 
(Bio-Rad). Relevant band sizes were excised from the gel and DNA fragments extracted using 
the Qiagen Gel extraction kit. 
8.1.7 Restriction enzyme digest of DNA 
All restriction endonuclease digests were performed under conditions recommended by the 
manufacturer. For example, the final volume of these reactions equate to 20 gl where the 
following volumes were added to the reaction: - 
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2 1A sure-cut buffer (x 10) 
I gl restriction endonulease A 
I ptl restriction endonulease B 
2 ng DNA 
DNase and RNase-free water was added to make the volume up to 20 RI. The digest 
conditions were 371C for 2 hours and the products then analysed on aI% agarose gel. 
8.1.8 Transformation of E. coli with plasmid DNA 
Electroporation 
To 50 gl of electrocompetent cells, I ng of plasmid DNA was added and mixed gently. This 
was transferred to an electro-cuvette and stored on ice for 5 minutes. Cells were 
electroporated using a Biorad Pulse controller and Biorad gene pulser with 2 mm cuvette gaps 
at the following conditions: 
Resistance = 200 0 
25 ptFD 
2.5 V 
Immediately after electroporation, 250 ýd of sterile LB broth was added to the cuvette, mixed 
gently and the incubated at 370C for I hour. The culture was plated out onto LB agar 
containing the relevant antibiotic and cultured overnight at 37T. 
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8.1-8.2 Heat shock 
To 50 gl of competent cells, I ng of plasmid DNA was added in Falcon 2054 tubes, gently 
mixed and incubated on ice for 30 minutes. The mixture was heat shocked at 42'C for 45 
seconds, and replaced on ice for 5 minutes. To allow the expression host to recover, 250 PI of 
fresh LB broth was added and incubated at 37C for I hour. The culture was spread on LB 
agar containing the relevant antibiotic and cultured overnight at 37T. 
8.1.9 Induction 
The induction of protein synthesis described in chapters 2,3 and 5 were performed using 
IPTG for pET/pQE vectors and acetamide for the pSD26 vector. A single transformant colony 
from the plates was used to inoculate 5 ml of LB Broth (pET/pQE) and Sauton's broth 
(pSD26/pVV16) containing the relevant antibiotic and incubated at 371C overnight. 
The overnight culture was added to fresh media containing the relevant antibiotic and 
incubated at 371C in an orbital incubator until the 0136oo was 0.5 4 0.7. Cells were induced 
by the addition of varying concentrations of IPTG (0.1 mM -I mM) or acetamide (0.01 %- 
0.2 %) followed by incubation for a further 4 hours, in some cases there was call for extended 
lengths of induction. The cells were harvested by centrifugation at 27,000 xg for 10 minutes 
and the supernatant discarded. Cell pastes were stored at -20'C. 
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8.1.10 Extraction of recombinant proteins 
8.1.10.1 Sonication 
The pelleted cells from the induction experiments were re-suspended in 4 volumes of 20 mM 
phosphate buffer pH 7.5. The cells were Iysed by sonication in a Soniprep 150, the suspension 
was stored on ice during the process and sonicated for 5-8 cycles (E. coli I cycle = 30 sec on, 
30 sec off) (M. smegmatis I cycle = 60 sec on, 90 sec oft). An aliquot of the resulting sample 
was store at 40C for analysis and the rest of the cell debris pelleted at 27,000 x g. The crude 
lysate, supernatant and the pellet analysed by SDS-PAGE electrophoresis. In some cases the 
pellet was resuspended in 20 mM phosphate buffer pH 7.5 containing 8M urea followed by 
re-centrifugation. 
8.1.10.2 French pressure cell 
The French pressure cell was cooled to 4'C for 2 hours before use. Samples were prepared by 
re-suspension in the appropriate buffer solution and then homogenised in a glass homogeniser. 
The slurry was then passed through the French press set at 3,000 psi. To ensure complete cell 
lysis, the homogenate was the passed through the French press again. DNase 1 (100 Pg) was 
added per gram wet weight of original cells and mixed for 5 minutes to reduce the viscosity. 
The cell debris was pelleted at 27,000 xg at 4"C. The crude lysate, supernatant and the pellet 
were analysed by SDS-PAGE. Again in some cases the pellet was resuspended in 20 mM 
phosphate buffer pH 7.5 containing 8M urea followed by re-centrifugation. 
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8.1.11 Purification 
Hi-trap Chelating SepharoseTm fast flow matrix columns (I ml or 5 ml) were equilibrated by 
washing with 4x column volumes of Hi-Trap running buffer (0.02 M Sodium Phosphate, 0.5 
M NaCl pH7.4). The column was charged using 2 column volumes of 0.1 M nickel chloride. 
The column was further washed with 4 column volumes of running buffer to re-equilibriate 
the column and remove excess nickel. The supernatant was applied to the column (maximum 
of 10 ml for aI ml column and 50 ml for a5 ml column) and non-absorbed material collected 
for analysis column. Proteins were eluted using increasing concentrations of imidazole (10 
mM - 500 mM). Fractions were collected and analysed by SDS-PAGE following protein level 
assessment using a BCA assay kit (Pierce). Samples were dialysed against the relevant 
dialysis buffer eg. mtFabH against 20 mM Tris-HCI pH 7.9,50 mM NaCl, I mM 
mercaptoethanol. 
8.1.12 Southern blotting 
DNA hybridisation was performed as described by (Southern, 1975). After gel electrophoresis 
the DNA was denatured by washing the agarose gel in denauturation solution (0.5 M NaOl-I, 
1.5 M NaCl) for 45 mins and then neutralised by washing in neutralsiation solution (0.5 M 
Tris-HCI pH 7.4,1.5 M NaCI) for 45 minutes. Finally the gel was rinsed in 20x SSC solution 
(3 M NaCl and 0.3 M trisodiurn citrate). The DNA was then transferred to Hybond N+ nylon 
membrane (Amersham) by capillary action. The cling film has a window shape of the gel 
removed to allow the moisture to be drawn upwards. This blotting procedure was allowed to 
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proceed overnight. The blot was then dismantled and the nylon mernbrane air-dried. The 
membrane was then visualised by DNA hybridisation. 
Drý 
Whatmann 
Figure 8.1 Schematic of Southern blotting technique. 
8.1.13 DNA hybridisation 
The Hybond N+ nylon membranes were overlaid onto wetted nylon supports. Membranes 
were then placed in glass hybridisation bottles (Hybaid) with 5-10 ml EasyHyb solution 
(Amersham) depending on the size of the membrane. Pre-hybridisation of mernbrane easyHyb 
was done at 42'C for a minimum of I hour in a rotating hybridisation oven (Hybaid). The 
probes used were labelled with digoxigenin (DIG)-dUTP5* using the PCR DIG probe 
synthesis kit (Boehringer Mannheim). Denatured labelled DNA probe was added to pre- 
hybridised membranes and allowed to hybridise in the presence of pre-hybridisation buft"er at 
500C for a minimum of 2 hours. Post-hybridisation washes were performed twice in 2x SSC, 
0.1 % SDS for 5 min at room temperature and twice in 0.1 x SSC, 0.1 % SDS 11or 15 min at 
68'C. the hybridised probe was detected using a DIG luminescence detection kit (Boehringer 
Mannheim) according to the manufacturer's recommendations. 
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8.1.14 Materials 
Sources of supplies were Amersharn Pharmacia Biotech, [2_14C]malonyl-CoA (specific 
activity, 56.0 Ci/mole); Sigma; Roche Molecular Biochemicals, restriction enzymes and T4 
DNA ligase; New England BioLabs, Vent polymerase; Novagen, pET vectors and expression 
strains; Qiagen, Plasmid extraction, Gel extraction, pQE vector and expression strains. All 
other chemicals were reagent grade or better. The antibiotics were from the following sources: 
CER, ETH, P-Acid and INH were from Sigma, TLM was a gift of GSK, triclosan, isoxyl, 
DZB gift from Prof. H6genauer (Austria). 
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8.2 KasA Cloning Primers 
pET28a 
Upper (5'-GATCGATCGCTAGCATGAGTCAGCCTTCCACCG-3') 
EcoRl 
Lower (5'-GACTGATCGCTAGCCTGCTTGCCTACCTCACTTG- 3') 
NheI 
pET23b 
Upper (5'-GATCGATCGCTAGCATGAGTCAGCCTTCCACCG-3') 
NheI 
Lower (5'-GACTGATCGCGGCCGCGTAACGCCCGAAGGCAAGC- 3') 
Nod 
pVV16 
Upper (5'-GATCGATCAAGCT7ATGAGTCAGCCTTCCACCG-3) 
HindIff 
Lower (5'-GACTGATCAAGCTTGTAACGCCCGAAGGCAAGC- 3') 
HindIff 
pQE60 
Upper (5'-GATCGATCCCATGGATGAGTCAGCCTTCCACCG-3') 
NcoI 
Lower (5'-GACTGATCAGATCTGTAACGCCCGAAGGCAAGC- 3') 
BgIII 
pSD26 
Upper (5'-GACTGATCGATATCATGAGTCAGCCTTCCACCG-3') 
EcoRV 
Lower (5'-GACTGATCGATATCGTAACGCCCGAAGGCAAGC- Y) 
EcoRV 
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8.3 Plasmid Diagrams 
8.3.1 PUC18 
(LAC) 
AMpR 
ORI 
PUC18 vector for cloning. Plac: Jac promotor, MCS: Multiple cloning site, ORI: origin of 
replication (pMBI replicon), AmPR : ampicillin resistance gene (Bla P-lactamase), LacZ: 
encodes the N-terminal fragment of P-galactosidase, Sma 1: Restriction site. 
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8.3.2 pET28(a)-mlFabH 
\- 
Kar 
ORI 
ffabH 
lac 0 
pET28(a) vector for N-terminal 6xHis tag constructs. T7: T7 promoter. lac 0: lac operator. 
lac 1: lac regulator, F1 origin: Helper Phage origin of replication. RBS: ribosorne-binding 
site, 6xHis: 6xHis tag sequence, MCS: Multiple cloning site. SC: stop codons in all three 
reading frames, ORL origin of replication, KanR: Kanamycin resistance gene (Neo: gene 
from Tn5 encodes an aminoglycoside 3'phosphotransferase (3'API I 11) that confiers resistance 
to the antibiotics kanamycin in bacteria). (Novagen, Wisconsin, USA) 
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8.3.3 pET28(a)-kasA 
Kar 
ORI 
r 
xHis 
D, la c0 
pET28(a) vector for N-terminal 6xHis tag constructs. T7: T7 promoter. lac 0: lac operator. 
lac 1: lac regulator, F1 origin: Helper Phage origin of replication, RBS: ribosomc-binding 
site, 6xHis: 6xHis tag sequence, MCS: Multiple cloning site, SC: stop codons in all three 
reading frames, ORL origin of replication, Kan 
R: Kanamycin resistance gene (Neo: gene 
from Tn5 encodes an aminoglycoside 3'phosphotransferase (3*APH 11) that conters resistance 
to the antibiotics kanamycin in bacteria). (Novagen, Wisconsin, USA) 
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8.3.4 pET23(b)-kasA 
Arr 
ORI 
ka, sA 
1.. 0 
pET23(a) vector for C-terminal 6xHis tag constructs. T7: 17 promoter, lac 0: lac operator. 
lac 1: lac regulator. F1 origin: Helper Phage origin of replication, RBS: ribosorne-binding 
site, 6xHis: 6xHis tag sequence, MCS: Multiple cloning site, SC: stop codons in all three 
R 
reading frames, ORL origin of replication, Am P: Ampicillin resistance gene (Bla 
lactamase) (Novagen, Wisconsin, USA). 
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8.3.5 pSD26-ka. v. 4 
kasA 7ý- 
Acetamide 
Promoter 
oriM 
tg 
'oriE 
pSD26 vector for C-terminal 6xHis tag constructs. Acetamide Promoter: pronlotcr RRS: 
ribosome-binding site, 6xHis: 6xIlis tag sequence, MCS: Multiple cloning s, le. SC: stop 
codons in all three reading frames, oriM: mycobacterial origin of' replication. 'oriE: /-. '. coli 
origin of replication HyaR : hygromycin resistance gene (phosphotransfierase). 
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8.3.6 PQE-60-kavA 
AmpR 
kasA 
Col El 
pQE vectors for C-terminal 6xHis tag constructs. PT5: T5 promotcr. Jac 0: lac operator. 
RBS: ribosome-binding site, 6xHis: 6xHis tag sequence, MCS: Multiple cloning site. Stop 
codons: stop codons in all three reading frames. Col El: Col FI origin ofreplication. Amp 
R 
ampicillin resistance gene (Bla P-lactarnase). 
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8.3.7 pVV16-ka,. vA 
Phsp60 
OriM 
kasA 
HygR 
mR 
Col El 
pVV 16 vector for C-ten-ninal 6xi fis tag constructs in Aticobaclei-him. Phsl)60: niý cobactcrial 
promoter, OHM: mycobacterial origin of replication. RBS: ribosorne-binding site. Wilk: 
6xHis tag sequence, MCS: Multiple cloning site, Coll Ell: Col 1: 1 origin of'replication. KanR : 
Kanamycin resistance gene (Neo: gene firom Tn 5 encodes an arninogl)coside 
3"phosphotransferase (3*API] 11) that conflers resistance to the antibiotics kanafnýcin in 
bacteria), HygR: Hygromycin resistance gene (phosphotransterase). 
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8.3.8 PET23(b)-pA-s]3 and pET23(b)-pksl3KAS 
pks 13 
or 
ks 13KAS 
fl origin 
sc 6xHis 
mcs 
AmpR// RBSýK\--- loco 
T7 \\ 
pET23(b)-pksl3 
pET23(b)-pksl3KA3 
ORI 
pET23(a) vector for C-terrninal 6xHis tag constructs. T7: T7 promoter. lac 0: lak: opcratoi. 
lac 1: lac regulator, F1 origin: Helper Phage origin of' replication. RIIS: ribosonle-hinding 
site, 6xHis: 6xHis tag sequence. MCS: Multiple cloning site. SC: smop c(Aons in all thrcc 
reading frames, ORL origin of' replication. Anil) Ampicillin resistaticc genc (Blit 11- 
lactamase). 
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8.3.9 pSD26-pks]3, pSD26-pksl3KAS and pSD26-pksl3Anli 
pksl3anti 
pksl3 or 
pksl3KAS 
I- MCS 6xHis SC RBS 
HygR 
pSD26-pksl3 
Acetamide pSD26-pksl3KAS 
Promoter pSD26-pksl3anti 'oriE 
oriM 
pSD26 vector for C-terminal 6xflis tag constructs. Acetamide Promoter: promotcr RBS: 
ribosome-binding site, 6xHis: 6xilis tau sCqLICIICC. MCS: %I1110111C ClOnIng SitC. SC: 
codons in all three reading Frames. oriM: imcobacterial ori, -, 
in of rcplication. 'oriF: /.. '. coli 
origin of replication Hyg": hygrornýcin rcsistance gene (phosphotransficrasc). 
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8.3.10 pJSC347: -pksl3KO 
Pac I 
1 Kb upstream 
Fragment 
Ori E 
gR 
1 Kb Downstream 
Fragment 
pJSC347 vector for creation of knock outs. Pac 1: rcstriction sitc I'or pak: 
kaglng. NICS: 
Multiple cloning site. OriE: E. coli origin ofreplication 
I]%-gR: IiNgroni\cln rcNisiancc genc 
(phosphotransferase). 
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8.4 Protein/DNA Sequences 
8.4.1 mtFabH (Rv0533c) (1008 bp) (335 aa) (34872.5 da) (Theoretical pI: 4.98) 
MTEIATTSGARSVGLLSVGAYRPERVVTNDEICQHIDSSDEWIYTRTGIKTRRFAADDES 
AASMATEACRRALSNAGLSAADIDGVIVTTNTHFLQTPPAAPMVAASLGAKGILGFDLSA 
GCAGFGYALGAAADMIRGGGAATMLVVGTEKLSPTIDMYDRGNCFIFADGAAAVVVGETP 
FQGIGPTVAGSDGEQADAIRQDIDWITFAQNPSGPRPFVRLEGPAVFRWAAFKMGDVGRR 
AM DAAGVRPDQIDVFVPHQANSRINELLVKNLQLRPDAVVANDIEHTGNTSAASIPLAMA 
ELLTTGAAKPGDLALLIGYGAGLSYAAQVVRMPKG 
1 - atg acg gag atc gcc acg acc agc ggc gcc 
31 - agg agc gtc ggg ctg ctc agt gtc ggg gcg 
61 - tac cgg ccc gaa cgc gtg gtc acc aac gac 
91 - gag ata tgc cag cac atc gac tcg tcc gac 
121 - gag tgg atc tac acc cga acc ggc atc aag 
151 - acc cgc cga ttc gcc gcc gac gac gag tcg 
181 - gcg gct tcc atg gcg act gag gcC tgt cga 
211 - cgg gca ctg tcg aac gcc ggc ctg tcg gcg 
241 - gcc gac atc gat ggc gtg atc gtc acc acc 
271 - aac acc cat ttc ctg caa acc ccg ccg gcc 
301 - gcC cca atg gtc gcg gcg tcg ctg g9c gcc 
331 - aag ggc ata ctc ggg ttC gat ctt tcg gcg 
361 - ggg tgc gcc gga ttc gga tat gcg ctt ggc 
391 - gca gcg gcC gac atg atc cgg ggc gga ggt 
421 - gcg gcc acg atg ctg gtg gtC ggc acg gaa 
451 - aaa ctg tcc ccc acg ata gac atg tac gac 
481 - cgc ggc aac tgc ttc atc ttc gcc gac ggc 
511 - gcg gcc gca gtg gtg gtg ggc gag aca. ccg 
541 - ttt caa ggC att gga cca acc gtg gcg ggt 
571 - agc gac ggc gaa cag gcc gat gcc ata. cgg 
601 - cag gac atc gac tgg atc act ttC gcC cag 
631 - aat ccc agc ggc cca cgC ccg ttt gtg C99 
661 - ctc gaa ggt CCC gcg gtC ttc cgt tgg gca 
691 - gcg ttc aaa atg ggc gac gtc ggt cgg cgC 
721 - gcg atg gac gcc gcc ggg gtg cga ccc gac 
751 - cag ata gac gtg ttc gtc cct cat cag gcc 
781 - aat agc cgc atc aac gag ctg ctg gtC aag 
811 - aac ctg cag ttg cgg ccc gac gcg gtg gtc 
841 - gcc aac gat atc gag cac acc gga aac acc 
871 - tcg gcg gcc tcc att ccg ctc gcg atg gcC 
901 - gaa tta ctg acg acc ggc gcg gcc aag ccc 
931 - ggc gat ctg gcc ctg ttg atc ggc tac ggC 
961 - gcc ggt ctg agc tat gcc gcc cag gtg gtg 
991 - cga atg ccg aag ggt tga 
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8.4.2 KasA(Rv2245) (1251 bp) (416 aa) (43284. Oda) (Theoretical p1: 5.11) 
MSQPSTANGGFPSVVVTAVTATTSISPDIESTWKGLLAGESGIHALEDEFVTKWDLAVKI 
GGHLKDPVDSHMGRLDMRRMSYVQRMGKLLGGQLWESAGSPEVDPDRFAVVVGTGLGGAE 
RIVESYDLMNAGGPRKVSPLAVQMIMPNGAAAVIGLQLGARAGVMTPVSACSSGSEAIAH 
AWRQIVMGDADVAVCGGVEGPIEALPIAAFSMMRAMSTRNDEPERASRPFDKDRDGFVFG 
EAGALMLIETEEHAKARGAKPLARLLGAGITSDAFHMVAPAADGVRAGRAMTRSLELAGL 
SPADIDHVNAHGTATPIGDAAEANAIRVAGCDQAAVYAPKSALGHSIGAVGALESVLTVL 
TLRDGVIPPTLNYETPDPEIDLDVVAGEPRYGDYRYAVNNSFGFGGHNVALAFGRY 
1- gtg agt cag cct tcc acc gct aat ggc ggt 
31 - ttc ccc agc gtt gtg gtg acc gcc gtc aca 
61 - gcg acg acg tcg atc tcg ccg gac atc gag 
91 - agc acg tgg aag ggt ctg ttg gcc ggc gag 
121 - agc ggc atc cac gca ctc gaa gac gag ttc 
151 - gtc acc aag tgg gat cta gcg gtc aag atc 
181 - ggc ggt cac ctc aag gat ccg gtc gac agc 
211 - cac atg ggc cga ctc gac atg cga cgc atg 
241 - tcg tac gtc cag cgg atg ggC aag ttg ctg 
271 - ggc gga cag cta tgg gag tcc gcc ggc agc 
301 - ccg gag gtc gat cca gac cgg ttc gcc gtt 
331 - gtt gtc ggc acc ggt cta ggt gga gcc gag 
361 - agg att gtc gag agc tac gac ctg atg aat 
391 - gcg ggc ggc ccc cgg aag gtg tcc ccg ctg 
421 - gcc gtt cag atg atc atg ccc aac ggt gcC 
451 - gcg gcg gtg atc ggt ctg cag ctt ggg gcC 
481 - cgc gcc ggg gtg atg acc ccg gtg tcg gcC 
511 - tgt tcg tcg ggc tcg gaa gcg atc gcc cac 
541 - gcg tgg cgt cag atc gtg atg ggc gac gcc 
571 - gac gtc gcc gtC tgc ggc ggt gtC gaa gga 
601 - ccc atc gag gcg ctg ccc atc gcg gcg ttc 
631 - tcc atg atg cgg gcc atg tcg acc cgc aac 
661 - gac gag cct gag cgg gcc tcc cgg ccg ttc 
691 - gac aag gac cgC gac ggc ttt gtg ttc ggc 
721 - gag gcc ggt gcg ctg atg ctc atc gag acg 
751 - gag gag cac gcc aaa gcc cgt ggc gcc aag 
781 - ccg ttg gcc cga ttg ctg ggt gcc ggt atc 
811 - acc tcg gac gcc ttt cat atg gtg gcg ccc 
841 - gcg gcc gat ggt gtt cgt gcc ggt agg gcg 
871 - atg act cgc tcg ctg gag ctg gcC ggg ttg 
901 - tcg ccg gcg gac atc gac cac gtc aac gcg 
931 - cac ggc acg gcg acg cct atc ggc gac gcc 
961 - gcg gag gcc aac gcC atc cgc gtc gcC ggt 
991 - tgt gat cag gcc gcg gtg tac gcg ccg aag 
1021 - tct gcg ctg ggc cac tcg atc ggc gcg gtc 
1051 - ggt gcg ctc gag tcg gtg ctc acg gtg ctg 
1081 - acg ctg cgc gac ggc gtC atc ccg ccg acc 
1111 - ctg aac tac gag aca ccc gat ccc gag atc 
1141 - gac ctt gac gtc gtc gcc ggc gaa ccg cgc 
1171 - tat ggc gat tac cgc tac gca gtC aac aac 
1201 - tcg ttc ggg ttc ggc ggc cac aat gtg gcg 
1231 - ctt gcc ttc ggg cgt tac tga 
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8.4.3 FabD (Rv2243) (909 bp) (302 aa) (30788.2 da) (Theoretical pl: 4.84) 
MIALLAPGQGSQTEGMLSPWLQLPGAADQIAAWSKAADLDLARLGTTASTEEITDTAVAQ 
PLIVAATLLAHQELARRCVLAGKDVIVAGHSVGEIAAYAIAGVIAADDAVALAATRGAEM 
AKACATEPTGMSAVLGGDETEVLSRLEQLDLVPANRNAAGQIVAAGRLTALEKLAEDPPA 
KARVRALGVAGAFHTEFMAPALDGFAAAAANIATADPTATLLSNRDGKPVTSAAAAMDTL 
VSQLTQPVRWDLCTATLREHTVTAIVEFPPAGTLSGIAKRELRGVPARAVKSPADLDELA 
NL 
1- gtg att gcg ttg ctc gca ccc gga cag ggt 
31 - tcg caa acc gag gga atg ttg tcg ccg tgg 
61 - ctt cag ctg ccc ggC gca gcg gac cag atc 
91 - gcg gcg tgg tcg aaa gcc gct gat cta gat 
121 - ctt gcC cgg ctg ggC acc acc gcc tcg acc 
151 - gag gag atc acc gac acc gcg gtc gcc cag 
181 - cca ttg atc gtc gcC gcg act ctg ctg gcC 
211 - cac cag gaa ctg gcg cgC cga tgc gtg ctc 
241 - gcC ggc aag gac gtc atc gtg gcC ggc cac 
271 - tcC gtC ggC gaa atc gcg gcC tac gca atc 
301 - gcc ggt gtg ata gcC gcC gac gac gcC gtc 
331 - gcg ctg gcc gcc acc cgc ggc gcc gag atg 
361 - gcC aag gcC tgc gcC acc gag ccg acc ggC 
391 - atg tct gcg gtg ctc ggc ggc gac gag acc 
421 - gag gtg ctg agt cgC ctc gag cag ctc gac 
451 - ttg gtC ccg gca aac cgC aac gcC gcC ggC 
481 - cag atc gtc gct gcC ggc cgg ctg acc gcg 
511 - ttg gag aag ctc gcC gaa gac ccg ccg gcC 
541 - aag gcg cgg gtg cgt gca ctg ggt gtC gcc 
571 - gga gcg ttC cac acc gag ttC atg gcg ccc 
601 - gca ctt gac ggC ttt gcg gcg gcc gcg gcc 
631 - aac atc gca acc gcc gac ccc acc gcC acg 
661 - ctg ctg tcC aac cgC gac ggg aag ccg gtg 
691 - aca tcC gcg gcc gcg gcg atg gac acc ctg 
721 - gtc tcC cag ctc acc caa ccg gtg cga tgg 
751 - gac ctg tgc acc gcg acg ctg cgC gaa cac 
781 - aca gtC acg gcg atc gtg gag ttC ccc ccc 
811 - gcg ggc acg ctt agc ggt atc gcC aaa cgc 
841 - gaa ctt cgg ggg gtt ccg gca cgC gcc gtc 
871 - aag tca ccc gca gac ctg gac gag ctg gca 
901 - aac cta taa 
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8.4.4 AcpM(Rv2244) (348 bp) (115aa) (12523.9 da) (Theoretical pl: 4.00) 
MPVTQEEIIAGIAEIIEEVTGIEPSEITPEKSFVDDLDIDSLSMVEIAVQTEDKYGVKIP 
DEDLAGLRTVGDVVAYIQKLEEENPEAAQALRAKIESENPDAVANVQARLEAESK 
1 - gtg cct gtc act cag gaa gaa atc att gcC 
31 - ggt atc gcc gag atc atc gaa gag gta acc 
61 - ggt atc gag ccg tcc gag atc acc ccg gag 
91 - aag tcg ttc gtc gac gac ctg gac atc gac 
121 - tcg ctg tcg atg gtC gag atc gcc gtg cag 
151 - acc gag gac aag tac ggc gtc aag atc ccc 
181 - gac gag gac ctc gcc ggt ctg cgt acc gtC 
211 - ggt gac gtt gtC gcc tac atc cag aag ctc 
241 - gag gaa gaa aac ccg gag gcg gct cag gcg 
271 - ttg cgc gcg aag att gag tcg gag aac ccc 
301 - gat gcc gtt gcc aac gtt cag gcg agg ctt 
331 - gag gcc gag tcC aag tga 
8.4.5 Pks13 (Rv3800c) (5202 bp) (1733 aa) (186445.6 da) (Theoretical pl: 4.83) 
MADVAESQENAPAERAELTVPEMRQWLRNWVGKAVGKAPDSIDESVPMVELGLSSRDAVA 
MAADIEDLTGVTLSVAVAFAHPTIESLATRIIEGEPETDLAGDDAEDWSRTGPAERVDIA 
IVGLSTRFPGEMNTPEQTWQALLEGRDGITDLPDGRWSEFLEEPRLAARVAGARTRGGYL 
KDIKGFDSEFFAVAKTEADNIDPQQRMALELTWEALEHARIPASSLRGQAVGVYIGSSTN 
DYSFLAVSDPTVAHPYAITGTSSSIIANRVSYFYDFHGPSVTIDTACSSSLVAIHQGVQA 
LRNGEADVVVAGGVNALITPMVTLGFDEIGAVLAPDGRIKSFSADADGYTRSEGGGMLVL 
KRVDDARRDGDAILAVIAGSAVNHDGRSNGLIAPNQDAQADVLRRAYKDAGIDPRTVDYI 
EAHGTGTILGDPIEAEALGRVVGRGRPADRPALLGAVKTNVGHLESAAGAASMAKVVLAL 
QHDKLPPSINFAGPSPYIDFDAMRLKMITTPTDWPRYGGYALAGVSSFGFGGANAHVVVR 
EVLPRDVVEKEPEPEPEPKAAAEPAEAPTLAGHALRFDEFGNIITDSAVAEEPEPELPGV 
TEEALRLKEAALEELAAQEVTAPLVPLAVSAFLTSRKKAAAAELADWMQSPEGQASSLES 
IGRSLSRRNHGRSRAVVLAHDHDEAIKGLRAVAAGKQAPNVFSVDGPVTTGPVWVLAGFG 
AQHRKMGKSLYLRNEVFAAWIEKVDALVQDELGYSVLELILDDAQDYGIETTQVTIFAIQ 
IALGELLRHHGAKPAAVIGQSLGEAASAYFAGGLSLRDATRAICSRSHLMGEGEAMLFGE 
YIRLMALVEYSADEIREVFSDFPDLEVCVYAAPTQTVIGGPPEOVDAILARAEAEGKFAR 
KFATKGASHTSQMDPLLGELTAELQGIKPTSPTCGIFSTVHEGRYIKPGGEPIHDVEYWK 
KGLRHSVYFTHGIRNAVDSGHTTFLELAPNPVALMQVALTTADAGLHDAQLIPTLARKOD 
EVSSMVSTMAQLYVYGHDLDIRTLFSRASGPQDYANIPPTRFKRKEHWLPAHFSGDGSTY 
MPGTHVALPDGRHVWEYAPRDGNVDLAALVRAAAAHVLPDAQLTAAEORAVPGDGARLVT 
TMTRHPGGASVQVHARIDESFTLVYDALVSRAGSESVLPTAVGAATAIAVADGAPVAPET 
PAEDADAETLSDSLTTRYMPSGMTRWSPDSGETIAERLGLIVGSAMGYEPEDLPWEVPLI 
ELGLDSLMAVRIKNRVEYDFDLPPIQLTAVRDANLYNVEKLIEYAVEHRDEVQQLHEHOK 
TQTAEEIARAQAELLHGKVGKTEPVDSEAGVALPSPQNGEQPNPTGPALNVDVPPRDAAE 
RVTFATWAIVTGKSPGGIFNELPRLDDEAAAKIAQRLSERAEGPITAEDVLTSSNIEALA 
DKVRTYLEAGQIDGFVRTLRARPEAGGKVPVFVFHPAGGSTVVYEPLLGRLPADTPMYGF 
ERVEGSIEERAQQYVPKLIEMQGDGPYVLVGWSLGGVLAYACAIGLRRLGKDVRFVGLID 
AVRAGEEIPQTKEEIRKRWDRYAAFAEKTFNVTIPAIPYEQLEELDDEGQVRFVLDAVSQ 
SGVQIPAGIIEHQRTSYLDNRAIDTAQIQPYDGHVTLYMADRYHDDAIMFEPRYAVRQPD 
GGWGEYVSDLEVVPIGGEHIQAIDEPIIAKVGEHMSRALGQIEADRTSEVGKO 
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1- atg gct gac gta gcg gaa tcc cag gag aac 
31 - gcc ccc gcc gaa agg gcc gag cta acg gtc 
61 - ccc gag atg cgc cag tgg ctg cgc aac tgg 
91 - gtg ggt aag gcc gtc gga aag gca ccg gac 
121 - tcg atc gac gaa tcg gtg ccc atg gtg gag 
151 - ctg ggt ctg tcg tcg cgc gat gcc gtc gcg 
181 - atg gcc'gcc gac ata gaa gac ctg acc ggg 
211 - gtc acg ctg tcg gtc gcg gtg gcg ttc gcg 
241 - cat ccg acc atc gaa tcg ctg gcc acc cgg 
271 - atc atc gag ggc gag ccg gag acc gac cta 
301 - gcg ggc gat gac gcc gaa gac tgg tcg cgc 
331 - acc ggc ccg gcc gag cgc gtC gac atc gcg 
361 - atc gtg ggc ttg tcc acc cgc ttC ccg ggc 
391 - gag atg aac acc ccc gag cag acc tgg cag 
421 - gcg ctg ctg gaa ggc cgc gac ggg atc acc 
451 - gac ctg ccc gac ggg cgc tgg tcg gaa ttC 
481 - ctc gaa gag ccg cgg ctg gcc gcg cgg gtC 
511 - gcc ggg gcc cgc acc cgg ggc ggc tac ctg 
541 - aag gac atc aag ggc ttc gat tcg gag ttc 
571 - ttc gcg gtg gcc aag acc gaa gcc gac aac 
601 - atc gac ccg cag cag cgg atg gcg ctg gag 
631 - ctg acc tgg gag gcg ctc gag cac gcc cgc 
661 - atc ccg gcg tcg agc ctg cgc ggc cag gcc 
691 - gtc ggt gtg tac atc ggc agc tcc acc aac 
721 - gac tac agc ttc ctg gcg gtg tcg gac ccg 
751 - acg gtc gcg cac ccg tat gcg atc acc ggc 
781 - acc agc agc tcg atc atc gcc aac cgg gtg 
811 - tcc tac ttc tac gac ttc cac gga ccg tcg 
841 - gtc acc att gac acc gcg tgc tcg agt tcg 
871 - ctg gtg gcc atc cac cag ggg gtg cag gcg 
901 - ctg cgc aac ggc gag gcc gac gta gtg gtc 
931 - gcc ggc ggg gtg aac gcg ttg atc aca ccg 
961 - atg gtc acc ctg ggt ttc gac gag atc ggt 
991 - gcg gtg ctg gcg ccc gac ggc cgg atc aag 
1021 - tcg ttc tca gcc gac gcc gac ggC tac acc 
1051 - cgc tcc gaa ggc ggc ggc atg ctg gtg ctc 
1081 - aag cgg gtc gac gac gcc cgc cgc gac ggc 
1111 - gac gcg atc ctg gcc gtg atc gcc ggC agc 
1141 - gcg gtc aac cac gac ggc cgg tcc aac ggc 
1171 - ctg atc gca ccc aac cag gac gcg cag gcc 
1201 - gac gtg ctg cgc cgg gcc tac aag gac gcC 
1231 - ggc atc gat ccg cgc acc gtc gac tac atc 
1261 - gag gcg cac ggc acc ggc acc atc ctc ggc 
1291 - gac cca atc gag gcc gag gcg ctg ggc Cgg 
1321 - gtg gtc ggt agg ggc cgt ccg gcc gat cgg 
1351 - ccg gcg ctg ctg ggt gcg gtg aaa acc aac 
1381 - gtc ggg cac ctg gaa tcg gcg gcc ggc gcg 
1411 - gcc agc atg gcc aag gtg gtg ctg gcg ctg 
1441 - cag cac gac aaa ctg ccg ccg tcg atc aac 
1471 - ttc gcc ggc ccc agc ccc tac atc gac ttC 
1501 - gac gcg atg cgg ttg aag atg atc acc acg 
1531 - ccc acc gac tgg ccg cga tac ggc ggC tac 
1561 - gcg ctg gcc ggg gtg tcc agc ttc ggc ttC 
1591 - ggc ggc gcc aac gcg cac gtg gtg gtg cgc 
1621 - gag gtc ctg ccg cgt gac gtg gtg gaa aag 
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1651 - gaa ccg gaa ccc gag ccg gaa ccc aag gcg 
1681 - gcc gcc gaa ccc gcc gag gcg ccc acg ttg 
1711 - gca ggc cac gcg ctg cgg ttc gac gag ttC 
1741 - ggC aac atc atc acc gac tcg gcg gtc gcc 
1771 - gaa gag ccg gag ccc gaa ctg ccc gga gtc 
1801 - acc gag gag gcg ctg cgg ctc aag gaa gcc 
1831 - gcg ttg gaa gag ctt gcg gcc caa gag gtt 
1861 - acg gca cca ttg gtc ccg ttg gcg gtg tcg 
1891 - gcg ttt ctg acg tcc cgc aag aag gcg gcg 
1921 - gcC gcc gag ttg gcg gac tgg atg caa agc 
1951 - ccg gaa ggc cag gcC tcc tcg ctg gaa tcg 
1981 - atc ggc agg tcg ttg tcg cgg cgc aac cac 
2011 - ggc cgt tcC cgc gcg gtg gtg ttg gcc cac 
2041 - gac cac gac gag gcc atc aag ggc ctg cgC 
2071 - gcg gtc gcc gcg ggc aag cag gcg ccg aac 
2101 - gtg ttc agc gtc gac ggg ccg gtg acc acc 
2131 - ggc ccg gtC tgg gtg ctc gcC gga ttc ggc 
2161 - gcC cag cat cgc aag atg ggc aag agc ctg 
2191 - tac ctg cgc aac gag gtg ttC gcg gcg tgg 
2221 - atc gag aag gtc gac gcc ctg gtc caa gac 
2251 - gag ctg ggc tac tcg gtg ctg gag ctg atc 
2281 - ctg gac gac gcg cag gac tac ggc atc gag 
2311 - acc acc cag gtc acc atc ttc gcg atc cag 
2341 - atc gcg ctg ggt gag ctg ctg cgc cat cac 
2371 - ggc gcc aaa ccg gcc gcg gtc atc ggc cag 
2401 - tcg ctg ggt gag gcc gcg tcg gcc tac ttc 
2431 - gcc ggc ggg ctg tcg ctg cgg gat gcc acc 
2461 - cgg gcg atc tgc tcg cgc tcg cac ctg atg 
2491 - ggc gag ggt gag gcg atg ctg ttc ggc gag 
2521 - tac atc cgg ttg atg gcg ctg gtg gaa tac 
2551 - tcc gcc gac gaa atc aga gaa gtg ttc tcc 
2581 - gac ttC ccc gat ctg gag gtg tgt gtc tac 
2611 - gcc gcg ccc acc cag acg gtC atc ggc ggc 
2641 - ccc ccc gag cag gtg gac gcg atc ctt gcc 
2671 - cgc gcc gag gcc gag ggc aag ttc gcC c9c 
2701 - aaa ttc gcg acc aag ggC gcc agc cac acc 
2731 - tcg cag atg gac ccg ctg ctg ggc gag ctc 
2761 - acc gcg gag ctg caa ggc atc aag ccg acg 
2791 - agc ccg acg tgt ggg atc ttc tcg acg gtg 
2821 - cac gag ggc cgc tac atc aaa ccc ggc ggc 
2851 - gaa ccc atc cac gac gtc gaa tac tgg aag 
2881 - aag ggg ctg C99 cat tcc gtc tac ttc acc 
2911 - cac ggc atc cgC aac gcc gtc gac agc ggg 
2941 - cac acc acc ttc ctg gag ctg gca ccc aat 
2971 - ccg gtg gcg ctg atg cag gtc gcc ctg acc 
3001 - acc gcc gat gcc ggg ctg cat gac gcc cag 
3031 - ttg atc ccg acg ctg gcc cgc aag caa gac 
3061 - gag gtc tcc tcg atg 9tc tcg acc atg gcg 
3091 - cag ctg tat gtg tac ggc cac gac ctg gac 
3121 - ata cgc acg ctg ttt agc cgc gcc agt ggg 
3151 - ccg cag gat tac gcg aac att ccg ccg acc 
3181 - cgg ttc aag cgc aag gag cac tgg ctg ccc 
3211 - gcg cac ttc tcC ggc gac ggc tcg acg tac 
3241 - atg ccg ggc acc cat 9tc 9cc ctg ccg gat 
3271 - ggg cgg cac gtc tgg gag tac gcg ccg cgg 
3301 - gac ggc aat gtg gac ttg 9cc gcg ttg 9tc 
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3331 - agg gcc gcc gcc gcc cac gtg ctt ccg gac 
3361 - gcg caa ctg acc gcC gcc gag cag cgC gcg 
3391 - gtg ccc ggC gac ggc gcc cgg ctg gtg acg 
3421 - acg atg acc cgt cac ccc ggc ggc gcc tcg 
3451 - gtg cag gtg cac gcc cgc atc gac gag tcc 
3481 - ttC acg ctg gtc tac gac gcC ctg gtg tcc 
3511 - cga gcg ggg tcC gaa tcg gtg ttg ccc acc 
3541 - gcg gtg ggt gcg gcg acg gcg atc gcg gtt 
3571 - gcg gac ggg gcg cct gtC gcg ccg gaa acg 
3601 - ccc gcc gaa gac gcg gac gcc gag acg ctt 
3631 - tcg gac agc ctg acc acc cgt tac atg ccg 
3661 - tcc ggc atg acc cga tgg tcg cct gat tcc 
3691 - ggt gag acc atc gcC gag cgg ctg ggC ctg 
3721 - att gtC ggg tct gcg atg ggc tat gag ccc 
3751 - gag gac ctg ccg tgg gag gtg ccg ctg atc 
3781 - gag ctt ggc ctg gac tcg ctg atg gcg gtg 
3811 - cgc atc aaa aac cgC gtc gag tac gac ttc 
3841 - gac ctg cca ccg atc cag ctg acc gcg gtg 
3871 - cgc gac gcC aac ctc tac aac gtg gag aag 
3901 - ctg atc gaa tac gcg gtC gag cac cgt gac 
3931 - gag gtg cag cag ctg cac gag cac cag aaa 
3961 - acc cag acc gct gag gag atc gcg cgg gcC 
3991 - cag gcc gaa ttg ctg cat ggc aag gtg ggC 
4021 - aag acc gag ccg gtc gac tcg gaa gcC ggg 
4051 - gtt gcg ctc ccg tcg ccg caa aac ggc gag 
4081 - cag cca aac ccg aca ggg ccc gcg ctc aac 
4111 - gtC gac gtg ccg ccg cgg gac gct gcC gag 
4141 - cgg gtc acc ttc gcC acc tgg gcg atc gtC 
4171 - acc ggc aag tcC ccg ggc ggC atc ttC aac 
4201 - gag ctg ccc agg ctg gac gac gag gcc gcg 
4231 - gcc aag att gcg cag cgg ctt tcC gag cgc 
4261 - gcc gaa ggc ccg atc acc gcC gag gac gtg 
4291 - ctg acg tcg tcg aac atc gag gcg ctg gcc 
4321 - gac aag gtg cgc acg tat ttg gag gcC ggg 
4351 - cag atc gat ggg ttc gtC cgc acc ctg cgg 
4381 - gcg cgg ccc gaa gca ggC ggg aag gtg ccg 
4411 - gtg ttc gtg ttt cat ccg gcc ggc ggc tcg 
4441 - acg gtg gtg tac gag ccg ctg ctg ggc cgg 
4471 - ctg ccg gcg gac acc cca atg tat ggc ttc 
4501 - gaa cgg gtc gag ggg tcg atc gaa gag cgt 
4531 - gca cag cag tac gtg ccg aag ctg atc gag 
4561 - atg cag g9c gac ggg ccc tat gtC ctg gtg 
4591 - ggt tgg tcg ctg ggc ggt gtg ctg gcc tac 
4621 - gcg tgc gcg atc ggt ttg cgg C99 ctg 99C 
4651 - aag gac gtg cgg ttC gtC ggg ctg atc gac 
4681 - gcg gtg cgC gcc ggt gag gag atc ccg cag 
4711 - acc aag gag gag atc cgc aag cgc tgg gac 
4741 - cgC tac gcc gcc ttc gcc gag aag acg ttC 
4771 - aac gtg acc atc ccg gcg atc ccg tac gag 
4801 - cag ctc gag gag ctc gac gac gag ggc cag 
4831 - gtc cgg ttc gtg ctg gac gcC gtC agc cag 
4861 - tcc ggt gtg cag atc ccg gcc ggg atc atc 
4891 - gaa cac caa cgc acg tcg tat ctg gac aac 
4921 - cgg gcg atc gac acc gcc cag atc cag ccg 
4951 - tac gac ggg cat gtc acc ctc tac atg gcc 
4981 - gat cgC tac cat gac gac gcg atc atg ttC 
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5011 - gag ccc cgc tac gcc gtg cgc cag ccg gac 
5041 - ggc ggg tgg ggc gag tac gtt tcc gac ctc 
5071 - gag gtg gtg ccg atc ggt ggc gag cac att 
5101 - cag gcc atc gac gag ccg atc atc gcc aag 
5131 - gtg ggc gaa cac atg agc cgc gcg ttg ggg 
5161 - cag atc gag gcc gat cga aca agt gag gta 
5191 - ggc aag cag tga 
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